

## P, INT COOPERATION TREA

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents  
 United States Patent and Trademark  
 Office  
 Box PCT  
 Washington, D.C.20231  
 ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 27 July 2000 (27.07.00)	
International application No. PCT/US99/26260	Applicant's or agent's file reference 178-53683
International filing date (day/month/year) 05 November 1999 (05.11.99)	Priority date (day/month/year) 06 November 1998 (06.11.98)
Applicant WONG, Scott, W. et al	

1. The designated Office is hereby notified of its election made:

☒

in the demand filed with the International Preliminary Examining Authority on:

03 June 2000 (03.06.00)

☐

in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was☐

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland  Facsimile No.: (41-22) 740.14.35	Authorized officer  Juan Cruz  Telephone No.: (41-22) 338.83.38
---	---

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
22 November 2001 (22.11.2001)

PCT

(10) International Publication Number  
**WO 01/88203 A1**

(51) International Patent Classification<sup>7</sup>: **C12Q 1/70**,  
G01N 33/53, C12P 19/34, C12N 5/06, 7/00, C07H 21/04,  
A61K 38/00

(21) International Application Number: PCT/US01/16274

(22) International Filing Date: 17 May 2001 (17.05.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/205,652 18 May 2000 (18.05.2000) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **OREGON HEALTH & SCIENCE UNIVERSITY** [US/US];  
Office of Technology Management, 3181 S.W. Sam Jackson Park Road, L335, Portland, OR 97201-8200 (US).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **WONG, Scott, W.** [US/US]; 7926 S.W. 167th Place, Beaverton, OR 97007 (US). **AXTHELM, Michael, K.** [US/US]; 1345 S.E. 35th Avenue, Hillsboro, OR 97123 (US).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(74) Agent: **NOONAN, William, D.**; Klarquist, Sparkman, Campbell, Leigh & Whinston, LLP, One World Trade Center, Suite 1600, 121 S.W. Salmon Street, Portland, OR 97204 (US).

(54) Title: CLONING OF RHADINOVIRUS GENOME AND METHODS FOR ITS USE

(57) Abstract: An isolated virus is provided (Japanese Macaque Herpesvirus, JMHV), as deposited with ATCC as deposit accession number PTA-1884, as are viral particles including this virus and host cells infected with this virus. A purified polypeptide is also provided that includes an amino acid sequence that has at least 95 % sequence identity to an amino acid sequence as set forth as SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, and SEQ ID NO:27, as are nucleic acid molecules encoding these polypeptides. A method is provided for testing the efficacy of a drug in the treatment of a condition associated with infection with JMHV. A model for multiple sclerosis is provided, as is a method for testing the efficacy of a candidate vaccine against JMHV infection, or conditions associated with JMHV infection. In a further embodiment, a method is provided for detecting the presence of JMHV or a related virus in a biological specimen, by amplifying by polymerase chain reaction a JMHV nucleic acid sequence, or by using hybridization technology, if such sequence is present in the sample. A method is also provided for detecting the presence of JMHV in a biological specimen. Kits are provided including an antibody that binds to a JMHV polypeptide or an oligonucleotide that hybridizes to a JMHV nucleic acid sequence.



WO 01/88203 A1

- 1 -

**CLONING OF RHADINOVIRUS GENOME AND METHODS FOR ITS USE****PRIORITY CLAIM**

5 This application is a continuation of U.S. Provisional Patent Application No. 60/205,652, filed May 18, 2000. This application is also related to PCT application US99/26260, which claims priority from U.S. Provisional Patent Application No. 60/109,409 and U.S. Provisional Patent Application No. 60/107,507. All of these applications are incorporated herein incorporated by reference.

**FIELD OF THE INVENTION**

10 This application relates to a Japanese macaque herpesvirus (JMHV), specifically to the nucleic acid sequence of open reading frames in the virus and to amino acid sequences encoded by these sequences. Compositions and methods are provided for the production of animal models useful  
15 in assessing the efficacy of drugs for the treatment or prevention of conditions associated with infection by the virus, such as multiple sclerosis. In addition, methods are provided for the isolation of related viruses.

**BACKGROUND**

20 Converging lines of evidence indicate that Kaposi's sarcoma-associated herpesvirus (KSHV) is the etiological agent responsible for Kaposi's sarcoma (KS) in individuals with and without HIV infection (Chang et al., 1994, *Science* 266:1865-9; Schalling et al., 1995, *Nature Med.* 7:707-8; Moore & Chang, 1995, *N. Engl. J. Med.* 332:1181-5; Whitby et al., 1995, *Lancet* 346:799-802; Ambroziak et al., 1995, *Science* 268:582-3.; Dupin et al., 1995, *Lancet* 345:761-2.; Chuck et al.,  
25 1996, *J. Infect. Dis.* 173:248-51; O'Neill et al., 1996, *J. Clin. Pathol.* 49:306-8; Gao et al., 1996, *Nature Med.* 2:925-8; Kedes et al., 1996, *Nature Med.* 2:918-24; Gao et al., 1996, *N. Engl. J. Med.* 335:233-41). In addition to KS, KSHV is also responsible for other acquired immunodeficiency syndrome (AIDS)-related and non-AIDS-related malignancies, such as primary effusion lymphomas (Cesarman et al., 1995, *N. Engl. J. Med.* 332:1186-91; Nador et al., 1996, *Blood* 88:645-56; Otsuki et al., 1996, *Leukemia* 10:1358-62), and multicentric Castleman's disease (MCD), a B cell proliferation disorder associated with overexpression of IL-6 activity (Soulier et al., 1995, *Blood* 86:1276-80; Yoshizaki et al., 1989, *Blood* 74:1360-7).

30 More recently, KSHV has been proposed to be involved in multiple myeloma, a B cell abnormality of monoclonal origin (Rettig et al., 1997, *Science* 276:1851-4; Said et al., 1997, *Blood* 90:4278-82; Parravicini et al., 1997, *Science* 278:1969-70; Masood et al., 1997, *Science* 278:1970-1; Whitby et al., 1997, *Science* 278:1971-2; Cottoni et al., 1997, *Science* 278:1972; Brousset et al., 1997, *Science* 278:290-4). Understanding how KSHV is involved in these malignancies is important for the generation of therapies against the spectrum of KSHV-associated diseases.

- 2 -

Testing the efficacy of therapeutics and vaccines against any disease, such as KHSV, is greatly facilitated by the availability of an animal model, such as a non-human primate model, because non-human primates are physiologically very similar to humans. Although such models have been developed for the study of HIV infection (for example, U.S. Patent Nos. 5,212,084 and 5,543,131) none has yet been developed for KSHV infection.

Infection of animals with some herpesviruses, namely *Herpesvirus saimiri* and murine herpesvirus type 68, can cause a lymphoproliferative disorder (LPD). However, these animals are not adequate models of KSHV pathogenesis because they lack certain KSHV genes that may contribute to viral pathogenesis or influence HIV infection, such as Interleukin 6 (IL-6) and macrophage inflammatory protein 1 (MIP-1) (Albrecht et al., 1992, *J. Virol.* 66:5047-58; Virgin et al., 1997, *J. Virol.* 71:5894-904). Thus, so far the establishment of a non-human primate model for KSHV infection has remained elusive.

The present invention addresses this problem, and others, in the development of animal models for a variety of pathological conditions and diseases.

#### SUMMARY OF THE DISCLOSURE

Rhesus macaques naturally harbor a virus related to KSHV, referred to as RRV, for rhesus rhadinovirus. The present disclosure also includes information about pathological conditions associated with RRV infection.

Japanese macaques can harbor a virus related to RRV, called Japanese Macaque Virus (JMHV).

An isolated virus is provided (Japanese Macaque Herpesvirus, JMHV) as deposited with ATCC as deposit accession number PTA-1884, deposited May 18, 2000, as are viral particles including this virus and host cells infected with this virus.

A purified polypeptide is also provided that includes an amino acid sequence that has at least 95% sequence identity to an amino acid sequence as set forth as SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, and SEQ ID NO:27, as are nucleic acid molecules encoding these polypeptides.

In another embodiment, a method is provided for testing the efficacy of a drug in the treatment of a condition associated with infection with JMHV. The method includes administering the drug to a non-human primate infected with an JMHV; and observing the non-human primate to determine if the drug prevents or reduces the presentation of one or more symptoms associated with JMHV infection.

In another embodiment, a method is provided for testing the efficacy of a candidate vaccine against JMHV infection, or conditions associated with JMHV infection. The method includes the steps of: (a) administering the vaccine to a non-human primate susceptible to infection with the JMHV; (b) inoculating the subject with the JMHV; and (c) observing the non-human primate to

- 3 -

determine if the vaccine prevents or reduces an incidence of JMHV infection or a symptom associated with JMHV infection.

In a further embodiment, a method is provided for detecting the presence of JMHV or a related virus in a biological specimen, by amplifying by polymerase chain reaction a JMHV nucleic acid sequence, or by using hybridization technology, if such sequence is present in the sample.

In yet another embodiment, a method is provided for obtaining JMHV-related nucleic acid sequence using amplification or hybridization.

A method is also provided for detecting the presence of JMHV in a biological specimen, including contacting the biological specimen with an antibody that binds to a JMHV polypeptide, and detecting binding of the antibody to the biological specimen or a component thereof. Binding of the antibody to the biological specimen indicates the presence of JMHV.

Kits are provided that include an antibody that binds to a JMHV polypeptide or an oligonucleotide that hybridizes to a JMHV nucleic acid sequence.

The foregoing and other objects, features, and advantages of the invention will become more apparent from the following detailed description of several examples which proceeds with reference to the accompanying figures.

#### BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows a phylogenetic comparison of the gammaherpesviruses Epstein-Barr virus (EBV), Alcelaphine herpesvirus (AHV), Murine herpesvirus (MHV), Herpesvirus saimiri (HVS), Kaposi's sarcoma-associated herpesvirus (KSHV), and Rhesus rhadinovirus 17577 (RRV). It shows that among the known sequenced viruses, RRV is the closest relative to KSHV, using an accepted maximum parsimony method of evaluating evolutionary relationships.

FIG. 2 is a table showing the *Bam*HI, *Eco*RI and *Hind*III restriction fragments of the RRV genome.

FIG. 3 is a schematic map of the 75 ORFs of RRV. Arrow direction represents direction of transcription.

FIG. 4 is a table showing the size, location and description (similarity to other proteins) of the proteins encoded by the ORFs of RRV.

FIG. 5 is a table showing a comparison of corresponding repeats in RRV and KSHV.

FIG. 6 is a table showing the comparison of interferon regulatory elements encoded by RRV and KSHV.

FIG. 7 is a table comparing the ORFs of RRV, KSHV and HVS. The table shows the start and stop points, the strand (+ or -) from which the ORF is transcribed, the size of the ORFs and the percentage similarity of KSHV and HVS when compared with RRV.

FIGS. 8A-8D are graphs showing CD20+ lymphocytes, antibody response and RhKSHV isolation/detection in macaques infected with SIVmac239 and RRV (A)18483 and (B) 18570 and macaques infected with SIVmac239 only (C) 18503 and (D) 18540. A "+" indicates positive for virus culture or viral DNA, as defined by PCR and Southern blot analysis; "-", negative for virus

- 4 -

culture or viral DNA.

FIG. 9 shows the result of the PCR analysis of PBLs and LNCs from each of the macaques (18483, 18503, 18540 and 18570) for RRV DNA and  $\beta$ -globin in (A) graphical form and (B) digital form.

5 FIG. 10 shows the DNA sequence of the RRV ORF that encodes the MIP protein (nucleotides 22245-22592 of SEQ ID NO:1).

FIG. 11 shows the DNA sequence of the RRV ORF that encodes the IL-6 protein (nucleotides 19921-20544 of SEQ ID NO 1).

10

### SEQUENCE LISTING

The nucleic and amino acid sequences listed in the accompanying sequence listing are shown using standard letter abbreviations for nucleotide bases, and the code for amino acids. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the displayed strand.

15

SEQ ID NO 1 shows the nucleotide sequence of the RRV genome. RRV R1 corresponds to nucleotides 1353-2624 of SEQ ID NO 1. RRV ORF2 corresponds to the complement of nucleotides 2692-3258 of SEQ ID NO 1, which encodes dihydrofolate reductase, and which has some similarity to Kaposi's sarcoma-associated herpesvirus (KSHV) ORF 2. RRV ORF 4 corresponds to nucleotides 20 3676-5613 of SEQ ID NO 1, which encodes complement binding protein, and which has some similarity to KSHV ORF 4. RRV ORF 6, corresponds to nucleotides 6045-9443 of SEQ ID NO 1, which encodes ssDNA binding protein, and which has some similarity to KSHV ORF 6. RRV ORF 7 corresponds to nucleotides 9468-11528 of SEQ ID NO 1, which encodes a transport protein, and which has some similarity to KSHV ORF 7. RRV ORF 8, corresponds to nucleotides 11515-14004 25 of SEQ ID NO 1, which encodes glycoprotein B, and which has some similarity to KSHV ORF 8. RRV ORF 9, DNA polymerase protein, corresponds to nucleotides 14122-17166 of SEQ ID NO 1, which has some similarity to KSHV ORF 9. RRV ORF 10 corresponds to nucleotides 17261-18511 of SEQ ID NO 1, which has some similarity to KSHV ORF 10. RRV ORF 11 corresponds to nucleotides 18520-19749 of SEQ ID NO 1, which has some similarity to KSHV ORF 11. RRV R2 30 corresponds to the complement of nucleotides 19921-20544 of SEQ ID NO 1, which has some similarity to the Kaposi's sarcoma-associated IL-6 gene. RRV ORF 70, thymidylate synthase, corresponds to the complement of nucleotides 20777-21778 of SEQ ID NO 1, and which has some similarity to KSHV ORF 70. RRV R3 corresponds to the complement of nucleotides 22245-22592 of SEQ ID NO 1, which has some similarity to the KSHV K4 viral MIP gene. RRV ORF 16, a Bcl-2 35 homolog, corresponds to nucleotides 26846-27409 of SEQ ID NO 1, which has some similarity to KSHV ORF 16. RRV ORF 17 corresponds to the complement of nucleotides 27515-29125 of SEQ ID NO 1, which has some similarity to KSHV ORF 17. RRV ORF 18 corresponds to nucleotides 28998-29897 of SEQ ID NO 1, which has some similarity to KSHV ORF 18.

RRV ORF 19 corresponds to the complement of nucleotides 29905-31548 of SEQ ID NO 1,

- 5 -

which encodes a tegument protein, and which has some similarity to KSHV ORF 19. RRV ORF 20 corresponds to the complement of nucleotides 31043-32095 of SEQ ID NO 1, and has some similarity to KSHV ORF 20. RRV ORF 21 corresponds to nucleotides 32094-33767 of SEQ ID NO 1, which encodes a thymidine kinase protein, and which has some similarity to KSHV ORF 21. RRV ORF 22 corresponds to nucleotides 33754-35868 of SEQ ID NO 1, and encodes a glycoprotein H protein, and which has some similarity to KSHV ORF 22. RRV ORF 23 corresponds to the complement of nucleotides 35865-37073 of SEQ ID NO 1, which has some similarity to KSHV ORF 23. RRV ORF 24 corresponds to the complement of nucleotides 37123-39321 of SEQ ID NO 1, and which has some similarity to KSHV ORF 24. RRV ORF 25, corresponds to nucleotides 39323-43459 of SEQ ID NO 1, which encodes a major capsid protein, and which has some similarity to KSHV ORF 25. RRV ORF 26 corresponds to nucleotides 43491-44408 of SEQ ID NO 1, which encodes a capsid protein, and which has some similarity to KSHV ORF 26. RRV ORF 27 corresponds to nucleotides 44433-45242 of SEQ ID NO 1, and which has some similarity to KSHV ORF 27. RRV ORF 28 corresponds to nucleotides 45408-45683 of SEQ ID NO 1, and which has some similarity to KSHV ORF 28. RRV ORF 29b corresponds to the complement of nucleotides 45733-46779 of SEQ ID NO 1, and which has some similarity to KSHV ORF 29b. RRV ORF 30 corresponds to nucleotides 46905-47135 of SEQ ID NO 1, and which has some similarity to KSHV ORF 30. RRV ORF 31 corresponds to nucleotides 47093-47746 of SEQ ID NO 1, and which has some similarity to KSHV ORF 31. RRV ORF 32 corresponds to nucleotides 47683-49077 of SEQ ID NO 1, and has some similarity to KSHV ORF 32. RRV ORF 33 corresponds to nucleotides 49049-50059 of SEQ ID NO 1, and which has some similarity to KSHV ORF 33. RRV ORF 29a corresponds to the complement of nucleotides 49977-50960 of SEQ ID NO 1, and has some similarity to KSHV ORF 29a. RRV ORF 34 corresponds to nucleotides 50959-51942 of SEQ ID NO 1, and has some similarity to KSHV ORF 34. RRV ORF 35 corresponds to nucleotides 51923-52372 of SEQ ID NO 1, has some similarity to KSHV ORF 35. RRV ORF 36, corresponds to nucleotides 52278-53585 of SEQ ID NO 1, which encodes a kinase, and which has some similarity to KSHV ORF 36. RRV ORF 37 corresponds to nucleotides 53566-55008 of SEQ ID NO 1, which encodes an alkaline exonuclease, and which has some similarity to KSHV ORF 37. RRV ORF 38 corresponds to nucleotides 54963-55172 of SEQ ID NO 1, and has some similarity to KSHV ORF 38. RRV ORF 39 corresponds to the complement of nucleotides 55255-56391 of SEQ ID NO 1, which encodes glycoprotein M, and which has some similarity to KSHV ORF 39. RRV ORF 40 corresponds to nucleotides 56526-57932 of SEQ ID NO 1, which encodes helicase/primase, and which has some similarity to KSHV ORF 40.

RRV ORF 41, corresponds to nucleotides 57917-58528 of SEQ ID NO 1, which encodes helicase/primase, and which has some similarity to KSHV ORF 41. RRV ORF 42 corresponds to the complement of nucleotides 58525-59343 of SEQ ID NO 1, which has some similarity to KSHV ORF 42. RRV ORF 43 corresponds to the complement of nucleotides 59297-61027 of SEQ ID NO 1, which encodes a capsid protein, and which has some similarity to KSHV ORF 43. RRV ORF 44 corresponds to nucleotides 60966-63338 of SEQ ID NO 1, which encodes helicase/primase, and

- 6 -

which has some similarity to KSHV ORF 44. RRV ORF 4, corresponds to the complement of nucleotides 63379-64437 of SEQ ID NO 1, and which has some similarity to KSHV ORF 45. RRV ORF 46 corresponds to the complement of nucleotides 64479-65246 of SEQ ID NO 1, which encodes uracil DNA glucosidase, and which has some similarity to KSHV ORF 46. RRV ORF 47

5 corresponds to the complement of nucleotides 65222-65731 of SEQ ID NO 1, which encodes glycoprotein L, which has some similarity to KSHV ORF 47. RRV ORF 48 corresponds to the complement of nucleotides 65999-67168 of SEQ ID NO 1, and which has some similarity to KSHV ORF 48. RRV ORF 49 corresponds to the complement of nucleotides 67398-68303 of SEQ ID NO 1, and which has some similarity to KSHV ORF 49. RRV ORF 50 corresponds to nucleotides 68494-

10 70038 of SEQ ID NO 1, which encodes a transactivator, and which has some similarity to KSHV ORF 50. RRV R4 corresponds to nucleotides 70355-70888 of SEQ ID NO 1. RRV R5 corresponds to nucleotides 71468-72160 of SEQ ID NO 1. RRV ORF 52 corresponds to the complement of nucleotides 72401-72820 of SEQ ID NO 1, and has some similarity to KSHV ORF 52. RRV ORF 5, corresponds to the complement of nucleotides 72884-73198 of SEQ ID NO 1, and has some

15 similarity to KSHV ORF 53. RRV ORF 54 corresponds to nucleotides 73274-74146 of SEQ ID NO 1, which encodes a dUTPase, and which has some similarity to KSHV ORF 54. RRV ORF 55 corresponds to the complement of nucleotides 74207-74839 of SEQ ID NO 1, and has some similarity to KSHV ORF 55. RRV ORF 56 corresponds to nucleotides 74851-77337 of SEQ ID NO 1, which encodes a DNA replication protein, and has some similarity to KSHV ORF 56. RRV ORF

20 5, corresponds to nucleotides 77578-78906 of SEQ ID NO 1, which encodes an immediate-early gene product, and which has some similarity to KSHV ORF 57. RRV R6 corresponds to the complement of nucleotides 79266-80513 of SEQ ID NO 1, which has some similarity to KSHV vIRF K9 gene. RRV R7 corresponds to the complement of nucleotides 80686-81933 of SEQ ID NO 1, which has some similarity to KSHV vIRF K9 gene. RRV R8 corresponds to the complement of nucleotides

25 82262-83317 of SEQ ID NO 1, which has some similarity to KSHV vIRF K9 gene. RRV R9 corresponds to the complement of nucleotides 83491-84252 of SEQ ID NO 1, which has some similarity to KSHV vIRF K9 gene. RRV R10, corresponding to the complement of nucleotides 85052-86209 of SEQ ID NO 1, which has some similarity to KSHV vIRF K9 gene. RRV R11 corresponds to the complement of nucleotides 86355-87527 of SEQ ID NO 1, which has some

30 similarity to KSHV vIRF K9 gene. RRV R12 corresponds to the complement of nucleotides 87894-88961 of SEQ ID NO 1, which has some similarity to KSHV vIRF K9 gene. RRV R13 corresponds to the complement of nucleotides 89122-90216 of SEQ ID NO 1, which has some similarity to KSHV vIRF K9 gene. RRV ORF 58 corresponds to the complement of nucleotides 90462-91544 of SEQ ID NO 1, which has some similarity to KSHV ORF 58. RRV ORF 59 corresponds to the complement of

35 nucleotides 91555-92739 of SEQ ID NO 1, which encodes a DNA replication protein, and which has some similarity to KSHV ORF 59. RRV ORF 60 corresponds to the complement of nucleotides 92868-93812 of SEQ ID NO 1, which encodes a small ribonucleotide reductase protein, and which has some similarity to KSHV ORF 60. RRV ORF 61 corresponds to the complement of nucleotides 93794-96160 of SEQ ID NO 1, which encodes a large ribonucleotide reductase protein, and which

- 7 -

has some similarity to KSHV ORF 61. RRV ORF 62 corresponds to the complement of nucleotides 96163-97158 of SEQ ID NO 1, which encodes a assembly/DNA maturation protein, and which has some similarity to KSHV ORF 62. RRV ORF 63 corresponds to nucleotides 97157-99976 of SEQ ID NO 1, which encodes a tegument protein, and which has some similarity to KSHV ORF 63. RRV

5 ORF 64 corresponds to nucleotides 99980-107626 of SEQ ID NO 1, which encodes a tegument protein, and which has some similarity to KSHV ORF 64. RRV ORF 6, corresponds to the complement of nucleotides 107637-108146 of SEQ ID NO 1, which encodes a capsid protein, and which has some similarity to KSHV ORF 65. RRV ORF 66 corresponds to the complement of nucleotides 108152-109498 of SEQ ID NO 1, which has some similarity to KSHV ORF 66. RRV

10 ORF 67 corresponds to the complement of nucleotides 109524-110198 of SEQ ID NO 1, which encodes a tegument protein, and which has some similarity to KSHV ORF 67. RRV ORF 68 corresponds to nucleotides 110609-111982 of SEQ ID NO 1, which encodes a glycoprotein, and which has some similarity to KSHV ORF 68. RRV ORF 69 corresponds to nucleotides 112004-112897 of SEQ ID NO 1, which has some similarity to KSHV ORF 69. RRV ORF 71, corresponds

15 to the complement of nucleotides 119211-119735 of SEQ ID NO 1, which encodes a FLIP protein, and which has some similarity to KSHV ORF 71. RRV ORF 72, corresponds to the complement of nucleotides 119794-120558 of SEQ ID NO 1, which encodes a cyclin D homolog, and which has some similarity to KSHV ORF 72. RRV ORF 73 corresponds to the complement of nucleotides 120866-122212 of SEQ ID NO 1, which encodes a latent nuclear antigen, and which has some

20 similarity to KSHV ORF 73. RRV R15 corresponds to nucleotides 122866-123627 of SEQ ID NO 1, which has some similarity to KSHV K14 and ox-2. RRV ORF 74 corresponds to nucleotides 123924-124952 of SEQ ID NO 1, which encodes a G protein coupled receptor, and which has some similarity to KSHV ORF 74. RRV ORF 75 corresponds to the complement of nucleotides 125057-128953 of SEQ ID NO 1, which encodes a tegument protein, FGARAT, and which has some

25 similarity to KSHV ORF 75.

SEQ ID NO 2 shows the nucleic acid sequence of the JMHV ORF21.

SEQ ID NO 3 shows the deduced amino acid sequence of the JMHV ORF21.

SEQ ID NO 4 shows the nucleic acid sequence of another region of the JMHV ORF21.

30 SEQ ID NO 5 shows the deduced amino acid sequence of a portion JMHVORF21, as encoded by SEQ ID NO:4.

SEQ ID NO 6 shows the nucleic acid sequence of a portion of JMHV cosmid 3 fragment 5 T7, which has similarity to the nucleic acid sequence found in and to the right of RRV repeat unit rDL-B1.

SEQ ID NO 7 shows the nucleic acid sequence of the JMHV ORF 17, a capsid protein.

35 SEQ ID NO 8 shows the amino acid sequence of the JMHV ORF 17, deduced from SEQ ID NO:7.

SEQ ID NO 9 shows the nucleic acid sequence of JMHV ORF 21 thymidine kinase, which includes frameshift mutations.

SEQ ID NO 10 shows the amino acid sequence of a portion of JMHV ORF 21, which is the

- 8 -

deduced amino acid sequence of the region between the frameshifts in SEQ ID NO:9.

SEQ ID NO 11 shows the nucleic acid sequence of JMHV ORF 24.

SEQ ID NO 12 shows the deduced amino acid sequence of JMHV ORF 24.

SEQ ID NO 13 shows the nucleic acid sequence of JMHV ORF 7 transport protein.

5 SEQ ID NO 14 shows the deduced amino acid sequence of the JMHV ORF 7 transport protein.

SEQ ID NO 15 shows the nucleic acid sequence of cosmid 3, fragment 1, sp6, which is similar to the sequence to the left of RRV repeat rDL-B1.

SEQ ID NO 16 shows the nucleic acid sequence of the JMHV ORF10.

10 SEQ ID NO 17 shows the deduced amino acid sequence of the JMHV ORF 10.

SEQ ID NO 18 shows the nucleic acid sequence of the ORF 9 DNA polymerase.

SEQ ID NO 19 shows the deduced amino acid sequence of the ORF 9 DNA polymerase.

SEQ ID NO 20 shows the nucleic acid sequence of JMHV ORF 10.

SEQ ID NO 21 shows the deduced amino acid sequence of the JMHV ORF 10.

15 SEQ ID NO 22 shows the nucleic acid sequence of the JMHV ORF 8 glycoprotein B.

SEQ ID NO 23 shows the deduced amino acid sequence of the JMHV ORF 8 glycoprotein

B.

SEQ ID NO 24 shows the nucleic acid sequence of the JMHV ORF 9 DNA polymerase.

20 SEQ ID NO 25 shows the deduced amino acid sequence of the JMHV ORF9 DNA polymerase.

SEQ ID NO 26 shows the nucleic acid sequence of the JMHV ORF8 glycoprotein B.

SEQ ID NO 27 shows the deduced amino acid sequence of the JMHV ORF 8 glycoprotein

B.

## 25 ATCC DEPOSITS

A Budapest Treaty deposit of RRV 17577 was made with the American Type Culture Collection (ATCC), Manassas, Virginia, on March 12, 1998, and has been accorded ATCC Accession No. VR-2601.

30 A Budapest Treaty deposit of JMHV 17792 was made with the American Type Culture Collection (ATCC), Manassas, Virginia, on May 18, 2000, and has been accorded ATCC Accession No. PTA-1884.

## DETAILED DESCRIPTION OF SEVERAL EMBODIMENTS

### 35 Abbreviations and Definitions

**Animal:** Living multicellular vertebrate organisms, a category which includes, for example, humans, non-human primates, mammals, and birds.

**Cell:** A plant, animal, insect, bacterial, or fungal cell.

- 9 -

**Homologs:** two nucleotide or amino acid sequences that share a common ancestral sequence and diverged when a species carrying that ancestral sequence split into two species. Homologs frequently show a substantial degree of sequence identity.

**IL-6:** Interleukin 6. IL-6 is a cytokine known to have pleiotropic immunological effects including anti-inflammatory and immunosuppressive effects (*Human Cytokines*, 1991, pg. 142-167, Blackwell Scientific Publications, Aggarwal and Gutterman, eds). Because IL-6 is a pleiotropic cytokine, IL-6 activity may be measured using a number of bioassays, including stimulation of immunoglobulin production in SKW6-CL4 cells as described by Hirano et al. (*Nature* 324:73-6, 1986) and stimulation of hybridoma cell growth as described by Matsuda et al., 1988 *Eur. J. Immunol.* 18:951-956, both of which are incorporated by reference. As used herein, the term "IL-6 biological activity" refers to the ability of a protein to show activity in at least one of these assay systems

**Immuno-compromised:** Lacking a normal immune response. Immuno-compromised refers to a condition in which some or all of an animal's immune system is inoperative, leaving the animal with an increased susceptibility to infection or disease. An animal may be rendered immuno-compromised by a biological agent such as, in the case of non-human primates, Simian Immunodeficiency Virus (SIV). Many strains of SIV have been isolated and characterized; any SIV strain that produces an immuno-compromised state can be used in the present invention including, but not limited to, for example, SIVmac239 (Kestler et al., 1990, *Science* 248: 1109-12), SIVmac251 (Daniels et al., 1985, *Science* 228: 1201-4), SIVdeltaB670 (Murphy-Corb et al., 1986, *Nature* 321:435) and SIVmne (Benveniste et al., 1988, *J. Virol.* 62:2091-101). In addition, hybrid SIV/HIV chimeras as known in the field can be employed, as can HIV-2. Simian type D retroviruses (SRVs) which cause an AIDS-like disease in rhesus monkeys, can alternatively be used to immuno-compromise the animals in place of SIV. These viral agents are administered to the animal using conventional means, such as intravenous or intramuscular injection, or oral, intrarectal or intravaginal inoculation (also see Example 24). Either intact viral particles or viral DNA may be administered. As known in the field, plasmid constructs containing the entire SIV genome are infectious when inoculated into animals and so may be employed in place of purified viral DNA.

Alternatively, an animal may be rendered immuno-compromised by administration of agents that target the immune system, including but not limited to anti-CD3 antibody (CD3 being the T-cell receptor) either alone or conjugated with a toxic moiety, or immunosuppressive compounds including prednisone, azathioprine, cyclosporine A, and cyclophosphamide. Where an immunosuppressive compound such as cyclosporine is employed, an allogenic stimulus (such as a blood transfusion) may be administered with the subsequent administration of RRV to activate infection.

Alternatively, other methods of rendering an animal immuno-compromised may be used, including radiation treatment and surgical intervention.

**Isolated:** An "isolated" biological component (such as a nucleic acid, peptide or protein) has been substantially separated, produced apart from, or purified away from other biological components in the cell of the organism in which the component naturally occurs, i.e., other

- 10 -

chromosomal and extrachromosomal DNA and RNA, and proteins. Nucleic acids, peptides and proteins which have been "isolated" thus include nucleic acids and proteins purified by standard purification methods. The term also embraces nucleic acids, peptides and proteins prepared by recombinant expression in a host cell as well as chemically synthesized nucleic acids.

5        **JMHV:** A virus having the virological, immunological or pathological characteristics of Japanese Macaque Herpesvirus (e.g. JMHV 17792). JMHV causes the symptoms of MS in Japanese macaque monkeys which are infected with the virus. In particular examples, the JMHV has at least 85% (for example at least 90%, 95% or 98%) sequence identity to the JMHV deposited with the virus deposited as ATTC Accession Number PTA-1884. In other examples, the JMHV has at least 90%,  
10       91%, 92%, 93%, 94%, 95%, or 98% homology with an RRV (e.g. ATCC VR-2901). Without being bound by theory, the JMHV may be derived from an RRV (see the experimental examples).

**JMHV 17792:** Japanese macaque herpesvirus isolate 17792. A Budapest Treaty deposit of JMHV 17792 was made with the American Type Culture Collection, Manassas, Virginia on May 18, 2001. This virus may be grown on primary Japanese macaque fibroblasts, using standard virological  
15       techniques. Alternatively, it may be grown on commercially available macaque cell lines. Infection of a non-human primate with JMHV 17792 can be accomplished using any standard method, including intravenous injection. In one embodiment, infection is achieved using  $10^6$  plaque forming units of JMHV 17792.

**KSHV:** Kaposi's sarcoma-associated herpesvirus. KSHV is a herpesvirus associated with  
20       (and thought to be the etiological agent of) Kaposi's sarcoma in humans.

**Lymphoproliferative Disorder:** a group of disorders characterized by proliferation of lymphoid tissue, such as lymphocytic leukemia and malignant lymphoma, and characterized by such signs as lymphocytosis, lymphadenopathy, and splenomegaly.

**MIP:** macrophage inflammatory protein. The acronym MIP is used to describe a family of  
25       cytokines that includes MIP1 (Davatelis et al., 1989, *Science* 243: 1066-8) and MIP2 (U.S. Patent No. 5,145,676). MIPs mediate pleiotropic immunological effects including activation of neutrophils to undergo an oxidative burst. MIPs are also intrinsically pyrogenic. MIP biological activity can be detected and quantified using bioassays as described in Kedal et al. (*Science* 277:1656-9, 1997) and Boshoff et al. (*Science* 278:290-4, 1997) that measure MIP concentrations using HIV inhibition and  
30       calcium mobilization, respectively. As used herein, the term "MIP biological activity" refers to the ability of a protein to show activity in at least one of these assay systems.

**Multiple Sclerosis:** A chronic, progressive disease of the central nervous system. Currently, the exact cause of the disease is unknown and there is no cure. Multiple sclerosis refers to  
multiple areas of patchy scarring, or plaques, that result from demyelination (destruction of myelin, a  
35       fatty insulation covering the nerve fibers). When the myelin sheath is destroyed during the MS disease process, signals transmitted throughout the CNS are slowed or disrupted. In many cases, the body may compensate for the loss of myelin by increasing the density of the sodium channels so that action potentials can continue to be carried, in spite of loss of myelin. The nerves also retain the capacity to remyelinate. Unfortunately, the disease process often outpaces these corrective actions.

- 11 -

The symptoms, severity, and course of MS vary widely depending partly on the sites of the plaques and the extent of the demyelination. Experts generally group multiple sclerosis into four types: relapsing-remitting, primary-progressive, secondary-progressive, and progressive-relapsing MS. Relapsing-remitting multiple sclerosis generally occurs in younger people and is the most common form of MS. Symptoms flare up for several days and then go into remission over the next four to eight weeks. The latter three forms (primary-progressive, secondary-progressive, and progressive-relapsing MS) generally fall under the category of chronic-progressive MS. In chronic-progressive MS the symptoms of the disease continue to worsen slowly without remission. About 20% of multiple sclerosis patients (usually those patients whose first symptoms occur after age 45) have the chronic-progressive form of MS without first developing relapsing-remitting MS. Chronic-progressive MS may lead to serious speech problems and paralysis, and generally the symptoms continue to worsen over time.

Multiple sclerosis is defined as an autoimmune disease; that is, the body's immune system is damaged by genetic or environmental factors or both, causing it to attack its own tissues. In the case of MS, these tissues are the myelin covering the nerve fibers in the brain.

Although the exact agent that triggers MS is unknown, it has been proposed that viral antigens could trigger the autoimmune response in MS. One factor that seems to support this theory is the geographical distribution of the disease; the number of MS cases increases the further one gets from the equator in either direction. Epidemics of multiple sclerosis also seem to occur. For example, four separate MS epidemics happened between 1943 and 1989 in the Faroe Islands, located between Iceland and Scandinavia. During World War II, this region was occupied by British troops; each year for 20 years after the war, the incidence of MS increased, leading some researchers to think that the troops might have brought with them some disease-causing agent.

Although several virus have been associated with MS, no one causative agent has been identified. It has been proposed that HHV-6, a form of herpesvirus, may be the causative agent. However, other viruses have been implicated in the disease process including herpesviruses 1 and 2, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus, measles virus, adenovirus, polyomavirus, and retroviruses, including HIV, HTLV-I, and HTLV-II. It has also been proposed that bacteria may be the causative agent. In one recent study, 17 patients who were admitted to a hospital and diagnosed with MS showed signs of infection with the microorganism *Chlamydia pneumoniae*, an atypical bacterium. However, the association of these any of these agents with MS is difficult, as infection in the general population is common.

Genetic factors are also believed to have a role in the development of MS. Children of MS patients have an increased risk 30 to 50 times that of the normal population. In addition, the odds of an MS sibling having the disease are about 20 times higher than in the normal population. A significant association between siblings with MS and the specific form of the disease, either relapsing-remitting or chronic progressive has been found. It is possible that a set of genes that somehow interact are responsible for the inherited risks. In addition, genetic variations that occur in

- 12 -

different ethnic populations are also believed to result in a variable disease course amongst the different ethnic groups.

A symptom of MS is any physical characteristic associated with the disease process. For example, the first symptom of MS is often optic neuritis, the inflammation of the optic nerve. Vision, usually in one eye, becomes unclear or doubled, and there may be a shimmering effect. Pain or nystagmus, involuntary jerking or movement of the eye, may also occur. In 20% of people with this condition, MS develops within two years; in 45% to 80% it develops within 15 years. Other early symptoms of multiple sclerosis include fatigue, heaviness or clumsiness in the arms and legs, tingling sensations, and poor coordination. Another indication of MS is a reaction known as Lhermitte's sign, whereby bending the neck produces an electrical sensation that runs down the back and into the legs.

As the disease develops over months or even years, other symptoms may include spasticity, imbalance, tremors, incontinence, constipation, sexual dysfunction, hearing loss, vertigo, facial pain, and difficulties in swallowing. Problems in speech may occur because of difficulty in controlling the quality of the voice and articulating words. About half of patients display changes in mental function, including problems in concentration and problem solving. In about 10% of cases, there is severe mental dysfunction which resembles dementia. One of the primary symptoms of MS is spasticity, which is characterized by weakness, loss of dexterity, and the inability to control specific movements.

In general, MS itself is not fatal, although people who have this disease generally have a shorter life span than average. However, the negative emotional impact of this disease and its symptoms is considerable. The severity of the disease varies widely from patient to patient; MS sometimes remains asymptomatic or becomes only mildly symptomatic even long after initial plaque formation. About 20% to 35% of patients have a very mild form of the disease, with little if any disability, no need for medication, and a normal life expectancy. At the other extreme, between 3% and 12% of patients have a very serious, rapidly progressive form of MS. Most patients fall somewhere in the middle. Life-threatening complications may occur as a result of infections in the lungs or kidneys. As the muscles that control breathing weaken, the ability to cough is impaired and the patient is at higher risk for pneumonia and other complications in the lungs. Complications in the urinary tract also place the patient at risk for kidney infections. In very severe cases of MS, paralysis may occur. The severity of disability incurred over a lifetime is unpredictable.

About 1.1 million people worldwide have multiple sclerosis, and the incidence appears to be increasing. Between 250,000 and 350,000 Americans have the disease. Onset of symptoms typically occurs between the ages of 15 and 40 years, with a peak incidence in people in their 20s and 30s. Women are affected twice as often as men. Multiple sclerosis occurs worldwide but is most common in Caucasian people of northern European origin, especially those of Scottish descent. It is extremely rare among Asians and Africans. In general, MS is more prevalent in temperate regions of the world than in the tropics. It is unclear whether this pattern is attributable to environmental factors or to genetics. A family history of the disease also puts people at risk, although the risk for someone inheriting all the genetic factors contributing to MS is only about 2% to 4%.

- 13 -

**Myelin:** A coating of nerve cells (neurons) made from layers of cell membranes that are produced in the brain and spinal cord by specialized cells called oligodendrocytes. Myelin coats lie in segments along the axons, the long filaments that carry electric impulses away from a nerve cell. The segments are separated from each other by tiny clusters called nodes of Ranvier, which house channels for sodium ions. These sodium ions are important for boosting the electrical charge required to pass signals from one nerve to another.

**Non-human primate:** Simian primates including chimpanzees, orangutans, baboons, and macaques. Any non-human primate may be used to produce a KSHV-disease animal model or a JMHV-disease animal model by the methods disclosed herein. Thus, in addition to the rhesus macaque and Japanese Macaque models described in detail below, pigtail and cynomologus macaques and baboons may also be used to produce KSHV-disease or JMHV-disease animal models by the methods disclosed herein.

**Oligonucleotide:** A linear polynucleotide sequence of up to about 200 nucleotide bases in length, for example a polynucleotide (such as DNA or RNA) which is at least 6 nucleotides, for example at least 15, 25, 50, 100 or even 200 nucleotides long.

**Operably linked:** A first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences are contiguous and, where necessary to join two protein coding regions, in the same reading frame.

**ORF:** open reading frame. Contains a series of nucleotide triplets (codons) coding for amino acids without any termination codons. These sequences are usually translatable into protein.

**PCR:** polymerase chain reaction. Describes a technique in which cycles of denaturation, annealing with primer, and then extension with DNA polymerase are used to amplify the number of copies of a target DNA sequence.

**Pharmaceutically acceptable carriers:** The pharmaceutically acceptable carriers useful in this invention include conventional carriers. Remington's Pharmaceutical Sciences, by E. W. Martin, Mack Publishing Co., Easton, PA, 15th Edition (1975), describes compositions and formulations suitable for pharmaceutical delivery of the viruses, nucleic acids and/or proteins herein disclosed.

In general, the nature of the carrier will depend on the particular mode of administration being employed. For instance, parenteral formulations usually comprise injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol, ethanol, combinations thereof, or the like, as a vehicle. The carrier and composition can be sterile, and the formulation suits the mode of administration. For solid compositions (e.g., powder, pill, tablet, or capsule forms), conventional non-toxic solid carriers can include, for example, pharmaceutical grades of mannitol, lactose, starch, sodium saccharine, cellulose, magnesium carbonate, or magnesium stearate. In addition to biologically-neutral carriers, pharmaceutical compositions to be administered can contain minor amounts of non-toxic auxiliary

- 14 -

substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.

The composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder. The composition can be formulated as a suppository, with  
5 traditional binders and carriers such as triglycerides.

Probes and primers: Nucleic acid probes and primers may readily be prepared based on the amino acid sequences provided by this invention. A probe is an isolated nucleic acid attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, fluorescent molecules, chemiluminescent molecules, and enzymes. In other embodiments, labels include co-  
10 factors, enzyme substrates; and haptens.

Methods for labeling and guidance in the choice of labels appropriate for various purposes are discussed, e.g., in Sambrook et al., in Molecular Cloning: A Laboratory Manual, Cold Spring (1989) and Ausubel et al., in Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley-Intersciences (1987).

15 Primers are short nucleic acids, such as DNA oligonucleotides 10 nucleotides or more in length. Primers may be annealed to a complementary target DNA strand by nucleic acid hybridization to form a hybrid between the primer and the target DNA strand, and then extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR) or other  
20 nucleic-acid amplification methods known in the art.

Methods for preparing and using probes and primers are described, for example, in Sambrook et al. (Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> ed., vol. 1-3, Cold Spring Harbor, New York, 1989); Ausubel et al. (Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, 1987) and Innis et al. (PCR Protocols, A Guide to Methods and  
25 Applications, 1990, Innis et al. (eds.), 21-27, Academic Press, Inc., San Diego, California). PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, © 1991, Whitehead Institute for Biomedical Research, Cambridge, MA).

Probes and primers as used in the present invention typically comprise at least 15 contiguous  
30 nucleotides of the RRV genome sequence (SEQ ID NO 1), or 15 contiguous nucleotides of a JMHV sequence. One of skill in the art will appreciate that the specificity of a particular probe or primer increases with its length. Thus, for example, a primer comprising 20 consecutive nucleotides will anneal to a target with a higher specificity than a corresponding primer of only 15 nucleotides. Thus, in order to obtain greater specificity, probes and primers may be selected that comprise 20, 25, 30, 35,  
35 40, 50 or more consecutive nucleotides. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 30, 40, 50, 60, 70, 80, 90, 100, or 150 consecutive nucleotides of the disclosed nucleic acid sequences.

Alternatively, such probes and primers may comprise at least 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, or 150 consecutive nucleotides that share a defined level of sequence identity with the

- 15 -

disclosed RRV or JMHV sequence, for instance, at least a 60%, 70%, 80%, 90%, 95% or 98% sequence identity. Alternatively, such probes and primers may be nucleotide molecules which hybridize under wash conditions of 70°C and about 0.2 x SSC for 1 hour, or alternatively under less stringent conditions of 65°C, 60°C, or 55°C with from about 0.2 to 2 x SSC (with, for instance, about 0.1% SDS) for 1 hour with a portion of the RRV sequence.

**Purified:** The term purified does not require absolute purity; rather, it is intended as a relative term. Thus, for example, a purified peptide preparation is one in which the peptide or protein is more enriched than the peptide or protein is in its natural environment within a cell. Preferably, a preparation is purified such that the protein or peptide represents at least 50% of the total peptide or protein content of the preparation.

**Recombinant:** A recombinant nucleic acid is one that has a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques.

**RRV 17577:** Rhesus macaque rhadinovirus RRV isolate 17577. A Budapest Treaty deposit of RRV 17577 was made with the American Type Culture Collection, Manassas, Virginia, on March 12, 1998, and has been accorded ATCC Accession No. VR-2601. This virus may be grown on primary rhesus fibroblasts, as described below (see Examples 1 and 14), using standard virological techniques. Alternatively, it may be grown on commercially available rhesus cell lines, including those available from ATCC, such as ATCC CRL-6306 and ATCC CL-160. Infection of a non-human primate with RRV 17577 may be accomplished using any standard method, including intravenous injection (see Examples 13, 23 and 24). Typically, infection is achieved by intravenous injection of around 10<sup>6</sup> plaque forming units (PFUs) of RRV 17577.

**RRV:** A virus having the virological and immunological characteristics of RRV 17577, and which causes Kaposi's sarcoma in immunocompromised Rhesus monkeys which are infected with the virus. In particular examples, the RRV has at least 85% (for example at least 90%, 95% or 98%) sequence identity to SEQ ID NO 1.

**Sequence Identity:** The similarity between two nucleic acid sequences, or two amino acid sequences, is expressed in terms of the similarity between the sequences, otherwise referred to as sequence identity. Sequence identity is frequently measured in terms of percentage identity (or similarity or homology); the higher the percentage, the more similar the two sequences are. Homologs or orthologs of nucleic acid or amino acid sequences will possess a relatively high degree of sequence identity when aligned using standard methods. This homology will be more significant when the orthologous proteins or nucleic acids are derived from species which are more closely related (e.g., human and chimpanzee sequences), compared to species more distantly related (e.g., human and *C. elegans* sequences). Typically, orthologs are at least 50% identical at the nucleotide

- 16 -

level and at least 50% identical at the amino acid level when comparing human orthologous sequences.

Methods of alignment of sequences for comparison are well known. Various programs and alignment algorithms are described in: Smith & Waterman, *Adv. Appl. Math.* 2:482, 1981;

- 5 Needleman & Wunsch, *J. Mol. Biol.* 48:443, 1970; Pearson & Lipman, *Proc. Natl. Acad. Sci. USA* 85:2444, 1988; Higgins & Sharp, *Gene*, 73:237-44, 1988; Higgins & Sharp, *CABIOS* 5:151-3, 1989; Corpet *et al.*, *Nuc. Acids Res.* 16:10881-90, 1988; Huang *et al.* *Computer Appls. Biosci.* 8, 155-65, 1992; and Pearson *et al.*, *Meth. Mol. Bio.* 24:307-31, 1994. Altschul *et al.*, *J. Mol. Biol.* 215:403-10, 1990, presents a detailed consideration of sequence alignment methods and homology calculations.

- 10 The NCBI Basic Local Alignment Search Tool (BLAST) (Altschul *et al.*, *J. Mol. Biol.* 215:403-10, 1990) is available from several sources, including the National Center for Biotechnology Information (NCBI, Bethesda, MD) and on the Internet, for use in connection with the sequence analysis programs blastp, blastn, blastx, tblastn and tblastx. Each of these sources also provides a description of how to determine sequence identity using this program.

- 15 Homologous sequences are typically characterized by possession of at least 60%, 70%, 75%, 80%, 90%, 95% or at least 98% sequence identity counted over the full length alignment with a sequence using the NCBI Blast 2.0, gapped blastp set to default parameters. Queries searched with the blastn program are filtered with DUST (Hancock and Armstrong, *Comput. Appl. Biosci.* 10:67-70, 1994). It will be appreciated that these sequence identity ranges are provided for guidance only; it is  
20 entirely possible that strongly significant homologs could be obtained that fall outside of the ranges provided.

- Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences, due to the degeneracy of the genetic code. It is understood that changes in nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid  
25 sequences that all encode substantially the same protein.

One indication that two nucleic acid sequences are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the polypeptide encoded by the second nucleic acid.

- An alternative indication that two nucleic acid molecules are closely related is that the two  
30 molecules hybridize to each other under stringent conditions, as described under "specific hybridization."

- Homologs of the disclosed RRV or JMHV nucleic acids typically possess at least 50% sequence identity counted over the length of one of the nucleic acids (the reference nucleic acid) using the NCBI Blast 2.0.6, gapped blastn set to default parameters. Nucleic acids showing  
35 substantial similarity when assessed by this method may show, for example, at least 50%, 60%, 70%, 80%, 90%, 95% or even 98% or greater sequence identity. When less than the entire sequence is being compared for sequence identity, substantially similar nucleotide sequences will typically possess at least 70% sequence identity over short windows of 30-90 nucleic acids, and may possess sequence identities of at least 80%, 90%, 95% or 98% or greater.

- 17 -

Homologs of the disclosed RRV or JMHV proteins typically possess at least 50% sequence identity counted over full-length alignment with the amino acid sequence of RRV using the NCBI Blast 2.0, gapped blastp set to default parameters. For comparisons of amino acid sequences of greater than about 30 amino acids, the Blast 2 sequences function is employed using the default  
5 BLOSUM62 matrix set to default parameters, (gap existence cost of 11, and a per residue gap cost of 1). When aligning short peptides (fewer than around 30 amino acids), the alignment should be performed using the Blast 2 sequences function, employing the PAM30 matrix set to default parameters (open gap 9, extension gap 1 penalties). Proteins with even greater similarity to the reference sequence will show increasing percentage identities when assessed by this method, such as  
10 at least 50%, at least 55%, at least 60%, at least 70%, at least 75%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 99% sequence identity. When less than the entire sequence is being compared for sequence identity, homologs will typically possess at least 70% sequence identity over short windows of 10-20 amino acids, and may possess sequence identities of at least 75%, at least 85% or at least 90%, at least 95% or 98% depending on their similarity to the reference sequence.

15 When comparing degrees of sequence identity between similar proteins, the degree of identity will be equal to or less than that the degree of similarity, due to the fact the similarity takes into account conservative amino acid substitutions. So, for instance, the degree of sequence identity between to substantially similar proteins may be at least 50%, 55%, 65%, 75%, 85%, 95%, 98% or more.

20 One of ordinary skill in the art will appreciate that these sequence identity ranges are provided for guidance only; it is entirely possible that strongly significant homologs could be obtained that fall outside of the ranges provided. The present invention provides not only the peptide homologs that are described above, but also nucleic acid molecules that encode such homologs.

25 An alternative indication that two nucleic acid molecules are closely related is that the two molecules hybridize to each other under stringent conditions, as described in Example 23.

Specific binding agent: An agent that binds substantially only to a defined target. As used herein, the term "RRV peptide specific binding agent" includes anti-RRV peptide antibodies and other agents that bind substantially only to the RRV peptide. Such "peptide specific binding agents" include anti-IL-6 and anti-MIP antibodies. Similarly, the term "JMHV peptide specific binding  
30 agent" includes anti-JMHV peptide antibodies and other agents that bind substantially only to the JMHV peptide. The antibodies may be monoclonal or polyclonal antibodies that are specific for an RRV or a JMHV peptide, as well as immunologically effective portions ("fragments") thereof.

In one embodiment, the antibodies used in the present invention are monoclonal antibodies (or immunologically effective portions thereof) and may also be humanized monoclonal antibodies  
35 (or immunologically effective portions thereof). Immunologically effective portions of monoclonal antibodies include Fab, Fab', F(ab')<sub>2</sub>, Fabc and Fv portions (for a review, see Better and Horowitz, *Methods. Enzymol.* 178:476-96, 1989). Anti-inhibitory peptide antibodies may also be produced using standard procedures described in a number of texts, including Antibodies, A Laboratory Manual by Harlow and Lane, Cold Spring Harbor Laboratory (1988).

- 18 -

Methods of making humanized monoclonal antibodies are well known, and include those described in U.S. Patent Nos. 5,585,089; 5,565,332; 5,225,539; 5,693,761; 5,693,762; 5,585,089; and 5,530,101 and references cited therein. Similarly, methods of making and using immunologically effective portions of monoclonal antibodies, also referred to as antibody fragments, are well known and include those described in Better and Horowitz, 1989, *Meth. Enzymol.* 178:176-496; Better et al., 1990, Better and Horowitz, 1990, *Advances in Gene technology: The Molecular Biology of Immune Disease & the Immune Response* (ICSU Short Reports); Glockshuber et al., 1990, *Biochemistry* 29:1362-7; and U.S. Patent Nos. 5,648,237; 4,946,778 and 5,455,030, and references cited therein.

The determination that a particular agent binds substantially only to an RRV peptide or a JMHV peptide may readily be made by using or adapting routine procedures. One suitable *in vitro* assay makes use of the Western blotting procedure (described in many standard texts, including *Antibodies, A Laboratory Manual* by Harlow and Lane). Western blotting may be used to determine that a given RRV peptide binding agent, such as an anti-IL-6 or MIP peptide monoclonal antibody, binds substantially only to the specific RRV protein.

**Specific hybridization:** Specific hybridization refers to the binding, duplexing, or hybridizing of a molecule only or substantially only to a particular nucleotide sequence when that sequence is present in a complex mixture (e.g. total cellular DNA or RNA). Specific hybridization may also occur under conditions of varying stringency.

**Supernatant:** The culture medium in which a cell is grown. The culture medium includes material from the cell. If the cell is infected with a virus, the supernatant can include viral particles.

**Subject:** This term includes both human and non-human subjects. Similarly, the term "patient" includes both human and veterinary subjects.

**Transformed:** A transformed cell is a cell into which has been introduced a nucleic acid molecule by molecular biology techniques. As used herein, the term transformation encompasses all techniques by which a nucleic acid molecule might be introduced into such a cell, including transfection with viral vectors, transformation with plasmid vectors, and introduction of naked DNA by electroporation, lipofection, and particle gun acceleration.

**Transgenic Cell:** Transformed cells which contain foreign, non-native DNA.

**Variants of Amino Acid and Nucleic Acid Sequences:** The production of RRV or JMHV proteins can be accomplished in a variety of ways (for example see Examples 17, 21 and 25). DNA sequences which encode the protein, or a fragment of the protein, can be engineered such that they allow the protein to be expressed in eukaryotic cells, bacteria, insects, and/or plants. In order to accomplish this expression, the DNA sequence can be altered and operably linked to other regulatory sequences. The final product, which contains the regulatory sequences and the therapeutic protein, is referred to as a vector. This vector can then be introduced into the eukaryotic cells, bacteria, insect, and/or plant. Once inside the cell the vector allows the protein to be produced.

One of ordinary skill in the art will appreciate that the DNA can be altered in numerous ways without affecting the biological activity of the encoded protein. For example, PCR may be used to produce variations in the DNA sequence which encodes RRV or JMHV proteins, such as IL-6 or

- 19 -

MIP. Such variants may be variants that are optimized for codon preference in a host cell that is to be used to express the protein, or other sequence changes that facilitate expression.

Two types of cDNA sequence variant may be produced. In the first type, the variation in the cDNA sequence is not manifested as a change in the amino acid sequence of the encoded polypeptide. These silent variations are simply a reflection of the degeneracy of the genetic code. In the second type, the cDNA sequence variation does result in a change in the amino acid sequence of the encoded protein. In such cases, the variant cDNA sequence produces a variant polypeptide sequence. In order to preserve the functional and immunologic identity of the encoded polypeptide, it is preferred that any such amino acid substitutions are conservative. Conservative substitutions replace one amino acid with another amino acid that has some homology in size, hydrophobicity, etc. Such substitutions generally are conservative when it is desired to finely modulate the characteristics of the protein. For example, conservative substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.

Examples of amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative substitutions include: Ser for Ala; Lys for Arg; Gln or His for Asn; Glu for Asp; Ser for Cys; Asn for Gln; Asp for Glu; Pro for Gly; Asn or Gln for His; Leu or Val for Ile; Ile or Val for Leu; Arg or Gln for Lys; Leu or Ile for Met; Met, Leu or Tyr for Phe; Thr for Ser; Ser for Thr; Tyr for Trp; Trp or Phe for Tyr; and Ile or Leu for Val.

The substitutions which in general are expected to produce the greatest changes in protein properties will be non-conservative, for instance changes in which (a) a hydrophilic residue, e.g., seryl or threonyl, is substituted for (or by) a hydrophobic residue, e.g., leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue having an electropositive side chain, e.g., lysyl, arginyl, or histadyl, is substituted for (or by) an electronegative residue, e.g., glutamyl or aspartyl; or (d) a residue having a bulky side chain, e.g., phenylalanine, is substituted for (or by) one not having a side chain, e.g., glycine.

Variations in the DNA sequence that result in amino acid changes, whether conservative or not, should be minimized in order to preserve the functional and immunologic identity of the encoded protein. The immunologic identity of the protein may be assessed by determining whether it is recognized by an antibody to an RRV (or JMHV) protein; a variant that is recognized by such an antibody is immunologically conserved. Any DNA sequence variant will preferably introduce no more than 20, and preferably fewer than 10 amino acid substitutions into the encoded polypeptide. Variant amino acid sequences can, for example, be 80%, 90%, 95% or even 98% identical to the native amino acid sequence.

Vector: A nucleic acid molecule as introduced into a host cell, thereby producing a transformed host cell. A vector may include nucleic acid sequences that permit it to replicate in the host cell, such as an origin of replication. A vector may also include one or more selectable marker genes and other genetic elements known in the art.

- 20 -

**Virion:** A complete viral particle including envelope, capsid (if any), and nucleic acid elements.

The present invention utilizes standard laboratory practices for the cloning, manipulation and sequencing of nucleic acids, purification and analysis of proteins and other molecular biological and biochemical techniques, unless otherwise stipulated. Such techniques are explained in detail in standard laboratory manuals such as Sambrook et al. (Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> ed., vol. 1-3, Cold Spring Harbor, New York, 1989) and Ausubel et al. (Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, 1987).

### EXAMPLE 1

#### Isolation of RRV

This example describes how RRV was isolated from a rhesus macaque monkey. Fresh, dispersed bone marrow (BM) cells were isopycnic gradient-purified (Ficoll-Paque, Pharmacia) from a 2 yr, 202 day old captive-reared rhesus macaque that was euthanized 503 days after intravenous infection with an STVmac239 variant. Gradient-purified BM mononuclear cells were seeded into T-25 culture flasks and grown in the presence of Endothelial SFM media (GIBCO) supplemented with 10% fetal bovine serum, 1% L-glutamine, 1% penicillin-streptomycin-neomycin and 30 µg/mL endothelial cell growth supplement.

Cultures developing cytopathic effects (CPE) were rapidly frozen in liquid N<sub>2</sub> and thawed, and supernatants clarified by centrifugation and filtered through a 0.45 µ membrane. Filtered extracts were then used as inoculum on primary rhesus macaque fibroblast cultures. Fibroblast cultures developing CPE were scraped free into medium, pelleted at 400 xg, washed in phosphate-buffered saline and suspended in cold Ito and Karnovsky's fixative (2.5% glutaraldehyde, 0.5% picric acid, 1.6% paraformaldehyde, 0.005% ruthenium red) in 0.1 M sodium cacodylate buffer, pH 7.4 for 2 hours. Fixed cells were washed in cacodylate buffer, post-fixed in 1% OsO<sub>4</sub> and 0.8% K<sub>3</sub>Fe (CN)<sub>6</sub> in cacodylate buffer for 1 hour, rinsed in distilled H<sub>2</sub>O and pre-stained in 2% aqueous uranyl acetate for 1 hour. Fixed and pre-stained cells were dehydrated in a graded series of acetone imbedded in Epon 812 epoxy resin, polymerized at 60°C and sectioned at 60 nm on an MT 5000 ultramicrotome. Copper grid mounted sections were stained with lead citrate and Uranyl acetate and viewed on a Phillips 300 electron microscope.

By electron microscopy, numerous herpesvirus particles were observed in the cells. This macaque developed LPD characterized as lymphocytic masses in myeloid and nonlymphoid tissues which were confirmed histopathologically as solid pleomorphic lymphoid masses.

### EXAMPLE 2

#### Initial Characterization of RRV

Infectious virus was purified from infected primary rhesus fibroblast cultures exhibiting 100% CPE (see Example 1). Infected cells were harvested and disrupted by freeze-thawing and the cell debris removed by low speed centrifugation. Supernatants were centrifuged in a Beckman JA-14

- 21 -

rotor for 1 hour at 9000 rpm to pellet the virus, which was further purified through a six-step sorbitol gradient ranging from 20 to 70%, spun in a Beckman SW41 rotor for 2 hours at 18,000 rpm. Virus was diluted in balanced buffered salts solution and then pelleted through a 20% sorbitol cushion. Pelleted virus was resuspended in Tris-EDTA buffer (TE; 10 mM Tris-HCl, pH 8.0, and 1 mM EDTA) and lysed in TE with 0.6% SDS and proteinase K (200 µg) at 37°C for 5 hours. Viral DNA was then isolated by CsCl<sub>2</sub> gradient centrifugation in a Beckman Ti 75 rotor at 38.4 K rpm for 72 hours, collected and dialyzed against TE.

The viral DNA was analyzed using degenerate primer polymerase chain reaction (PCR) amplification and Southern blot hybridization with a probe specific for the KSHV thymidylate synthase (TS) gene: The probe itself had the sequence of the KSHV TS (Orf 70 gene). Four genes were identified by these methods. A fragment encoding a portion of the viral DNA polymerase was obtained and DNA sequence analysis revealed that the virus was most likely a gamma herpesvirus, as amino acid sequence identity was highest among this class of herpesviruses. DNA sequence analysis of the viral DNA fragment found to hybridize to the KSHV TS probe revealed three open reading frames (ORFs) with homology to KSHV (Nicholas et al., 1997, *Nature Med.* 3:287-92; Russo et al., 1996, *Proc Natl Acad Sci USA* 93:14862-7). One ORF encodes a homologue of macrophage inflammatory protein MIP-1 with amino acid sequence identity with KSHV MIP-II, the second ORF encodes a thymidylate synthase homologue and the third ORF encodes a homologue of interleukin-6 (IL-6) with homology to the rhesus IL-6 and KSHV IL-6. The presence of an IL-6-like cytokine and an MIP-1-like CC-chemokine flanking TS resembles the genomic organization of KSHV, indicating this virus is related to KSHV and is referred to herein as rhesus rhadinovirus (RRV).

To determine if RRV is present in tissue containing the lymphocytic masses, oligonucleotide PCR primers specific for the RRV MIP gene (see PCT Application No. US 99/26260) were designed in an attempt to detect viral DNA in tissue from the macaque. By semi-quantitative PCR analysis, viral DNA sequences were detected in DNA samples from bone marrow at approximately 590 copies per 0.1 µg of tissue DNA. Because rhesus macaques held in captivity are reported to be naturally infected with a herpesvirus similar to KSHV, bone marrow DNA samples were isolated from normal and SIVmac239-infected macaques without LPD and analyzed by PCR. There was no evidence of viral DNA sequences. Additionally, since simian Epstein-Barr virus (EBV) has been found to be present in high copy number in lymphomas from SIV-infected macaques (Baskin et al., 1986, *J. Natl. Cancer Inst.* 77:127-39; Feichtinger et al., 1990, *Amer. J. Pathol.* 137:1311-5), the tissue samples from the macaque with disease were also analyzed by PCR for rhesus EBV (RhEBV) using oligonucleotide primers for RhEBV latent membrane protein 1. By this analysis, no signal for RhEBV was detected, suggesting that the RRV may be a contributing factor for LPD in this SIV-infected macaque.

- 22 -

**EXAMPLE 3****Preparation of RRV DNA for Cloning**

Primary rhesus fibroblasts grown in two 850 cm<sup>2</sup> roller bottles were infected with RRV at an MOI of 0.1 and the virus was harvested from the culture supernatant and the infected monolayers 10 to 12 days post-infection. Cellular debris was removed from the culture supernatant by centrifugation at 1,000 x g for 10 minutes. Intracellular virus particles were released by sonication followed by centrifugation to pellet debris.

The two clarified supernatants were then combined and the virus was pelleted by centrifugation at 12,500 x g for 1 hour at 4°C, and further purified through a six-step sorbitol gradient ranging from 20 to 70%. Gradients were centrifuged in a Beckman SW41 rotor for 2 hours at 18,000 rpm at 4°C. The interface containing the virus was collected and diluted with cold buffered saline solution. The virus was then pelleted by centrifugation in the SW41 for 50 minutes at 18,000 rpm. The virus pellet was resuspended in 9.2 ml of TE (see Example 2) before the addition of 0.6 ml of 10% sodium dodecylsulfate (SDS) and 0.2 ml of proteinase K (10 mg/mL) to release the viral DNA. Viral DNA was isolated by CsCl<sub>2</sub> gradient centrifugation in a Beckman Ti75 rotor at 38,400 rpm for 72 hours, collected, and dialyzed against TE.

To ensure that the DNA isolated contained all the necessary sequences required for RRV replication, DNA was transfected, in duplicate, into primary rhesus fibroblasts by the calcium phosphate method without dimethyl sulfoxide shock and observed for cytopathic effects (CPE). Control transfections, lacking viral DNA or calcium phosphate, did not develop CPE.

**EXAMPLE 4****Construction of the Cosmid Library**

Approximately 100 µg of purified RRV DNA (Example 3) was partially digested with Sau3A I. Aliquots taken at various time points were run on a 0.5% agarose gel and examined for the fraction which gave the desired range of fragments (30 - 42 kb). The selected fraction was dephosphorylated with calf intestinal alkaline phosphatase and 1 µg ligated into the cosmid vector SuperCos 1, prepared essentially as described by the manufacturer (Stratagene, La Jolla, CA). The resulting ligation product was packaged using GigaPack II Gold packaging extract (Stratagene) and grown for the isolation of recombinant cosmids.

Individual recombinant cosmids were grown in 3 ml cultures and the cosmid DNA was isolated by alkaline lysis. Cosmid DNA was digested with EcoR1 and the DNA fragments separated on a 0.8% agarose gel. The separated fragments were transferred to nitrocellulose and probed with various PCR amplification products corresponding to specific KSHV ORFs. Hybridization of the probes to the transferred recombinant cosmids was done under conditions of moderate stringency (2x SSC-0.1%SDS at 55°C) with each of the KSHV-specific probes and at high stringency (0.2x SSC-0.1%SDS at 60°C) with the RRV-specific probes. By this analysis and restriction endonuclease mapping, the recombinant cosmids were aligned and a set of recombinants was identified that represented the entire viral genome when compared to digested viral DNA.

- 23 -

**EXAMPLE 5****Cloning and Sequencing**

Ten micrograms of each purified recombinant cosmid (Example 4) were digested with EcoRI and the resulting fragments isolated from a 0.8% agarose gel using the QiaQuick gel extraction protocol (Qiagen). Recovered fragments were ligated into pSP73 (Promega). Individual clones were selected by restriction enzyme screening of DNA recovered by alkaline lysis from overnight cultures. Sequencing templates were prepared by alkaline lysis, followed by precipitation with 6.5% polyethylene glycol and 0.8 M NaCl. Templates were resuspended at a concentration of 0.1 µg/µl and end sequences were determined using primers corresponding to the SP6 and T7 promoters of pSP73. Internal sequences were determined using a combination of subcloning using convenient restriction sites and custom primers. DNA sequencing reactions were performed with the Applied Biosystems (ABI) PRISM Dye Terminator Cycle Sequencing Ready Reaction kits with AmpliTaq DNA polymerase per the manufacturer's instructions. Sequence data was acquired using an ABI 373A Sequencer in the Molecular Biology Core at the Oregon Regional Primate Research Center.

The primary EcoRI fragments were sequentially arranged by sequencing across the EcoRI sites in the intact cosmids using custom primers. Except for those regions containing long, high GC repeat units, the entire viral DNA sequence was determined with a redundancy of 3- to 4-fold.

Sequences not accessible to custom primers or restriction subcloning were determined following deletion subcloning using the Exo Size Deletion kit (New England Biolabs). To accommodate this protocol, fragments were subcloned into vectors with restriction sites capable of generating the needed 3' and 5' overhanging ends. Double restriction digests to generate 3' and 5' overhanging ends were performed on 10 µg of recombinant plasmid DNA, which was then subjected to exonuclease III digestion. Aliquots were removed from the exonuclease III digests at empirically-determined time points, frozen on dry ice, then, after all the time points had been collected, incubated for 15 minutes at 65°C to inactivate the enzyme. The DNA was then treated with Mung bean nuclease (MBN) for 30 minutes at 30°C. Prior to addition of 3 µl of MBN to the 12 µl exonuclease III product, the enzyme was diluted 1/25 to reduce nonspecific digestion. Nuclease-treated DNA was recovered using the Wizard prep system (Promega), then incubated for 30 minutes with 2.5 units of T4 DNA polymerase (Life Technologies) and 1 µM dNTPs at 37°C. The final product was ligated overnight with T4 DNA ligase and used to transform competent XL1 blue bacteria. Deletion products were size selected by restriction digests of DNA recovered from 3 ml cultures.

- 24 -

**EXAMPLE 6****Assembly of the RRV Sequence, Assignment of ORFs, and Nomenclature**

Factura (ABI) and Autoassembler (ABI) were used to assemble the final sequence from individual sequencing runs. Open reading frames in the RRV sequence were determined with the program MacVector (Oxford Molecular Group), using a setting of 100 or more amino acids. Putative ORFs were then translated and compared to a database of KSHV ORFs. RRV ORFs which matched KSHV ORFs were then compared to GenBank using BLASTP to verify the similarity, followed by a Gap analysis (Wisconsin GCG analysis package; Oxford Molecular Group) to determine the levels of similarity and identity between the RRV and KSHV proteins. When a gap in the genome of RRV corresponded to the location of a KSHV ORF with less than 100 amino acids, MacVector was reset to a lower limit. RRV ORFs were assigned the names of HVS ORFs when they showed similarity to KSHV ORFs with the same name.

The nucleotide sequence data from this study have been deposited in the GenBank, EMBL, and DDBJ nucleotide sequence databases under accession number AF083501 (SEQ ID NO 1).

**EXAMPLE 7****Primary Structure Of the RRV Genome**

The genomic nucleotide sequence of the RRV genome (as shown in SEQ ID NO 1) was determined using twenty-nine EcoRI fragments (as shown in FIG. 2) from seven overlapping isolates of a partial Sau3A I cosmid library. Cosmids were selected by hybridization with PCR products from KSHV ORFs. EcoRI fragments from each cosmid were subcloned into pSP73 (Promega) and sequenced. The EcoRI fragments were arranged in the proper order by sequencing across the EcoRI junctions in the parent cosmids using custom primers. Greater than 98% of the viral genome was determined on both strands. The average sequencing redundancy was between 3 and 4, but three regions were sequenced on only one strand. One of these regions is a 106 bp segment of ORF 61 that was blocked on one side by an apparent hairpin. This segment was sequenced multiple times in one direction using templates derived from independent overlapping cosmids. The other two regions are 1 kb, high G + C, repetitive sequences. These segments, which are discussed in more detail below, were sequenced completely on one strand using a combination of custom primers and exonuclease III deletions.

Terminal repeats were identified on both the left and right ends of the genome and the sequence between them was designated as the LUR of the genome. The first base to the right of the left terminal repeat was designated base one. The LUR is 131,634 bp long (SEQ ID NO 1). The G + C content of RRV is 52.2%, which is comparable to the 53.5% G + C content of KSHV, but considerably higher than the 34.5% G + C content of the HVS genome. The CpG ratio is 1.11, which is substantially higher than the ratio found for other gamma-herpesviruses.

ORFs were identified by MacVector and compared to a database containing the full complement of known KSHV ORFs. Matches between RRV and KSHV proteins were verified by a BLASTP search of GenBank with the RRV proteins and then by Gap analysis. The initial screening

- 25 -

for ORFs used a minimum size limit of 100 amino acids. This limit was reduced when smaller KSHV ORFs existed in locations corresponding to unassigned regions of RRV. Using this approach, 82 ORFs were identified, with 67 of these corresponding to ORFs found in both KSHV and HVS. In accordance with the standard nomenclature for rhadinoviruses, these ORFs were labeled according to the HVS designation. The 15 ORFs not found in HVS were assigned labels beginning with R (for rhesus), indicating their presence in RRV, but not HVS. Some of these genes have counterparts in KSHV.

A map of the genome of RRV is presented in FIG. 3, with all identified ORFs and their orientations. The BamHI, EcoRI, and HindIII restriction sites in relation to the genome are shown in FIG. 2. The BamHI and Hind III maps were generated from the final compiled sequence. The EcoRI map was also generated from the final compiled sequence, but it was further characterized by sequencing across the EcoRI junctions in the parent cosmids. Fragment sizes for each restriction map are presented in FIG. 4.

15

#### EXAMPLE 8

##### Genomic Organization of RRV

The overall genomic organization of RRV matches the general structure of gamma-herpesviruses, with blocks of shared ORFs interrupted at specific locations (referred to as divergent loci) where the viral genomes code for acquired cellular genes. The primate rhadinoviruses form a subset of the gamma-herpesviruses and their genomes are correspondingly more similar to each other than to other members of the family.

20

The genomic sequence of RRV is presented in SEQ ID NO 1. FIG. 3 shows a schematic representation of the ORFs of RRV with a corresponding restriction map. FIG. 4 shows the location, size and description of the RRV ORFs.

25

#### EXAMPLE 9

##### Comparison of RRV and KSHV ORFs

A comparison of corresponding repeats in RRV and KSHV is shown in FIG. 5. In addition, FIG. 5 presents data for RRV ORFs along with the results of the Gap analysis of ORFs shared by RRV, KSHV, and HVS. All HVS-like ORFs found in KSHV are found in RRV. A comparison table of interferon regulatory elements encoded by the RRV and KSHV genomes is shown in FIG. 6.

30

#### EXAMPLE 10

##### Comparison of RRV and HVS ORFs

FIG. 7 shows the results of the Gap analysis of ORFs shared by RRV, KSHV, and HVS. In general, RRV and HVS ORFs are highly similar when the corresponding RRV and KSHV ORFs are highly similar, although the Gap values are generally lower.

35

- 26 -

**EXAMPLE 11****ORFs Unique to RRV and KSHV**

RRV includes 14 genes which are not found in HVS (R1; R2, R3, R4; R5; R6; R7; R8; R9; R10; R11; R12, R13; and R15 (see US 99/26260). These are designated in FIG. 3 as "R" ORFs. Of these  
5 fifteen genes, 11 have counterparts in the genome of KSHV. R2 and R3 are cytokine genes. R2 has functional homology to K2, the vIL-6 gene of KSHV. Gap analysis of the vIL-6 genes from KSHV and RRV shows no notable similarity, but both possess four conserved cysteines found in cellular IL-6. In addition, RRV vIL-6 has IL-6-like activity in cell culture. R3 has a small, but clear, similarity to KSHV K4, a vMIP1 $\beta$  gene. It is the only vMIP gene in RRV, as compared to the three vMIP  
10 genes found in KSHV.

RRV R6 through R13 are vIRFs as are KSHV K9 through K11 (FIG. 6). K9, the most studied of the KSHV vIRFs, does not have a DNA binding domain, but has been demonstrated to inhibit the endogenous cellular interferon response pathways. Five of the RRV vIRFs (R6, R7, R8, R10, and R11) are similar to K9, though only R10 has a similarity greater than 30%. The remaining  
15 similarities fall between 26% and 30%. There is no measurable similarity between any RRV vIRF and any KSHV vIRF other than K9. There is, however, a pattern of higher similarity between members of the RRV vIRF family. R6, R7, R8, and R9 are most similar to R10, R11, R12, and R13, respectively, with the similarities falling between 50% and 62%. The pattern of similarity suggests a single, possibly recent, gene duplication event for RRV which increased the number of vIRFs in the  
20 genome from four to eight.

The final RRV gene with a unique KSHV counterpart is R15, which has some similarity to K14, a viral NCAM Ox-2 homologue. The similarity between R15 and K14 (35.2%) is relatively low compared to most other shared proteins.

A number of genes in RRV appear to be truly unique. R1 colocalizes with, but has no  
25 similarity to, K1, a KSHV gene that has been demonstrated to have *in vivo* transforming ability. K1 and R1 both colocalize with ORF1, or STP (saimiri transforming protein), although both K1 and R1 are in opposite orientations compared to STP. A BLASTP search of GenBank using R1 reveals a limited amino-terminal similarity to a series of Fc receptors, including a potential transmembrane domain. These data suggest that R1, like K1 and STP, may have transforming potential via  
30 transmembrane signaling.

R4 and R5 are located between ORF 50 and 52, the same location as K8 and K8.1 in KSHV; however, there is no similarity between either R4 or R5 and the KSHV proteins. A BLASTP search of GenBank failed to show any significant alignments with either R4 or R5, so their functions are unknown.

RRV has no confirmed ORFs in the region corresponding to K12, the ubiquitously  
35 expressed kaposin gene. A large ORF exists to the right of ORF 71, but it has no apparent control regions (TATA box or polyadenylation signal), so it has not been designated as a true ORF, pending identification of transcripts from this region. No ORFs corresponding to KSHV K15 have been identified.

- 27 -

**EXAMPLE 12****Co-localization of Repeat Units in RRV and KSHV**

5 The RRV genome contains three highly repetitive regions, which correspond to three of the repetitive regions of KSHV: *frnk*, *zppa*, and *mdsk* (FIG. 5). KSHV *frnk* and *zppa*, and the corresponding RRV repetitive regions, *rDL-B* and *rDL-E*, respectively, are tandem repeats.

10 The first element of the RRV *syko* repeat is much lower in G + C content than the corresponding KSHV element, although the sizes are comparable (FIG. 5). The second element is over 700 bp longer than the corresponding KSHV element. The first element of the RRV *vrigo* repeat is 30% longer than the corresponding KSHV element, and the second RRV element is over four times as long as the second KSHV element. There is no sequence similarity between the various elements of the two viruses nor is there any similarity between any two repeat sequences in RRV.

15 Not all repeat elements found in KSHV have corresponding repeats in RRV. This includes the KSHV *vnct* and *waka/jwka* repeats. This also includes the *moi* repeat, which is located in the center of the KSHV ORF 73 and is responsible for the divergent lengths of RRV and KSHV ORF 73. *Moi* is described in the annotations to the KSHV GenBank entry as having 15 different 11-16 bp repeats. The result of this repeat element is the presence in ORF 73 of a highly acidic central domain, with a large number of glutamate residues coded by a repeating GAG codon. KSHV ORF 73 is a potential leucine zipper protein, with a number of leucine zipper sites in the repeat region. RRV 20 lacks the *moi* repeat and its concomitant acidic domain. It also lacks any evidence for a leucine zipper, indicating that the biology of ORF 73 in RRV may be substantially different than the biology of ORF 73 in KSHV.

**EXAMPLE 13****25 Production of Simian Kaposi's Sarcoma (KS) and Lymphoproliferative Disorders Model**

This example describes how the RRV cloned above can be used to produce a non-human primate model for Kaposi's sarcoma and lymphoproliferative disorders. Four rhesus macaques (identification numbers 18483, 18503, 18540 and 18570) that were approximately 1.5 years old, and PCR- and seronegative for RRV were selected. To perform the antibody analysis, infected cells were 30 solubilized with 0.5% Nonidet P-40 and 1% sodium deoxycholate in phosphate buffered saline, and clarified in a Beckman SW28 rotor at 23,500 rpm for 1 hour at 4°C. The clarified supernatant was used as antigen for coating enzyme-linked immunosorbent assay (ELISA) plates (500 ng/well). ELISAs were then performed essentially as described by Kodama et al. (*AIDS Res Hum Retroviruses* 5:337-43, 1989).

35 All of the animals were then inoculated intravenously with cell-free supernatants containing the equivalent of 5 ng of p27 prepared from COS-1 cells transfected with an SIVmac239 molecular clone (Endres et al., 1995, *SW. J Med. Primatol.* 24:141-4). The PBMCs from all macaques were prescreened for *in vitro* susceptibility to virus infection as described by Naidu et al. (*J. Virol.* 62:4691-6, 1988). All inoculations and animal manipulations were performed according to

- 28 -

institutional guidelines at the Oregon Regional Primate Research Center (Beaverton, OR). Every 3-4 days for 4 weeks, then at 2-week intervals, macaques were sedated with ketamine hydrochloride (10 mg per kilogram of body weight) and examined for fever, weight loss, cutaneous signs, lymphadenopathy, and hepatomegaly or splenomegaly. At these times, venipuncture was performed and blood specimens collected. Plasma was monitored for virus during the first 4 weeks with the SIV p27 enzyme-linked immunosorbent assay (ELISA) (Coulter Corp. Hialeah, FL.). T cell subsets and B cells were measured by flow cytometry with the OKT4 (CD4, Ortho), B9.11 (CD8, Coulter), and B-Ly-1 (CD20, Coulter) monoclonal antibodies.

At 8 weeks post-SIV infection, rhesus macaques 18483 and 18570 were inoculated intravenously with  $5 \times 10^6$  plaque forming units of gradient purified RRV that was grown and titered by plaque assay on primary rhesus fibroblasts. The two remaining macaques (18503 and 18540) were kept as SIV-infected controls. Every 3-4 days for 2 weeks, once a week for 4 weeks, then at 2 week intervals, the macaques were examined and blood samples collected and analyzed. Virus isolations were performed by cocultivation of  $2 \times 10^5$  PBMCs from each of the macaques with primary rhesus fibroblasts in duplicate. Cell cultures were monitored every 2-3 days for 3-4 weeks for cytopathic effects characteristic of RRV. PBLs were also analyzed by PCR for the presence of viral DNA. PCR analysis for RRV was performed with the following oligonucleotide primers: vMIP-1 and vMIP-2 (see PCT US 99/26260). The conditions for PCR were 94°C for 2 minutes (1 cycle); 94°C for 0.5 minutes, 50°C for 0.5 min, 72°C for 0.5 minutes (30 cycles); 72°C extension for 5 minutes (1 cycle). Each PCR reaction used 0.1 Fg of total DNA, 50 pmole of each primer, 1 U of Vent polymerase, 40  $\mu$ M each of deoxynucleotide triphosphate, 10 mM KCl, 10 mM Tris-HCl (pH 8.8), 10 mM  $(\text{NH}_4)_2\text{SO}_4$ , 2 mM  $\text{MgSO}_4$  and 0.1% Triton X-100 in a final volume of 50  $\mu$ L. The PCR reactions were run out on a 1% agarose gel, transferred to nitrocellulose, and probed with a  $^{32}\text{P}$ -ATP-labeled oligonucleotide primer specific for vMIP-3 (see PCT US 99/26260). Hybridizations were performed overnight at room temperature in 6X SSC, 0.1% SDS and 10  $\mu\text{g/mL}$  *E. coli* tRNA. Southern blots were then washed with 2X SSC and 0.1% SDS twice at room temperature followed by two washes for 1 hour in 2X SSC and 0.1% SDS at 47°C. Bound probe was visualized by exposing NEN duPont reflection film to the washed membrane at 80°C with an NEN duPont Reflection screen.

Infectious RRV was recovered from the peripheral blood mononuclear cells (PBMCs) of both RRV macaques injected with RRV as early as 4 weeks after inoculation for one macaque (18570) and 8 weeks for the other macaque (18483), but not from the control macaques. The peripheral blood leukocytes (PBL) from both macaques were also shown to harbor viral DNA as determined by PCR and Southern blot analysis for the viral MIP gene, as early as 4 weeks after inoculation for one macaque (18483) and as late as 14 weeks for the second macaque (18570). Additionally, antibody responses to RRV were observed as measured by ELISA in the RRV-infected macaques beginning 4 weeks post-infection, but not in the control macaques.

Flow cytometry analysis (FACS) of PBLs at the indicated weeks post-infection (FIGS 8A-8D) showed there was limited CD4+ lymphocyte depletion after SIV infection in both groups of macaques followed by a rebound and sustained CD4+ lymphocyte counts. However, examination of

- 29 -

CD20+ B lymphocytes revealed significant differences between the two groups. The two control macaques exhibited a dramatic and sustained decline in CD20+ B lymphocytes (FIGs. 8C and 8D), whereas both co-infected macaques exhibited a transient increase in B lymphocytes beginning 6 weeks after RRV infection (FIGs. 8A and 8B). The increase in CD20+ B lymphocytes correlated with the isolation and/or detection of RRV in both macaques; however, viral load did not appear to correlate with the increase in CD20+ B lymphocytes when all samples from each macaque were analyzed simultaneously. It has been reported that CD23, a B cell activation marker, is induced by RhEBV infection of macaques (Moghaddam et al. 1997, *Science* 276:2020-33). FACS analysis of PBMCs from RRV-infected macaques revealed no detectable CD23+ cells. This would suggest that the mechanism responsible for increased numbers of CD20+ B lymphocytes following RRV infection differ from the activation of B lymphocytes by RhEBV.

Routine physical examinations were performed on all four macaques, and early symptoms of SIV infection were observed in all four macaques by 2 weeks, including fever, rash and malaise. However, 11 weeks after inoculation with RRV, macaques 18483 and 18570 developed marked lymphadenopathy and splenomegaly, estimated to be enlarged 10 to 20 times the size of a normal spleen. In contrast, there was only slight lymph node enlargement in the control macaques not infected with RRV and no detectable enlargement of the spleen. Lymph node biopsies of the RRV-infected macaques revealed almost identical histology, characterized by a predominately follicular lesion with giant germinal centers and paracortical hyperplasia with increased vascularity, resembling angiofollicular lymph node hyperplasia associated with KSHV in Castleman's disease (Lachant et al. 1985, *Am. J. Clin. Pathol.* 83:27-33). In contrast, the lymph nodes of the control macaques exhibited atrophied lymphoid follicles and paracortical depletion characteristic of SIV-induced lymphoid atrophy (Chalifoux et al., 1987, *Am. J. Pathol.* 128:104-10; Ringler et al., 1989, *Am. J. Pathol.* 134:373-83; Wyand et al, 1989, *Am. J. Pathol.* 134:385-93). By FACS analysis, the majority of the lymph node mononuclear cells were CD20+ B lymphocytes in RRV-infected macaques, whereas CD4+ and CD8+ T lymphocytes predominated in the control macaques.

The presence of viral DNA was determined by PCR analysis on DNA derived from PBLs. Detection of antibodies to RRV was determined by enzyme-linked immunosorbent assay (ELISA) on plates coated with extracts derived from RRV-infected cells. By PCR analysis, RRV sequences were more prevalent in the lymph nodes than in the peripheral blood of RRV-infected macaques, whereas control macaques were negative for RRV sequences (FIGs. 9A and 9B).

Additional disease manifestations were also observed in the RRV-infected macaques that parallel clinical features and B cell abnormalities observed in AIDS patients. Hypergammaglobulinemia was observed in the RRV-infected macaque that the virus was derived from, as well as in the macaques experimentally infected with RRV, whereas the two control macaques had gammaglobulin levels similar to those before SIV infection. In addition, one of two RRV-infected macaques (18570) developed severe autoimmune hemolytic anemia 30 weeks after RRV infection, a condition frequently observed in MCD patients (Parravicini et al., 1997, *Am. J. Pathol.* 151:1517-22).

- 30 -

The second of the two RRV-infected macaques developed other unique clinical manifestations that paralleled those of AIDS patients with KS. At 60 weeks post-RRV infection it developed a distended abdomen that was clinically evident upon physical examination. Palpation revealed a pronounced fluid accumulation in the peritoneal cavity. This animal was euthanized due to persistent fluid accumulation and hyperbilirubinemia. Necropsy analysis on this animal revealed an abundance of ascites fluid, which was comprised predominately of CD20 B cells, as identified by FACS analysis. In addition, this animal exhibited a mesenchymal proliferative lesion throughout the viscera, that was identified by histopathological examination to be retroperitoneal fibromatosis (RF). RF is an abnormal highly vascularized mesenchymal proliferative lesion that exhibits histological features resembling Kaposi's Sarcoma. Analysis of DNA isolated from the ascites and RF lesion by PCR with RRV MIP primers (given in Example 2) revealed a high viral load, implying RRV infection was responsible for these abnormal proliferations.

#### EXAMPLE 14

##### Other Methods to Prepare RRV Nucleic Acid Sequences

###### *Obtaining the RRV Viral Genome*

The RRV genome (SEQ ID NO 1) can be procured by *de novo* isolation from a viral culture. A biological sample of the virus (accession number VR-2601) may be obtained from the ATCC in Manassas, VA. This virus can be grown *in vitro* using primary rhesus fibroblasts (see Example 1). The virus is harvested from the culture supernatant and the infected host cells. Cellular debris is removed by centrifugation and intracellular virus particles may be released by sonication followed by centrifugation to pellet debris. The virus is then pelleted by centrifugation and further purified through a six-step sorbitol gradient. The interface containing the virus is collected and the virus then pelleted by centrifugation, and the viral DNA released by SDS disruption. Viral DNA may be isolated by CsCl<sub>2</sub> gradient centrifugation.

###### *Obtaining Selected Polynucleotides from the Viral genome*

The isolated viral genome can be used as a source of polynucleotides as identified by the sequence as disclosed herein (SEQ ID NO 1). The polymerase chain reaction (PCR) may be used to amplify any polynucleotide selected from the known viral sequence using the viral genome as a source of template DNA. The template DNA may also be provided in the form of one or more cosmids that contain fragments of the viral genome. Alternately, cDNA, produced by reverse transcription of RNA extracted from RRV infected host cells, may be used as a template in a reverse-transcription PCR (RT-PCR) reaction. Methods and conditions for PCR and RT-PCR amplification are described in Innis et al. (PCR Protocols, A Guide to Methods and Applications, 1990, Innis et al. (eds.), 21-27, Academic Press, Inc., San Diego, California).

The selection of PCR primers may be made according to the portions of the genome to be amplified. Primers may be chosen to amplify small fragments of the genome, ORFs or fragments including many contiguous genes from the genome. Variations in amplification conditions may be

- 31 -

required to accommodate primers of differing lengths, and such considerations are well known in the art and are discussed in Innis et al. (PCR Protocols, A Guide to Methods and Applications 1990, Innis et al. (eds.), 21-27, Academic Press, Inc., San Diego, California), Sambrook et al. (Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> ed., vol. 1-3, Cold Spring Harbor, New York. 1989) and Ausubel et al. (Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences. 1987). For example, the ORF corresponding to the MIP gene may be amplified from an RRV genomic (or appropriate cosmid) template using a pair of primers (see PCT US 99/26260). Likewise, the ORF corresponding to the IL-6 gene may be amplified from an RRV genomic (or appropriate cosmid) template using a pair of primers (see PCT US 99/26260).

Many different primers may be selected from the sequence disclosed and used in PCR amplification reactions to amplify DNA sequences of interest from the RRV genome.

Polynucleotides that may be obtained by the above methods include, for example: the entire polynucleotide genome of RRV as shown in SEQ ID NO 1; ORFs of this genome; oligonucleotides comprising at least 15, 20, 30, 40, 50, 70, 100 and 150 consecutive nucleotides of the genome sequence as shown in SEQ ID NO 1; nucleic acid sequences defined by nucleotides 1 to 11031 of SEQ ID NO 1 and nucleotides 21625 to 131634 of SEQ ID NO 1; and ORFs selected from these nucleic acid sequences. It is readily apparent that fragments of any length may be made using the above methods and information.

#### EXAMPLE 15

##### Therapeutic and Diagnostic Uses of the RRV or JMHV IL-6 Protein

As disclosed herein, the genome of RRV possesses an IL-6 gene (FIG. 1), and the genome of JMHV possesses an IL-6 gene, similar to that found in KSHV. The IL-6 and MIP proteins of KSHV are thought to be important in disease pathology, such as in Kaposi's sarcoma. The primary structure of the RRV IL-6 protein is shown in FIG. 10 (SEQ ID NO 21). Given the sequence information, one can readily make derivative proteins of RRV IL-6 or JMHV IL-6. In one specific, non-limiting example, such derivative proteins include proteins that differ from the primary amino acid sequence as shown in FIG. 10 (SEQ ID NO 21) by one or more conservative amino acid substitutions. Examples of such conservative substitutions are given in the DEFINITIONS section of the specification. Derivative proteins also include proteins consisting of an amino acid sequence that has a defined degree of amino acid similarity with the RRV IL-6 or JMHV IL-6 protein. For instance, such derivative proteins will typically have at least 50% sequence similarity (and may have at least 60%, 70%, 80%, 90%, 95%, 98% or even 99% sequence similarity) with the RRV IL-6 protein. Such derivative proteins will not only share sequence similarity with KSHV IL-6 but will also possess IL-6 biological activity.

IL-6 is a cytokine known to have pleiotropic immunological effects including anti-inflammatory and immunosuppressive effects, and may be used in several therapeutic and diagnostic applications. RRV IL-6 or JMHV IL-6 of the invention may be likewise be used. For instance, IL-6 may be used to induce stimulation of hematopoietic stem cells, and to encourage proliferation,

- 32 -

differentiation and terminal maturation of erythroid cells from hematopoietic cells. Thus, for instance, RRV IL-6 or JMHV IL-6 may be used *in vivo* or *ex vivo* to treat diseases that involve leukopenia and thrombocytopenia. Such uses include stimulation of hematopoietic cells of radiotherapy patients or people exposed to radiation accidentally. IL-6 may be used in such applications in conjunction with GM-CSF (granulocyte-macrophage stimulating factor) (see U.S. Patent Nos. 5,610,056 and 5,620,685, herein incorporated by reference). IL-6 can also be used to stimulate growth of megakaryocytes and platelets, and for the inhibition of tumor growth (see U.S. Patent No. 5,620,685, herein incorporated by reference). IL-6 can also be used for the treatment of leukemias, such as chronic myeloid leukemia (CML) and acute myeloid leukemia, by inducing terminal differentiation of cells with IL-6 (see WO 90/01943, herein incorporated by reference). RRV IL-6 or JMHV IL-6 may be used for all such applications.

Therapeutic applications may involve the administration of RRV IL-6 or JMHV IL-6 in a number of ways. RRV IL-6 or JMHV IL-6 may be administered *in vivo*, e.g., by injection systemically or locally, for instance, into a subject. Many other forms of *in vivo* administration are possible including intravenous, subcutaneous, across a mucous membrane (anally, vaginally or sublingually), transdermal or by direct injection. Additionally, it may be administered *ex vivo*, by the removal of cells from a subject, the treatment of these cells *in vitro* with RRV IL-6 or JMHV IL-6, and the replacement of these cells into the subject. Another recently developed method of delivery of a protein drug is by introducing the gene coding for the drug into a subject, for instance within the genome of a virus, such as an adenovirus or a retrovirus, whereby the protein is expressed in the subject. Other modes of administration are provided in Example 25.

Such examples are provided for illustrative purposes only and it will be seen that RRV IL-6 or JMHV IL-6 may be used in a variety of topical and systemic immunological treatments where it would be desirable to stimulate cell proliferation or to induce anti-inflammatory or immunosuppressive effects. Additionally, IL-6 of the invention may be used for research and diagnostic purposes as discussed generally herein. For instance, IL-6 may be used to produce antibodies for diagnostic purposes to diagnose diseases characterized by increased or decreased production of IL-6, and the nucleic acid sequence encoding IL-6 may be used to produce probes and primers for diagnostic and research purposes or for gene therapy applications. The IL-6 could also be used as a targeting molecule for identifying cells with receptors for IL-6, and for directing therapeutic agents to these cells, for example by linking detector or therapeutic molecules to IL-6.

#### EXAMPLE 16

##### Therapeutic and Diagnostic Uses of the RRV or JMHV MIP Protein

The genome of RRV as disclosed herein possesses an MIP gene (FIGS. 1 and 11) similar to that found in KSHV. The primary structure of the RRV MIP protein is shown in FIG. 11 (SEQ ID NO 25). Similarly, JMHV encodes a MIP protein (see below). Given the sequence information, one can readily make derivative proteins of RRV or JMHV MIP. Such derivative proteins include

- 33 -

proteins that differ from the primary amino acid sequence as shown in FIG. 11 (SEQ ID NO 25), or from a JMHV MIP protein, by one or more conservative amino acid substitutions. Derivative proteins also include proteins consisting of an amino acid sequence that has a defined degree of amino acid similarity with the RRV or JMHV MIP protein. Typically such derivative proteins will have at least 50% sequence similarity with the RRV or JMHV MIP protein, and may have at least 60%, 70%, 80%, 90%, 95%, 98%, or even 99% sequence similarity. Such derivative proteins will not only share sequence similarity with KSHV MIP but will also possess MIP biological activity. MIP biological activity can be detected and quantified using bioassays as described in Kedal et al. (*Science* 277:1656-9, 1997) and Boshoff et al. (*Science* 278:290-4, 1997) that measure MIP concentrations using HIV inhibition and calcium mobilization, respectively.

MIP is a cytokine that activates neutrophils to undergo an oxidative burst and is also intrinsically pyrogenic. The MIP genes and proteins of the invention may be used in several therapeutic and diagnostic ways. The RRV MIP protein may be used for the same applications as other MIP proteins. Treatment of wounds to promote healing by application of MIP to the wound site is discussed in U.S. Patent No. 5,145,676. U.S. Patent No. 5,474,983 (herein incorporated by reference) discusses various methods of treatment of inflammatory diseases including asthma, allergies and dermatitis. U.S. Patent No. 5,656,724 (herein incorporated by reference) discloses the use of MIP to suppress proliferation of dividing myeloid cells e.g., for the treatment of neutropenia. Use of MIP to inhibit HIV is discussed by Kedal et al. (*Science* 277:1656-9, 1997). RRV or JMHV MIP may be used for all such applications.

As illustrated for IL-6 above, MIP may be administered in various ways to provide a therapeutic effect including *in vivo*, *ex vivo* and by gene therapy.

Such examples are provided for illustrative purposes only and it will be seen that MIP may be used in a variety of topical, systemic, *in vivo* and *ex vivo* immunological treatments where it would be desirable to activate neutrophils or to induce fever. Additionally, MIP of the invention may be used for diagnostic purposes as discussed generally herein. For instance, MIP may be used to produce antibodies for diagnostic purposes to diagnose diseases characterized by increased or decreased production of MIP, and the nucleic acid sequence encoding MIP may be used to produce probes and primers for diagnostic and research purposes, or for gene therapy applications.

The MIP could also be used as a targeting molecule for identifying cells with receptors for MIP, and for directing therapeutic agents to these cells, for example by linking detector or therapeutic molecules to MIP.

Although Examples 15 and 16 provide examples of therapeutic uses of the RRV or JMHV IL-6 and MIP proteins, any of the other proteins encoded by the RRV or JMHV can also be administered therapeutically, or diagnostically. For example, RRV or JMHV proteins that induce pathological or physiological conditions in a recipient can be administered to stimulate that condition for study, or to provide an animal or human model of the condition. That model can then be used to study the condition, or treatments for it.

- 34 -

## EXAMPLE 17

## Expression of RRV or JMHV cDNA Sequences

With the provision of the RRV genomic (SEQ ID NO 1), and the provision of JMHV sequences, the expression and purification of any of the RRV proteins, or JMHV proteins, by standard laboratory techniques, is now enabled. Fragments amplified as described herein can be cloned into standard cloning vectors and expressed in commonly used expression systems consisting of a cloning vector and a cell system in which the vector is replicated and expressed. Purified proteins may be used for functional analyses, antibody production, diagnosis, and patient therapy. Furthermore, the DNA sequences of the RRV cDNAs or JMHV cDNAs can be manipulated in studies to understand the expression of RRV genes or JMHV genes and the function of their products. Mutant forms of RRV or JMHV may be isolated based upon information contained herein, and may be studied in order to detect alteration in expression patterns in terms of relative quantities, and functional properties of the encoded mutant RRV protein. Partial or full-length cDNA sequences, which encode for the protein, may be ligated into bacterial expression vectors. Methods for expressing large amounts of protein from a cloned gene introduced into *E. coli* may be utilized for the purification, localization and functional analysis of proteins. For example, fusion proteins consisting of amino terminal peptides encoded by a portion of the *E. coli* lacZ or trpE gene linked to RRV protein or JMHV protein may be used to prepare polyclonal and monoclonal antibodies against this protein. Thereafter, these antibodies may be used to purify proteins by immunoaffinity chromatography, in diagnostic assays to quantitate the levels of protein and to localize proteins in tissues and individual cells by immunofluorescence and microscopy.

Intact native protein may also be produced in *E. coli* in large amounts for functional studies. Standard prokaryotic cloning vectors may also be used, for example *pBR322*, *pUC18* or *pUC19* as described in Sambrook et al. (Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> ed., vol. 1-3, Cold Spring Harbor, New York, 1989). Nucleic acids of RRV or JMHV may be cloned into such vectors which may then be transformed into bacteria such as *E. coli* which may then be cultured so as to express the protein of interest. Other prokaryotic expression systems include, for instance, the arabinose-induced pBAD expression system that allows tightly controlled regulation of expression, the IPTG-induced pRSET system that facilitates rapid purification of recombinant proteins and the IPTG-induced pSE402 system that has been constructed for optimal translation of eukaryotic genes. These three systems are available commercially from Invitrogen and, when used according to the manufacturer's instructions, allow routine expression and purification of proteins.

Methods and plasmid vectors for producing fusion proteins and intact native proteins in bacteria are described in Sambrook et al. (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, New York, 1989, Chapter 17). Such fusion proteins may be made in large amounts, are easy to purify, and can be used to elicit antibody response. Native proteins can be produced in bacteria by placing a strong, regulated promoter and an efficient ribosome binding site upstream of the cloned gene. If low levels of protein are produced, additional steps may be taken to increase protein production; if high levels of protein are produced, purification is relatively easy. Suitable methods

- 35 -

are presented in Sambrook et al. (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, New York, 1989) and are well known in the art. Often, proteins expressed at high levels are found in insoluble inclusion bodies. Methods for extracting proteins from these aggregates are described by Sambrook et al. (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, New York, 1989, Chapter 17).

Vector systems suitable for the expression of lacZ fusion genes include the pUR series of vectors (Ruther and Muller-Hill, 1983, *EMBO J.* 2:1791), pEX1-3 (Stanley and Luzio, 1984, *EMBO J.* 3:1429) and pMR100 (Gray et al., 1982, *Proc. Natl. Acad. Sci. USA* 79:6598). Vectors suitable for the production of intact native proteins include pKC30 (Shimatake and Rosenberg, 1981, *Nature* 292:128), pKK177-3 (Amann and Brosius, 1985, *Gene* 40:183) and pET-3 (Studier and Moffatt, 1986, *J. Mol. Biol.* 189:113). The RRV or JMHV fusion protein may be isolated from protein gels, lyophilized, ground into a powder and used as an antigen. The DNA sequence can also be transferred to other cloning vehicles, such as other plasmids, bacteriophages, cosmids, animal viruses and yeast artificial chromosomes (YACs) (Burke et al., 1987, *Science* 236:806-12). These vectors may then be introduced into a variety of hosts including somatic cells, and simple or complex organisms, such as bacteria, fungi (Timberlake and Marshall, 1989, *Science* 244:1313-7), invertebrates, plants (Gasser and Fraley, 1989, *Science* 244:1293), and mammals (Pursel et al., 1989, *Science* 244:1281-8), which cell or organisms are rendered transgenic by the introduction of one or more heterologous RRV DNAs and/or JMHV DNAs.

Various yeast strains and yeast-derived vectors are commonly used for expressing and purifying proteins, for example, *Pichia pastoris* expression systems are available from Invitrogen (Carlsbad, CA). Such systems include suitable *Pichia pastoris* strains, vectors, reagents, transformants, sequencing primers and media.

Non-yeast eukaryotic vectors can also be used for expression of the RRV or JMHV proteins. Examples of such systems are the well known Baculovirus system, the Ecdysone-inducible mammalian expression system that uses regulatory elements from *Drosophila melanogaster* to allow control of gene expression, and the Sindbis viral expression system that allows high level expression in a variety of mammalian cell lines. These expression systems are available from Invitrogen.

For expression in mammalian cells, the cDNA sequence may be ligated to heterologous promoters, such as the simian virus SV40, promoter in the pSV2 vector (Mulligan and Berg, 1981, *Proc. Natl. Acad. Sci. USA* 78:2072-6), and introduced into cells, such as monkey COS-1 cells (Gluzman, 1981, *Cell* 23:175-82), to achieve transient or long-term expression. The stable integration of the chimeric gene construct may be maintained in mammalian cells by biochemical selection, such as neomycin (Southern and Berg, 1982, *J. Mol. Appl. Genet.* 1:327-41) and mycophenolic acid (Mulligan and Berg, 1981, *Proc. Natl. Acad. Sci. USA* 78:2072-6).

DNA sequences can be manipulated with standard procedures such as restriction enzyme digestion, fill-in with DNA polymerase, deletion by exonuclease, extension by terminal deoxynucleotide transferase, ligation of synthetic or cloned DNA sequences, site-directed sequence-

- 36 -

alteration via single-stranded bacteriophage intermediate or with the use of specific oligonucleotides in combination with PCR.

The cDNA sequence (or portions derived from it) or a mini gene (a cDNA with an intron and its own promoter) may be introduced into eukaryotic expression vectors by conventional techniques. These vectors are designed to permit the transcription of the cDNA in eukaryotic cells by providing regulatory sequences that initiate and enhance the transcription of the cDNA and ensure its proper splicing and polyadenylation. Vectors containing the promoter and enhancer regions of the SV40 or long terminal repeat (LTR) of the Rous Sarcoma virus and polyadenylation and splicing signal from SV40 are readily available (Mulligan and Berg, 1981, *Proc. Natl. Acad. Sci. USA* 78:2072-6; Gorman et al., 1982, *Proc. Natl. Acad. Sci. USA* 78:6777-81). The level of expression of the cDNA can be manipulated with this type of vector, either by using promoters that have different activities (for example, the baculovirus pAC373 can express cDNAs at high levels in *S. frugiperda* cells (Summers and Smith, 1985, Genetically Altered Viruses and the Environment, Fields et al. (Eds.) 22:319-328, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.) or by using vectors that contain promoters amenable to modulation, for example, the glucocorticoid-responsive promoter from the mouse mammary tumor virus (Lee et al., 1982, *Nature* 294:228). The expression of the cDNA can be monitored in the recipient cells 24 to 72 hours after introduction (transient expression).

In addition, some vectors contain selectable markers such as the *gpt* (Mulligan and Berg, 1981, *Proc. Natl. Acad. Sci. USA* 78:2072-6) or *neo* (Southern and Berg, 1982, *J. Mol. Appl. Genet.* 1:327-41) bacterial genes. These selectable markers permit selection of transfected cells that exhibit stable, long-term expression of the vectors (and therefore the cDNA). The vectors can be maintained in the cells as episomal, freely replicating entities by using regulatory elements of viruses such as papilloma (Sarver et al., 1981, *Mol. Cell Biol.* 1:486) or Epstein-Barr (Sugden et al., 1985, *Mol. Cell Biol.* 5:410). Alternatively, one can also produce cell lines that have integrated the vector into genomic DNA. Both of these types of cell lines produce the gene product on a continuous basis. One can also produce cell lines that have amplified the number of copies of the vector (and therefore of the cDNA as well) to create cell lines that can produce high levels of the gene product (Alt et al., 1978, *J. Biol. Chem.* 253:1357).

The transfer of DNA into eukaryotic, in particular human or other mammalian cells, is now a conventional technique. The vectors are introduced into the recipient cells as pure DNA (transfection) by, for example, precipitation with calcium phosphate (Graham and vander Eb, 1973, *Virology* 52:466) or strontium phosphate (Brash et al., 1987, *Mol. Cell Biol.* 7:2013), electroporation (Neumann et al., 1982, *EMBO J.* 1:841), lipofection (Felgner et al., 1987, *Proc. Natl. Acad. Sci. USA* 84:7413), DEAE dextran (McCuthan et al., 1968, *J. Natl. Cancer Inst.* 41:351), microinjection (Mueller et al., 1978, *Cell* 15:579), protoplast fusion (Schafner, 1980, *Proc. Natl. Acad. Sci. USA* 77:2163-7), or pellet guns (Klein et al., 1987, *Nature* 327:70). Alternatively, the cDNA can be introduced by infection with virus vectors. Systems are developed that use, for example, retroviruses

- 37 -

(Bernstein et al., 1985, *Gen. Engrg.* 7:235), adenoviruses (Ahmad et al., 1986, *J. Virol.* 57:267), or Herpes virus (Spaete et al., 1982, *Cell* 30:295).

These eukaryotic expression systems can be used for studies of RRV or JMHV genes and mutant forms of these genes, and the RRV or JMHV proteins and mutant forms of these proteins.

- 5 Such uses include, for example, the identification of regulatory elements located in the 5' region of RRV genes or JMHV genes on genomic clones that can be isolated from genomic DNA libraries, such as human or mouse libraries, using the information contained in the present invention. The eukaryotic expression systems may also be used to study the function of the normal complete protein, specific portions of the protein, or of naturally occurring or artificially produced mutant proteins.
- 10 Naturally occurring RRV or JMHV wild-type or mutant proteins may exist in a variety of cancers or diseases, while artificially produced mutant proteins can be designed by site directed mutagenesis as described above. These latter studies may probe the function of any desired amino acid residue in the protein by mutating the nucleotide coding for that amino acid.

- Using the above techniques, the expression vectors containing RRV or JMHV genes or
- 15 cDNA sequence or fragments or variants or mutants thereof can be introduced into human cells, mammalian cells from other species or non-mammalian cells as desired. The choice of cell is determined by the purpose of the treatment. For example, monkey COS cells (Gluzman, 1981, *Cell* 23:175-82) that produce high levels of the SV40 T antigen and permit the replication of vectors containing the SV40 origin of replication may be used. Similarly, Chinese hamster ovary (CHO),
- 20 mouse NIH 3T3 fibroblasts or human fibroblasts or lymphoblasts may be used.

- One method that can be used to express RRV or JMHV polypeptides from the cloned RRV or JMHV cDNA sequence in mammalian cells is to use the cloning vector, pXTI. This vector is commercially available from Stratagene, contains the Long Terminal Repeats (LTRs) and a portion of the GAG gene from Moloney Murine Leukemia Virus. The position of the viral LTRs allows highly
- 25 efficient, stable transfection of the region within the LTRs. The vector also contains the Herpes Simplex Thymidine Kinase promoter (TK), active in embryonal cells and in a wide variety of tissues in mice, and a selectable neomycin gene conferring G418 resistance. Two unique restriction sites BglII and XhoI are directly downstream from the TK promoter. RRV or JMHV cDNA, including the entire open reading frame for an RRV protein or JMHV protein such as IL-6 and the 3' untranslated
- 30 region of the cDNA is cloned into one of the two unique restriction sites downstream from the promoter.

- The ligated product is transfected into mouse NIH 3T3 cells using Lipofectin (Life Technologies, Inc.) under conditions outlined in the product specification. Positive transfectants are selected after growing the transfected cells in 600 µg/ml G418 (Sigma, St. Louis, MO). The protein
- 35 is released into the supernatant and may be purified by standard immunoaffinity chromatography techniques using antibodies raised against RRV proteins (see Example 18).

Expression of RRV or JMHV proteins in eukaryotic cells can be used as a source of proteins to raise antibodies. The RRV or JMHV proteins may be extracted following release of the protein into the supernatant as described above, or, the cDNA sequence may be incorporated into a

- 38 -

eukaryotic expression vector and expressed as a chimeric protein with, for example,  $\beta$ -globin. Antibody to  $\beta$ -globin is thereafter used to purify the chimeric protein. Corresponding protease cleavage sites engineered between the  $\beta$ -globin gene and the cDNA are then used to separate the two polypeptide fragments from one another after translation. One useful expression vector for  
5 generating  $\beta$ -globin chimeric proteins is pSG5 (Stratagene). This vector encodes rabbit  $\beta$ -globin.

The present disclosure thus encompasses recombinant vectors which comprise all or part of RRV or JMHV genome or cDNA sequences, for expression in a suitable host. The RRV or JMHV DNA is operatively linked in the vector to an expression control sequence in the recombinant DNA molecule so that a RRV or JMHV polypeptide can be expressed. The expression control sequence  
10 may be selected from the group consisting of sequences that control the expression of genes of prokaryotic or eukaryotic cells and their viruses and combinations thereof. The expression control sequence may be specifically selected from the group consisting of the lac system, the trp system, the tac system, the trc system, major operator and promoter regions of phage lambda, the control region of fd coat protein, the early and late promoters of SV40, promoters derived from polyoma,  
15 adenovirus, retrovirus, baculovirus and simian virus, the promoter for 3-phosphoglycerate kinase, the promoters of yeast acid phosphatase, the promoter of the yeast alpha-mating factors and combinations thereof.

The host cell, which may be transfected with the vector of this invention, may be selected from the group consisting of: *E. coli*, *Pseudomonas*, *Bacillus subtilis*, *Bacillus stearothermophilus* or  
20 other bacilli; other bacteria; yeast; fungi; plant; insect; mouse or other animal; or human tissue cells.

It is appreciated that for mutant or variant RRV or JMHV DNA sequences, similar systems are employed to express and produce the mutant or variant product.

#### EXAMPLE 18

##### 25 Production of Antibodies to RRV and RRV Proteins or JMHV and JMHV proteins

Polyclonal or monoclonal antibodies (including humanized monoclonal antibodies) and fragments of monoclonal antibodies such as Fab, F(ab')<sub>2</sub> and Fv fragments, as well as any other agent capable of specifically binding to an RRV or JMHV protein, may be produced to the RRV virion, the JMHV virion, or any of the RRV or JMHV proteins (for example odd-numbered SEQ ID Nos 3-165).  
30 Optimally, antibodies raised against an RRV or JMHV protein would specifically detect the RRV or JMHV protein of interest (or a virion containing the protein of interest). That is, such antibodies would recognize and bind the protein and would not substantially recognize or bind to other proteins found in human or other cells. The determination that an antibody specifically detects the RRV or JMHV protein is made by any one of a number of standard immunoassay methods; for instance, the  
35 Western blotting technique (Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York).

To determine that a given antibody preparation (such as one produced in a mouse) specifically detects the RRV or JMHV protein by Western blotting, total cellular protein is extracted

- 39 -

from murine myeloma cells and electrophoresed on a SDS-polyacrylamide gel. The proteins are then transferred to a membrane (for example, nitrocellulose) by Western blotting, and the antibody preparation is incubated with the membrane. After washing the membrane to remove non-specifically bound antibodies, the presence of specifically bound antibodies is detected by the use of

5 an anti-mouse antibody conjugated to an enzyme such as alkaline phosphatase; application of the substrate 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium results in the production of a dense blue compound by immuno-localized alkaline phosphatase. Antibodies which specifically detect an RRV or JMHV protein will, by this technique, be shown to bind to the RRV or JMHV protein band (which will be localized at a given position on the gel determined by its molecular

10 weight). Non-specific binding of the antibody to other proteins (such as serum albumin) may occur and may be detectable as a weak signal on the Western blot. The non-specific nature of this binding will be recognized by one skilled in the art by the weak signal obtained on the Western blot relative to the strong primary signal arising from the specific antibody-VIAP protein binding.

A substantially pure virion can be obtained, or substantially pure RRV or JMHV protein

15 suitable for use as an immunogen is isolated by purification or recombinant expression. Concentration of protein in the final preparation is adjusted, for example, by concentration on an Amicon filter device, to the level of a few micrograms per milliliter. Monoclonal or polyclonal antibody to the protein can then be prepared as described by Harlow and Lane (Antibodies, A Laboratory Manual, Cold Spring Harbor Press. 1988).

20 Alternatively, antibodies may be raised against synthetic RRV or JMHV peptides synthesized on a commercially available peptide synthesizer (see Example 26) based upon the predicted amino acid sequence of the RRV or JMHV protein (Harlow and Lane, Antibodies, A Laboratory Manual, Cold Spring Harbor Press. 1988).

Another method of raising antibodies against RRV or JMHV proteins is by subcutaneous

25 injection of a DNA vector which expresses the RRV protein into laboratory animals, such as mice. Delivery of the recombinant vector into the animals may be achieved using a hand-held form of the Biolistic system (Sanford et al., 1987, *Particulate Sci. Technol.* 5:27-37) as described by Tang et al. (*Nature* 356:152-4, 1992). Expression vectors suitable for this purpose may include those which express the RRV protein under the transcriptional control of either the human  $\beta$ -actin promoter or the

30 cytomegalovirus (CMV) promoter.

#### ***Monoclonal Antibody Production by Hybridoma Fusion***

Monoclonal antibody to epitopes of the RRV or JMHV protein identified and isolated as described can be prepared from murine hybridomas according to the classical method of Kohler and

35 Milstein (*Nature* 256:495, 1975) or derivative methods thereof. Briefly, a mouse is repetitively inoculated with a few micrograms of the selected protein over a period of a few weeks. The mouse is then sacrificed, and the antibody-producing cells of the spleen isolated. The spleen cells are fused by means of polyethylene glycol with mouse myeloma cells, and the excess unfused cells destroyed by growth of the system on selective media comprising aminopterin (HAT media). The successfully

- 40 -

fused cells are diluted and aliquots of the dilution placed in wells of a microtiter plate where growth of the culture is continued. Antibody-producing clones are identified by detection of antibody in the supernatant fluid of the wells by immunoassay procedures, such as ELISA, as originally described by Engvall (*Enzymol.* 70:419, 1980), and derivative methods thereof. Selected positive clones can be expanded and their monoclonal antibody product harvested for use. Detailed procedures for monoclonal antibody production are described in Harlow and Lane (Antibodies: A Laboratory Manual, 1988, Cold Spring Harbor Laboratory, New York).

#### ***Polyclonal Antibody Production by Immunization***

Polyclonal antiserum containing antibodies to heterogeneous epitopes of a single protein can be prepared by immunizing suitable animals with the expressed protein (e.g. see Example 17), which can be unmodified or modified to enhance immunogenicity. Effective polyclonal antibody production is affected by many factors related both to the antigen and the host species. For example, small molecules tend to be less immunogenic than others and may require the use of carriers and adjuvant. Also, host animals vary in response to site of inoculations and dose, with both inadequate or excessive doses of antigen resulting in low titer antisera. Small doses (ng level) of antigen administered at multiple intradermal sites appears to be most reliable. An effective immunization protocol for rabbits can be found in Vaitukaitis et al. (*J. Clin. Endocrinol. Metab.* 33:988-91, 1971).

Booster injections can be given at regular intervals, and antiserum harvested when antibody titer thereof, as determined semi-quantitatively, for example, by double immunodiffusion in agar against known concentrations of the antigen, begins to fall. See, for example, Ouchterlony et al. (In: Handbook of Experimental Immunology, Wier, D. (ed.). Chapter 19. Blackwell. 1973). Plateau concentration of antibody is usually in the range of 0.1 to 0.2 mg/ml of serum (about 12  $\mu$ M). Affinity of the antisera for the antigen is determined by preparing competitive binding curves, as described, for example, by Fisher (Manual of Clinical Immunology, Chapter 42. 1980).

#### ***Labeled Antibodies***

Antibodies of the present invention can be conjugated with various labels for their direct detection (see Chapter 9, Harlow and Lane, Antibodies: A Laboratory Manual, 1988). The label, which may include, but is not limited to, a radiolabel, enzyme, fluorescent probe, or biotin, is chosen based on the method of detection available to the user.

### **EXAMPLE 19**

#### **Diagnostic Methods**

An embodiment of the present invention is a method for screening a subject to determine if the subject has been infected with RRV or JMHV. One major application of the RRV sequence information presented herein is in the area of diagnostic testing for predisposition to a disease (such as Kaposi's Sarcoma and lymphoproliferative disorders for RRV, or for multiple sclerosis for JMHV) that develops in at least a sub-set of hosts infected with RRV or JMHV. The gene sequence of the

- 41 -

RRV genes, including intron-exon boundaries is also useful in such diagnostic methods. The method includes providing a biological sample obtained from the subject, in which sample includes DNA or RNA, and providing an assay for detecting in the biological sample the presence of any of the RRV or JMHV genes or proteins. Suitable biological samples include samples obtained from body cells,  
5 such as those present in peripheral blood, urine, saliva, tissue biopsy, surgical specimen, fine needle aspirate specimen, amniocentesis samples and autopsy material. The detection in the biological sample may be performed by a number of methodologies, as outlined below.

The foregoing assay may be assembled in the form of a diagnostic kit and preferably comprises either: hybridization with oligonucleotides; PCR amplification of the gene or a part  
10 thereof using oligonucleotide primers; RT-PCR amplification of the RNA or a part thereof using oligonucleotide primers; or direct sequencing of any of the RRV genes present in a subject using oligonucleotide primers. The efficiency of these molecular genetic methods should permit the rapid identification of patients infected with RRV.

One embodiment of such detection techniques is the polymerase chain reaction  
15 amplification of reverse transcribed RNA (RT-PCR) of RNA isolated from cells (for example lymphocytes) followed by direct DNA sequence determination of the products. The presence of one or more RRV genes is taken as indicative of a potential RRV infection. The presence of one or more JMHV genes is taken as indicative of potential JMHV infection.

Alternatively, DNA extracted from lymphocytes or other cells may be used directly for  
20 amplification. The direct amplification from genomic DNA would be appropriate for analysis of an entire RRV or JMHV gene including regulatory sequences located upstream and downstream from the open reading frame. Recent reviews of direct DNA diagnosis have been presented by Caskey (*Science* 236:1223-1228, 1989) and by Landegren et al. (*Science* 242:229-37, 1989).

Further studies of RRV or JMHV genes isolated from subjects may reveal particular  
25 mutations, deletions or alterations in gene sequences, which occur at a high frequency within particular populations of individuals. In this case, rather than sequencing the entire RRV gene, it may be possible to design DNA diagnostic methods to specifically detect the most common RRV mutations, deletions or alterations in gene sequences.

The detection of specific DNA mutations or alterations in gene sequences may be achieved  
30 by methods such as hybridization using specific oligonucleotides (Wallace et al., 1986, *Cold Spring Harbor Symp. Quant. Biol.* 51:257-61), direct DNA sequencing (Church and Gilbert, 1984, *Proc. Natl. Acad. Sci. USA.* 81:1991-5), the use of restriction enzymes (Flavell et al., 1978, *Cell* 15:25; Geever et al., 1981, *Proc. Natl. Acad. Sci. USA* 78:5081), discrimination on the basis of electrophoretic mobility in gels with denaturing reagent (Myers and Maniatis, 1986, *Cold Spring Harbor Symp. Quant. Biol.* 51:275-284), RNase protection (Myers et al., 1985, *Science* 230:1242),  
35 chemical cleavage (Cotton et al., 1985, *Proc. Natl. Acad. Sci. USA* 85:4397-401), and the ligase-mediated detection procedure (Landegren et al., 1988, *Science* 241:1077).

Oligonucleotides specific to normal, mutant or alternative sequences are chemically synthesized using commercially available machines, labeled radioactively with isotopes (such as <sup>32</sup>P)

- 42 -

or non-radioactively, with tags such as biotin (Ward and Langer et al., 1981. *Proc. Natl. Acad. Sci. USA* 78:6633-57), and hybridized to individual DNA samples immobilized on membranes or other solid supports by dot-blot or transfer from gels after electrophoresis. The presence of these specific sequences are visualized by methods such as autoradiography or fluorometric (Landegren et al., 1989, *Science* 242:229-37) or colorimetric reactions (Gebeyehu et al., 1987, *Nucleic Acids Res.* 15:4513-34). The absence of hybridization would indicate a mutation in the particular region of the gene, or that the patient is not infected with RRV or JMHV.

Sequence differences between disclosed and other forms of RRV or JMHV genes may also be revealed by the direct DNA sequencing method of Church and Gilbert (*Proc. Natl. Acad. Sci. USA* 81:1991-5, 1988). Cloned DNA segments may be used as probes to detect specific DNA segments. The sensitivity of this method is greatly enhanced when combined with PCR (Wrichnik et al., 1987, *Nucleic Acids Res.* 15:529-42; Wong et al., 1987, *Nature* 330:384-6; Stoflet et al., 1988, *Science* 239:491-4). In this approach, a sequencing primer which lies within the amplified sequence is used with double-stranded PCR product or single-stranded template generated by a modified PCR. The sequence determination is performed by conventional procedures with radiolabeled nucleotides or by automatic sequencing procedures with fluorescent tags.

Sequence alterations may occasionally generate fortuitous restriction enzyme recognition sites or may eliminate existing restriction sites. Changes in restriction sites are revealed by the use of appropriate enzyme digestion followed by conventional gel-blot hybridization (Southern, 1975, *J. Mol. Biol.* 98:503). DNA fragments carrying the site (either normal, mutant, or alternative) are detected by their reduction in size or increase of corresponding restriction fragment numbers. Genomic DNA samples may also be amplified by PCR prior to treatment with the appropriate restriction enzyme; fragments of different sizes are then visualized under UV light in the presence of ethidium bromide after gel electrophoresis.

Screening based on DNA sequence differences may be achieved by detection of alteration in electrophoretic mobility of DNA fragments in gels with or without denaturing reagent. Small sequence deletions and insertions can be visualized by high-resolution gel electrophoresis. For example, a PCR product with small deletions is clearly distinguishable from a normal sequence on an 8% non-denaturing polyacrylamide gel (WO 91/10734; Nagamine et al., 1989, *Am. J. Hum. Genet.* 45:337-9). DNA fragments of different sequence compositions may be distinguished on denaturing formamide gradient gels in which the mobilities of different DNA fragments are retarded in the gel at different positions according to their specific "partial-melting" temperatures (Myers et al., 1985, *Science* 230:1242). Alternatively, a method of detecting a mutation comprising a single base substitution or other small change could be based on differential primer length in a PCR. For example, an invariant primer could be used in addition to a primer specific for a mutation. The PCR products of the normal and mutant genes can then be differentially detected in acrylamide gels.

In addition to conventional gel-electrophoresis and blot-hybridization methods, DNA fragments may also be visualized by methods where the individual DNA samples are not immobilized on membranes. The probe and target sequences may be both in solution, or the probe

- 43 -

sequence may be immobilized (Saiki et al., 1989, *Proc. Nat. Acad. Sci. USA* 86:6230-4). A variety of detection methods, such as autoradiography involving radioisotopes, direct detection of radioactive decay (in the presence or absence of scintillant), spectrophotometry involving calorogenic reactions and fluorometry involved fluorogenic reactions, may be used to identify specific individual

5 genotypes.

If more than one mutation or alternative sequence is frequently encountered in one or more RRV or JMHV genes, a system capable of detecting such multiple mutations would be desirable. For example, a PCR with multiple, specific oligonucleotide primers and hybridization probes may be used to identify all possible mutations or alternative sequences at the same time (Chamberlain et al.,

10 1988, *Nucl. Acids Res.* 16:1141-55). The procedure may involve immobilized sequence-specific oligonucleotides probes (Saiki et al., 1989, *Proc. Nat. Acad. Sci. USA* 86:6230-4).

#### EXAMPLE 20

##### Quantitation of RRV or JMHV Proteins

An alternative method of determining if a subject has been infected with RRV or JMHV is to quantitate the level of one or more RRV (or JMHV) proteins in the cells of a subject. This diagnostic tool would be useful for detecting the levels of RRV proteins which result from, for example, infection by RRV. This diagnostic tool would also be useful for detecting the levels of the JMHV proteins which result from infection by JMHV. These diagnostic methods, in addition to

15 those described in EXAMPLE 19, provide an enhanced ability to diagnose susceptibility to diseases caused by RRV or JMHV infection.

The determination of RRV or JMHV protein levels would be an alternative or supplemental approach to the direct determination of the presence of one or more RRV (or JMHV) genes by the methods outlined above in EXAMPLE 19. The availability of antibodies specific to one or more of

25 the RRV (or JMHV) proteins (for example those described in Example 18) will facilitate the quantitation of cellular RRV or JMHV proteins by one of a number of immunoassay methods which are well known in the art and are presented in Harlow and Lane (*Antibodies, A Laboratory Manual*, Cold Spring Harbor Laboratory, New York. 1988).

Such assays permit both the detection of RRV or JMHV proteins in a biological sample and

30 the quantitation of such proteins. Typical methods involve: providing a biological sample of the subject in which the sample contains cellular proteins, and providing an immunoassay for quantitating the level of RRV or JMHV protein in the biological sample. This can be achieved by combining the biological sample with an RRV or JMHV specific binding agent, such as an antibody (e.g. monoclonal or polyclonal antibodies that bind an RRV or JMHV protein), so that complexes

35 form between the binding agent and the viral protein present in the sample, and then detecting or quantitating such complexes.

In particular forms, these assays may be performed with the RRV specific binding agent or the JMHV specific binding agent immobilized on a support surface, such as in the wells of a microtiter plate or on a column. The biological sample is then introduced onto the support surface

- 44 -

and allowed to interact with the specific binding agent so as to form complexes. Excess biological sample is then removed by washing, and the complexes are detected with a reagent, such as a second anti- RRV protein antibody, or anti-JMHV protein antibody, that is conjugated with a detectable marker.

5 In an alternative assay, the cellular proteins are isolated and subjected to SDS-PAGE followed by Western blotting, for example as described in Example 18. After resolving the proteins, the proteins are transferred to a membrane, which is probed with specific binding agents that recognize any of the RRV proteins or JMHV proteins. The proteins are detected, for example with HRP-conjugated secondary antibodies, and quantitated.

10 In yet another assay, the level of one or more RRV or JMHV proteins in cells is analyzed using microscopy. Using specific binding agents which recognize RRV or JMHV, samples can be analyzed for the presence of one or more RRV or JMHV proteins. For example, frozen biopsied tissue sections are thawed at room temperature and fixed with acetone at -200°C for 5 minutes. Slides are washed twice in cold PBS for 5 minutes each, then air-dried. Sections are covered with 20-  
15 30 µl of antibody solution (15-45 µg/ml) (diluted in PBS, 2% BSA at 15-50 µg/ml) and incubated at room temperature in humidified chamber for 30 minutes. Slides are washed three times with cold PBS 5 minutes each, allowed to air-dry briefly (5 minutes) before applying 20-30 µl of the second antibody solution (diluted in PBS, 2% BSA at 15-50 µg/ml) and incubated at room temperature in humidified chamber for 30 minutes. The label on the second antibody may contain a fluorescent  
20 probe, enzyme, radiolabel, biotin, or other detectable marker. The slides are washed three times with cold PBS 5 minutes each then quickly dipped in distilled water, air-dried, and mounted with PBS containing 30% glycerol. Slides can be stored at 4°C prior to viewing.

For samples prepared for electron microscopy (versus light microscopy), the second antibody is conjugated to gold particles. Tissue is fixed and embedded with epoxy plastics, then cut  
25 into very thin sections (~1-2 µm). The specimen is then applied to a metal grid, which is then incubated in the primary anti-RRV antibody, washed in a buffer containing BSA, then incubated in a secondary antibody conjugated to gold particles (usually 5-20 nm). These gold particles are visualized using electron microscopy methods.

For the purposes of quantitating the RRV or JMHV proteins, a biological sample of the  
30 subject, which sample includes cellular proteins, is required. Such a biological sample may be obtained from body cells, such as those present in which expression of the protein has been detected. The expression of RRV or JMHV proteins in peripheral blood leukocytes is clearly the most accessible and convenient source from which specimens can be obtained. Specimens can be obtained from peripheral blood, urine, saliva, tissue biopsy, amniocentesis samples, surgical specimens, fine  
35 needle aspirates, and autopsy material, particularly cancer cells. Quantitation of RRV or JMHV proteins would be made by immunoassay and compared to levels of the protein found in non-RRV or non-JMHV expressing cells, or to the level of RRV proteins in non-RRV infected cells (cells of the same origin that are not infected), or to the level of JMHV proteins in non-JMHV infected cells (cells of the same origin that are not infected). A significant (preferably 50% or greater) increase in the

- 45 -

amount of one or more RRV proteins in the cells of a subject compared to the amount of one or more RRV proteins found in non-RRV infected cells or that found in normal cells, would be taken as an indication that the subject may have been infected with RRV. Similarly, a significant (preferably 50% or greater) increase in the amount of one or more JMHV proteins in the cells of a subject compared to the amount of one or more JMHV proteins found in non-JMHV infected cells or that found in normal cells, would be taken as an indication that the subject may have been infected with JMHV.

#### EXAMPLE 21

##### Sequence Variants of RRV or JMHV

Sequence information for JMHV is shown in Example 31, and in the attached sequence listing. The amino acid sequence of JMHV proteins now facilitates the creation of DNA molecules, and thereby proteins, which are derived from those disclosed by vary in their precise nucleic acid or amino acid sequence from those disclosed. Such variants may be obtained through a combination of standard molecular biology laboratory techniques and the nucleotide sequence information disclosed by this invention.

Variant DNA molecules include those created by standard DNA mutagenesis techniques, for example, M13 primer mutagenesis. Details of these techniques are provided in Sambrook et al. (In: Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, New York, 1989, Chapter 15). By the use of such techniques, variants may be created which differ in minor ways from those disclosed. DNA molecules and nucleotide sequences which are derivatives of those specifically disclosed herein and which differ from those disclosed by the deletion, addition or substitution of nucleotides while still encoding a protein which possesses the functional characteristics of the RRV proteins are comprehended by this invention. Also within the scope of this invention are small DNA molecules which are derived from the disclosed DNA molecules. Such small DNA molecules include oligonucleotides suitable for use as hybridization probes or polymerase chain reaction (PCR) primers. These small DNA molecules will comprise at least a segment of the RRV or cDNA molecules or the RRV gene and, for the purposes of PCR, will comprise at least a 15 or a 20-50 nucleotide sequence of the RRV cDNAs (even-numbered SEQ ID Nos 2-164) or the RRV genes (i.e., at least 20-50 consecutive nucleotides of the RRV cDNA or gene sequences). Alternatively, these small DNA molecules will comprise at least a segment of the JMHV or cDNA molecules or the JMHV gene and, for the purposes of PCR, will comprise at least a 15 or a 20-50 nucleotide sequence of the JMHV cDNAs or the JMHV genes (i.e., at least 20-50 consecutive nucleotides of a nucleic acid encoding a JMHV protein). DNA molecules and nucleotide sequences which are derived from the disclosed DNA molecules as described above may also be defined as DNA sequences which hybridize under stringent conditions to the DNA sequences disclosed, or fragments thereof.

Hybridization conditions resulting in particular degrees of stringency will vary depending upon the nature of the hybridization method of choice and the composition and length of the hybridizing DNA used. Generally, the temperature of hybridization and the ionic strength (especially

- 46 -

- the  $\text{Na}^+$  concentration) of the hybridization buffer will determine the stringency of hybridization. Calculations regarding hybridization conditions required for attaining particular degrees of stringency are discussed by Sambrook et al. (In: Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, New York, 1989 ch. 9 and 11), herein incorporated by reference. By way of illustration only, a
- 5 hybridization experiment may be performed by hybridization of a DNA molecule (for example, a deviation of the RRV cDNA) to a target DNA molecule (for example, the RRV cDNA) which has been electrophoresed in an agarose gel and transferred to a nitrocellulose membrane by Southern blotting (Southern, *J. Mol. Biol.* 98:503, 1975), a technique well known in the art and described in Sambrook et al. (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, New York, 1989).
- 10 Hybridization with a target probe labeled with [ $^{32}\text{P}$ ]-dCTP is generally carried out in a solution of high ionic strength such as 6xSSC at a temperature that is 20-25°C below the melting temperature,  $T_m$ , described below. For such Southern hybridization experiments where the target DNA molecule on the Southern blot contains 10 ng of DNA or more, hybridization is typically carried out for 6-8 hours using 1-2 ng/ml radiolabeled probe (of specific activity equal to  $10^9$  CPM/ $\mu\text{g}$  or greater).
- 15 Following hybridization, the nitrocellulose filter is washed to remove background hybridization. The washing conditions should be as stringent as possible to remove background hybridization but to retain a specific hybridization signal. The term  $T_m$  represents the temperature above which, under the prevailing ionic conditions, the radiolabeled probe molecule will not hybridize to its target DNA molecule. The  $T_m$  of such a hybrid molecule may be estimated from the following equation (Bolton and McCarthy, *Proc. Natl. Acad. Sci. USA* 48:1390, 1962):  $T_m = 81.5^\circ\text{C} - 16.6(\log_{10}[\text{Na}^+]) + 0.41(\%G+C) - 0.63(\% \text{ formamide}) - (600/l)$ ; where  $l$  = the length of the hybrid in base pairs.
- 20

- This equation is valid for concentrations of  $\text{Na}^+$  in the range of 0.01 M to 0.4 M, and it is less accurate for calculations of  $T_m$  in solutions of higher  $[\text{Na}^+]$ . The equation is also primarily valid for DNAs whose G+C content is in the range of 30% to 75%, and it applies to hybrids greater than
- 25 100 nucleotides in length (the behavior of oligonucleotide probes is described in detail in Ch. 11 of Sambrook et al. (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, New York, 1989).

- Thus, by way of example, for a 150 base pair DNA probe derived from the open reading frame of the RRV cDNA (with a hypothetical %GC = 45%), a calculation of hybridization conditions required to give particular stringencies may be made as follows: For this example, it is assumed that
- 30 the filter will be washed in 0.3 x SSC solution following hybridization, thereby:  $[\text{Na}^+] = 0.045\text{M}$ ; %GC = 45%; Formamide concentration = 0;  $l = 150$  base pairs;  $T_m = 81.5 - 16.6(\log_{10}[\text{Na}^+]) + (0.41 \times 45) - (600/150)$ ; and so  $T_m = 74.4^\circ\text{C}$ .

- The  $T_m$  of double-stranded DNA decreases by 1-1.5°C with every 1% decrease in homology (Bonner et al., *J. Mol. Biol.* 81:123, 1973). Therefore, for this given example, washing the filter in
- 35 0.3 xSSC at 59.4-64.4°C will produce a stringency of hybridization equivalent to 90%; that is, DNA molecules with more than 10% sequence variation relative to the target RRV cDNA will not hybridize. Alternatively, washing the hybridized filter in 0.3 xSSC at a temperature of 65.4-68.4°C will yield a hybridization stringency of 94%; that is, DNA molecules with more than 6% sequence variation relative to the target RRV cDNA molecule will not hybridize. The above example is given

- 47 -

entirely by way of theoretical illustration. One skilled in the art will appreciate that other hybridization techniques may be utilized and that variations in experimental conditions will necessitate alternative calculations for stringency.

5 In particular embodiments of the present invention, stringent conditions may be defined as those under which DNA molecules with more than 25%, 15%, 10%, 6% or 2% sequence variation (also termed "mismatch") will not hybridize.

10 The degeneracy of the genetic code further widens the scope of the present invention as it enables major variations in the nucleotide sequence of a DNA molecule while maintaining the amino acid sequence of the encoded protein. In one specific, non-limiting example, the eleventh amino acid residue of the RRV MIP protein is alanine. This is encoded in the RRV cDNA by the nucleotide codon triplet GCG. Because of the degeneracy of the genetic code, three other nucleotide codon triplets, GCT, GCA and GCC, also code for alanine. Thus, the nucleotide sequence of the RRV DNA could be changed at this position to any of these three codons without affecting the amino acid composition of the encoded protein or the characteristics of the protein. Based upon the degeneracy  
15 of the genetic code, variant DNA molecules may be derived from the DNA molecules disclosed herein using standard DNA mutagenesis techniques as described above, or by synthesis of DNA sequences. DNA sequences which do not hybridize under stringent conditions to the DNA sequences disclosed by virtue of sequence variation based on the degeneracy of the genetic code are herein also comprehended by this invention.

20 The invention also includes DNA sequences that are substantially identical to any of the DNA sequences disclosed herein, where substantially identical means a sequence that has identical nucleotides in at least 75%, 80%, 85%, 90%, 95%, 98%, or even 99% of the aligned sequences.

One skilled in the art will recognize that the DNA mutagenesis techniques described above may be used not only to produce variant DNA molecules, but will also facilitate the production of  
25 proteins which differ in certain structural aspects from the RRV or JMHV proteins, yet which proteins are clearly derivative of this protein and which maintain the essential characteristics of the RRV or JMHV proteins. Newly derived proteins may also be selected in order to obtain variations on the characteristic of the RRV or JMHV proteins, as described above. Such derivatives include those with variations in amino acid sequence including minor deletions, additions and substitutions.

30 While the site for introducing an amino acid sequence variation is predetermined, the mutation per se need not be predetermined. For example, in order to optimize the performance of a mutation at a given site, random mutagenesis may be conducted at the target codon or region and the expressed protein variants screened for the optimal combination of desired activity. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence as described  
35 above are well known.

Amino acid substitutions are typically of single residues; insertions usually will be on the order of about from 1 to 10 amino acid residues; and deletions will range about from 1 to 30 residues. Deletions or insertions preferably are made in adjacent pairs, i.e., a deletion of two residues or insertion of two residues. Substitutions, deletions, insertions or any combination thereof may be

- 48 -

combined to arrive at a final construct. Obviously, the mutations that are made in the DNA encoding the protein must not place the sequence out of reading frame and preferably will not create complementary regions that could produce secondary mRNA structure.

Substitutional variants are those in which at least one residue in the amino acid sequence has been removed and a different residue inserted in its place. Such substitutions generally are made conservatively, as defined above.

The effects of these amino acid substitutions or deletions or additions may be assessed for derivatives of the JMHV proteins by assays in which DNA molecules encoding the derivative proteins are transfected into cells using routine procedures. These JMHV proteins are expressed recombinantly (for example see Example 17), purified, and analyzed for their ability to cause symptoms associated with JMHV infection.

#### EXAMPLE 22

##### Cloning Virus in Other Species

The genomic sequence of the rhesus macaque RRV (SEQ ID NO 1) and sequences of JMHV, facilitates the identification of DNA molecules, and thereby proteins, which are the RRV or JMHV homologs in other species. These other homologs can be derived from those sequences disclosed, but which vary in their precise nucleotide or amino acid sequence from those disclosed. Such variants may be obtained through a combination of standard molecular biology laboratory techniques and the nucleotide and amino acid sequence information disclosed by this invention.

The Japanese macaque virus isolate was isolated from a lesion that was minced and co-cultured with primary rhesus fibroblasts. The isolate was then cloned by limiting dilution and a stock of virus generated from this clone. Total cellular DNA was harvested from virus infected cells and the DNA subjected to degenerate PCR for viral DNA polymerase, exactly as described above for RRV. Once confirmed, a cosmid library of this virus was made from purified viral DNA (as described for RRV) and then a portion of the protein genes was cloned and sequenced.

Results for this analysis are shown in the following Table 1:

TABLE 1

##### RRV Sequences from Japanese Macaque

Total number of amino acid residues inferred: 972

Number of differences compared to RRV: 29

Percent identity: 97.02%

##### Japanese Macaque Data

These are end sequences. For ORFs represented twice, section I is from one plasmid, section II is from another plasmid. These are non-overlapping sections.

- 49 -

Orf 7 section I (see SEQ ID NO: 14)

GLFNSIDDTINALSRDCSVTFFQQANYTNVMRKQNELFTRLNSILCQGSAGSQKPATPSEPRT  
 ATVAATAASDVIKDAQYRKEQYMKKVARDGFKKLTECLQTQSAVLANALCMRVWGGVA  
 YGEASELVNHFLRRRFVALPWEARCRSNQILFENSKYIKNSLYSQRLSREHVEITLQFYGLI  
 5 TGPLTRQSDLFPGPANVVLAQCFAAGMLPHHKMLVSEMIW

Orf 7 section II (see SEQ ID NO: 14)

PIESLFCGGLFNSIDDTINALSRDCSVTFFQQANYTNXMRKQNELFTRLNSILCQGSAGSXKP  
 ATPSEPRTATVXATAASDVIKDAQYRXEQYMKKVARDXFKKLTECLQTQSAVLANALCMR  
 10 RMGGRI

Orf 8 (see SEQ ID NO: 24 and SEQ ID NO: 27)

YRKVATSVTVYRGWTETAVTGKQEVIRVPVQYBINHMDTTYQCFSSMRVNVNGIENTYTDR  
 DFTNQTVFLQPVEGLTDNIQRYFSQPVLTYTPGWFPGIYRVRTTVNCEIVDMIARSAEPYSYF  
 15 VTALGDTVEVSPFCLNDSTCSVADKAENGLGVRVLTNYTIVDFATRTPTTETRVFADSGEYT  
 VSWKAEDPKSAVCALTLWKTFPRAIQTTHESQLPLCGQRR

Orf 9 section I (see SEQ ID NO: 20 and SEQ ID NO: 25)

VPSRFQTDIIPSGTVLKLGRTENGTSVCNVFRQQVYFYAKVPAGVNVTHVLQQALKNTA  
 20 GRAACGFSTRRVTKKILKTYDVAEHPVTEITLSSGSMSTLSDRLVACGCEVFESNVDVRR  
 FVLDHGFTTFGWYSCARATPRLAXRDARTALEFDCSWEDLSV

Orf 9 section II (see SEQ ID NO: 20 and SEQ ID NO: 25)

MDFFNPYLGPRGPRPPSHKCTDAPAPAGAVQPPDVCRLIPACLRTPGAGGMIPVTIPFPPTYF  
 25 ENGARGDVLLAHERSMWTARGQRPVVPDPQDQSITFHA YDVVETTYAADRCAEV

Orf 10 (see SEQ ID NO: 18)

AQMKIYAPGDPNAEIVLGQSGPVLPTHTGGRVLGVYADAETIQPGSSAEVRVQLIFPTGSA  
 ARGDLAFLVAGVAPEPLFIVTPTLLSGCTTHLRLFPNGT  
 30

Orf 29b (SEQ ID NO: 28)

NVAVEGNSSQDAGVAIATVLNEICSVPLSFLHHADKNTLIRSPIYMLGPEKAKAFESFTYALN  
 SGTFSASQTVVSHTIKLSFDPVAYLIDQIKAIRCIPLKDGGHTYCAKQKTMSDDVLVATVMA  
 HYMATNDKFVFKSLE  
 35

The clones containing the Japanese macaque gamma2 herpesvirus was subsequently sequenced. The nucleic acid sequence from the Japanese macaque gamma2 herpesvirus was then compared with the sequence of the rhesus macaque gamma2 herpesvirus 17577. Based on a comparison of 2328 amino acid residues from fourteen independent regions (average length  $166 \pm 71$ ), the percent similarity

- 50 -

between the two viruses was calculated to be an average of 94.12% at the polypeptide level (range 75.652% to 99.422%) when JMHV and RRV sequences were compared (see Example 22).

Similarly, this invention now also facilitates the identification of other DNA molecules, and thereby proteins, which are the JMHV homologs in other species. These other homologs are derived or related to those sequences disclosed, but vary in their precise nucleotide or amino acid sequence. Such variants may be obtained through a combination of standard molecular biology laboratory techniques and the JMHV nucleotide and amino acid sequence information disclosed by this invention.

In one specific, non-limiting example, a human homolog of JMHV is isolated from a human MS lesion that is minced and co-cultured with primary fibroblasts, using the methods described herein. In one specific, non-limiting example, primary tissue explant cultures and cocultivation of leukocytes with target cells are used to enhance the isolation of a human virus. Fresh tissue (e.g. spinal chord) is dissected from visible human MS lesion identified during necropsy. Tissue explant cultures are established from small tissue fragments cultured in flasks (e.g. T-25 flasks) in media, such as Dulbecco's Modified Eagle Medium (DMEM) supplemented with serum, L-glutamine and antibiotics. In one example, 20% fetal calf serum is utilized. In another example, human serum is utilized. The explant cultures are fed by partial medium replacement, and passaged at confluence. Confluent monolayer explant cultures are rinsed in calcium and Magnesium-free phosphate buffered saline, pH 7.4, and digested with trypsin-EDTA at 37°C, washed with growth medium and seeded into flasks. These first passage explant cultures are fed by complete medium replacement, and watched for the development of cytopathic effects. Once cytopathic effects are noted, the cells are rapidly frozen in liquid nitrogen and thawed. Cell-free supernatants are clarified by centrifugation, filtered, and frozen at -80°C.

Peripheral blood mononuclear cells (PBMC) are then isopycnic gradient-purified (Ficoll-Paque, Pharmacia) from fresh ammonium heparin anti-coagulated blood obtained from a human MS patient at necropsy. Gradient-purified PBMC are washed in calcium- and magnesium-free phosphate-buffered saline and approximately  $3 \times 10^6$  PBMC are cocultured with  $1 \times 10^5$  primary human fibroblasts in T-25 culture flasks containing DMEM growth medium supplemented with serum, 1% L-glutamine and antibiotics (e.g. 1% penicillin-streptomycin-neomycin). The PBMC-fibroblast cocultures are fed by partial medium replacement after several days in culture, and passaged at confluence at approximately day 9. Confluent PBMC-fibroblast cocultures are rinsed in calcium- and magnesium-free phosphate-buffered saline, pH 7.4, digested with trypsin-EDTA at 37°C, washed with growth medium and then seeded into culture flasks. First passage PBMC-fibroblast cultures are fed by complete medium replacement at 3 to 5 day intervals and exhibit cytopathic effects (CPE) one to two weeks after passage. Once cytopathic are noted the cultures are rapidly frozen in liquid N<sub>2</sub> and thawed. Cell-free supernatants are clarified by centrifugation, filtered through a 0.45 micron membrane and stored frozen at -80°C.

To prepare virus stocks, cell-free filtered supernatants are harvested from the explant cultures and the PBMC-fibroblast cocultures and separately inoculated onto primary human fibroblast

- 51 -

cultures. Fibroblast cultures inoculated with explant supernatant and PBMC-fibroblast coculture supernatant develop CPE after inoculation. The cultures are rapidly frozen in liquid N<sub>2</sub> and thawed and cell-free supernatants are clarified by centrifugation, filtered through a 0.45micron membrane and stored frozen at -80°C.

- 5           The isolate is then cloned by limiting dilution, and a stock of virus is generated from this clone. Total cellular DNA is harvested from virus infected cells. The harvested DNA is then subjected to degenerate PCR for viral DNA polymerase, exactly as described above for JMHV and RRV. Once confirmed, a cosmid library of this virus is made from purified viral DNA (as described above for JMHV and RRV). The viral genes included in the cosmid library are subsequently  
10       cloned and sequenced.

### EXAMPLE 23

#### Screening Assays for Pharmaceutical Agents of Interest

- 15           The present disclosure provides a virus that is involved in the causation or progression of certain diseases, such as KS or multiple sclerosis, and therefore provides an animal model and assays directed to identifying potential pharmaceutical agents that inhibit the biological activity of the virus. Drug screening assays which determine whether or not a drug has activity against the virus can  
20       include incubating a compound to be evaluated for use in treatment of the condition with cells which express the RRV or JMHV proteins or peptides, and determining the effect of the compound on the activity of the virus. In vitro assays in which the virus is maintained in suitable cell culture are preferred, though in vivo animal models would also be effective.

- In vitro assays include infecting cells such as rhesus or Japanese macaque fibroblasts,  
25       neuronal cells, peripheral blood leukocytes or susceptible T cell lines such as MT-4 with the agent of interest in the presence of varying concentrations of compounds targeted against viral replication. These compounds include, but are not limited to nucleoside analogs, chain terminators, antisense oligonucleotides and random polypeptides. (Asada et al., *J. Clin. Microbiol.* 27:2204, 1989; Kikuta et al., *Lancet* 7:861, 1989). Infected cultures and their supernatants can be assayed for the total  
30       amount of virus, including the presence of the viral genome, by quantitative PCR, by dot blot assays, or by using immunologic methods. For example, a culture of susceptible cells could be infected with the RRV or JMHV in the presence of various concentrations of drug, fixed on slides after a period of days, and examined for viral antigen by indirect immunofluorescence with monoclonal antibodies to viral polypeptides (Kikuta et al, supra). Alternatively, chemically adhered MT-4 cell monolayers can  
35       be used for an infectious agent assay using indirect immunofluorescent antibody staining to search for focus reduction (Higashi, *J. Clin. Microbiol.* 27:2204, 1989, incorporated by reference).

          As an alternative to whole cell in vitro assays, purified enzymes isolated from the RRV or JMHV can be used as targets for rational drug design to determine the effect of the potential drug on enzyme activity, such as thymidylate synthase or DNA polymerase. The genes for these two RRV

- 52 -

enzymes are provided herein. A measure of enzyme activity indicates an effect on the infectious agent itself. Drug screens using herpes viral products are known and have been previously described in EP 0514830 (herpes proteases) and WO 94/04920 (U<sub>L</sub> 13 gene product).

5 In particular embodiments, this invention provides an assay for screening anti-KS or anti-MS chemotherapeutics. Infected cells can be incubated in the presence of a chemical agent that is a potential chemotherapeutic against KS (e.g. acyclo-guanosine). The level of virus in the cells is then determined after several days by IFA for antigens or Southern blotting for viral genome or Northern blotting for mRNA and compared to control cells. This assay can quickly screen large numbers of chemical compounds that may be useful against KS. This invention also provides an assay system  
10 that is employed to identify drugs or other molecules capable of binding to the DNA molecule or proteins, either in the cytoplasm or in the nucleus, thereby inhibiting or potentiating transcriptional activity. This assay would be useful in the development of drugs that are specific against particular cellular activity, or that would potentiate such activity, in time or in level of activity. Also included are drugs identified by this assay which have an anti-viral activity, and an effect against conditions  
15 associated with RRV infection, such as KS.

Similarly, this invention provides an assay for screening anti-multiple sclerosis (MS) therapeutics. Infected cells can be incubated in the presence of a chemical agent that is a potential anti-inflammatory agent or other agent of use in treating MS. The level of virus in the cells is then determined by IFA for antigens, Southern blotting for the viral genome, Northern blotting for mRNA,  
20 or PCR, and compared to control cell. This assay can quickly screen large numbers of agents that may be useful in the treatment of MS. This invention also provides an assay system that is employed to identify drugs or other molecules capable of binding to the DNA molecule or proteins, either in the cytoplasm or in the nucleus, thereby inhibiting or potentiating transcriptional activity. This assay would be useful in the development of drugs that are specific against particular cellular activity, or  
25 that would potentiate such activity, in time or in level of activity. Also included are drugs identified by this assay which have an anti-viral activity, and an effect against conditions associated with JMHV infection, such as MS.

#### EXAMPLE 24

##### 30 Generating Animal Models

Animal models are useful for resolving a number of fundamental problems of infectious diseases that include, but are not limited to, determinants of virulence of the organism, mechanisms of host resistance, mechanisms of pathogenicity, establishment and regulation of chronic infection, and antimicrobial and chemotherapeutic actions of drugs on infectious agents. Variables that are  
35 commonly manipulated to address fundamental problems include, but are not limited to, the strain of infectious agent, the infecting dose of infectious agent and the route of administration of the infectious agent, the species or subspecies of animal, the age of animal, and the genetic background of the animal (Viral pathogenesis, N. Nathanson, Lippincot-Raven, Philadelphia, 1997).

- 53 -

In an embodiment in which one or more RRV strains are employed for generating an animal model, the RRV used may be naturally occurring variant isolates recovered from rhesus macaques and other non-human primate species, molecular clones generated from these naturally occurring variant isolates and recombinant viruses with introduced mutations, deletions or recombined genomes designed to address function of specific genes.

By manipulating the infecting dose and route of RRV administration virus-host interactions dependent upon dose and tissue or organ-specific disease manifestations can be explored. Thus, the present invention includes various doses of RRV administered by oral, inhalation, intratracheal, intravaginal, intrarectal and parenteral routes including, but not limited to intravenous, intraarterial, intradermal, subcutaneous, intramuscular, intraperitoneal and organ-specific administration routes such and intracerebral and intraocular administration.

Many disease manifestations with a given infections agent are highly influenced by age and species or subspecies of the host and the particular genetic makeup of the host. The present disclosure provides a virus that is involved in the causation or progression of certain diseases, such as KS, in the rhesus macaque, but is also useful for the study of and discovery of disease manifestations that are host species, age and genetic background dependent. In particular embodiments, one skilled in the art may vary the species of animal to which the RRV is administered to produce or discover a particular disease manifestation, or similarly vary the genetic background of the animal to produce or discover a particular disease manifestation, even including the use of genetically engineered animals.

In another embodiment, in which one or more JMHV strains are employed for generating an animal model, the JMHV used may be naturally occurring variant isolates recovered from Japanese macaques and other non-human primate species, molecular clones generated from these naturally occurring variant isolates and recombinant viruses with introduced mutations, deletions or recombined genomes designed to address function of specific genes.

By manipulating the infecting dose and route of JMHV administration virus-host interactions dependent upon dose and tissue or organ-specific disease manifestations can similarly be explored. Thus, the present invention includes various doses of JMHV administered by oral, inhalation, intratracheal, intravaginal, intrarectal and parenteral routes including, but not limited to intravenous, intraarterial, intradermal, subcutaneous, intramuscular, intraperitoneal and organ-specific administration routes such and intracerebral and intraocular administration.

Many disease manifestations with a given infections agent are highly influenced by age and species or subspecies of the host and the particular genetic makeup of the host. The present disclosure provides a virus that is involved in the causation or progression of certain diseases, such as MS, in the Japanese macaque, but is also useful for the study of and discovery of disease manifestations that are host species, age and genetic background dependent. In particular embodiments, one skilled in the art may vary the species of animal to which the JMHV is administered to produce or discover a particular disease manifestation, or similarly vary the genetic background of the animal to produce or discover a particular disease manifestation, even including the use of genetically engineered animals.

- 54 -

**EXAMPLE 25****Pharmaceutical Compositions and Modes of Administration**

Various delivery systems for administering pharmaceutical proteins from the RRV or JMHV  
5 include encapsulation in liposomes, microparticles, microcapsules, expression by recombinant cells,  
receptor-mediated endocytosis (see Wu and Wu, *J. Biol. Chem.* 1987, 262:4429-32), and construction  
of a therapeutic nucleic acid (such as an anti-sense molecule) as part of a retroviral or other vector.  
Methods of introduction include, but are not limited to, intradermal, intramuscular, intraperitoneal,  
intravenous, subcutaneous, intranasal, and oral routes. The compounds may be administered by any  
10 convenient route, for example by infusion or bolus injection, by absorption through epithelial or  
mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered  
together with other biologically active agents. Administration can be systemic or local. In addition,  
the pharmaceutical compositions may be introduced into the central nervous system by any suitable  
route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated  
15 by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir.

The use of liposomes as a delivery vehicle is another delivery method of the present  
invention. The liposomes fuse with the target site and deliver the contents of the lumen  
intracellularly. The liposomes are maintained in contact with the target cells for a sufficient time for  
fusion to occur, using various means to maintain contact, such as isolation and binding agents.  
20 Liposomes may be prepared with purified proteins or peptides that mediate fusion of membranes,  
such as Sendai virus or influenza virus. The lipids may be any useful combination of known  
liposome forming lipids, including cationic lipids, such as phosphatidylcholine. Other potential lipids  
include neutral lipids, such as cholesterol, phosphatidyl serine, phosphatidyl glycerol, and the like.  
For preparing the liposomes, the procedure described by Kato et al. (*J. Biol. Chem.* 1991, 266:3361)  
25 may be used.

The present invention also provides pharmaceutical compositions which include a  
therapeutically effective amount of one or more RRV, or one or more JMHV proteins, or RRV or  
JMHV DNA, alone or with a pharmaceutically acceptable carrier.

The pharmaceutical compositions or methods of treatment may be administered in  
30 combination with other therapeutic treatments, such as other antineoplastic or antitumorigenic  
therapies.

**Administration of Nucleic Acid Molecules**

In an embodiment in which one or more RRV or JMHV nucleic acids are employed for  
35 generating an animal model, the analog may be delivered intracellularly (e.g., by expression from a  
nucleic acid vector or by receptor-mediated mechanisms). In a specific embodiment where the  
therapeutic molecule is a nucleic acid, administration may be achieved by an appropriate nucleic acid  
expression vector which is administered so that it becomes intracellular, e.g., by use of a retroviral  
vector (see U.S. Patent No. 4,980,286), or by direct injection, or by use of microparticle

- 55 -

bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox-like peptide which is known to enter the nucleus (see e.g., Joliot et al., *Proc. Natl. Acad. Sci. USA* 1991, 88:1864-8). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.

The vector pCDNA, is an example of a method of introducing the foreign cDNA into a cell under the control of a strong viral promoter (CMV) to drive the expression. However, other vectors can be used. Other retroviral vectors (such as pRETRO-ON, Clontech), also use this promoter but have the advantages of entering cells without any transfection aid, integrating into the genome of target cells ONLY when the target cell is dividing (as cancer cells do, especially during first remissions after chemotherapy) and they are regulated. It is also possible to turn on the expression of the RRV or JMHV nucleic acid by administering tetracycline when these plasmids are used. Hence these plasmids can be allowed to transfect the cells, then administer a course of tetracycline with a course of chemotherapy to achieve better cytotoxicity.

Other plasmid vectors, such as pMAM-neo (also from Clontech) or pMSG (Pharmacia) use the MMTV-LTR promoter (which can be regulated with steroids) or the SV10 late promoter (pSVL, Pharmacia) or metallothionein - responsive promoter (pBPV, Pharmacia) and other viral vectors, including retroviruses. Examples of other viral vectors include adenovirus, AAV (adeno-associated virus), recombinant HSV, poxviruses (vaccinia) and recombinant lentivirus (such as HIV). All these vectors achieve the basic goal of delivering into the target cell the cDNA sequence and control elements needed for transcription. The present invention includes all forms of nucleic acid delivery, including synthetic oligos, naked DNA, plasmid and viral, integrated into the genome or not.

Also contemplated are inhibitory nucleic acid therapeutics which can inhibit the activity of RRV, for example in subject with KS or other diseases associated with RRV infection. Similarly, inhibitory nucleic acid therapeutics are provided which can inhibit the activity of JMHV, for example in subject with MS or other diseases associated with JMHV infection. Inhibitory nucleic acids may be single-stranded nucleic acids, which can specifically bind to a complementary nucleic acid sequence. By binding to the appropriate target sequence, an RNA-RNA, a DNA-DNA, or RNA-DNA duplex or triplex is formed. These nucleic acids are often termed "antisense" because they are usually complementary to the sense or coding strand of the gene, although recently approaches for use of "sense" nucleic acids have also been developed. The term "inhibitory nucleic acids" as used herein, refers to both "sense" and "antisense" nucleic acids.

By binding to the target nucleic acid, the inhibitory nucleic acid can inhibit the function of the target nucleic acid. This could, for example, be a result of blocking DNA transcription, processing or poly(A) addition to mRNA, DNA replication, translation, or promoting inhibitory mechanisms of the cells, such as promoting RNA degradation. Inhibitory nucleic acid methods therefore encompass a number of different approaches to altering expression of RRV or JMHV genes. Cleavage, and therefore inactivation, of the target nucleic acids may be effected by attaching a substituent to the inhibitory nucleic acid which can be activated to induce cleavage reactions. The substituent can be

- 56 -

one that affects either chemical, or enzymatic cleavage. Alternatively, cleavage can be induced by the use of ribozymes or catalytic RNA. In this approach, the inhibitory nucleic acids would include either naturally occurring RNA (ribozymes) or synthetic nucleic acids with catalytic activity.

- 5 The inhibitory nucleic acid therapies can be used to target nucleic acids to sequences of RRV or JMHV for use in treating conditions caused by the RRV or JMHV, or proteins of the RRV (or JMHV), for example for treating KS or KS-like syndromes, or MS or MS-like syndromes.

#### *Administration of Antibodies*

- 10 Therapeutic, intravenous, polyclonal or monoclonal antibodies has been used as a mode of passive immunotherapy of herpesviral diseases, such as infection with CMV. Immune globulin from subjects previously infected with the RRV and bearing a suitably high titer of antibodies against the virus can be given in combination with antiviral agents (e.g. ganciclovir), or in combination with other modes of immunotherapy that are currently being evaluated for the treatment of KS, which are targeted to modulating the immune response (i.e. treatment with copolymer-1, antiidiotypic  
15 monoclonal antibodies, T cell "vaccination"). In one embodiment, antibodies specific for an epitope expressed on cells infected with the RRV are utilized and can be obtained as described above. Similarly immune globulin from subjects previously infected with the JMHV and bearing a suitably high titer of antibodies against the virus can be given in combination with antiviral agents (e.g.  
20 ganciclovir), or in combination with other modes of immunotherapy that are currently being evaluated for the treatment of MS, which are targeted to modulating the immune response. In one embodiment, antibodies specific for an epitope expressed on cells infected with the JMHV, obtained as described above, are utilized.

- 25 The present invention also provides pharmaceutical compositions which include a therapeutically effective amount of the antibody, and a pharmaceutically acceptable carrier or excipient.

- 57 -

**EXAMPLE 26****Vaccines**

This invention provides substances suitable for use as vaccines for the prevention of diseases associated with RRV infection, such as KS, and diseases associated with JMHV infection, or infection by related viruses which cause disease such as MS, and methods for administering them. Particular vaccines are directed against RRV or related viruses, and may include antigens obtained from RRV or those related viruses, or the vaccines are directed against JMHV or related viruses, and may include antigens obtained from JMHV or its related viruses. In one embodiment, the vaccine contains attenuated RRV or JMHV, or related viruses found in humans. In another embodiment, the vaccine contains killed RRV or JMHV. In another embodiment, the vaccine contains a nucleic acid vector encoding RRV or JMHV, or a surface protein of RRV or JMHV, such as a capsid protein. In another embodiment, the vaccine is a subunit vaccine containing an RRV or JMHV subunit, such as glycoprotein B, major capsid protein, or other gene products found to elicit appropriate humoral and/or cell mediated immune responses.

This invention also provides a method of vaccinating a subject against Kaposi's sarcoma and lymphoproliferative disorders, comprising administering to a susceptible subject an effective amount of the peptide or polypeptide encoded by an isolated DNA molecule encoding a polypeptide or combination of polypeptides expressed by the DNA molecule, and a suitable acceptable carrier. In one embodiment, naked DNA is administered to the subject in an effective amount to vaccinate the subject against Kaposi's sarcoma and lymphoproliferative disorders, or other disease associated with RRV infection.

In another embodiment, a method is provided for vaccinating a subject against multiple sclerosis, comprising administering to a susceptible subject an effective amount of the peptide or polypeptide encoded by an isolated DNA molecule encoding a polypeptide or combination of polypeptides expressed by the DNA molecule, and a suitable acceptable carrier. In one embodiment, naked DNA is administered to the subject in an effective amount to vaccinate the subject against multiple sclerosis, or other disease associated with JMHV infection.

The vaccine can be made using synthetic peptide or recombinantly-produced polypeptide described above as antigen. Typically, a vaccine will include from about 1 to 50 micrograms of antigen, for example from about 15 to about 45 micrograms. Typically, the vaccine is formulated so that a dose includes about 0.5 milliliters. The vaccine may be administered by any route known in the art, for example parenteral, subcutaneous or intramuscular.

There are a number of strategies for amplifying an antigen's effectiveness, particularly as related to the art of vaccines. For example, cyclization of a peptide can increase the peptide's antigenic and immunogenic potency. See U.S. Pat. No. 5,001,049. More conventionally, an antigen can be conjugated to a suitable carrier, usually a protein molecule. This procedure can allow multiple copies of an antigen, such as a peptide, to be conjugated to a single larger carrier molecule. Additionally, the carrier may possess properties which facilitate transport, binding, absorption or transfer of the antigen.

- 58 -

For parenteral administration, such as subcutaneous injection, examples of suitable carriers are the tetanus toxoid, the diphtheria toxoid, serum albumin and lamprey, or keyhole limpet, hemocyanin because they provide the resultant conjugate with minimum genetic restriction. Conjugates including these universal carriers can function as T cell clone activators in individuals  
5 having very different gene sets. The conjugation between a peptide and a carrier can be accomplished using one of the methods known in the art. Specifically, the conjugation can use bifunctional cross-linkers as binding agents as detailed, for example, by Means and Feeney, "A recent review of protein modification techniques," *Bioconjugate Chem.* 1:2-12 (1990).

Vaccines against RRV can be made from the RRV envelope glycoproteins, and vaccines  
10 against JMHV can be made from the JMHV envelope glycoproteins. These proteins can be purified and used for vaccination (Lasky, L. A., 1990, *J. Med. Virol.* 31:59). MHC-binding peptides from cells infected with the human herpesvirus can be identified for vaccine candidates per the methodology of Marloes, et al., 1991, *Eur. J. Immunol.* 21:2963-2970. The RRV or JMHV antigen may be combined or mixed with various solutions and other compounds as is known in the art. For example, it may be  
15 administered in water, saline or buffered vehicles with or without various adjuvants or immunodiluting agents. Examples of such adjuvants or agents include aluminum hydroxide, aluminum phosphate, aluminum potassium sulfate (alum), beryllium sulfate, silica, kaolin, carbon, water-in-oil emulsions, oil-in-water emulsions, muramyl dipeptide, bacterial endotoxin, lipid X, *Corynebacterium parvum* (*Propionibacterium acnes*), *Bordetella pertussis*, polyribonucleotides,  
20 sodium alginate, lanolin, lysolecithin, vitamin A, saponin, liposomes, levamisole, DEAE-dextran, blocked copolymers or other synthetic adjuvants. Such adjuvants are available commercially from various sources, for example, Merck Adjuvant 65 (Merck and Company, Inc., Rahway, N.J.) or Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, Mich.). Other suitable adjuvants are Amphigen (oil-in-water), Alhydrogel (aluminum hydroxide), or a mixture of  
25 Amphigen and Alhydrogel. Only aluminum is approved for human use.

The proportion of antigen and adjuvant can be varied over a broad range so long as both are present in effective amounts. For example, aluminum hydroxide can be present in an amount of about 0.5% of the vaccine mixture ( $Al_2O_3$  basis). On a per-dose basis, the amount of the antigen can range from about 0.1  $\mu$ g to about 100  $\mu$ g protein per subject, for example about 1  $\mu$ g to about 50  $\mu$ g  
30 per dose, or about 15  $\mu$ g to about 45  $\mu$ g. A suitable dose size is about 0.5 ml. Accordingly, a dose for intramuscular injection, for example, would comprise 0.5 ml containing 45  $\mu$ g of antigen in admixture with 0.5% aluminum hydroxide. After formulation, the vaccine may be incorporated into a sterile container which is then sealed and stored at a low temperature, for example 4°C., or it may be freeze-dried. Lyophilization permits long-term storage in a stabilized form.

35 The vaccines may be administered by any conventional method for the administration of vaccines including oral and parenteral (e.g., subcutaneous or intramuscular) injection. Intramuscular administration is preferred. The treatment may consist of a single dose of vaccine or a plurality of doses over a period of time. Also, the antigen could be a component of a recombinant vaccine which

- 59 -

is adaptable for oral administration. Vaccines of the invention may be combined with other vaccines for other diseases to produce multivalent vaccines. A pharmaceutically effective amount of the antigen can be employed with a pharmaceutically acceptable carrier such as a protein or diluent useful for the vaccination of mammals, particularly humans. Other vaccines may be prepared according to methods well-known to those skilled in the art.

Those of skill will readily recognize that it is only necessary to expose a mammal to appropriate epitopes in order to elicit effective immunoprotection. The epitopes are typically segments of amino acids which are a small portion of the whole protein. Using recombinant genetics, it is routine to alter a natural protein's primary structure to create derivatives embracing epitopes that are identical to or substantially the same as (immunologically equivalent to) the naturally occurring epitopes. Such derivatives may include peptide fragments, amino acid substitutions, amino acid deletions and amino acid additions of the amino acid sequence for the viral polypeptides from the human herpesvirus. For example, it is known in the protein art that certain amino acid residues can be substituted with amino acids of similar size and polarity without an undue effect upon the biological activity of the protein. The human herpesvirus proteins have significant tertiary structure and the epitopes are usually conformational. Thus, modifications should generally preserve conformation to produce a protective immune response.

#### EXAMPLE 27

##### Peptide Synthesis and Purification

The peptides provided by the present invention can be chemically synthesized by any of a number of manual or automated methods of synthesis known in the art. For example, solid phase peptide synthesis (SPPS) is carried out on a 0.25 millimole (mmole) scale using an Applied Biosystems Model 431A Peptide Synthesizer and using 9-fluorenylmethyloxycarbonyl (Fmoc) amino-terminus protection, coupling with dicyclohexylcarbodiimide/ hydroxybenzotriazole or 2-(1H-benzo-triazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate/ hydroxybenzotriazole (HBTU/HOBT), and using p-hydroxymethylphenoxymethylpolystyrene (HMP) or Sasrin resin for carboxyl-terminus acids or Rink amide resin for carboxyl-terminus amides.

Fmoc-derivatized amino acids are prepared from the appropriate precursor amino acids by tritylation and triphenylmethanol in trifluoroacetic acid, followed by Fmoc derivitization as described by Atherton et al. (Solid Phase Peptide Synthesis, IRL Press: Oxford, 1989).

Sasrin resin-bound peptides are cleaved using a solution of 1% TFA in dichloromethane to yield the protected peptide. Where appropriate, protected peptide precursors are cyclized between the amino- and carboxyl-termini by reaction of the amino-terminal free amine and carboxyl-terminal free acid using diphenylphosphorylazide in nascent peptides wherein the amino acid sidechains are protected.

HMP or Rink amide resin-bound products are routinely cleaved and protected sidechain-containing cyclized peptides deprotected using a solution comprised of trifluoroacetic acid

- 60 -

(TFA), optionally also comprising water, thioanisole, and ethanedithiol, in ratios of 100 : 5 : 5 : 2.5, for 0.5 - 3 hours at room temperature.

Crude peptides are purified by preparative high pressure liquid chromatography (HPLC), for example using a Waters Delta-Pak C18 column and gradient elution with 0.1% TFA in water modified with acetonitrile. After column elution, acetonitrile is evaporated from the eluted fractions, which are then lyophilized. The identity of each product so produced and purified may be confirmed by fast atom bombardment mass spectroscopy (FABMS) or electrospray mass spectroscopy (ESMS).

#### EXAMPLE 27

##### Spontaneous Demyelinating Encephalomyelitis in Japanese Macaques

Multiple sclerosis (MS) is a chronic, debilitating inflammatory disease limited to central nervous system (CNS) white matter for which there are very few effective treatments. The disease may not be etiologically homogeneous, but rather a complex set of diseases that have in common pathogenic mechanisms that involve genetically predisposed individuals, and infectious agents as initiators and diverse mechanisms of inflammatory white matter destruction (Hafler, J Clin Invest 104:527-529, 1999). Genetic studies in families with MS-affected members have revealed that MS is a complex trait, that the contribution of individual genes to susceptibility is probably small, and that differences are possible between familial and sporadic forms of the disease (Kalman and Lublin, Biomed Pharmacother 53:358-370, 1999.).

The inflammatory response in MS is characterized by T lymphocyte-mediated demyelination of the CNS and by autoimmune responses to myelin proteins such as myelin basic protein (MBP), proteolipid-protein (PLP), and myelin oligodendrocyte glycoprotein (MOG) (e.g. Wekerle, Curr Opin Neurobiol 3:779-784, 1993). No aspect of the inflammatory response in MS has been identified as being specific for the disease (Prineas and McDonald, In: Graham DI, Lantos PL (eds.), Greenfield's Neuropathology, 6<sup>th</sup> Edn. Oxford Univ. Press, New York, pp. 813-896, 1997). The lesions are vasocentric and initially characterized by leukocyte investment of small blood vessels, endothelial cell activation, edema and myelin swelling. Secondly, there is macrophage and microglial cell activation and selective myelin destruction. Chronic-active lesions are characterized by ongoing myelin breakdown and foamy macrophages are actively engaged in removing and digesting myelin. Oligodendroglial cells are typically reduced in number, astrocytes in the demyelinated zone are reactive and axons are, for the most part, preserved. Chronic plaques are, in general, quiescent glial scars. There is extensive variability in the clinical course of the disease and heterogeneity in the distribution and character of the lesions and there are five, and possibly six, clinical syndromes that seem to belong to the narrow group of immune-mediated demyelinating diseases considered to be MS or MS variants (Hickey, J Neuroimmunol 98:37-44, 1999).

Epidemiological evidence strongly supports the hypothesis that MS may be initiated by a virus infection. However, no single virus has been consistently found in MS lesions and no fewer than 16 infectious agents have been associated with the disease (Johnson, Viral Infections of the

- 61 -

Nervous System, 2<sup>nd</sup> Ed, Lippincott-Raven, Philadelphia, 1998). The JMHV, and related human viruses, are believed to be involved in the pathogenesis of this constellation of diseases.

Determining the mechanisms by which infections trigger autoimmune sequelae is an area of great interest, and may provide important clues about the pathogenesis and regulation of autoimmune diseases. While there is no evidence of an active cytolytic viral infection in the CNS in MS, viruses may participate in the pathogenesis of MS in one or more ways. First, viruses are postulated to share sequence homologies with myelin epitopes and, through the mechanism of molecular mimicry, activate autoreactive T cells (e.g. see Fujinami and Oldstone, Science 230:1043-1045, 1985). In general, there is little direct evidence to support this mechanism. Second, viral antigens expressed in the CNS as a result of chronic, non-cytolytic infection may serve as targets for virus-specific T cells entering into the CNS resulting in non-specific inflammatory, or bystander damage to myelin and myelin-producing oligodendrocytes (Miller and Gerety, Semin Virol 1:263-272, 1990). Third, CNS viral infections that initially cause cytolytic or bystander damage to myelin secondary to virus-specific T cells may promote induction of autoimmunity to the myelin proteins released by viral damage to the CNS by epitope spreading (Lehmann et al., Nature 558:155-157, 1992).

Several virus-induced and autoimmune models have been used to study the underlying mechanisms of myelin destruction in MS. These models include demyelinating diseases induced by infection with mouse hepatitis virus, Sindbis virus, Semliki Forest virus, herpesvirus, or Theiler's murine encephalomyelitis virus, as well as immunization with CNS autoantigens. Although these models have provided a wealth of knowledge about mechanisms of inflammatory demyelination and are attractive parallel models for human MS, their direct relevance to MS is unknown.

Demyelinating encephalomyelitis with morphologic features similar to multiple sclerosis was first observed in the Oregon Regional Primate Research Center Japanese macaque troop in July, 1986. The troop originated from 55 founder animals imported from Japan in 1965 and has been maintained as a close group. No additional animals have been introduced (Eaton, Adv Behav Biol 11:287-297, 1974). The incidence of the disease peaked the following year, affecting 3% of the population. Subsequently, approximately 1% of the population developed demyelinating encephalomyelitis annually. The age of the affected animals ranges from 97 days to 20 years, with approximately equal sex distribution (20 males and 18 females). The mean age at disease onset is 5 years, 22 days and young animals are over-represented among the 38 cases identified to date (median age = 3 years, 284 days).

Clinically, the disease is characterized by acute onset paresis or paralysis involving one or more limbs in robust, healthy animals that lack evidence of chronic disease. The severity is variable ranging from limb weakness to tetraparesis. Cerebrospinal fluid analysis generally reveals moderate to marked pleocytosis dominated by lymphocytes and elevated protein (Table 2). Regardless of the initial severity, the disease is uniformly progressive and necessitates euthanasia of the animal. Treatment with high doses of corticosteroids delays progression for several days to weeks. However, all animals treated with corticosteroids to date have manifested relapsing, progressive disease.

- 62 -

Table 2 - Japanese Macaque Demyelinating Encephalomyelitis, CSF Analysis					
ID No.	Glucose (mg%)	Total Protein (mg/dL)	WBC (□L)	Lymph (%)	PMN (%)
13762	58	20	1	100	0
14871	nd	nd	336	9	4
12800	nd	107	186	9	4
13754	nd	112	2,710	100	0
07804	nd	nd	58	100	0
09179	nd	11	0		
08234	nd	104	11	100	0
08420	52	113	30	100	0
12133	41	32	0		
16376	42	29	204	95	5
15997	nd	71	83	90	10
13768	56	56	112	100	0
16387	54	48	70	85	15
13744	46	12	8	100	0
15306	33`	195	12	100	0
19400	nd	144	341	93	7
Range (Mean)	33-58 (48)	11-195 (75)	0-2,710 (260)	(89)	(5)

Pathologically, Japanese macaque demyelinating encephalomyelitis is characterized by multifocal dull yellow or pale tan plaques that range from 0.2 to 1.0 cm in greatest dimension

- 63 -

distributed primarily in the cerebellar and spinal cord white matter. Gray matter is exquisitely spared. Most animals lack lesions in the mid- and forebrain. Histologically, they are vasocentric and vary considerably in age. Acute lesions are dominated by perivenous lymphocytic cuffs that frequently track perforating venules from pia-arachnoid surfaces into adjacent white matter. The infiltrating lymphocytes frequently have large, activated nuclei as do endothelial cells lining the venules within the lymphocytic cuffs. The adjacent myelin is edematous, vesiculated and sparsely infiltrated with lymphocytes and macrophages. Occasionally, small focal hemorrhages are present in the edematous myelin. Subacute lesions are densely infiltrated with macrophages and lymphocytes and there is conspicuous myelin damage and phagocytosis of myelin debris by macrophages. Necrosis and microcystic spaces are dominant features in some subacute lesions. Chronic lesions consist of crisp plaques composed principally of fibrous astrocytes with foamy macrophages and occasional lymphocytes entrapped in the meshwork of glial fibers. The propensity for these lesions to occur only in white matter, their inflammatory demyelinating character and variable age are recognized features of MS. The acute fulminant course despite the histologic evidence of both acute and chronic lesions, the presence of necrosis in some subacute lesions and the predilection for the cerebellum and spinal cord are most consistent with the neuromyelitis optica or Devic's disease variation of MS (Prineas and McDonald, In: Graham DI, Lantos PL (eds.), Greenfield's Neuropathology, 6<sup>th</sup> Edn. Oxford Univ. Press, New York, pp. 813-896, 1997; Raine, In: Davis RL, Robertson DM (eds.), Textbook of Neuropathology, 3<sup>rd</sup> Edn. Williams and Wilkins, New York, pp. 627-714, 1997). While Devic's disease has clinical and pathologic features that are distinct from those of classical MS, individuals that survive the acute episode often progress to develop a disease course typical of classical MS, suggesting that the underlying process is similar or identical.

25

#### EXAMPLE 28

##### Isolation of Japanese Macaque Herpesvirus 17792

Attempts to isolate bacteria from cerebrospinal fluid and lesioned brain in these animals were negative in all cases, as were initial attempts to isolate viruses by inoculating cell cultures with homogenized brain. Thus, primary tissue explant cultures and cocultivation of leukocytes with target cells were used to enhance the probability of isolating highly cell-associated agents. Fresh tissue was dissected from visible spinal cord lesions identified during necropsy examination of Japanese macaque 17792 on 05/22/95. Spinal cord tissue explant cultures were established from small spinal cord tissue fragments cultured in T-25 culture flasks in Dulbecco's Modified Eagle Medium (DMEM, Gibco) supplemented with 20% fetal bovine serum, 1% L-glutamine and 1% penicillin-streptomycin-neomycin. Spinal cord explant cultures were fed by partial medium replacement every 7-10 days and passaged at confluence after 30 days in culture. Confluent monolayer explant cultures were rinsed in calcium- and magnesium-free phosphate-buffered saline, pH 7.4, digested with trypsin-EDTA at 37°C, washed with growth medium and seeded into T-25 culture flasks. First

- 64 -

passage spinal cord explant cultures were fed by complete medium replacement at 5 to 7 day intervals and developed cytopathic effects (CPE) 7 days after passage. Cytopathic effects spread through the first passage spinal cord explant cultures after 14 days in culture and they were rapidly frozen in liquid N<sub>2</sub> and thawed. Cell-free supernatants were clarified by centrifugation, filtered through a 0.45µ membrane and stored frozen at -80°C.

Peripheral blood mononuclear cells (PBMC) were isopycnic gradient-purified (Ficoll-Paque, Pharmacia) from fresh ammonium heparin anti-coagulated blood obtained from Japanese macaque 17792 at necropsy. Gradient-purified PBMC were washed in calcium- and magnesium-free phosphate-buffered saline and 3x10<sup>6</sup> PBMC were cocultured with 1x10<sup>5</sup> primary rhesus macaque fibroblasts in T-25 culture flasks containing DMEM growth medium supplemented with 10% fetal bovine serum, 1% L-glutamine and 1% penicillin-streptomycin-neomycin. The PBMC-fibroblast cocultures were fed by partial medium replacement after 3 days in culture and passaged at confluence at day 9. Confluent PBMC-fibroblast cocultures were rinsed in calcium- and magnesium-free phosphate-buffered saline, pH 7.4, digested with trypsin-EDTA at 37°C, washed with growth medium and seeded into T-25 culture flasks. First passage PBMC-fibroblast cultures were fed by complete medium replacement at 3 to 5 day intervals and exhibited CPE 12 days after passage. Cytopathic effects spread through the first passage PBMC-fibroblast cultures after 15 days in culture and the cultures were rapidly frozen in liquid N<sub>2</sub> and thawed. Cell-free supernatants were clarified by centrifugation, filtered through a 0.45 micron membrane and stored frozen at -80°C.

To prepare virus stocks, cell-free filtered supernatants harvested from the spinal cord explant cultures and the PBMC-fibroblast cocultures were separately inoculated onto primary rhesus macaque fibroblast cultures. Fibroblast cultures inoculated with spinal cord explant supernatant and PBMC-fibroblast coculture supernatant developed CPE 5 days post-inoculation. The cultures were rapidly frozen in liquid N<sub>2</sub> and thawed and cell-free supernatants were clarified by centrifugation, filtered through a 0.45micron membrane and stored frozen at -80°C. Using similar techniques, vero cells (American Type Culture Collection ATCC CCL-81) were shown to be susceptible to infection and suitable for propagation of virus.

For transmission electron microscopy, passage primary spinal cord explant cultures exhibiting CPE and fibroblast cultures developing CPE following inoculation with cell-free filtered supernatant from primary spinal cord explant cultures or PBMC-fibroblast cocultures were scraped free into medium, pelleted at 400 xg, washed in calcium- and magnesium-free phosphate-buffered saline and suspended in cold ITO and Karnofsky's fixative (2.5% glutaraldehyde, 0.5% picric acid, 1.6% paraformaldehyde, 0.005% ruthenium red) in 0.1 M sodium cacodylate buffer, pH 7.4, for 2 hours. Fixed cells were washed in cacodylate buffer, post-fixed in 1% OsO<sub>4</sub> and 0.8% K<sub>3</sub>Fe(CN)<sub>6</sub> in cacodylate buffer for 1 hour, rinsed in distilled H<sub>2</sub>O and pre-stained in 2% aqueous uranyl acetate for 1 hour. Fixed and pre-stained cells were dehydrated in a graded series of acetone imbedded in Epon 812 epoxy resin, polymerized at 60°C and sectioned at 60 nm on an MT 5000 ultramicrotome. Copper grid mounted sections were stained with lead citrate and uranyl acetate and viewed in a Phillips 300 electron microscope. Numerous herpesvirus particles were observed in the primary

- 65 -

spinal cord explant cells and in fibroblasts inoculated with cell-free filtered supernatant from primary spinal cord explant cultures and the PBMC-fibroblast cocultures.

#### EXAMPLE 29

##### 5 Japanese Macaque Herpesvirus Epidemiology

To retrospectively and prospectively evaluate the relationship between Japanese macaque herpesvirus (JMHV) infection and encephalomyelitis, animals were identified in the troop that were actively infected with JM herpesvirus by cocultivating PBMC with rhesus macaque fibroblasts (see above), the seroconversion rate using an enzyme-linked immunoassay (ELISA) constructed with strain 17792 JM herpesvirus was established as follows. JM herpesvirus strain 17792-infected primary rhesus macaque fibroblasts were solubilized with 0.5% Nonidet P-40 and 1% sodium deoxycholate in phosphate-buffered saline, pH 7.2, and clarified in a Beckman SW28 rotor at 23,500 rpm for 1 hour at 4°C. The clarified supernatant was used as antigen for coating 96-well Maxisorp plates (2 ng/ well) (Nunc, Roskilde, Denmark). ELISAs were then performed essentially as described (Kodama et al., AIDS Res Hum Retroviruses 5:337-343 1989).

In 1995-1996, 70-75% of the infected animals were less than 7 years of age. Analysis of samples from these animals revealed that 16% of the animals in the troop had culturable simian spumaretrovirus (simian foamy virus; SFV) and 8% of the animals in the troop had JM herpesvirus in peripheral blood leukocytes (PBL). Virus isolation from PBL was repeated for 199 animals in 1997; SFV was recovered from 11 (5.5%), the JM herpesvirus was recovered from 120 (60.3%), and 5 (0.25%) had dual infections.

The number of JMHV-positive animals decreased with age; 97% of animals less than 1 year of age and 27% of animals greater than 10 years of age were isolation-positive. One hundred percent of the animals greater than 300 days of age were seropositive for JM herpesvirus. Eight animals developed demyelinating encephalomyelitis in 1995-1997 and all were seropositive for the JM herpesvirus, and 6 of 8 were animals previously identified as JM herpesvirus isolation-positive. Two of the JM herpesvirus-infected animals were co-infected with SFV. SFV was isolated from 1 of 2 JM herpesvirus isolation-negative animals and no virus was isolated in the remaining animal. Brain and spinal cord were available for virus isolation from 7 of the 8 animals with demyelinating encephalomyelitis; MRV was isolated from lesioned brain or spinal cord explant cultures from 3, both MRV and SFV were recovered from 2, 1 yielded only SFV and virus was not isolated from 1. Virus was not recovered from explant cultures of normal appearing white matter from the cerebrum in any animal.

#### 35 EXAMPLE 30

##### JMHV Sequence

The Japanese macaque virus isolate was isolated from a lesion that was minced and co-cultured with primary rhesus fibroblasts. The isolate was then cloned by limiting dilution and a stock of virus generated from this clone. Total cellular DNA was harvested from virus infected cells and

- 66 -

the DNA subjected to degenerate PCR for viral DNA polymerase, exactly as described above for RRV. Once confirmed, a cosmid library of this virus was made from purified viral DNA (as described for RRV) and then a portion of the protein genes was cloned and sequenced.

- 5 Cosmid 3 is an isolate from a Japanese macaque virus library. It contains about 35,000 bp of viral sequence and 7000 bp of vector. The viral sequence was sub-cloned using Eco R1. The fragments below are these EcoR1 fragments. The terms T7 and SP6 are the names of universally used primers for sequencing - they sequence opposing ends of the viral fragment. Because the lengths of the viral inserts vary, and may be quite large, the open reading frame found at one end of the insert may or may not differ from the open reading frame found at the other end of the insert.
- 10 Protein sequences are in the standard single letter code.

Cosmid 3 Fragment 7 T7 Sequence

Orf 21 - Thymidine kinase

- 15 DNA sequence (SEQ ID NO:2)  
GAATTCATATTGCATATGTCCTCTATGGACACAGTTTGTACACACAACTGAACCATTTGT  
TCCGGTGTGAGATATTGCATCATCCACGTACAGAACACGGCGTGGTACGCCCACGC  
TACCTGTCGCAAGTAGTTTTGCGTGATTCTTTTTCTTCCTTGCGGCCTCGACTTTGAATG  
CGCCTGTGCGCCTCOGAACTGTTGAGCGTTAGCAAAACGACCACATCACCGTCGTGTGC  
20 CGAGAAAAGAGATAGGATTTGAAACAAATGATCCGGCGTTAGCCTGTTGTACTTTACGT  
GAACCAGCGGAAAAACAACGGTGGCGGACAGTAGGTGTCTGTCAAAAACAATCCAATT  
CGCTGGCTTTGTGCTACCGTTTCCCACTAGCCACGGTTGCAGGTTGCGACCGATGCCGGC  
GGCCGTTGCA
- 25 Deduced amino acid sequence (SEQ ID NO:3)  
ATAAGIGRNLQPWLVGNGSTKPANWIVFDRHLLSATVVFPLVHVKYNRLTPDHLFQILSLFS  
AHDGDVVLLTLN SSEAHRRIQSRGRKEEKGITQNYLRQVAWAYHAVFCTWVMMQYLTP  
QMVQLCVQTVSIEDICNMN

- 30
- Cosmid 3 Fragment 7 SP6 sequence  
Orf 21 - Thymidine kinase

- DNA sequence (SEQ ID NO:4)
- 35 GAATTCAATGACTGGCATGGTGCCGCAGGAAAACGTCCTTAAGCTGTCCAGAGCCCATGA  
AATTTTGGACGTGTGTTTATTCAAATTGCCTTAAAGAGCAGCGCAGCATAGTTAAGCAA  
GGCACCCACGGGAAATCGATCACTTCTGCTCGCGTATACGCGTGTGAGCAAGTTTGC  
GCTACCTTTTCTGTCGAACGGCCGCGGCATCGGTCGCAACCTGCAACCGTGGCTAGTGG  
GAAACGGTAGCACAAAGCCAGCGAATTGGATTGTTTTTGACAGACACCTACTGTCCGCC

- 67 -

ACCGTTGTTTTTCCGCTGGTTCACGTAAAGTACAACAGGCTAACGCCGGATCATTTGTTT  
CAAATCCTATCTCTTTTCTCGGCACACGACGGTGATGTGGTCGTTTTGCTAACGCTCAAC  
AGTTCGGAGGGCGCACAGGCGCATTCAAAGTCGAGGCCGCAAGGAAGAAAAAGGAATCA  
CGCAAAACTACTTGCGACAGGTAGCGTGGGCGTACCACGCCGTGTTCTTGT

5

Deduced amino acid sequence (SEQ ID NO:5)

NSMTGMVPQENVLSCPEPMKFWTCVYSNCLKEQRSIVKQGTHGKSITSARVYACQSKFALP  
FRATAAGIGRNLQPWLVGNGSTKPNWIVFDRHLLSATVVFPLVHVKNRLTPDHLFQILSL  
FSAHDGDVVLLTLNSSEAHRIQSRGRKEEKGITQNYLRQVAWAYHAVFL

10

Cosmid 3 Fragment 5 T7

No ORF associated, but highly similar to the DNA sequence found in and to the right of RRV repeat  
unit rDL-B1.

15

DNA sequence (SEQ ID NO:6)

AGCGAGTCMGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCG  
CGCGTTGGCCGATTCAATTAATGCAGGTTAACCTGGSKTRTCGAAATTAATACGACTCACT  
ATAGGGAGACCGGCCTCGAGCAGCTGAAGCTTGCATGCCTGCAGGTCGACTCTAGAGGA  
20 TCCCCGGGTACCGAGCTCGAATTCCAGACAGGTAAGATTTTAGCTCCTAATGTTTGCCTT  
GCCGCCTAGCTCCTAATGTTTGCCTTGCCGCCTAGCTCCTAATGTTTGCCTTGCCGCCTAG  
CTCCTAATGTTTGCCTTGCCGCCTAGCTCCTAATGKTTGCCTTGCCGCCTAGCTCCTAATG  
TTTGCCTTGCCGCCTAGCTCCTAATGTTTGCCTTGCCGCCTAGCTCCTAATGTTTGCCTTG  
CCGCCTAGCTCCTAATGTTTGCCTTGCCGCCTAGCTCCTAATGTTTGCCACGTTTATGTT  
25 TAAGCACACTAAAATTTAAAAACGTTTGTGTTGGTTTTATGACCGGCTTGGTACAAAAC  
CTGCTGGTGATTTTTTACCCAACAAAAATAATAAATAAAAAAGTTAAACCTATTCTGT  
TGTCGTGGTAATTGCGTTCGCCGAGGGT

30

Cosmid 3 Fragment 5 SP6

Orf 17 - a capsid protein

DNA Sequence (SEQ ID NO:7)

GAATTCGCAGCCCCTCTTGAAACACTGATGGCCAAGGCGATCGACGCCGGATTTATCCG  
35 AGATCGCACAGACCTGCTCAAAACAGATAAAGGCGTGGCCAGAGTCGCGAGAAGTACG  
TATTTAAAGGCCAGCCAGTCTCCCTCCTCTCAGCACGGCGGTAACCGCGACACCCAAAC  
CATGAGCGCCCTCCCGGATGACAACATCACCATTCCAAGAGCACCTTTCTAACCATGGT  
GCAGAGCAGTCTCGATCACATGCGCAACCAGGGCCAACGCGCGTACGTTTCCGCGCCAC

- 68 -

CCTCGATGCCGGCAACGGCGGCGTATCCCTCGTGGATACCGCCACCAGAACTGACCGTC  
CCGTCGTACGCGCCGCGCCGTAGCGCCACCGTTCCTTTTCAGTCGGCGTTTG

Deduced amino acid sequence (SEQ ID NO:8)

5 EFAAPLETLMAKAIDAGFIRDRTDLLKTDKGVARVARSTYLKASQSPSSQHGGNRDTQTMS  
ALPDDNITIPKSTFLTMVQSSLDHMRNQGQRAYVSAPPSMPATAAYPSWIPPELTVPSYAPP  
VAPPPFFQSAF

10 Cosmid 3 Fragment 3 T7  
Orf 21 Thymidine kinase

DNA sequence (SEQ ID NO:9), includes frameshift mutations

15 GRGCGCAGCGAGTCAGTGAGCGAGGNAAGCGGAAGAGCGCCCAATACGCAAACCGCCT  
CTCCCCGCGCGTTGGCCGATTCATTAATGCAGGTTAACCTGGSTTATCGAAATTAATACG  
ACTCACTATAGGGAGACCGGCCTCGAGCAGCTGAAGCTTGCATGCCTGCAGGTCGACTC  
TAGAGGATCCCCGGGTACCGAGCTCGAATTCCAGATTGACTCATCGGTTTCTAACCCCTAA  
CAAAGTTGCATGAACAGAGTATGATACCAATGGTGGTAGAAATGTTAGCAGCGGTTAAA  
20 GAACACGTGACCTTAATGGAGGTCTGTTTGGGCCTCTTTAAAGAGCTACGAAAGCTTCA  
GATTTTAATTGTTGACGCGGGAGAACATTTAGATGATACGTGTGGCCTTTGGGGAAATAT  
TTATGGGCAGGTAATGTCAAATGAGGCTATTAAACCACGAGCCGTGAACTGGCCAGCCC  
TTGAAAGCTACATTCAAACGCTAACCAGCTTGGAAAGCAATGCAGCCAATTAACCACGG  
TTTGTGTTTGTGTTGTAATTACATTCTCTGTAATTAATGGATATGAATATAATGAAGAAA  
25 TGTACCTGGACTTGAAATAGTTCTTTTACCCCTGCC

Deduced amino acid sequence - region between frameshifts (SEQ ID NO:10)

SLHACRSTLEDPRVPSSNSRLTHRFLTTLKLHEQSMIPMVVEMLAAVKEHVTLMEVCLGLFK  
BLRKLQILIVDAGEHLDDTCGLWGNIVGQVMSNEAIKPRAVNWPALESYIQTLSLESNAAN  
30

Cosmid 3 Fragment 3 SP6  
Orf 24 Unknown function

DNA sequence (SEQ ID NO:11)

35 GAATTCAATACGCTCCAAAAGATAGAGATCACAATTTTATTTTGGACGCCAATCAAAAC  
CCAGATCGACATAAAACAAGTGCACCACGACCACCAGACCGAACCGCTTCCAGACATGTT  
CGATCCAGTAAAGCACCTAAGTTTACACAACCTCAAAATCTCAGTTTCAATACCAATAT  
GGTAATTAATACAAAATCACGTGCCGGTCTCTACCGGTACCTTCGAGTCAATCATCGA  
CATCCCCAGGCTCACAAATAACTTTGTAATGAAAAAATTCTCCGTGAAAGAACCGTCAT

- 69 -

TCACTGTGAGCGTGTCTACTCCGACAACTGTGCAACGGGGCTGCGATTAACGTTAACA  
TAAGCGGGGACATGCTGCACTTTATGTTGCTATGGGAAACCTGAGGTGCTTTTGGCCG  
TGAAGCACATTTTCCCGGTTTCGATTGCGAACTGGAACCTACGTTAGACCTCCACGGGC  
TCGAAAACCAATACATAGTTAGACGGGGGCGGCGAGACGTTTTCTGG

5

Deduced amino acid sequence (SEQ ID NO:12)

IQYAPKDRDHNFIIDANQNPDRHKQVHHDHQTEPLPDMFDPVKHLSLHNFKISVFNTNMVIN  
TKITCRSLTGTFESIIPRLTNNFVMKKFSVKEPSFTVSVFYSDNLCNGAAINVNISGDMLEH  
MFAMGNLRCFLPVKHIFPVSIANWNSTLDLHGLENQYIVRRGRRDVFW

10

Cosmid 3 Fragment 1 T7

Orf 7 Transport protein

DNA sequence (SEQ ID NO:13)

15 GATCCCATAGAGTCCCTGTTCTGCGGCGTCTTTTAACTCTATAGACGATACCATTAAAC  
GCACTGAGCCGGGATTGTTTCGGTAACGTTCTTTCAACAGGCAAACTATACCAACGTCAT  
GCGAAAACAAAACGAGCTGTTTACCAGACTCAACAGCATATTGTGTCAGGGGAGCGCGG  
GATCGCAAAACCGGCCACCCCTCGGAGCCACGGACCGCCACCGTCGCGGCGACCGCG  
GCAAGCGACGTCATTAAAGACGCACAATATCGCAAAAGAACAGTACATGAAAAAGGTGG  
20 CCAGGGACGGCTTTAAAAAACTAACAGAGTGTCTGCAGACGCAAAGCGCGGTGTTGGCA  
AACGCGCTCTGCATGCGCGTATGGGGGGGCGTCGCATACGGCGA

Deduced amino acid sequence (SEQ ID NO:14)

DPIESLFCGGFLNSIDDTINALSRDCSVTFQQAANYTNVMRKQNELFTRLNSILCQGSAGSQK  
25 PATPSEPRATVAATAASDVIKDAQYRKEQYMKKVARDGFKKLTECLQTQSAVLANALCM  
RVWGGVAYG

Cosmid 3 Fragment 1 SP6

30 No ORF. Similar to sequence to the left of the RRV repeat rDL-B1

DNA sequence (SEQ ID NO:15)

GAATTCACACCCGAACAAATCTAAAAGCAAAATTACACAAATTAACAAAAATACAATA  
TAACACAGTTAAAAAATTCATACATAATTACAATGGTAAAAATTCACGCGTACATAATT  
35 ACAATTTTAAATTCATTTAAAAATTCACGTGTACACAATTACAAAATTCACACAATTTT  
AAAATCCTTTTAACCATAAAATTAGAACGGCACTGTATATATGCAGCGTATTGCAAACT  
GGCAGCTTTGTGTTAAAGACCACGGCATTAATTTTAAATTCGCCAGGTGCGCAAAAGT  
ACTGGTTACGTTAGTTCATCTAAAAGCTTAACGTGCTTGTGCTTAAATTTACGCCGTGCC  
ATTGCTCCATTTTAAATTAATAATTTAAATGTAGTGCGAGCGAGCTAGAAACAGAAACC

- 70 -

GCGACGCGGGGAGGTTGCGTAGGTTGCGCGTTTTTGGCTCCAGTGACAATCCAAAAGC  
TGCGGTTTACGAGCCATTGTTTTGTCAACCACTAAACCGAAAGCATGCG

5

Large EcoR1 fragments were then further reduced using Kpn 1

Cosmid 3 EcoR1 Fragment 1 Kpn 1 fragment 1 T7

Orf 10 Unknown protein

10

DNA sequence (SEQ ID NO:16)

GGTACCCCCACGACTATAAAAAGAGACACCCTGGTGGCCGCCGCCGCCCTGCCCCGT  
GGTGCAGTAAGCTCCGCCGACGACGCGCCGCCGGGATCTCGTCGCGTCAACAGACACCG  
GGGCGCTCTCCATTGACGCGTTCACAATCCCGGTCGGTCTCCCCGGGGTGGTCTCGGCGG  
15 AGTGTCACGTGTCTATGCGCGACAACGGGGTCCACGAACGCATGAGCCATTAACGGCGA  
CAATGGGAACACCGGTGCGTTTCTTTCGCGGCGAGTGGCAAACCTCGAGTCTGGTGGAC  
AACGGCACGCCACGGTACAGCTCCCTGGTGTGGGCCGCCACTATCCACGACGGCTACCT  
GACACTGGTGAACAGGTGCGAGCTGTGCGTCACGGAGCGGTCTCCGTGTCTGCCGGCGT  
GCCCCAGCATCGGGAGACTGGTTCG

20

Deduced amino acid sequence C-terminus of protein (SEQ ID NO:17)

GTPTTIKRDTLVAAAAPCPVVRVSSADDAPRDLVASPDGALSIDAFTIPVGLPGVVSABCHV  
SMRDNGVHERMSH

25

Cosmid 3 EcoR1 Fragment 1 Kpn 1 fragment 2 SP6

Orf 9 DNA polymerase

DNA sequence (SEQ ID NO:18)

30 GGTACCGAGCCGCTTCCAGACGGACATTATTCGAGCGGAACCGTGCTCAAGCTCCTGG  
GGCGAACCGAGAACGGCACCAGCGTGTGCGTGAACGTGTTCCGTCAACAGGTATATTTC  
TACGCGAAGGTCCAGCCGGCGTCAACGTCACCACGTCTCCAGCAGGCCCTCAAGAA  
CACCGCCGGCAGGGCCGCGTGC GGCTTCTCGACACGAGTAACCAAAAAAATTCTCA  
AAACGTACGACGTGCGGAGCATCCCGTCACTGAAATCACGCTATCGTCCGGTTCCATG  
35 CTCTCGACCCTCAGCGACCGCCTCGTCGCGTGC GGGTGCGAGGTGTTGAGTCAAACGT  
GGACGCCGTTCCCGGTTTCGTCTTGATCACGGGTTTACCACGTTCCGGGTGGTACTCGTG  
CGCGCGTGCCACGCCCCGCCTAGCGGNACAGAGATGCCAGAACGGCCCTGGAGTTTGACT  
GCAGCTGGGAGGACCTCAGCGTTC

- 71 -

Deduced amino acid sequence (SEQ ID NO:19)

VPSRFQTDIIPSGTVLKLLGRTENGTSVCVNVFRQQVYFYAKVPAGVNVTHVLQQALKNTA  
GRAACGFSTRRVTKKILKTYDVAEHPVTEITLSSGSMSTLSDRLVACGCEVFESNVDVRR  
FVL DHGFTTFGWYSCARATPRLAXRDARTALEFDCSWEDLSV

5

Cosmid 3 EcoR1 Fragment 1 Kpn 1 fragment 2 T7

Orf 10 Unknown protein

10 DNA sequence (SEQ ID NO:20)

GGTACCGTTGGGGTTGAATAGGCGCAGGTGTGTTGTGCAACCGGAAAGCAAAAAGTGTG  
GGGTGACGATGAATAGGGGCTCCGGTGCCACGCCCGCAACTAGAAAACGCCAGATCGCCC  
CGAGCGGCGCTCCCTGTTGGAAAGATTAAGTGAACCCGGACTTCCGCGGAGCTTCCAGG  
TTGGATGGTTTTTTCGGCGTCGGCGTACACCCCAATACGCGGCCGCCGGTGTGGGTGGG  
15 CAGGACGGGTCCGGACTGGCCCAAGACTATCTCGGCGTTGGGGTCCCCCGGAGCGTAAA  
TGATTTTCATTTGCGCCG

Deduced amino acid sequence (SEQ ID NO:21)

AQMKIYAPGDPNAEIVLGQSGPVLPTHTGGRVLGVYADA EKTIQPGSSAEVRVQLIFPTGSA  
20 ARGDLAFLVAGVAPEPLFIVTPTLLLSGCTTHLRLEFPNGT

Cosmid 3 EcoR1 Fragment 1 Kpn fragment 3 SP6

Orf 8 Glycoprotein B

25

DNA sequence (SEQ ID NO:22)

GGTACCGCAAGGTGGCCACCTCGGTAACCGTCTATCGAGGGTGGACCGAGACCGCCGTG  
ACCGGTAAGCAAGAGGTCATTTCGACCGGTGCCCGAGTACGAGATTAACCATGACAC  
GACCTACCAAGTGTTCAGCTCCATGCGCGTGAACGTTAACGGCATCGAAAACACCTACA  
30 CGGACAGGGACTTCACTAACCAGACCGTGTTCCTGCAACCGGTCGAGGGGCTCACGGAT  
AACATTACGCGATACTTCAGTCAGCCGGTGCTGTACACGACACCGGGATGGTTTCCTGG  
AATCTACAGGGTCCGAACCACGGTCAACTGCGAGATCGTGGACATGATCGCGCGTTCGG  
CGGAACCGTACTCTTACTTTGTACCCGCCCTGGGAGACACGGTAGAGGTATCGCCGTTCT  
GCTTAAACGACTCGACGTGCTCCGTCGCTGATAAAGCCGAAAAACGGCCTCGGCGTGCGC  
35 GTGCTTACAAATTACACCATTTGTTGACTTCGCTACCCGCACGCCACCACCGAAACGCGA  
GTTTTCGCAGACTCGGGAGAATACACCGTATCGTGGAAGGCGGAAGACCCTAAGTCGGC  
AGTCTGTGCGCTGACGCTCTGGAAAACCTTTCCAGGGCCATACAGACGACGCACGAAA  
GCCAGCTACCACTTTGTGGCCAACGACGTG

- 72 -

Deduced amino acid sequence (SEQ ID NO:23)

YRKVATSVTVYRGWTTETA VTGKQEVIRVPVQYEINHMDTTYQCFSSMRVNVNGIENTYTDR  
DFTNQTVFLQPVEGLTDNIQRYFSQPVL YTTPGWFPGIYRVRTTVNCEIVDMIARSAEPYSYF  
VTALGDTVEVSPFCLNDSTCSVADKAENGLGVRVL TNYTTIVDFATRTPTTETRVFADSGEYT  
5 VSWKAEDPKSAVCALTLWKTFPRAIQTT HESQLPLCGQRR

Cosmid 3 EcoR1 Fragment 1 Kpn 1 fragment 3 T7

Orf 9 DNA polymerase

10

DNA sequence (SEQ ID NO:24)

GGTACCTCGGCGCACCTGTCCGCGCGTACGTCGTTTCAACGACGTCGTACGCGTGAAA  
CGTAATGGATTGGTCTTGGGGGTCCGGGACGACTGGCCGTTGGCCGCGCGCCGTCCACA  
TGGACCGTTCGTGGGCGAGCAGCACGTCTCCGCGCGCGCCGTTTTCAAAGTACGTCGGC  
15 GGGAACGGGATCGTGACCGGGATCATCCCGCTGCCCCCGGCGTTCGGAGGCAGGCGGG  
AATGAGCCTGCAGACGTCTGGTGGCGGCTGAACGGCGCCGGCGGGGGCGGGCGCATCG  
GTGCATTTGTGTGAGGGGGGGCGTGGTCCTCGAGGACCCAGGTACGGGTAAAAAAATC  
CATGCTCGATACAGAACGCTGACGCCCCGGGGGCGCC

20 Deduced amino acid sequence (SEQ ID NO:25)

GAPGRQRSVSSMDFNPNYLGPRGPRPPSHKCTDAPAPAGAVQPPPDVCRLIPACLRTPGAGG  
MIPVTIPFPPTYFENGARGDVLLAHERSMWTARGQRPVVPDPQDSITFHAYDVVETTYAAD  
RCAEV

25

Cosmid 3 EcoR1 Fragment 1 Kpn 1 fragment 4 T7

Orf 8 Glycoprotein B

DNA sequence (SEQ ID NO:26)

30 GGTACCGCCTAACCTTAAAGATGTGGGGGACGATATTTTTTTTAAACACCATTAGAATGC  
CTTCTTGGTGCGTTTTGNCCCTCGGTGCCAGGACACGTCTTTTCCAGGTAAACCTGAAGA  
GTTCCGCCGTTGGCCGAGGCGCTGCACACGCGAAACTTGAACGCCCTCGGCCCTGGGTGGG  
TTTTCGGGAGGTGTGGGCGTCGACGGGCCCCGGCGTGGACTTTGCAGTGGTGGTCACGCC  
CTTTGGGGTGGTGACGTTTTCGCCAACCGGCGCGCAATCGCGATTATCACGACCCACGC  
35 CCGCAGCAGACGACGCGTCCGGTTAGGTATCA

Deduced amino acid sequence (SEQ ID NO:27)

IPNRTRLLRAWVVI AIGAPVGENVTTPKGVT TTTAKSTPGPSTPTPPENPPRAEAFKFRVCSA  
SATGELFRFNLEKTCPGTEXKTHQEGILMVFKKNIVPHIFKVRRY

- 73 -

The sequence of the Japanese macaque gamma2 herpesvirus were compared with the rhesus macaque gamma2 herpesvirus 17577. The results are shown in Figs. 12-25. Based on a comparison of 2328 amino acid residues from 14 independent regions (average length of 166+71 amino acids), the percent similarity between the two viruses at the protein level was found to be 94.12%. The range among the 14 regions was 75.652% to 99.422%. The lowest identity was found in the MIP region of the two genomes, while the highest identity was found in ORF 21. The calculations are shown below in Table 3:

10

Table 3 Calculation of % Similarity and % Identity					
Gene Region	Length of Alignment	% similarity	# similar	% identity	# identical
IL6	207	94.203%	195	91.304%	178
MIP	120	80.870%	97	75.652%	73
Orf 07	226	98.230%	222	98.230%	218
Orf 08	109	94.495%	103	94.495%	97
Orf 08	226	97.235%	220	96.774%	213
Orf 09	120	94.915%	114	93.220%	106
Orf 09	165	98.182%	162	96.364%	156
Orf 10	104	94.231%	98	93.269%	91
Orf 10	76	94.737%	72	93.421%	67
Orf 17	135	94.074%	127	93.333%	119
Orf 21	174	99.422%	173	99.422%	172
Orf 24	174	95.977%	167	94.253%	157
Orf 29b	140	98.571%	138	98.571%	136
TS	352	93.994%	331	93.093%	308

- 74 -

These results were then used to estimate the % similarity and identity across the viral genome, as shown below in Table 4:

Table 4 – Estimated % Similarity and Identity Across Entire Viral Genome			
	similarity		identity
Mean	95.011%		93.716%
Std. Error	1.199%		1.532%
n	14		14
Avg. length	166.3		166.3
Std dev	70.5		70.5

5

Over the entire genome, the JMHV and the RRV17577 are estimated to have 95% similarity. The present invention includes the entire JMHV genome, and each of the peptides (including variants and fragments thereof), as well as DNA sequence which encodes them, such as the OFRs set forth in this specification.

10

#### EXAMPLE 31

##### Reactivity of Human MS Patient Serum to Japanese Macaque

15

To determine if there was evidence for JM herpesvirus or a closely related virus in MS patients, serum antibodies were measured that reacted with strain 17792 JM herpesvirus. A panel of 15 coded human serum samples that contained serum from normal control and MS patients were used. The results of this study are summarized in Table 5. Six of 15 samples yielded positive O.D. values ( $> 0.150$ ), 5 of the 6 positive samples were from MS patients. The 9 samples with O.D. values of  $< 0.150$  included 5 MS patients and 4 controls. However, when the O.D. values were ranked, 8 of 10 samples with the highest O.D. values segregated to MS patients, suggesting that some MS patients have a humoral immune response to JM herpesvirus or a related human virus.

20

25

The present invention includes the antibodies that recognize JM herpesvirus, as well as antigens recognized by these antibodies. Thus viral antigen (such as a viral antigens expressed in humans) which are recognized by an anti-JMHV antibody, are included herein. Examples of such antigens include antigens encoded by a human virus that is associated with the development of MS. A human viral antigen that is encoded by a human virus can have, for example, 80%, 90%, 95%, or

- 75 -

98% sequence homology with a JMHV antigen encoded by the virus deposited as ATCC accession no. PTA-1884.

- 5 Variants of the JMHV include variants that infect humans, and which are associated with the development of MS, or pathological lesions (such as demyelination) that are associated with MS in humans. Such variants can be isolated using the techniques disclosed in this specification for obtaining viruses with similar nucleic acid sequences, or the viruses can be recognized by the specific binding of simian antibodies against JMHV to the human variant, as illustrated in Table 5.

<b>Table 5 - MS and Control Patient Serum Reactivity to Japanese Macaque Herpesvirus</b>			
<b>Rank</b>	<b>ID No.</b>	<b>O.D. Value</b>	<b>Status</b>
1	4	0.047	MS
2	11	0.052	Control
3	8	0.065	Control
4	1	0.082	Control
5	3	0.106	MS
6	2	0.112	Control
7	10	0.112	MS
8	7	0.120	MS
9	5	0.122	MS
10	12	0.169	MS
11	15	0.214	MS
12	14	0.253	MS
13	13	0.415	MS
14	9	0.419	Control
15	6	0.430	MS

- 76 -

Having illustrated and described the principles of cloning the RRV and JMHV nucleic acid molecules, cDNA, proteins encoded by the cDNA, and modes of use of these biological molecules, it should be apparent to one skilled in the art that the invention can be modified in arrangement and detail without departing from such principles. In view of the many possible embodiments to which  
5 the principles of our invention may be applied, it should be recognized that the illustrated embodiments are only examples of the invention and should not be taken as a limitation on the scope of the invention. Rather, the scope of the invention is in accord with the following claims. We therefore claim as our invention all that comes within the scope and spirit of these claims.

- 77 -

We claim:

1. An isolated virus (Japanese Macaque Virus, JMHV) as deposited with ATCC as deposit accession number PTA-1884.
- 5       2. A host cell infected with the virus of claim 1.
3. A purified polypeptide comprising an amino acid sequence that has at least 95% sequence identity to an amino acid sequence as set forth as SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, and SEQ ID NO:27.
- 10       4. A purified polypeptide of claim 3, wherein the polypeptide has at least 98% sequence identity to an amino acid sequence as set forth as SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, and SEQ ID NO:27.
- 15       5. The purified polypeptide of claim 2, wherein the polypeptide has an amino acid sequence as set forth as SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, and SEQ ID NO:27.
- 20       6. An antibody that binds to the purified polypeptide of claim 2.
7. An isolated nucleic acid sequence encoding the polypeptide of claim 3.
- 25       8. An isolated nucleic acid sequence comprising a sequence having at least 95% sequence identity to one of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, or SEQ ID NO: 26.
- 30       9. The isolated nucleic acid sequence of claim 8, wherein the nucleic acid comprises a sequence as set forth as SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, or SEQ ID NO: 26.
- 35       10. An isolated nucleic acid sequence comprising a promoter operably linked to the nucleic acid sequence of claim 7.
11. A vector comprising the nucleic acid sequence of claim 7.

- 78 -

12. A host cell transformed with the vector of claim 11.

13. The vector of claim 11, wherein the vector is a viral vector.

5

14. A viral particle comprising the viral vector of claim 12.

15. An isolated nucleic acid molecule that hybridizes under highly stringent conditions with a nucleic acid molecule encoding the polypeptide of claim 5.

10

16. A method for testing the efficacy of a drug in the treatment of a condition associated with infection with Japanese macaque herpesvirus (JMHV), the method comprising:

(a) administering the drug to a non-human primate infected with a Japanese macaque herpesvirus (JMHV); and

15

(b) observing the non-human primate to determine if the drug prevents or reduces the presentation of one or more symptoms associated with Japanese macaque herpesvirus (JMHV) infection.

17. The method of claim 16, wherein the drug is a drug used to treat multiple sclerosis.

20

18. The method of claim 16, wherein the non-human primate is a Japanese macaque monkey.

19. A method for testing the efficacy of a candidate vaccine against Japanese macaque herpesvirus (JMHV) infection, or conditions associated with Japanese macaque herpesvirus (JMHV) infection, the method comprising:

25

(a) administering the vaccine to a non-human primate susceptible to infection with the Japanese macaque herpesvirus (JMHV);

(b) inoculating the subject with the Japanese macaque herpesvirus

30

(JMHV), and

(c) observing the non-human primate to determine if the vaccine prevents or reduces an incidence of Japanese macaque herpesvirus (JMHV) infection or a symptom associated with Japanese macaque herpesvirus (JMHV) infection.

35

20. The method of claim 19, wherein the non-human primate is a Japanese macaque monkey.

21. The method of claim 19, wherein the symptom is associated with multiple sclerosis.

- 79 -

22. A method of detecting the presence of Japanese macaque herpesvirus (JMHV) or a related virus in a biological specimen, comprising:

- 5 (1) amplifying by polymerase chain reaction a Japanese macaque herpesvirus (JMHV) nucleic acid sequence, if such sequence is present in the sample, using two or more oligonucleotide primers comprising 20 contiguous nucleotides of the nucleic acid sequence of claim 7; and
- (2) determining whether an amplified sequence is present.

10 23. The method of claim 22, wherein the step of determining whether an amplified sequence is present comprises one or more of:

- (a) electrophoresis and staining of the amplified sequence; or
- (b) hybridization to a labeled probe of the amplified sequence.

15 24. The method of claim 23, wherein the amplified sequence is detected by hybridization to a labeled probe.

25. The method of claim 24, wherein the probe comprises a detectable non-isotopic label chosen from the group consisting of:

- 20 a fluorescent molecule;
- a chemiluminescent molecule;
- an enzyme;
- a co-factor;
- an enzyme substrate; and
- 25 a hapten.

26. The method of claim 23, wherein the biological specimen is a primate specimen.

27. The method of claim 26, wherein the primate specimen is a non-human primate specimen.

30 28. A method of detecting the presence of Japanese macaque herpesvirus (JMHV) in a biological specimen, comprising:

- 35 exposing the biological specimen to a probe that hybridizes to a Japanese macaque herpesvirus (JMHV) nucleic acid sequence of claim 7, if the sequence is present in the sample to form a hybridization complex; and
- determining whether the hybridization complex is present.

- 80 -

29. The method of claim 28, wherein the biological specimen is a primate specimen.

30. The method of claim 29, wherein the primate specimen is a non-human primate specimen.

5

31. A method of obtaining a Japanese macaque herpesvirus (JMHV) -related nucleic acid sequence comprising:

10

- (a) amplifying a for rhesus rhadinovirus (RRV) nucleic acid sequence using two or more oligonucleotide primers comprising 20 contiguous nucleotides of the nucleic acid sequence of claim 7 to generate a product amplified nucleic acid sequence; and
- (b) detecting the presence of a product amplified nucleic acid sequence; and
- (c) isolating the product amplified nucleic acid sequence.

15

32. The method of claim 31, wherein amplifying the for rhesus rhadinovirus (RRV) nucleic acid sequence comprises polymerase chain reaction amplification.

33. The method of claim 31, wherein the detection of an amplified sequence is present comprises detecting the amplified sequence using one or more of:

20

- (a) electrophoresis and staining of the amplified nucleic acid sequence;
- (b) hybridization of a labeled probe to the amplified nucleic acid sequence; or
- (c) sequencing the amplified nucleic acid sequence.

34. The method of claim 33, wherein the amplified sequence is detected by hybridization.

25

35. A method of obtaining a Japanese macaque herpesvirus (JMHV) -related nucleic acid sequence from a sample comprising

30

- (a) contacting a nucleic acid of the sample with a probe or primer that hybridizes under moderately stringent hybridization conditions to the nucleic acid of the sample, wherein the probe or primer comprises 15 consecutive nucleotides of the nucleic acid sequence of claim 7; and
- (b) isolating the nucleic acid of the sample to which the probe hybridizes.

36. The method of claim 35, further comprising sequencing the nucleic acid of the sample to which the probe hybridizes.

35

- 81 -

37. A method of detecting the presence of Japanese macaque herpesvirus (JMHV) in a biological specimen, comprising:

5           contacting the biological specimen with the antibody of claim 6,  
          detecting binding of the antibody to the biological specimen or a component  
          thereof, wherein binding of the antibody to the biological specimen indicates the  
          presence of a Japanese macaque herpesvirus (JMHV).

38. The method of claim 37, wherein the antibody is detectably labeled.

10       39. The method of claim 37, wherein the probe comprises a detectable non-isotopic label  
          chosen from the group consisting of:

          a fluorescent molecule;  
          a chemiluminescent molecule;  
          an enzyme;  
15       a co-factor;  
          an enzyme substrate; and  
          a hapten.

20       40. A kit comprising a container means comprising an oligonucleotide primer comprising at  
          least 15 contiguous nucleotides of the nucleic acid sequence of claim 8.

41. A kit comprising a container means comprising an antibody of claim 6.

25       42. A virus comprising a nucleic acid sequence that has 95% sequence identity with a  
          nucleic acid sequence of the virus of claim 1.

43. The virus of claim 42, wherein infection with virus in a subject results in demyelinating  
encephalomyelitis in the subject.

30       44. The virus of claim 42, wherein the virus is a human virus.

45. A nucleic acid sequence obtained by the method of claim 31 or claim 35.

46. The nucleic acid sequence of claim 45, wherein the sequence is a viral sequence.

35       47. The nucleic acid sequence of claim 46, wherein the viral sequence infects human cells.


- 82 -

48. A non-human primate model for multiple sclerosis, comprising a non-human primate infected with a Japanese macaque herpesvirus (JMHV), wherein the non-human primate exhibits a symptom or a pathological feature of multiple sclerosis.
- 5      49. The non-human primate model of claim 48, wherein the symptom is acute onset paresis or paralysis involving one or more limbs.
50. The non-human primate model of claim 48, wherein the pathological feature is myelin destruction in a central nervous system.
- 10      51. The non-human primate model of claim 48, wherein the non-human primate is a Japanese macaque.

1/14

**FIG. 1**

Phylogenetic Comparison of the Gammaherpesviruses



EBV - Epstein-Barr virus  
AHV - Alcelaphine herpesvirus  
MHV - Murine herpesvirus 68  
HVS - Herpesvirus saimiri  
KSHV - Kaposi's sarcoma-associated herpesvirus  
RRV - Rhesus rhadinovirus 17577

2/14


**FIG. 2****Restriction Fragments of the RRV 17577 Genome**

BamHI		EcoRI		Hind III	
fragment number	fragment size (bp)	fragment number	fragment size (bp)	fragment number	fragment size (bp)
1	17189	1	12476	1*	22006
2	15598	2	10342	2	17108
3	15441	3	9565	3	16542
4	12360	4	9213	4	14134
5*	8943	5	8465	5	11516
6	7747	6	8036	6	10743
7	7718	7	7969	7	8452
8	7142	8	7416	8	5995
9	6667	9	7278	9	4679
10	6474	10	7002	10	3374
11	6333	11*	5400	11	2963
12	3978	12*	5054	12	2891
13	3411	13	4907	13	2849
14*	3157	14	4771	14*	2832
15	3008	15	4272	15	1599
16	2916	16	4099	16	1272
17	2210	17	3516	17	1016
18	1343	18	2102	18	853
		19	1868	19	811
		20	1603		
		21	1512		
		22	1221		
		23	910		
		24	624		
		25	609		
		26	592		
		27	584		
		28	122		
		29	107		

\* Indicates that the fragment size excludes terminal repeat sequences

3/14

**FIG. 3**



4/14  
**FIG. 4**

MacVector Output for long unique region of rhesus  
rhadinovirus 17577

LOCUS	LONG UNIQUE 131634 BP DS-DNA		UPDATED	06/26/98
DEFINITION	-			
ACCESSION	-			
KEYWORDS	-			
SOURCE	-			
FEATURES	From	To/Span	Description	
pept	513	1784	1 R1	
pept	2418	1852	(C1 Similar to HHV8 Orf 2 - dihydrofolate reductase	
pept	2836	4773	1 Similar to HHV8 Orf 4 - complement binding protein	
pept	5205	8603	1 Similar to HHV8 Orf 6 - ssDNA binding protein	
pept	8628	10688	1 Similar to HHV8 Orf 7 - transport protein	
pept	10675	13164	1 Similar to HHV8 Orf 8 - glycoprotein B	
pept	13282	16326	1 Similar to HHV8 Orf 9 - DNA polymerase	
pept	16421	17575	1 Similar to HHV8 Orf 10	
pept	17681	18910	1 Similar to HHV8 Orf 11	
pept	19705	19082	(C1 R2 viral IL-6	
pept	20939	19938	(C1 Similar to HHV8 Orf 70	
pept	21753	21406	(C1 R3 similar to HHV8 MIP ..	
frag	22829	22559	(C) misc. feature MIP homology, but no initiation codon	
rpt	24226	24529	repeat sequence	
rpt	24679	25686	repeat sequence	
pept	26007	26570	1 Similar to HHV8 Orf 16 - Bcl-2 homolog	
pept	28286	26676	(C1 Similar to HHV8 Orf 17 - capsid protein	
pept	28159	29058	1 Similar to HHV8 Orf 18	
pept	30709	29066	(C1 Similar to HHV8 Orf 19 - tegument protein	
pept	31256	30204	(C1 Similar to HHV8 Orf 20	
pept	31255	32928	1 Similar to HHV8 Orf 21 - thymidine kinase	
pept	32915	35029	1 Similar to HHV8 Orf 22 - glycoprotein H	
pept	36234	35026	(C1 Similar to HHV8 Orf 23	
pept	38482	36284	(C1 Similar to HHV8 Orf 24	
pept	38484	42620	1 Similar to HHV8 Orf 25 - major capsid protein	
pept	42652	43575	1 Similar to HHV8 Orf 26 - capsid protein	
pept	43600	44409	1 Similar to HHV8 Orf 27	
pept	44575	44850	1 Similar to HHV8 Orf 28	
pept	45946	44900	(C1 Similar to HHV8 Orf 29b	
pept	46072	46302	1 Similar to HHV8 Orf 30	
pept	46260	46913	1 Similar to HHV8 Orf 31	
pept	46850	48244	1 Similar to HHV8 Orf 32	
pept	48216	49226	1 Similar to HHV8 Orf 33	
pept	50127	49144	(C1 Similar to HHV8 Orf 29a	
pept	50126	51109	1 Similar to HHV8 Orf 34	
pept	51090	51539	1 Similar to HHV8 Orf 35	
pept	51445	52752	1 Similar to HHV8 Orf 36 -kinase	
pept	52733	54175	1 Similar to HHV8 Orf 37 - alkaline exonuclease	
pept	54130	54339	1 Similar to HHV8 Orf 38	
pept	55558	54422	(C1 Similar to HHV8 Orf 39 - glycoprotein M	
pept	55693	57099	1 Similar to HHV8 Orf 40 - helicase - primase	
pept	57084	57695	1 Similar to HHV8 Orf 41 - helicase - primase	
pept	58510	57692	(C1 Similar to HHV8 Orf 42	
pept	60194	> 58464	(C1 Similar to HHV8 Orf 43 - capsid protein	
pept	60133	> 62505	1 Similar to HHV8 Orf 44 - helicase -primase	
pept	63604	62546	(C1 Similar to HHV8 Orf 45	

5/14

**FIG. 5****Comparison of Corresponding Repeats in  
RRV and KSHV**

virus	insert name	total length	repeat unit length	G + C content
KSHV	<i>fmk</i> <sup>1</sup>	332 bp 292 bp	20 bp 30 bp	80.1% 84.9%
RRV	<i>syko</i> <sup>1</sup>	304 bp 1008 bp	26 bp 25 bp	53.3% 79.9%
KSHV	<i>zppa</i> <sup>1</sup>	308 bp 244 bp	23 bp 23 bp	74.0% 77.9%
RRV	<i>vrtgo</i> <sup>1</sup>	405 bp 1029 bp	19 bp 32 bp	74.6% 84.4%
virus	insert name	total length	repeat unit length	G + A content
KSHV	<i>mdsk</i>	409 bp	— <sup>2</sup>	75.4%
RRV	<i>brds</i>	196	13 bp	81.6%

1 KSHV *fmk* and *zppa* and RRV *syko* and *vrtgo* are tandem repeats.

2 KSHV *mdsk* is a complex repeat with no defined unit length.

6/14

FIG. 6

Comparison of Interferon regulatory elements coded by RRV and KSHV<sup>a</sup>

	KSHV K9	KSHV K10	KSHV K10.1	KSHV K10.5	KSHV K11	Rh R6	Rh R7	Rh R8	Rh R9	Rh R10	Rh R11	Rh R12	Rh R13
KSHV K9	100.000 100.000	100.000 100.000				26.044 21.130	28.281 20.728	28.857 19.427		33.705 28.184	28.972 21.849		
KSHV K10		100.000 100.000	100.000 100.000										
KSHV K10.1			100.000 100.000	32.036 21.895									
KSHV K10.5				100.000 100.000									
KSHV K11					100.000 100.000	100.000 100.000		26.393 19.082	29.818 22.131	54.427 47.917			
Rh R6							100.000 100.000	34.513 26.254			50.773 41.495	33.038 24.484	
Rh R7								100.000 100.000		31.412 24.207	35.693 23.849	61.254 50.997	28.818 21.037
Rh R8									100.000 100.000	28.980 18.367	28.216 21.577	30.364 18.623	58.103 52.964
Rh R9										100.000 100.000	32.951 23.498	33.526 25.723	
Rh R10											100.000 100.000	33.923 23.849	31.124 25.072
Rh R11												100.000 100.000	
Rh R12													100.000 100.000
Rh R13													

<sup>a</sup> Blank cells indicated no similarity; upper number is percent similarity; lower number is percent identity.

**FIG. 7A**

Comparison of RRV, KSHV and HVS ORFs

ORF	RRV			KSHV			HVS			Putative Function
	Start	Stop	Strand	Size aa	% Sim	% I	Size aa	% S	% I	
R11	513	1784	+	423						
Orf 2	2418	1852	-	188						
Orf 42	2836	4773	+	645	55.1%	48.0%	187	65.6%	54.8%	Dihydrofolate reductase
					40.9%	35.7%	360	42.0%	35.3%	Complement binding protein
Orf 6	5205	8603	+	1132	71.3%	63.3%	287	44.0%	38.6%	ssDNA binding protein
Orf 7	8628	10688	+	686	60.1%	51.5%	1128	65.2%	53.5%	Transport protein
Orf 8	10675	13164	+	829	73.3%	65.5%	808	58.1%	47.7%	Glycoprotein B
Orf 9	13282	16326	+	1014	75.0%	67.0%	1009	71.0%	53.1%	DNA polymerase
Orf 10	16421	17575	+	384	43.5%	34.8%	407	33.6%	23.3%	
Orf 11	17681	18910	+	409	41.3%	31.7%	405	46.3%	32.4%	
R21	19705	19082	-	207						
Orf 70	20939	19938	-	333	72.1%	66.1%	294	72.1%	64.6%	Thymidylate synthase
R33	21753	21406	-	115	41.9%	32.3%				
Orf 16	26007	26570	+	187	58.0%	46.0%	160	31.4%	21.4%	Bcl-2 homolog
Orf 17	28286	26676	-	538	50.6%	44.3%	475	49.0%	42.2%	Capsid protein
Orf 18	28159	28058	+	299	68.1%	58.0%	256	60.2%	48.8%	
Orf 19	30709	29088	-	547	61.1%	52.8%	543	55.5%	46.9%	Tegument protein
Orf 20	31256	30204	-	350	51.8%	44.7%	303	43.2%	35.6%	
Orf 21	31255	32928	+	557	54.0%	44.6%	527	39.0%	31.7%	Thymidine kinase
Orf 22	32915	35029	+	704	50.1%	40.7%	717	42.3%	31.5%	Glycoprotein H
Orf 23	36234	35026	-	402	56.8%	48.5%	253	40.5%	29.8%	
Orf 24	38482	36284	-	732	66.3%	58.7%	731	56.3%	46.8%	
Orf 25	38484	42820	+	1378	79.9%	72.5%	1371	76.7%	67.5%	Major capsid protein
Orf 28	42652	43576	+	307	71.8%	64.3%	304	69.1%	58.2%	Capsid protein
Orf 27	43600	44409	+	269	33.6%	25.3%	280	35.0%	27.1%	
Orf 28	44575	44850	+	91	30.1%	26.5%	93			
Orf 29b	46946	44900	-	348	30.1%	26.5%	387	74.4%	62.9%	Packaging protein
Orf 30	46072	46302	+	76	77.6%	68.4%	75	40.3%	29.2%	
Orf 31	46260	46913	+	217	51.3%	38.2%	208	50.5%	39.9%	

7/14

FIG. 7B

ORF	RRV			KSHV			HVS			Putative Function
	Start	Stop	Strand	Size aa	% Sim	% I	Size aa	% S	% I	
Orf 32	48850	48244	+	464	49.9%	41.8%	441	43.2%	34.1%	Packaging protein
Orf 33	48216	49226	+	336	52.1%	42.1%	330	49.1%	39.1%	
Orf 28a	50127	49147	-	327	66.7%	61.2%	303	57.8%	49.8%	
Orf 34	50126	51109	+	327	58.9%	48.5%	316	53.7%	40.6%	Kinase
Orf 35	51090	51539	+	149	47.7%	35.6%	150	51.0%	37.4%	
Orf 36	51445	52752	+	435	56.0%	46.1%	431	38.4%	28.7%	
Orf 37	52733	54175	+	480	72.4%	63.5%	483	63.0%	53.2%	Alkaline exonuclease
Orf 38	54130	54339	+	69	56.7%	45.0%	66	39.4%	34.8%	
Orf 39	55558	54422	-	378	73.0%	59.3%	366	67.1%	57.0%	
Orf 40	55693	57099	+	468	42.2%	32.7%	450	39.1%	28.1%	Glycoprotein M Helicase-primase α
Orf 41	57084	57695	+	203	33.5%	26.0%	161	37.3%	29.1%	
Orf 42	58510	57692	-	272	56.8%	48.1%	265	51.2%	38.1%	
Orf 43	60194	58464	-	576	69.7%	61.6%	563	66.4%	56.6%	Helicase-primase β
Orf 44	60133	62505	+	780	73.9%	66.0%	781	71.1%	62.6%	
Orf 45	63604	62546	-	352	31.2%	24.9%	257			
Orf 46	64413	63846	-	255	71.9%	60.1%	252	67.5%	59.1%	Uracil DNA glucosidase
Orf 47	64898	64389	-	169	31.9%	27.7%	141	33.3%	23.9%	
Orf 48	66335	65166	-	389	36.2%	29.2%	797	34.1%	25.8%	
Orf 49	67470	66565	-	301	66.1%	54.2%	303	35.1%	23.3%	Capsid protein Helicase-primase
Orf 50	67661	69205	+	514	46.6%	37.8%	535	29.7%	21.6%	
R41	69315	69935	+	206						
R51	70637	70972	+	111						Transactivator
Orf 52	71990	71571	-	139	58.5%	45.4%	115	41.7%	30.4%	
Orf 53	72368	72054	-	104	51.0%	46.2%	90	43.3%	28.9%	
Orf 54	72444	73316	+	290	48.6%	41.0%	287	46.5%	36.4%	dUTPase
Orf 55	74009	73377	-	210	62.9%	55.2%	200	52.5%	44.4%	
Orf 56	74021	76507	+	828	61.2%	62.5%	835	54.0%	43.6%	
Orf 57	76748	78076	+	442	60.6%	47.1%	416	40.3%	31.5%	DNA replication protein Immediate-early protein
R64	79683	78436	-	415	26.0%	21.1%				
R74	81103	79856	-	415	28.3%	20.7%				
R84	82487	81432	-	351	28.9%	19.4%				



9/14

FIG. 7C



ORF	RRV			KSHV			HVS			Putative Function	
	Start	Stop	Strand	Size aa	Size aa	% Sim	% I	Size aa	% S		% I
R94	83422	82661	-	253							DNA replication protein Ribonucleotide reductase, small
R104	85378	84222	-	385		33.7%	26.2%				
R114	86697	85625	-	390		30.0%	21.8%				
R124	88131	87084	-	355							
R134	89386	88292	-	364							
Orf 58	90714	89632	-	360	357	45.2%	38.2%	357	39.9%	29.5%	
Orf 59	91909	90725	-	394	396	60.3%	51.8%	388	40.7%	32.7%	Ribonucleotide reductase, large
Orf 60	92982	92038	-	314	305	78.2%	70.0%	305	71.0%	62.4%	
Orf 61	95330	92984	-	788	792	69.3%	61.7%	767	64.4%	53.3%	Assembly / DNA maturation Tegument protein Tegument protein Capsid protein
Orf 62	96328	95333	-	331	331	64.4%	56.5%	330	53.8%	41.9%	
Orf 63	96327	99148	+	939	927	51.8%	42.6%	899	43.4%	34.6%	
Orf 64	99150	106796	+	2548	2635	49.6%	40.2%	2469	39.2%	29.4%	
Orf 65	107316	106807	-	169	170	48.2%	38.6%	139	41.0%	33.1%	Tegument protein Glycoprotein
Orf 66	108668	107322	-	448	429	51.9%	46.4%	435	43.6%	32.3%	
Orf 67	109368	108694	-	224	271	69.6%	64.7%	263	58.6%	51.4%	Flip homolog Cyclin D homolog Immediate-early gene
Orf 68	109779	111152	+	457	545	53.2%	44.8%	436	53.5%	44.3%	
Orf 69	111174	112087	+	297	225	73.1%	65.5%	261	57.5%	49.0%	
R141	118222	117536	-	228							G-protein coupled receptor Tegument protein / FGARAT
Orf 71	118905	118381	-	174	139	38.8%	30.9%	167	25.3%	15.1%	
Orf 72	119728	118964	-	254	257	49.8%	38.6%	254	37.5%	29.2%	
Orf 73	121379	120036	-	447	1162	23.6%	16.8%	407	29.0%	20.8%	
R155	122033	122794	+	253	348	35.2%	31.2%				
Orf 74	123091	124119	+	342	342	51.6%	41.1%	321	41.1%	32.1%	
Orf 75	128120	124224	-	1298	1296	52.2%	44.0%	1299	43.2%	34.4%	

% Sim., percent similar; % Id., percent identical; ssDNA, single-stranded DNA; FGARAT, N-formalglycylamide ribotide amidotransferase; 1, no similarity found; 2, compared to HVS ORF 4a and 4b; 3, compared to KSHV R4; 4, compared to KSHV K9; 5, compared to KSHV K14.

10/14



11/14





13/14

## FIG. 10

atg ttc cct gtc tgg ttc gtc ttg ttt tac ctg tcg tgt tgg gcg gcc	48
Met Phe Pro Val Trp Phe Val Leu Phe Tyr Leu Ser Cys Trp Ala Ala	
1 5 10 15	
agc cct acg ctg gcg cct ccc ccg act gcc gct gga att aac gtt ctc	96
Ser Pro Thr Leu Ala Pro Pro Pro Thr Ala Ala Gly Ile Asn Val Leu	
20 25 30	
ccc cag tgg gcc ggc aac cgc gcc tct ctt gac agg acc agg ggg cgc	144
Pro Gln Trp Ala Gly Asn Arg Ala Ser Leu Asp Arg Thr Arg Gly Arg	
35 40 45	
ctg tct gaa gtg ggg tta aac ata cag cgc tgg ttc gtt tac ctg tgc	192
Leu Ser Glu Val Gly Leu Asn Ile Gln Arg Trp Phe Val Tyr Leu Cys	
50 55 60	
cac cac tcc act ctc tgt cgg gtg cgt gag tac ccg cgc atc atg tcg	240
His His Ser Thr Leu Cys Arg Val Arg Glu Tyr Pro Arg Ile Met Ser	
65 70 75 80	
ttt gtt cac ttc cct ata ttg atg tct aac gtt gag tgc cag cgc cgc	288
Phe Val His Phe Pro Ile Leu Met Ser Asn Val Glu Cys Gln Arg Arg	
85 90 95	
gag ttt cgc ggg gcc gag tgt atg aac gcc atg gtt cgc ggg ctc cgg	336
Glu Phe Arg Gly Ala Glu Cys Met Asn Ala Met Val Arg Gly Leu Arg	
100 105 110	
gcc tac gag agt tac ctg acg cga ctg agg atg ctg ctg gac gac gcg	384
Ala Tyr Glu Ser Tyr Leu Thr Arg Leu Arg Met Leu Leu Asp Asp Ala	
115 120 125	
ccc ggg gac gcg gac gcc gcg gcc att ggc tcc gcg gtg acc gtg gtg	432
Pro Gly Asp Ala Asp Ala Ala Ala Ile Gly Ser Ala Val Thr Val Val	
130 135 140	
ctg tcc gcc ctc gac tct cta att gag gag ctt ccc gta aat aac aag	480
Leu Ser Ala Leu Asp Ser Leu Ile Glu Glu Leu Pro Val Asn Asn Lys	
145 150 155 160	
ata ggt ggc gcg gag tct aat gaa aaa acc gtg cgt gcg ttg gga ggg	528
Ile Gly Gly Ala Glu Ser Asn Glu Lys Thr Val Arg Ala Leu Gly Gly	
165 170 175	
cag agc ccc ccg gac gtt gtt ctc agc gcg ttt cgc ata ctg gaa tat	576
Gln Ser Pro Arg Asp Val Val Leu Ser Ala Phe Arg Ile Leu Glu Tyr	
180 185 190	
cta cag atg ttt ttg cgg gac ggg cgc cgc gca ata gct atg atg taa	624
Leu Gln Met Phe Leu Arg Asp Gly Arg Arg Ala Ile Ala Met Met	
195 200 205	

14/14

## FIG. 11

atg agg ggc ctt ttc gtg tgc gtt ttt ttt gcg gtg ttc gcg tgt gta	48
Met Arg Gly Leu Phe Val Cys Val Phe Phe Ala Val Phe Ala Cys Val	
1 5 10 15	
gtt gat tat gcc ttt cct atg ggc tcc atg agc gga ccc gcg ccc gaa	96
Val Asp Tyr Ala Phe Pro Met Gly Ser Met Ser Gly Pro Ala Pro Glu	
20 25 30	
ctc tgc tgt ttg ggg tat gta act cat ctg ccg cca ccc ggt tta gtg	144
Leu Cys Cys Leu Gly Tyr Val Thr His Leu Pro Pro Pro Gly Leu Val	
35 40 45	
gtc tct tac tcc cac acc tcg tcg cag tgc tcg gtg gac gcc gtg ata	192
Val Ser Tyr Ser His Thr Ser Ser Gln Cys Ser Val Asp Ala Val Ile	
50 55 60	
tta aac act cgc cgc ggt aaa aag ctg tgt gcc aat ccc ggg gac gac	240
Leu Asn Thr Arg Arg Gly Lys Lys Leu Cys Ala Asn Pro Gly Asp Asp	
65 70 75 80	
gca gtg aag aaa ctg ctt cag gcg gtg gac aag cgt ccc aaa aag ggc	288
Ala Val Lys Lys Leu Leu Gln Ala Val Asp Lys Arg Pro Lys Lys Gly	
85 90 95	
aga aga acc cgg cgc agc ctg att gac gat tcc gaa gag ggc ctt ggc	336
Arg Arg Thr Arg Arg Ser Leu Ile Asp Asp Ser Glu Glu Gly Leu Gly	
100 105 110	
agc ggg att tag	348
Ser Gly Ile	
115	

## Cloning of Radinivirus Genome and Methods for its Use.ST25

&lt;110&gt; Oregon Health Sciences University

&lt;120&gt; Cloning of Radinivirus Genome and Methods for its Use

&lt;130&gt; 53683

&lt;140&gt; PCT/US99/26260

&lt;141&gt; 1999-11-05

&lt;150&gt; 60/107,507

&lt;151&gt; 1998-11-06

&lt;160&gt; 28

&lt;170&gt; PatentIn version 3.0

&lt;210&gt; 1

&lt;211&gt; 133719

&lt;212&gt; DNA

&lt;213&gt; Macaca mulatta rhadinovirus 17577

&lt;400&gt; 1

```

gacgagggaaa acgagggggg agcggggggac agggggacggc gtgtgcgtgc ttgtgagaca      60
ccgggtacgg ctgcctgcct gctcgctggc ctgcttgctg aggggacagt aggcctgctt      120
gctcgctggc ctgcttgctg aggggacagt aggcctgctt gctgagggga cagtaggcct      180
gcttgctgc tggcctgctt gctgagggga cagtagggct gctggcttgc tagtagggct      240
gctcgctggc ctgcttgctt gctcgctggc ctgcttgctt gctcgctggc ctgcttgctt      300
gctcgctggc ctgcttgctt gctcgctggc ctgcttgctt gctcgctggc ctgcttgctt      360
gctcgctggc ctgcttgctt gctcgctggc ctgcttgctt gctcgctggc ctgcttgctg      420
aggggacagt aggcctgctt gcttgcctaa gggacggtag gcctgcctga tggcttgata      480
gtagggctgc tgggctgcta gtagggctgc tgggctgcta gtagggctgc tgggctgcta      540
gtagggctgc tgggctgcta gtagggctcc tgggctgcta gtagggctgc tgggctgcta      600
gtagggctcc tgggctgcta gtagggctgc tgggctgcta gtagggctgc tgggctgcta      660
gtagggctgc tgggctgcta gtagggctgc ctgctggctt gcttgcttgc ttgctagtgg      720
ggccgcttgc ctgctactag ggctgctgtg cagctgggag aacagagtag ggctgccggc      780
cagctgcgtg cgagggcgct cgagggccag acgaggacac gggacccggg cctctcccc      840
aggcacaag cagtagggct ggccagggga aacagtaagg ctgattgctt gctgaaaaac      900
agtagggctg ctggtttgtt gctaacggaa aaaggggagg tgtgtgtatg cttttgtgac      960
tttccagcgg aggggggtaca gtgcacggcc aagttacaag cacctgctta acttgctttg     1020
gctctgtgcg gttttgttgc taggtactag tagtaacaca tagtatttca tcgcatggcg     1080
cctgcatacg ctccacagca tccgaaacac gttatttcta tagactaact ttagtgcttct     1140
tcttggttgg taccatttta cgaagtttgc tccgttgaat aataagaaat ccgttggtgt     1200
tacaatacac ctgccaacgt attggatggg tccttttgcc atcaaccttt gcttgcatte     1260
taacattgaa ttttcacatt acaccctagt cttctcatgc aattaggtat gtctttgctc     1320
gtgtttaatt ttctctacac atttctgtgg aaatgtttgt gttggtttta tttatgttat     1380

```

Cloning of Radinovirus Genome and Methods for its Use.ST25

```

tgcaacctgt atcgggtggag cttttgcctg caaaattaac ttctgttcca acgtggtgtc 1440
caccacatcc cggagatacc tacttgctaa cctgccgcgg gacgtctacg gccagagacc 1500
agcgaagcac acaatggttt cgacaacaac cgcttatgcg tgggagtaat ttctacggca 1560
gactggtatc tgtgactccc aatgctacga tatctgaccg gtatgctgtt caaacaaaaa 1620
caacaacgcg gagtaacaac atcgattttc gggtaaagctc atcgcgcctc acgctccaag 1680
aacggtgctc ttcatacggc tatacttacg cgaataaacac aagggtattg aggtgttact 1740
ctggtggaaa cgtaacttta agaaacgttg tctttcattt aaacggtaca gcggtcatca 1800
acggtactac aacaaacata catacatttg tgttaacaga aaagacagga gggacgtatt 1860
tctgttctgc gtttattggg aatgaaaaat tctattctca gacaattaat gtgtttttta 1920
cttcattttac ctttaaacct acaaacgaca ttcccaatga gtcacatttt aataaaaactg 1980
ggcaaataca acaaacagct agtgtacaac atcctgaaaa ctacgttggtg ttctctgttc 2040
ccgttttttc tattggcggt ttaacaggta ttgcaatata gttgattatg tgttggttat 2100
ttacaatacg ctgcaacgag aactctgaat catcaactaa tagttatgca agccagacaa 2160
gctacattca accctcccat aatcagcgtt ccaatactaa tgaatgtagt cgccatacct 2220
acagaaatgc tcatcaagaa gagagtattg aagaactacc aaaccaacac acaagtgaaa 2280
ctgattcttg ctgtcaatta gttttacttg aagtgaaaaa tgtagcctac gatggaccgc 2340
aggaaaacac aattaacgaa gttatggaac agtatgatga tgtggttgta aaaaatatag 2400
aacaacatc atatgaggat aatgttgagc acatggacta tagtgatact ataaatccca 2460
attttaatta ctacagtgga ctaatattgg aagaagtaga tgaagttttt tacaatgaac 2520
tagaaaatca atatcatgga ttaatactgg agaatttaga tcacaatgag tacaatcatt 2580
taaataaatt aaacatgata gaacaatatg attgggttaga ataaataact tgtgggttat 2640
ttttaaatta aaacataaac aacattaaag cagcattttt gtgtaaatcc tttatttatt 2700
aaaatttttt tcatatacct gaaacttata tttaattcca ttttcctcaa agtttgtatc 2760
tttgcccggt atctctgata acatggtgta ttcggtaaaa ttaattgatg gaaaaaatac 2820
atcacaatca aaactctcca taatgcgcgt aatataatag tttaaggagc acttatagtt 2880
aagaacactc tcataaacag attttcctcc aataaccag accgtgttta attgttcttt 2940
tagtttgtat tgtctataga aattaaacgc atcgtctagc gttctcgtc gaaagtgtgc 3000
tccgtgcggt gggtcacgta attctctgct caaaataata ttaattctgt tcaccagagg 3060
gcgcttcttt tcagggatgg aaaacatgt tcttttcccc ataataacca cattcttttc 3120
acctacaacc gatggcgtag acgtcatttt ctgaaaatac atcatttcgt ttctaaggta 3180
cggccaaggc attgttccgt ttttaccat tcctaattgt tcatcaactg caacgatgca 3240
gttaactgta atgtccatgg ttttagttgc cactgacggg tttaacacag aagtatttca 3300
caattataaa caaataaacc acgtgacatg tacttactaa tgtaagtacg taacgtgata 3360
tagttaatca tattcgtttt cacataatgg acaaaacgaa aaaatgttac ctgtgttaag 3420
cctaccttgt ttggatggat ttatggttac aatgaaaaat aaaaatatat atataacgtt 3480

```

## Cloning of Radinovirus Genome and Methods for its Use. ST25

ttttacgtaa aacatattgt aatttaataca cgtgatgttt atgttggcta ctaacacaca 3540  
 atgtttgcat aaaagcactt atgttagtga gcttcaatct ttatatTTTA ttcaaattgt 3600  
 ttaaagagggc atgtgaatat atttaacacg cattcagaaa taggcgcaac gctgtgccgt 3660  
 ataactggta aaaacatgac gtttaaacct tttcctctgt ttttattaca cgccataatg 3720  
 tacgtccact gcgatgaaaa ctgtaaacct ccacatttca cggaatatcg cgtcaagtct 3780  
 aacacagaaa aggacttata tagtgttgga gaaacagctg aattaatttg tcgtcctggg 3840  
 tatgtttaca atacaaaaat aataacaaca gaatgtttac aaaatggtac gtggtcaaca 3900  
 ccaaattttc catgcgacag aaaaagatgt cccacacctg ctgacttgct gaatggagcc 3960  
 gtgcacattc acggggggaga taatgcctta aaatttggat ccaatatTTc ctatgagtgt 4020  
 aatgaagggt atgatttaat tggtagtaat gtgcgttttt gtattttaca agacacagaa 4080  
 aacgtaaaatt gggattcaaa tgaaccagtc tgtgaaattc agaaatgtat taaaccaccg 4140  
 gcagtggAAC atgggggacta cctacctaac caagatgttt ataactatgg agatgcaatt 4200  
 acatttAAAT gttcattgtc gtatacactc gttggatcaa caacattagt atgcacgtca 4260  
 aacaaaaagt ggtcaaactc tttcccaacg tgtttaatgc tcgtatgtga aagtcacaaa 4320  
 atagacaatg ggtacataga cattggcttg tccagaagat acaaccatgg acaatcaatt 4380  
 actgtAAAGT gtagcgacgg gtacaacatt gttgggcctg aaacattaac gtgcacaaac 4440  
 acaacttggg ttccaccatt acctaagtgt gtattagtta caaataaccc aagcacaccc 4500  
 atgccagaaa caccatgcc agaaacaccc acgcagatt atcaaaaaat aaatttgtca 4560  
 accgctaaaa ctgcaacaac accaaatgcg tttgttaca ctgttgtttc tccagagaaa 4620  
 gacgacgtta cttgtgtaaa gcctcatTTT gagcgattca tggtaaaggc tgaaatgac 4680  
 aaggaaaaat acagtgttg tgcgagcgtt gagctaatat gtcgaccagg atttactaaa 4740  
 atgcagtcta cagtTTctgt tgaatgttg tccaacggaa catggactgc tccaaatgcc 4800  
 aagtgtcata gaaaaaaatg tccaaccct caagaacttt taaacggaga gtatatagtt 4860  
 acaagcggag aagatgcttt taagtacgga acaaatataa catataaatg taatgaagg 4920  
 tatcaacttt taggaagtat ggtgcggatt tgtatgctta aagacgattt aaaaacagtt 4980  
 gactgggagc caaaagcgc tatatgtgat attgaaaaat gtaagccacc gccacaaatt 5040  
 acaaacggaa aataccatcc ggtgaaagac ttttatcagt atttgacac cgtaacattt 5100  
 tcgtgcaatc gtgacttttc tttagtTgga gatgaaatga caacgtgtat aagtaatacg 5160  
 tggaataaac cgtttccaag atgtgaacaa atcacttgca gcgtcctaa tattgcacac 5220  
 ggaaagctgc taacaggttc ttcaagcgtt tacaatacg gtcaatctgt taccattgg 5280  
 tgtgaaactg gatttactct aattggcagt gaaatttcta catgcaagga ttcacgtgg 5340  
 gatccaccac ttcctacgtg cgtgccagct gtttcaatgc cttctgacac acctaaacca 5400  
 gaaacaaaa aaccaaacac gccaacgcca gaagcacca aaccaaacac cccaaacgtt 5460  
 ggaacacata caccattcaa accaccacca caaaatccac caatagcacc cccaatgagt 5520  
 aaatggaaaa ggcattgctg gttagtTctt tttgcaagtg tcgcgtcctt gttattcgta 5580

Cloning of Radinovirus Genome and Methods for its Use.ST25

```

cttgctgccc ttattgttg ttttctaaaa taactgtttt ttgtcttcag caggttcgcc 5640
aggcaaacctc gcacgcatta accaatctgc caaccgccgt tgattccgga attaatgtta 5700
cattattcaa ggttgccaat aaaggtggtt taaaaatatt ctattggtgt tcattgtttt 5760
atgttgaccc gtttatagtt atcgcgccac cttgtggcta cattatatag cacgatcact 5820
ttccacgtta tactttcacg tactatgact catacgcctt aacgtcacgt ggcgtgcgat 5880
tgtggccggg gctgaaaata acacaagggg tacataatcc atccaggcgg cacacattag 5940
acacggttta taaaactata tcggatgcmc caacaatcac tgctcgtagc gacactgata 6000
gaaaaacatt ttaacgtttg tttagcgaac ttgaataaca cataatggct tccaaaggca 6060
acgccggaca acccctggaa gataatcagg ggtctcgtgc cccgataggt gcgtgcggat 6120
acgtgtacgc gtattcgaaa caagactttc cctttgccga ggcgtccata ctcggaaca 6180
gaccatctgg atctggcgtt ttctcgtac caatccttta cggacttaca gttgaacacg 6240
aattccctct caccgtaaaa gccgcataca aaaaagttga caccacgacg ctgccggtta 6300
aggtgacgtg ctttcacaga gaggttattg tgtttcacia tgcaagttta ttcaggccgg 6360
tgtttgacgg taccggctctt aacgaactat gcgaggaagc cagggtctc tttgggtaca 6420
cgcagtttat agaaccgggt ccacctcaca gcatatggaa ccctctggaa tgtccgcagt 6480
taccggacaa ggatgagatg tttcttgccg ttgttggtac ggaagggttt aaggaaagac 6540
tgtggagggg ctgtctcgtt cccgcgggtt tccagaccca gcaggtgcag attgccggac 6600
gccaggcgtt taaagtgccg ttgtacgacg aagacctgtt tgcacctcac ggtcatagaa 6660
tgccaagggt ttaccataaa gacgttagcg cgtacctcta cgactccctc tttaccagca 6720
tcgcccaggc cctgagactc aaagacgtga cggcgggtcat ccacgccaca gaaaagcaat 6780
tcatgcagga ccattacaaa attgccaaga tagtgcagc aaaacagttt tcaacgacgc 6840
tgccgaaaac gacagacggg tcgtcccaca tgattgtgga cagcgtcgtc gccgagctcg 6900
cccttagtta cggctgtatg tttctcagat gtcccagga cgcgtgcgag ttgctgaact 6960
acgatagctg gcccatattt gatggttgtg actcaccaga ggctaggggt aacgcgttag 7020
agcgtgtgtc ggcggaacag gccgttcacg tggcgggtca actgttcgct gccaatcgg 7080
tgctgtacct aactaaagtg cagaagcaag cggccagggg aaaaaggga gacgtaaacg 7140
tgtacaactc ctttttctc caacacggac tgggggtttt aaatgaggcc acgatcaagg 7200
aaaacggcag cgaagccttt aagggcgtac cctcaaacgc cctcgatggt tcttcgttca 7260
cgccgtatca cctggcctac gccgcgtctt tctcgccca tctgctggcg aagtattgtt 7320
attacatgca gttcttgcaa caccacaaaa gctccacgaa ccaggcgttt aacatggtcc 7380
attatgtcgg caccgccgcc aactcagaga tgtgcacgct atgtcacggc aacacgccgg 7440
caacgtgcct caacacgctg ttctatagac tgaaggatag gtttcccgcc gtaaccaccc 7500
ctcagcgtag ggacccctac gtggtgaccg gaacagccgg gacctttaac gacctggaga 7560
ttctgggcaa cttcgcgagc tttagagacc gcgaagagga cggaaacccg gccgacgagc 7620
acccaaagta cacgtactgg cagctatgtc agaccgtgac agaaaagcta tccgcgattg 7680

```

Cloning of Radinivirus Genome and Methods for its Use.ST25

```

gaatcaccga agaccacgat aatcacgtga acctcatcac caacatccaa agttttctca 7740
gggtgttcaa gggatatcgac tcaattgtgg acggagaggt catgaagttc gttaattcga 7800
tgattaaaaa taactttaat ttccgcgagc acgtcaaadc ggtccatcac atactccagt 7860
tctgctgcaa cgtgtattgg caggcgccgt gcgcggtgtt cctgaatctg tactacaaat 7920
ccctgctgtg gatcattcag gatattctgc tgccgtactg catgatctac gaacaagata 7980
atccggcgat gggcatcctc ccctccgagt ggctaaagat gcattttcag acgttgtgga 8040
cgaactttaa agcggcggtg ctcgaccgcg gggctcctac ggggtgcgaa ctgaaaaatcg 8100
tacaccggga catgtttctg gactttcttc acaccgacgc ggggtccaac ggcttaatgg 8160
ccccctttaa aatgcagggt agaatagcc gagccatgat ggtcgttccg aaatcaatta 8220
aaataaaaaa tagaatcatt ttttccaaca ccgcgggacg cgaggcggtg cagtcggggg 8280
tcgtcaaacc gacgggaacc agggacactt acgtggtggc cggaccgtac atgaagtctc 8340
tcaactcgct gcacgcgcg ctgttccccg acaccaagac cgccgcgtg tacctgtggc 8400
acaagatctc ccagaccaac aaaacccag ttctgaaaga cgtcccggac gacgagctgg 8460
cggagctggt gtcgtacgta aagaccaaca gcctcgcgtt cgaggaaacg aacgtgctgg 8520
acgtggttcc ggattcactc atgtcgtacg cgaggatcaa actgaacggg gccattctaa 8580
gggcatgtgg ccagattcag ttctacgcca cgacgctgca ctgcctcacg ccggtgctac 8640
agacgatcga tgccgaggaa tacccccacg tgctgggctc cgcggaatc gccacaccgg 8700
tggtttacct ggcagaaata cgcgcccgca ccgccctcac cgtccagacg acggcgcgctc 8760
agccggtcgc cgccacaggg gcctcgcgtc ccgtgataac cgttcccatg gtagtcaaca 8820
aatacacggg ggtcaacggg aacaacaacg ttttccactg cggaacactg gggactttcg 8880
cggggcgcgg cgtggaccgc aacctgtggc cggaagctc cccctttaag aaaacgggcg 8940
tcagcgccat gctaagaaag agacacgtca tgatgacccc cattatcgac cgcctaataa 9000
agcgagccgc gggacagaca atcagcacgt tcgaggcgga aagcgttaaa aggagcgtgc 9060
aggcgtgtt agaggataag gacaacccta acctattgaa gtcggtaatc ttggagctta 9120
tacgacacct ggggaagggc tgccaggact taagctccga ggacgtgcaa tattacctcg 9180
gtgactattg tatgttgacg gacgaggtt tatttacgtt ggataatata gcacagtcag 9240
gcgtgccgtg gactatcgag gacgcgggtg ccctaataga ggatcgccag gacgcagacg 9300
atcttcagtt cgtagacagc gacgatatcg ccaccgcttc ctgtcagccc cccgaggaac 9360
agctaccgac ccctagcgcc ggccgacctac tggccgggaa gaagcgaaaa attaacgcgc 9420
tgctgagcga tctagacctt taggaaaacc gtggcaggcg ggcaacaatg gccagggaac 9480
tcgcagcatt atacgcgcag ctgtcggccc tcgccgtcga cttgagtctg gttatctttg 9540
cggacccgcg aagtatcgac ggtgcccgca ttctaaaaac aaaaacacag atagagaacc 9600
tgaaccgcga ccttctgccg ctgtacgcg agcaaaactc ggtagagacg tccagcctgt 9660
cgctcgaagt ggagcacctg gccaaaaaca tcgaggacaa actcggcgag ctggagcgca 9720
gtctcgggca gagatattcg agccgagagc attttgaac actacacctg agaccggaat 9780

```

## Cloning of Radinovirus Genome and Methods for its Use.ST25

gtcactatca ctctacggtt acttttcagt ttacggggg cgggtaata gatgtaaaca 9840  
 tgtgcctaataaacgatgta gaactgctgt gtaaaagact agggagtgtg ttttattgca 9900  
 tcgggtgcaaa cgaagctctg tccggattga accgggttct gacgtttctg tcaacactgc 9960  
 ggggtatctc cccgatcccg caccagacc tatacgtcac gtcagtgcct tgcgtacagt 10020  
 gcctgaggga aatcgaactc gtacaaaatc aggggtccag ttactcgcg gtgttgccag 10080  
 accgacactg cgatcacctc tgtaagaagg ttagggcgga gccaatcac ggcctgtttg 10140  
 agacagaact gagccagctg ggtctaaaag taacaaaacg ttcggacgcc acgcagcacg 10200  
 gcgtccggtc ctctgcagat cagttaaggg agtcgtcgtt ggcggccata caagatcaca 10260  
 atatattcaa acgggtgtcc gcgtcaatca tggaactatc caatctaatt tattggaacg 10320  
 ccgggcaaac cggcctccag accgggaccg aaaacgagt ctcacaaatg gccagactgc 10380  
 taacacacga ggccgatatg cagcagcacc gtgcgctaataacacccaaa ctaagcgcga 10440  
 ctacttcta cgactgtttc cgaccggatc ccatagaatc cctgttctgc ggcggctctt 10500  
 ttaactctat agacgacacc ataaacgcac tgagccggga ttgctccgtg acgttctttc 10560  
 aacaggcaaa ctataccaac gttatgcgaa aacaaaacga gctgttcacc agactcaata 10620  
 gcctcctgcg tcaggggagc gcgggatcgc aaaaaccggc caccctcgc gagccacgga 10680  
 ccaccaccgt ggcggcaacc gcggcaagc acgtcatcaa agacgcacag tatcgcaaag 10740  
 aacagtacat gaaaaagggt gccagggacg gctttaaaa actaacagag tgtctgcaga 10800  
 cgcagagcgc ggtgttgga aacgcactct gcatgcgcgt atgggggggc gtcgcctacg 10860  
 gcgaggcgtc cgagctgggt aaccattttc tcctcaggcg gcgcttcgtc gcgcttcctt 10920  
 gggaggcgcg ctgccgctcg gatcagattt tttcgaaaa ctcaaagtac attaaaaact 10980  
 cactatattc ccagcgctc agtcgcgaac acgtagagat tatcacgtg cagttttacg 11040  
 gcctgataac cggccccctg acgcgccaga gcgatctctt tcccggcccc gccaacgtcg 11100  
 cgctggccca gtgtttcgag gggccggaa tgcttcgcga tcacaagatg ctggtgtcag 11160  
 agatgatatg gcccagatt caaccgaaag actggataga ccagacattt aatcgttttt 11220  
 accaacttcc cgaaggtgat ctcaacgcgg taaaaagtc cgcctggtgc tttatacag 11280  
 agctcgtcct ctcggtggcg ctttataatc gcacgtggga aaagacgtg cggatatttt 11340  
 ccctagcgcg cgagaaactc tccatctcca acctagacgt taaaggcctg acgtccggcc 11400  
 tgtatctaac gtacgagcaa gacgcgccgc tcgttctaatt ttctcaaat accggctgga 11460  
 tatttaaga cctgtacgt cttctgtacc atcacctgca actgtccgac ggccatgatg 11520  
 ataactaacc gaacgcgtcg tctcctgcg gcgtgggtcg tgataatcgc gatcggcacg 11580  
 gcggttggtg aaaacgtcac caccccaag ggcgcgacca ccaccgcga gccaacgccg 11640  
 ggcccgtcga cgcacacacc tcccagaac ccacctagg cggaggcgtt taagtctgc 11700  
 gtgtgcagcg cctcgccac cggcgaactc ttcaggttta acctggaaaa aacgtgtccg 11760  
 ggcaccgagg acaagacgca ccaagaaggc atcctgatgg tgtttaaaaa aaatattgtc 11820  
 ccgcacatct ttaaggctcag acggtaccgc aaggtggcca cctcggtgac cgtctatcga 11880

## Cloning of Radinovirus Genome and Methods for its Use.ST25

ggggtggaccg agaccgccgt gaccggcaag caagaggtca tccgaccggt gccgcagtag 11940  
 gagatcaacc acatggacac gacctaccag tgtttcagct ccatgcgcgt aaacgtcaac 12000  
 ggcatagtaa acacctacac ggacagggac ttcactaacc agaccgtgtt tctgcaaccg 12060  
 gtcgaggggc tcacggataa catccagcga tacttcagtc agccggtgct gtacacgaca 12120  
 ccgggatggt ttccgggaat ttacagggtc agaaccacgg tcaactgcga gatcgtggac 12180  
 atgatcgcg cgttcggcga accgtactcg tattttgtca ccgccctggg agacacggta 12240  
 gaggtgtccc cgtttctgcca caacgactca acgtgctcgg tcgcgagaaa aaccgaaaaac 12300  
 ggccctcgcg cccgcgtgct cacaattac accatcgctg acttcgcgac ccgccagccc 12360  
 accaccgaaa cgcgggtctt cgccgactcg ggagaatata ccgtatcgtg gaaggcggag 12420  
 gaccccaagt cggcgtctg cgcgctgacg ctctggaaaa ccttccccag ggcgatacag 12480  
 acgacgcacg aggccagcta ccacttcgtg gccaacgacg tgacggcgac cttcacgtcc 12540  
 ccgctctccc aggtaactaa cttcacgggc acgtaccctt gcctcaatga tgttattcag 12600  
 aaaaccctca acgccaccat caagaagctg tccgataccc acgcaacaaa cggatcggag 12660  
 cagtactacg aaaccgaggg gggctctgtt ctctgtggc agccgttaac gccgctaagc 12720  
 ctagctgacg agatgcgcga attaaacggc accacgccag cccccccac cacaacctca 12780  
 accgccaacc gcgttcgaag aagcgtcggc acgaacgagc aggcaacgga cgacctagcg 12840  
 gcgccccagc tgcatgtcgc ctacgacaag ctccgcgcga gcatcaacaa ggtgctggag 12900  
 gagctctcca gggcgtgggt ccgagaacag gtgagggaca cctacatgtg gtacgaactg 12960  
 agcaagatta accccaccag cgtaatgacg gcgatatacg ggcggccggt gtcggccaag 13020  
 ttcgtgggag acgccatctc cgtgacggac tgcgtggcgg tggaccaggc gtccgtcagc 13080  
 atccacaaga gcctccgcac gtccaccccg gggatctgct actcgcgccc cccggtcacg 13140  
 ttcaggttcc tcaacagcac cacgtgttcc aagggccagc tgggaccagc aaacgagatc 13200  
 atactgacgg acaaccaggc ggaggcgtgc aaagagacgt gcgaacacta cttcatagcg 13260  
 agcaacgtaa cctactacta caaagactac gtcttcgtga aaaaaattaa cacctccgag 13320  
 atatccaccc tcggtacgtt catcgccctg aacctgtcgt ttatagagaa catagatttc 13380  
 agggcatcag agctgtacag ccgcgcggag aaaaagctgt ccgggagcgt tttcgatata 13440  
 gaaaccatgt tcagggaata caactactac acgcaacgcc tggcgggact ccgggaggac 13500  
 ctggacaaca cgatcgacct gaaccgcgac cgcctggccc gcgacctgtc cgagatagtc 13560  
 gcggacctgg gcgatgtcgg ccgcacggtc gttaacgtgg ccagtagcgt gataaccctg 13620  
 ttcggatcaa tcgtgagcgg gttcattaac ttataaaga gtccgttcgg gggcatgctc 13680  
 atgatcctgg tgattgtggc ggtcgtcctg atcgtgtttg cgctaaaccg gcgcaccaac 13740  
 gccatcgccc agggcccat caggatgacg taccocgaca tagacaaaat gcagccctct 13800  
 ggcggtaaag tcgaccagga gcagattaaa aacattctcg ccggcatgca ccagctacag 13860  
 caggaagagc gtaggcgggt agacgaacag cagaggtcag cgcctcgtt tttccggcgc 13920  
 gcgtcagacg gactaaaacg tcgcttttagg ggatataaac cgctggaaaa cgaagaggct 13980

Cloning of Radinovirus Genome and Methods for its Use.ST25  
caagagtatg aaatgagcaa ataaccacac ccacacgcct gtacttgccg cccgccagag 14040  
ccgcgcggcc aatcgattcg cgcacccggc cgggtcccca caccctctag cgccccggg 14100  
cgtccgcggg ctgtatcaat catggatttc ttttaaccgt acctgggccc tcgcggacca 14160  
cgccccact cacacagagg caccgatgct cccgccctg ccggcgccgg agccgttcag 14220  
ccgccaccag acgtttgcag gtcacatccc gcctgcctcc gaacgccagg ggcaggcggg 14280  
atgatcccgg tcacgatccc gttcccgcca acgtacttcg agaacgggtgc tcgcggagac 14340  
gtgtgctcgc ccaacgaacg gtccatgtgg acggcgcgcg accgcaagcc cgtcgccccg 14400  
gaccccaag accaatccat cacgtttcac gcgtacgacg tcgttgaaac aacgtacgcg 14460  
gcggacagggt gtgccgagggt acctagccgc ttccaaacgg acattatccc aagcggaacc 14520  
gtgtcaagc tcctggggcg aaccgaggac ggcaccagcg tgtgcgtgaa cgtgttccgt 14580  
caacagggtat atttctacgc gaaggttcca gccggcatta acgtaccca catcctccag 14640  
caggccctca agaacacagc cggccgtgcc gcgtgcggct tctcgaccag aagagtgaac 14700  
aaaagaattc tcaaaacgta cgacgtcgcg gagcatcccg tcacggaaat cacgctatcg 14760  
tccggttcca tgctctcgac cctcagcgac cgctcgtcg cgtgcgggtg cgagggttcc 14820  
gagtcaaacg tggacgccgt tcgccgggtc gttctggatc acgggtttac cacgttcggg 14880  
tggtactcgt gcgcgcgcgc cacgccccgc ctggcgccca gagatgccag gacggccctg 14940  
gagtttgact gcagctggga ggacctcagc gttcaagcgg accgcagcga ctggcccccg 15000  
taccgcatcg tggcctttga tatcgagtgc actggagagg cgggatttcc gtgcgccacg 15060  
cgcgacggcg acgcggtgat ccagatctcc tgcgtcttct acacgaccag ggaaggcgcg 15120  
cccaatccgc caaacatact gttcagcgtc gggacgtgcg acccatccc ggacaccgac 15180  
gttttgaggt ttccgtcgga atatgacatg ctggtgtcgt tcttcgccat gatccgcgac 15240  
ttcgagggtg actttttaac cggctataac atctcaaact tcgatctccc gtacctaate 15300  
acgcgagcgt ccaggtgta caaccttca ttaaacgaat acacaaaaat aaaaaccggc 15360  
tccatctttg aagttcacga gccccgtggc gggggagggg ggttcatgag gtcggtctca 15420  
aaaattaaaa tagcgggcat cgtccccata gacatgtacc aggtgtgtcg cgaaaagctc 15480  
agcctctccg actacaaact ggacacggtg gccaggcagt gtctgggtgg gaaaaagag 15540  
gacgtatcgt acaaggacat tccccctctg tttcgctcag gtccggcgcg cagggtctag 15600  
gtgggcagct attgcgtgat ggactcggtc ctggtgatgg acctcttaa aatgtttatg 15660  
atacagtgag agatttcgga gatagccaag ctggccaaga ttcaggccag gcgcgtcctg 15720  
acggacggcc aacagctccg cgtgttctcc tgcctgctgg aggccgcggc cagggagAAC 15780  
tttatectcc cggttccaac gcccgaggga caggggggct atcagggcgc gacggtgatc 15840  
aaccatttc cgggggtttta cgacgagccg gtcctggtgg tcgattttgc cagcctgtac 15900  
ccgagcatca tccaggcgca caacctgtgc tactccacca tgatacacgg acgagacctg 15960  
cacctgcacc ccaacctgac gccggacgac tacgagacgt tcgtgctgag cggcggaccg 16020  
gtacattttg taaaaaaca caagcgggag tctctgctgg gaagactgct aaccgtgtgg 16080

Cloning of Radinovirus Genome and Methods for its Use. ST25

```

ttagaaaagc gaagggcgat ccggcgacc ctggcgcggt gcgatgaccc gtcgctaaaa 16140
accatcttag ataaacaaca gctggccatc aaggtgacat gtaacgcggt ttacgggttc 16200
accgggggtg ccagcggcct cctcccatgc attaacatag cggaaccgt gacgctccgg 16260
gggcgcacga tgctggagat gtcaaagtct tacgtggagg ccctgacgac ggaagacctg 16320
cgaacgcgtc tcggtcgca ggtgaccgcc cgtcacggcg cgcggtttcg cgtcgtctac 16380
ggtgacaccg actccctctt tatcgctgc gacggttatt ccgcggaagc cgtttccgct 16440
ttctgtgacg atctggccgc caggatcact gcggacctgt tccccccacc cattaagcta 16500
gaggcggaag agacgttcaa gtgtctgctg ctgctgacga aaaagcgcta catcggggtc 16560
ctattgaacg acaaaatggt catgaaagg gtcgacctca ttcgcaaac ggcctgcaag 16620
tttgtccagg agcgatgccg cgccatcctg gacctggtgc tccacgatcc ggaggtcaag 16680
gctgcggcgc ggctgttgtg caagcggccg ccgcacggcg tatacgagga ggggctgccg 16740
gctggttcta taaaaatcgt agaggtcctc aacgcgagct atctggacct ccgaaacagc 16800
gtcgtgcca tcgagcagtt aacgttctcc accgagctca gccgcccgt ctgcgattac 16860
aagaccacca acctgcccc cctggcggtg taccaaaagc tggcgagcag gtgcgaggag 16920
ctgccccagg tgcacgatag aatcccctac gtgttcgttg acgcgcccgg gtcctaaag 16980
tcggacctgg ccgaacaccc ggattacgtc agacagcacc agattccgt cgcggtcgac 17040
ctatatttcg acaaactggt gcacggcgcg gccaacatcc tccagtgtct gttcggaac 17100
aacgcggaca ccacggtggc catcctctac aattttctca acgtcccgt taagctgttc 17160
tcgtgaacgc caattggaga acgccaacat aagacgccg gccagcggag tccgcaggga 17220
gagctcgagc ggcgaggagc gaccaacgga gaccgccacc atgctggtta acgaactgtc 17280
gggtggtcctc ggcgactggg aggtgacttt tcaccggggt agattcagct tcgtcaacct 17340
caccgcctg caaacgttca agggccacgg gggctacgcc aggggtccgac tccccttctc 17400
gctcgaccag ttactccacc aacatttcgc gttcggactc gtgacgcgtc tcaaggaact 17460
gcccccttc tccgactgcg tggcccttat cgcccgttg gattccggcg gcgacgcgga 17520
cgcgcgcgcg gtggccccg ggttcgtgct ggactcctct cgcccgtga ccgtgtgggt 17580
aaacgcgagc gggcggcaca cgatccggtt ctgcctcctc tttctaaagc cgatcgacct 17640
ggagcgcgcg gtcacgtacg tcttcggcga gaacggcgcg gcgcgctcg agggcacccc 17700
aaagcccacc tgcgcgaccg aaagcctgcc cgggtggacc ctgcgcgtct ccggcgaggc 17760
gtctcagacg tcgccccatt ctttcgttgc gtattttccc acggccaact cgggtgcctg 17820
cctaagcctg ttgcggttac aggtgaggcc gtttcggat gacgcggcg acagggacgc 17880
gcggtatctc ccgaaatacg tcacgttag taactccgg ggtaacgtct gcaaggcgtc 17940
cgttcacacg ctgtccccgt cgcggtgtaa aacggcgcaa atggaaatca tctacgtcc 18000
cggggacccc aacgcgaga tagtcctgg ccagtcggga cccgtcctgc ccaccacac 18060
cggcggccgc gtattggggg tctacgccga cgccgaaaa accatccaac ctggaagctc 18120
cgcggaagtc cgggttcagt taatcttcca acagggagcg gccgctcgg gcgatctggc 18180

```

## Cloning of Radinovirus Genome and Methods for its Use.ST25

gtttctggtc acgggcgtgg caccggagcc cctattcgtc gtcaccccg cactcttgc 18240  
 ttccggttgc acaaccacc tgcgcctatt caacccaac ggtaccccca cgactataaa 18300  
 aagagacacc cttgtggcgg ccgcccgcgc ctgcccctg gtgcgattaa gctccgccga 18360  
 cgacgcgcgg cgagacctcg tcgcgtcacc agacaccggg gcgctctcca ttaacgcgtt 18420  
 cacaatcccg gtcggtttcc caggggtggt ctcggcggag tgtcacgtgt ccctacgcga 18480  
 caacgggggc cacgaacgca tgaaccattg acggcaacga tgggaacacc ggtgcgtttc 18540  
 ttccgcggcg agtggcagac ctcgagtcta gtggacaacg gcacgccacg gtacagctcc 18600  
 ctggtgtggg ccgccactat tcacgacggc tacctgacac tggatgaacag gtcagagctg 18660  
 tgcgtcacgg agaggtctcc gtgtctgcgg gcatgcccca gcatcgggag actggtcggg 18720  
 aagaggtttc ccggtctcgc ctttgcagc gccactctgg gcgatcgggg aacacgcacc 18780  
 gtgtttctacg cgttcggtca ccgcgacaac ccactggaca tagtaccgcg cgtggtcgag 18840  
 cgcgcggtac gcgagctggt gctgcgggtt cacgctccgc aaacaacgcg ggtgtcgcga 18900  
 tacggactta aggtattcgt ggcgatcgtt acgggtggtg gcccgcccg ggtgttccta 18960  
 cactttccac aagaccgcgt tccgatcgcg ctgacagacg cgtgcagcca ggagggctcc 19020  
 aggctaacct ctgaagagcc gtggataaaa attcaaggct ttcccgtcct atctgacgag 19080  
 accgcgcacc ctttctctt aaccagaag accaagccct ttaccgagcg aaagttttgc 19140  
 cgcctgatca tggacaacga ccagcgcagc gccgtcaaca ccgtctacct gggaaagcag 19200  
 cacgtgaggg tgaccgtgac ccgcccccg gaaacaatcg tcaccgacgg ccccgtagc 19260  
 gcgaccctgt ccctaccgg taatgcgcca atcgcccttc gccacaacc atactttgaa 19320  
 ctcccgtggt cgtccacaac ggcatattc acgcccgtgg tgtacgtggg cctgaccgtg 19380  
 tgcacccac ccaactgtag caaattcgta aggtacggta acacctacgt ctcggcattt 19440  
 aaccgcaagc tgacggcgat tattagcaat cacgccaca acggcgggtt ccggattcag 19500  
 gactgcgagt ggccaccgaa ccgggagata gagattttg taaccaacgt gtcccaggcc 19560  
 ccggtgtaca tcagcaccgg gacgcagctg gggcaagcca tcttcgtgtt cgcgcccg 19620  
 ttccgtggcc cggcgaaact gcggcagctc ctcggccacc gatcgcgcgc cctggagctg 19680  
 ccgggggggg tgacagtga cagcaaaaa ctgtgtaggt ttgagaccat gtacctgtt 19740  
 tccacgtaaa ttactaataa accgtttgct cgtatcgctc acacaacgcc aaaccgtctc 19800  
 tcattctcgg ggtcgcgcgc ctgcgaaca cacaaggtgg ctcaaacacc cccctccgc 19860  
 accctgcgca caaaaacca gttaacgcct tccgttagat gcagtttatt tattatttta 19920  
 ttacatcata gctattgcgc ggcccgcgc ccgcaaaaac atctgtagat attccagtat 19980  
 gcgaaacgcg ctgagaacaa cgtcccgggg gctctgccct cccaacgcac gcacggttt 20040  
 ttcatagac tccgcgccac ctatctgtt atttacggga agctcctcaa ttagagagtc 20100  
 gagggcgagc agcaccacgg tcaccgcgga gccaatggcc gcggcgccg cgtccccggg 20160  
 cgcgtcgtcc agcagcatcc tcagtcgcgt caggtaactc tcgtaggcc ggagcccgcg 20220  
 aaccatggcg ttcatacact cggccccgcg aaactcgcgg cgctggcact caacgttaga 20280

Cloning of Radinovirus Genome and Methods for its Use. ST25  
catcaatata gggaagtga caaacgacat gatgcgcggg tactcacgca cccgacagag 20340  
agtggagtgg tggcacaggt aaacgaacca gcgctgtatg ttttaaccca cttcagacag 20400  
gcgccccctg gtcctgtcaa gagaggcgcg gttgccggcc cactggggga gaacgttaat 20460  
tccagcggca gtcgggggag gcgccagcgt agggctggcc gcccaacacg acaggtaaaa 20520  
caagacgaac cagacagga acatgaccgg ttaaattact cgcttacaat cgcgggcggc 20580  
ggccggtcaa cgccaggtcc attaaaaaca caccggccgc caaccccaa cgcggggccg 20640  
cgccctggaa cgcggttcct tccaatcgca aagaaccgcg tcacaaaag ggctcgtttt 20700  
gaaccatttt tgtgccatcg ggtttcgttt tcagatacgg aaacggctcg tccaaaaaca 20760  
cccaacgggg gtgtgctcaa acggccatct ccatctctat gtggggatgg gggtcgtagc 20820  
cctcgagact cagatccgcg cgcgtaaagt cctccagacg cgccaccttt ctcaaatct 20880  
tcagccgagg aaacggagcg ggggtcctcc gcagctgaag cagcagggga tcaacgtggt 20940  
tgttgtaaac gtgggcgtca cccaaggtgt gcacaaagtc tcccggggtc agggccgtga 21000  
cgtgagcgat cagatacgtc aggaggcggt agctggcgat gttaaaccggg accccgaggc 21060  
ccatgtcggc ggacctctgg tacagctggc aggacagctc cccccgagcc acgtaaaact 21120  
gacacaaaac gtgacaagga gggagagcca tccgcgcgag gtccgcgggg ttccacgcgc 21180  
acataacgat gcgccgatcg tggggccgcc tgttaattag atccaccacg taacgcagct 21240  
ggtcaccccc ctgacctcg tagttggcgt cgccccct gtactccgcc ccaaatgtc 21300  
tccactggaa cccgtacacc ggcccagat cgccctcgcg gcggtccccg aagccctgcg 21360  
ccgcaaaaaa ggcgcgggac ccgtgcgcgt cccaaatttt tacgcccgcg cgcgacagtt 21420  
cggtgaggtc ggtggagccc ctgataaacc acagcaactc ctccacgacg cccctccaaa 21480  
acaccttttt ggtggttaac agaggaaact cgtccctgag gttatatcgg gcctgaagcc 21540  
cgaacacgga cctggtgccc acgcccgtcc tgcctccct ctgcacgccg tgtttaataa 21600  
ttaaatccag gtgcgccaa tactgcagct cgccgtggtc gccgcggcac gcgcagcgga 21660  
cggccgcggc accttcgggt gcggaaaaaa cccggagtcg tgccggccgc attccagcca 21720  
cgaaacggg tataattttt ttaacgtagc agataccgag atgcaccagg acaatcataa 21780  
ttacaaccga ggtgctttac aactataacc gtaaaccggct gaagacgaaa cttattttta 21840  
aggcagcttg ggcggggcgg accacaggcg cgcccggt gttagcgagt aataaaccca 21900  
cgtggtctcc ccaagcgtct ccccgagcgt gagcgtctcc ccaaaccgca aaaacaacac 21960  
agataataaa ataaataaca tgtttatttt ttataaactt aacgcgcgat tatgcttctt 22020  
aacaggggcc aatagaagca acgtgcgagg cggcattcgc gcgctcaaag gcaaccgcaa 22080  
caccggcgct cgtaacagcg taaacaaaca actattagcc attcgtaacc gtaaaatcca 22140  
accctctgcy tcccagacca ttgccccagc tgcgtctacg tcgaggggtg ttctaagtcg 22200  
cattttgagc ccttggcagc gccgcgtctg cgtaaatggt gtttctaaat cccgctgcca 22260  
aggccctctt cggaatcgct aatcaggctg cgccgggttc ttctgccctt tttgggacgc 22320  
ttgtccaccg cctgaagcag tttcttact gcgtcgtccc cgggattggc acacagcttt 22380

Cloning of Radinovirus Genome and Methods for its Use. ST25

ttaccgcggc gagtggttaa tatcacggcg tccaccgagc actgcgacga ggtgtgggag 22440

taagagacca ctaaaccggg tggcggcaga tgagttacat accccaaca gcagagttcg 22500

ggcgcgggtc cgctcatgga gcccatagga aaggcataat caactacaca cgcgaaacacc 22560

gcaaaaaaaaa cgcacacgaa aaggccctc atggtgacaa aaacacaaaa caaagacggg 22620

gtcgctcgtg cgttgccacc agcgccacgc tcgccgtgct cggccacggg tgacggcgtc 22680

cattaatacc cgcgggcccg gcccgccctg acggaacaca ggcgtgggta gccacctgac 22740

gcacgtgcct ccgctccaga tgtggcattg cgagtcacca aacgggcgtg tctaactacg 22800

gtcgcccccg ggttcaaaga acggggatcc cccaaacagg taaaaagctt tttgtccaaa 22860

cagaaagcca acagcaaccg aaaggaatct ccaaaacaag caaggggtccc gtgccggcga 22920

taaacggaat atttccctca cctaaacaca cgcgccgctg aaactgttaa aacacgcaat 22980

acttcctagg cctgtgttta ataaacaca caagggttgt aatttcgagg ggccctttgg 23040

gccccgcgcg tctgggggtg cgttgtctcg ttgtggttcg caatcaccac cccgcctgcc 23100

cgaaaacagg gcaacaaccc cctggcctag ttttttaaaa acttaacacc ggcaagggga 23160

gaggagagaag gggtcgggct aaatgggctg ttagcagcca accgcagcgg ggaaaaaagg 23220

gggcaaacgc cgggttaaca caaacagcaa caggcgccaa acccaatata acacaacgca 23280

tattccgtgt gtttcgaggg ccggggctcg tacggctaac ccgctgtggg cgtttgcaca 23340

agcacgcccc cgccctgcac ccggctcccc gaggtcaccg aagggtcagg aaacatagtt 23400

ttcacggctg ccagtcgcgc gcgtggcaac atctttcggg gccctccgaa cgaccgggaa 23460

aaatccccgc cgcgccgggt cgttcggagg gcaccgaaag atatcccaa acgcaaccta 23520

aagcatcatg tttgggggtt cggtagcgcg cgccgcagag gaggcgggtg gtggcgctgg 23580

cgaagatagt ggccgcagag cacgggtttc ggtagtgacg cgccgtggacg gctgccacct 23640

ggcagcaggc caaaaacacg ggccgcgga gcggccggca ggtggcgccg cgctttcccc 23700

cacgccgga tttggcaaaa tggcggaacc gcagcgccg ttggacgcgg cggacgtcaa 23760

tcacgacgga gagaagcgca gttggtcagt tgtcccgtca atcaccgagg gccgcgcccg 23820

ttggcggaata atatgaaacc ggcgcgcca ttggacgctg gcggcagcca atgggcgctg 23880

tgggttttgt ttacaagttc cctatatata ttatattata ccttcctgt taagggaatc 23940

ccatgttctt aaatctaac agctgggtta tataattaga atatcagtaa ttactattat 24000

tactgtatta tttattaaat tatttatttt attatttatt taataaatta attcttgcgt 24060

tattatgtaa tcagatactg ggaatctac tcccagttta ataaaaataa ataattaatt 24120

ctattatggg gggggttcta aatattgtac aaaacaaca ttttttttaa atttattcac 24180

taaaaatgct ccatttttac ttgtgacgta catgttagga atgtgggagt ggtttgtaac 24240

tatgttttca aacaacaccc ttttggccg tctgaaactc atataagcg aaggctcggc 24300

gttaattgcc actggccgct aaccagtcca ccttgccagt tggagtttta ttgctgctta 24360

tggctttacc tcgcattccg ggcacaagct gatttacgta gcacgcattg ggggtttaac 24420

ccggttgaat ttagtggttt gcacgtgtaa aaaagccac cgaggcttg gtttaagcgt 24480

Cloning of Radinovirus Genome and Methods for its Use. ST25  
ttaaagcggtt gctgggttta taacatgcga ttaattgct atgggagcta gcttgattc 24540  
cgcatgcttt cggtttagta gttgtacaaa acagaattgt agcccgcaa ttgttactgg 24600  
taccctaaac ggcaagcccg cttaacacgc cccgcgctgc ggcttttgtt cctagcccg 24660  
tcgcaatata atcgagattt taatttaaaa tggggcaatg gcgtagcgca aatttaagcg 24720  
cgtcaaaaat ttaaaatgga ctaacgtaac cgggtgctttt agtgacctat ggcgaatttt 24780  
aaaatttaaa gccgtgggtt ttaacacaga gctgccagct tgtaatacgt tgcatatata 24840  
gtgccgttgt gatattatgg ttaagtggat ttaacattg aattttgtaa tgggtgtacac 24900  
gtggattttt aaattgaatt taaaattgta attacgtgcg cgtggattttt aaaattgtat 24960  
ttatgtaaca ttgttaaatt ttaactgcgt tatggttgta ttttggttaa tttatgtaat 25020  
tttgctttta gatattgttcg ggtgtgaatt ccagacaggt aagagcctag ctccctaatgt 25080  
ttgccttgcc gcctagctcc taatgtttgc cttgccgcct agctcctaata gtttgccctg 25140  
ccgcctagct cctaattgtt gccttgccgc ctagctccta atgtttgcct tgccgcctag 25200  
ctccctaatgt ttgccttgcc gcctagctcc taatgtttgc cttgccgcct agctcctaata 25260  
gtttgccttg ccgcctagct cctaattgtt gccttgccgc ctagctccta atgtttgcct 25320  
tgccgcctag ctccctaatgt ttgccttgcc gcctagctcc taatgtttaa caacattaat 25380  
gtttaagcac actaaaaattt aaagacgttt gtgttggttt ttatgaccag cttggtacaa 25440  
aacctgctgg tgatttttta cccaacaaat aataaataaa aaagttaaaa cttatttctg 25500  
ttgtctgtgg taattgggtt ccccgagggt cccgggctcc ccgttccccg aggggtccccg 25560  
gtccccggt ccccgagggt cccgggctcc ccgttccccg aggggtccccg gctccccgtt 25620  
ccccgagggt cccgggctcc ccgttccccg aggggtccccg gctccccgtt ccccgagggt 25680  
ccggggtcc ccgttccccg aggggtccccg gctccccgtt ccccgagggt cccgggctcc 25740  
ccgttccccg aggggtccccg gctccccgtt ccccgagggt cccgggctcc ccgttccccg 25800  
aggggtccccg gctccccgtt ccccgagggt cccgggctcc ccgttccccg aggggtccccg 25860  
gctccccgtt ccccgagggt cccgggctcc ccgttccccg aggggtccccg gctccccgtt 25920  
ccccgagggt cccgggctcc ccgttccccg aggggtccccg gctccccgtt ccccgagggt 25980  
ccggggtcc ccgttccccg aggggtccccg gctccccgtt ccccgagggt cccgggctcc 26040  
ccgttccccg aggggtccccg gctccccgtt ccccgagggt cccgggctcc ccgttccccg 26100  
aggggtccccg gctccccgtt ccccgagggt cccgggctcc ccgttccccg aggggtccccg 26160  
gctccccgtt ccccgagggt cccgggctcc ccgttccccg aggggtccccg gctccccgtt 26220  
ccccgagggt cccgggctcc ccgttccccg aggggtccccg gctccccgtt ccccgagggt 26280  
ccggggtcc ccgttccccg aggggtccccg gctccccgtt ccccgagggt cccgggctcc 26340  
ccgttccccg aggggtccccg gctccccgtt ccccgagggt cccgggctcc ccgttccccg 26400  
aggggtccccg gctccccgtt ccccgagggt cccgggctcc ccgttccccg aggggtccccg 26460  
gctccccgtt ccccgagggt cccgggctcc ccgttccccg aggggtccccg gctccccgtt 26520  
ccccgattca acgttaaagt ggtttattta gaaacacac gttttttgcc gcggtttggg 26580

Cloning of Radinovirus Genome and Methods for its Use.ST25

```

ttgtacatac acgcggtg gcattggccc gcccatgcaa aaaaataacg ttgggtttcc 26640
gaaacgcgta ggtgctttag tgtttcatgg cacgttttcg tgtcacggta ggagtgggta 26700
gttttttggg agcgaatgca accaggtagc tcgcctgacc gggaaaggga acgtttttaa 26760
ccgcagtggt accgcggtgc ggcatacggg ttaacgtgca actgccggtc ccgcgcgtgg 26820
taccttaagt ttacgtgtag caattatggc ggctgttcag ggccctccgc cgccccctga 26880
ggaagaaaat gaaaattcct tgccagttga cgtttatgct atagagggca tctttcttta 26940
ctgtgggctc gggcaggcgg agtacttgca ccatcccgtg tttagcccta ttaaggaatt 27000
tatcagcgcc tttctcaagg acagcgctcg cctgtacgag aggtccttgc gccacaccga 27060
ttaccgctct ctgcggggac taaacgccat aggccaaagg atgctgcaa taaacacgga 27120
cggacgccac aactggggtc gcgctttggc cgtgttgggt cttggtgcgt atgtggtgga 27180
taagggtaaa gacgacgagc gtcttttaac gttcgccata gccgttctac ccgtgtacgc 27240
gtacgaggcg ctggagtctc agtggtttcg ttcacacggc gaatgggagg gactcaggaa 27300
ttactgcgag cgaatactga ggcacgccc caacgcgagg agacacatgt gctacggagt 27360
tgcggtggt cttctggcgc tagtggcgct gtttgccatc aggcgatagg tgtgcgttta 27420
accggtatt cccccacct gaccttaagt gagccgattg tatatgagac caataaaaca 27480
aaacaagcta acgtggtatt cgttgaaca ttttttattt gagcagttcc tcgcagaaca 27540
ttttttgtat ctgtgacacg ggggcccggc gtgcgctggc ctccaccggg gcccgcgcg 27600
actgtccgca ttctggatcg aggggcgggc acgcgccagc gcggggggca gaggctgaag 27660
gaatggcggt tgacattaca gattcttggg cggcgggggc tggagtggcc ggctgcgtgg 27720
cgagaccggc gtggtggctc gccggctgcg ggggcgggtg ttgcgtttgc tggatgccct 27780
gcgcgctctg gtacggctgt ggggcgtgga gatgggtgtc cggtccggaa taccactgcg 27840
gctgttacgc taggtacggc gcagacgcgt aggtctgtgg ccacgagaac tgaacgggcg 27900
gtggttgcg tcgttggtcg gcgtcctgtg cgccggaggt ctgcgacgcg gctcgtttta 27960
gggccctcag atccgcctga atgtccaata tgtttttgga cagcgccatg acgtccttgt 28020
gtatgccgac ctccctgcct ggaaacacgg gctcgtcgga aagctccacg tcccgtttgc 28080
gcttctggtg gcgagacggt gccggagcgt agccgtacgt cggagaatag tacgtggccg 28140
catacggaga ggggtggggg gcaaacgcc actggaagg gaacggtggc gcgacgggcg 28200
gtgcgtacga tgggacggtc agctcaggcg gcggtatcca cgatggatac gccgccgttg 28260
ccggcatcga ggggtggcga gaaacgtacg tgcggtggcc ctggttgcg atgttatcga 28320
gactgctctg caccatggtc agaaagggtc tcttggaat ggtgatgttg tcctccggga 28380
gggcgctcat ggttcgggtg tcgcggttac cgagtgctg agcgaggga aactggcttg 28440
cctttaaata cgtacttctc gcgactctgg ccacgccttt atctgttttg agcaggtctg 28500
tgcatctctg gataaatccg gcgtcgatcg ccttgccat cagtgtctca agaggggccg 28560
cgaattcttg cgggtgcacc tgacgttcgc aaagatctaa acaattgacc gttattttac 28620
cggcttctc tcgcgtaaga gaatcaaact tggagacgac ccatgtaggg tctggtccgt 28680

```

Cloning of Radinovirus Genome and Methods for its Use. ST25

```

aaacggcgat tgaccccta cgcctccca gtgcgcacag agagacgtgc tgaaacgcgg 28740
gtgggtgatt ggggtcttgc agctcttctg ggtggaggga cgagagggag agctccggga 28800
gccatgtgtg taacatctcc aacagggggt cccgaggcat ggggtttagc tggatctggg 28860
ccgctcgcga gtccccgcg agccgtgacg ccagggccaa gaaatcgtgg ctcgttagct 28920
tgcccaggca aaatatcccc tgtgttactt ggaagagacc gattgtgtga cctacgtggg 28980
cttcggggac gtgctctatg tttatcggtg gaggggccgt atacgggagc agggtcgcca 29040
cgattgaggg ctctaaatac agctcctttt ctatcttttg taggctgacc acgtccacgt 29100
atccccaac gtacacggga gtcattgttg gtcggtgtct gcgtgagccg aaggagatga 29160
gcgccggtct tcgggggctg atgtggcgcg ttatccgttg tgagaattta aatacgtttc 29220
tccctggcga gctcagggtt cttcacctgg tgctgtgcga aatgtacaac tacggctctta 29280
acgtgtacct tctgaaggag gcaattgcc aatacgggac gagggacgat attgtcctcg 29340
ggcgtaagggt tccgtgggag ttctggaaaa tcgtttacga tgggttaaag gagatggggg 29400
tttctgacgc aacgttgctc tcagaaacca aaaggggggc tctgtggctt tacttcaacg 29460
ggcgctccgtg cctgttaaaa ggtctaggcg actacgtttt ttgccaactg gggttaagcc 29520
acagcgtacg cgtggttccg gaaaacctaa cggatgggaa ttatctctat aacctaggca 29580
gcgtcatacc atgtcgctg cttgtggcac tgagctactg tttggcggtt tgggggcacg 29640
ctgaccacga gccctgggtc aggttggtcg ccggcaagat ttttatactg tacttaataa 29700
tttccggcca cattatgcc cggaagtcaa tcttagaaca ggtgggaacg tccgggtacg 29760
gtggcttcgt cgaggcagtg tgtcgcgatg ttcgcgcggt acacgggatt ccggcggtgg 29820
atthtgcgtc cgcggtccg gcgttaacgt ctcaacagac ggactacttg tttgcgttca 29880
ataacagcgt agttaggggt cgcctcacac taccgacgtg gcgaccggca ggtatcccag 29940
gacaaaaaa taaactctgt cgtagtcgtc gtaaaactccg aattggcttt tcattatctc 30000
gtgtgccaga ccggggggcg atgggtgcga aaggatggcg gccaggcctt cctcggccgt 30060
taaacgtagc gacgtttgag cctgaatcag gctgccagcg tccctgaacg tgagcttttg 30120
gttcaggatg tcaaagattt cgttaaactc ggaaccggtc aggttgacga acggacgagt 30180
gtgttttaga tgggatattg cctttgcctc cagcgccgct agatacgac ccgggaacaa 30240
aaacgacgtg ggggcgtctg gcgcgcgcga aagaattggg gagatgtaat tttctgtcag 30300
gaaatcaaaa agttgtccct ttttaaggta ttgtttggac ccggacgggt cttctacctt 30360
ggaaaatctc ccaccaggga gcgaggccag gttgaggcgc cgggtggggcg atctgggtgt 30420
gatttgggac agctccaata gcacgtaaac caaaactaaa cagcctagtg ccgagaggcc 30480
ggctcggagg ttccattggt acgcttgaaa gggaggcacg tcttcgctga acaaagtgg 30540
cgcaaggatg tatacagat ctggtccagg tggctgaccg gtaccggggg tcttgggaacc 30600
gggtagcagt ccgctctgtg ccaacgtcgc gtatatcacg tggtttgtaa agaagtccgc 30660
gttgtacttt gtttctttgt ttaggggcgc tagagaggcg cgttgcctcg gattcgaata 30720
tgtaaaactc aaaccaggc ccttcgtgtt ttgttttagg tgagagacaa gcgtcgccag 30780

```

Cloning of Radinovirus Genome and Methods for its Use.ST25

```

ctttgtgccg aggttatccc agaggccgtt tcgagttggc ggcaacgggg tacctgtccg 30840
gtgacagtag taccggttga ggaggcacag cgcggcctgc gtgtccgata cgttgccggac 30900
atccgcgtaa aagtcttgtg tgatcgaggc ggctgttgag attacggcag acattagctt 30960
tagagacgtg gagttttgaa agtttgttgt gcctcgcaaa tctctgggga acaccctgcg 31020
ttgcatggcg ttatctgtga ggctactgta ccacggcccc tattgtggca gccattgggt 31080
ttggttcattg tacaggcttg gcaggagctc cagacggaga tcctggttta ccgtgaatcc 31140
cgggtctccg ggggctattg tgacaacgaa cgcgtctcca tgtgtctgcg gggcgatttt 31200
gggttgccgg tttagtgatg tttgggcatt ggcggtttcc ctgcccgggg accgcagatc 31260
cccgaacctg ttttgaattg tttctaggtc gcgcatgacc acttctgttt ccggttggtg 31320
cgtttgagc acgttgtcta gttctagccg gagcagggtt tttcgagcg tgtgaacctt 31380
tagcgccagc tgttgatttc gcatcacaaa cgcgtttctt ctttcttcta tcagagatgg 31440
tttgaataa aacagaacgt tgtttggatg gggggcccaa aaagttgcg taatttgccg 31500
cgctggtttt cgtgggtatc tcatacagca ttttctgac gtgcgcatct tcccattggc 31560
taaaaaaccc gttaagcgcc gccgacgttg tgttgataaa tgtaggcgga aacgctgatg 31620
actcagtatg aattgtttta agtgttttct gggtcttaaa tagcagccag ggccttaccg 31680
accagttttc gtgtcctctt ggcgcggctc tgcctatata tgccacgga tctgtcagtt 31740
gggtgaagcc ctgccatcgc tgtgatattt ttattgcgtt gccgggaaat acagccgcgc 31800
ttaggcacgt cttgagttca attacgtagc acgttttttg atgttcgcta ttaacggtaa 31860
gcacacaatc tgctattcgc ctacctaggg aaacctcgaa aaaaatccta aatttaacgt 31920
ttttggttgc cctgagtggt gggcgaattg aaagaaactt taaaatatca tcaagcgacc 31980
gggtgttgat taaccgtcgg tatactgcta agtgggcgcg agttccagcc cgtttgcgtg 32040
aggccggaag ggcttcgagg gtcgcgacgt gcttacattg atttgcaaac gccatggccg 32100
aaggagggtc tggctttggc gacgagcttg tccgtcagat gcgggatcgg aagcctagat 32160
gggacgagtc ttccgacgat actgatgacg ttgacaccga aagcaccgat cttgagtatg 32220
atgatgtgtt ccccggtgga gatacgacg gcttaatgag ccctggaagt caaaactatg 32280
acgtaccac gtctccgtcc ggaacgccgt ggggaattact gcaccgggac gccctgtatg 32340
cacatccgag gtgccgcct aaaaggcggt tgggtccggg cgggtggcgcg cgtcccaagg 32400
tgtccgcgtt ctccgctaga cttcaatatg ttggacgaca gagttttggg gatagagaga 32460
cgcggcagct taccggggct cagttttctt ccgagagcga gcacgaatat gcggaaatac 32520
cggagcgtac tactacacgc ccggttgaaa gcggtgacaa gagaaatttc acctccgggc 32580
gtaggggtgc aatctcgga ccctcgtcga caaaacctag tcacggtgcg gggtaaacac 32640
gtaagactaa aacgtcgctg agtggttagtc ttaaaaactt gctgcggata aaggacgatg 32700
atgctaaggt tgatgtaccc aggcgggtta ccgtgccggt tcattctcatg cagccgcatc 32760
ctatgacgga atatagaaat gcctttttaa tctatctaga gggggtcag ggtgttgga 32820
aaacaacgct attgaattca atgactggca tgggtccgca ggaaaacgtc ttaagctgtc 32880

```

Cloning of Radinovirus Genome and Methods for its Use. ST25

```

ccgagcccat gaaattttgg acgtgtgttt attcaaattg ccttaaagaa cagcgagca 32940
tagttaagca aggcacccac gggaaattga tcacttctgc tcgctatac gcgtgtcaga 33000
gcaagtttgc gctaccgttt cgtgcgacag ccgccggcat cggtcgcaac ctgcaaccgt 33060
ggctggtggg aaacggtagc acaaagccag cgaattggat tgtttttgac agacacctac 33120
tgtccgcaac ggtggttttt ccgctggttc acgtaaagta caacaggcta acgccggatc 33180
atctgtttca aatcctatct cttttctcgg cacacgacgg cgatgtggtc gttttgctaa 33240
cgctcaacag ttcggaggcg cacaggcgca ttcaaagtcg aggccgtaag gaagaaaaag 33300
gaatcacgca aaactacttg cgacaggtag cgtgggcgta ccatgccgtg ttctgtacgt 33360
gggtgatgat gcaatatctc acaccggagc aaatggttca gctgtgtgta caaactgtgt 33420
ccatagagga catatgcaat atgaattcca gattgactca tcggtttcta accctaaca 33480
aactacatga acagagtatg ataccatgg tggcagaaat gttagtatcg gttaaagaac 33540
acgtgacctt aatggaggtc tgtttgggac tctttaaaga gctacgaaag cttcaaattt 33600
taattgttga cgcaggagaa catctagatg atgcgtgtgg cctctgggga aatatttatg 33660
ggcaggtgat gtcaaatgag gctattaaac cagcagcagt gaactggcca gctcttgaaa 33720
gctacattca aacgctaacc aaattggaag gcaatggcgc gtattagttt tatatttttt 33780
tttactataa taagggttgc tgtaacggac aaatacgtgt atgatgaaaa atcaaatgta 33840
gagttggaat ttaatggaac aatttacc aaattaattgga gaaacgtaag caaagaatta 33900
acatctattg taatggaaga tgcgtggtac gattctttac tgctggaacc attgtctgtg 33960
actttgaaa aaagaaaaag tttgctgcga tcaagtatag ttaatgtgca taataatgac 34020
tatacathtt gtaaatcttc aagtgacct gtaattaacc ttacggtgga ttttaattac 34080
agttctttgc caggttttac tgggaatttt aatgtaatga cacatgcttt aacacaaggc 34140
gttttattaa cgaaacgtga attatttacc aactcaaca acattatgga tcttttttac 34200
gcggaaaaaa taaatgcaga aatgttcaag attacttttg attattccaa tgtaataatt 34260
tccggcatta taacagaaaa ttggatatta gtatcagtta caaattcaag tgtaaaatca 34320
aatatgcaat gtgttgcaat gttgtttggt gttcctagca catttccagc gttaaaaggc 34380
tatgtatctt atcgtgattt attggtcgtt aaaaattcaa actatgctct ggggtgaatt 34440
gcgccgaaat cttataatac tcttgatttg gcatttttac caaaaaattt tacagaaatg 34500
tttgtttcag ttatagatag tccgcttaat gccattgatt atctcaaagg aaaacttttg 34560
gctattgaag caaaggggtc ctgtcaaaat ccttcaaag aaaaatgat cttatctttc 34620
ttttttgaag ttactgcagt aaatttttta ttataaaaa atcttcaaaa gcagcaatta 34680
gttaacgttg ggtgtgttgt acggcatgtt gcagcgtag aaagttaaat gcatttatta 34740
aggctctgct acccaacgtt taagtatat gagctaaatt tggaacgtt gtcgcatatt 34800
gcagagtccc aggtttttta cttgccggca aatagcatgt tatcgttatc agtaaatgat 34860
caagaggctg tattttcaat gtttaaaatt gtatataata cacctaaggt tgggtgtaaa 34920
attctaaacg aaattgtata tattactaat tacatgtaca ccaatacag tgaaaattat 34980

```

Cloning of Radinivirus Genome and Methods for its Use.ST25

cagctaacca acacatttag gcggaatgta atgaacatgt atgaagtttt aacaacaatt 35040

aaattaaacg tcacagattc ttctgtgttt tatccgtata tattgttcac atccatgtgt 35100

aataatgtag agatatcata tatgattaat caaatagcaa agcccgatga catcaccata 35160

tttcgcgtgt tttgccttg ttttttaagc ttaaggtttg atttagatga aaacaagcta 35220

cgatccgacg caccgcagac gtcaaaaaga accggctcgg aactggcaca aggagcgtct 35280

ggtttttggc ggctgttgca cgcttttcac gccacgcgta taaacgagtt ttcagtcata 35340

aattgtacca ggctggcatg gaagcaagta accgcgctga tgccgcttac gaacatcacg 35400

tacgtcataa gctccgtgcg ccctgatcac gctcgcgttt acgaggtttc ggaggtgttc 35460

cttaacagcg cgatgtttgt ctcggccgtt tatccaaatt gttctcattt tacaccgccc 35520

ggtagccgcc tacacattcc gatattgtat aacttttccg ccccgaggat aggatgtccg 35580

ctgtgtgatt cgattgtttt gagctatgat gagaaccagg gactacagac catgatgtac 35640

gtgtcaaacc ccacagtcca agccaacctg ttttccccgt attctccttt ctttgacaac 35700

gataattttc atatccatta tttgtggtta atgaacaacg gtaccgttgt ggaaattcgg 35760

ggattgtaca gaagacacgc actcagtgtt attgcattag tatttgcttt tattggaaca 35820

atgtctgtc tgtattttct gtttaagctg ttttccatcc tggcctaaac tgtaataaa 35880

gcgtaaaact ttaaaaggtt gtttccccgt tctttttgga tggttacgcg gggactgaga 35940

ttagcgagaa cctcggatag aggcgtgccg tcacatattg attcaatcac ctctgcgcca 36000

acttgaatgg ccagctctcg attttgggga ggaaacatta aaaaatattt gtcggtcgcg 36060

gttaataatc gctgcggagc ccgcgacaaa actcgaaaat ccttctgaaa gtcgtgggac 36120

tctatggagt ttaaacaaaa caccatgtct tccaggcgct gttttacgcg cgagagcatg 36180

gattcgaagt attctctctg atacgggccc gccgccttac acgtattcgc gtatagcatt 36240

ttaaagtga acagaatatt ttccaaaccc aaacgctgca ataggacgtg ctttaaaaaa 36300

agggtttgga taggctttag ttttaaatga ggtaaaaaca ttatagagtt gttggcgcgc 36360

tgcataattg tcacggtgtt aaacgcggtg atcgggctct cgcctatttg tggctggcgc 36420

gaaccatgg caaaaaatat gtctgccagt aaacagtccg actgtacatt tgactcgtg 36480

gtcgtggcg gttgcttgag gatggatcga agttttttat tatccggcgg aagcgcgcta 36540

cataaggtcg gtggcgcat tggatcgtat tcttgctggg tgtttgccag ctcttttatg 36600

gttatctgtt tgttatttgt aagagttacc ggtggggtct tgacggtcgc cgggacggaa 36660

aatggcctgc agtgcaaaaa aagagagtta ctgcgaatca ctaattttga gtttacggtg 36720

attggtgtgt cctcaaagtc agaacttcta attactgggt ctctgaacaa tgatacgct 36780

ctctcgctt cgtccgttcc cagcacaag cagctgttta gcgcgtagg atgggtgac 36840

accataattc gcagcattga taattccgga cgttttgggg cgtacaatgg catcatgttt 36900

gaatagatgg tgctgaattt tttaacaac aggggaagg gtacggccgg tcccgaagt 36960

ccgaccattg cggcaagtgc cgacgagtac acgacatgac agacgtactc gccgttgat 37020

agctgcaccg ccccccaac taagcgagcc tttaaatctg agatttttat cattgatttt 37080

Cloning of Radinovirus Genome and Methods for its Use.ST25  
cctttggtag tttcaggaac cgcagcgcc ttggcttcgc gggtatattt ttgctttatg 37140  
tctccagtga agtcccaaac gtctaatagt gtgtcgaatt acctgcggtt ttaagtttga 37200  
aaacgcgtga cgggtcgtag ctatgaaaga cataaaattg gcgttcgctc ctaactcgtc 37260  
taaccgtatt tttttacttc gcacgtatat ctttggaaatg aggttgcat ttttatatcc 37320  
cagaatagcg cattcgtgtt tgcttttgggt gtgactaatg atgcgttttg aaaagtcaaa 37380  
cgtaccaagg cgggcggcgc gggttcagggc tcccagatcc aaacgcaaaa acgaacaaca 37440  
ttccacaaa cactcgataa aacgcttgtg tagagtgtgt atttgcgctt ttttcttgt 37500  
ctccagcgtt gtgaatattg tgtttttcac ctggtctatt ctagcatatg gaacgcttaa 37560  
tattgggttc aattcatccg aaagtgtttt aagtaagggc ctaccgtata ttttagaaat 37620  
tgtcgcagtt gccgccttaa accaggaaac gttgcatccg tctttactag aaaccacaga 37680  
agggaaatta gtggtccaga aaacgtctcg ccgccccgt ctaactatgt attggttttc 37740  
aagcccggtg aggtctaacg tagagttcca gttcgcaatc gaaaccggga aaatgtgctt 37800  
caccggtaaa aagcacctga ggtttcccat agcgaacata aagtgcagca tgtccccgt 37860  
tatgttaacg ttaattgcag ccccggtgca cagggtgtcg gagtagaaca cactcacggt 37920  
gaatgacggt tctttcacgg agaatttttt cattacaaag ttattagtga gcctggggat 37980  
gtcgataatt gactcgaagg taccggcgag agaccagcac gtgatttttg tattaattac 38040  
catattggtg ttgaaaactg agattttgaa gttgtgtaaa ctcatgtgct taactggatc 38100  
gaacatgtct ggaagagggt cgggtctggtg gtcgtgacgc gcttgttcat atcgatctgg 38160  
gttttgatcg gcgttaaaaa taaaattgta atctctatct tttggtgcgt attgaattcg 38220  
cgaaaacatg gcctctagga cgcgaggcgt ttcgcctggc ccagaaaact cgggtgttagg 38280  
atacagcctg tcgcacgaat ggcacacgtg ttccgccaca gacatgcaca ttgcgacgcg 38340  
gaatattggt acctcggggtg gaaacggttag atagtacgtt gactttggcg tcacaacaac 38400  
tacctgttac ggttttttgc cgggacccct tttgttaatt ttcacctgta gatttacgtc 38460  
aagcgattga tttactatgt tttggtagtc tatgattaat tcgctcgcca ctttgatgtc 38520  
ctgaaatttg ttttgctttg agaggttttt taaaagtacc ggattggatt cgatgttgtg 38580  
aataattacc gtttgacgc gatgcagttc gggatgcgaa atccaatccg aagtaaaacc 38640  
caaaatgta aattttaagt aattcagatg cagttttgca cacgggggcg gacaccgagc 38700  
tagcgtgagg attttgaatg gctctaaaag tttaaagtaa ttctgataac acgtgccgat 38760  
cagatgttcc ggcagtgtgc gcgtaaaggc agcaaagcat tcctcgaatt cccatatttg 38820  
aaggtaacga cagaggattc gaaacatgct ttgataattt acgccacata ccattaatgg 38880  
cgaacagtac agcgaccgta ggattcgttc gtcgctttga accaaaaccg tgcggacag 38940  
ttcgtagggtg aaaacgggtg gtaaaaacgt atgcgtctcg atatgggaaa atgtacatcc 39000  
gatagcatca tcaattatta aaccgggtcc cgcgtactcg ttaccggtct tgccaacgat 39060  
accaccttgg cgggtgataa aagggtatag tccttctccc aataccagac gccggagcgc 39120  
acggcacgcg taaaagggtg tctctgtttg catagccctg tccaaggcct ctagcgagac 39180

## Cloning of Radinovirus Genome and Methods for its Use.ST25

gttttcaaga atctcattat tgggtgccag gcagcaaaaa attgccagtt gagttttaaa 39240  
 atcgggaattg gccggtgacg gggcgttcgc tgccaccgta gcaggacacg cgggcagaag 39300  
 aacaggggccc tgcaacagca taatggaggc ggctctggag gtacgaccct ttccatata 39360  
 ggccacggag gccaatctgc ttcgtcaaat gaaagagtcg gcagccagcg gacttttta 39420  
 aagttttcaa ctgctgttgg gaaaagacgc caggaggagg ggagttcaat ttgagggctc 39480  
 tttgggcgtg tataccaacg taattcagtt tgtgaagttt ctggaaacgt cgctagcgg 39540  
 tgcgtgcgtt aacaccgagt ttaaggacct caaacgaatg acggatggaa aaattcagtt 39600  
 taaggatatc gtaccgacca tcgctatgg ggacggcagg cggcccacaa aacaaaaaca 39660  
 atacattatc atgaaggcct gcaataagca tcacattggt gccgagatag agctgtcgac 39720  
 tgatgacatc gagctgctat tcattgacag agaaacccca ctcgattaca cagaatacgc 39780  
 cggggccgta aagacgatta ccgcctctct ccagtttggc gtggacgcgc tggagagggg 39840  
 cctggtagat accgtattga atgttaagct taggtccgcc ccgcgatgt ttattctaaa 39900  
 aacactatca gaccgggtct acaccgaacg gggctctaaag aaggctgtta agtcagacat 39960  
 ggtgtccatg ttcaaaagct accttatgga taactcgttt ttcctcgaca aatcagacat 40020  
 cgccgtcaag ggaaagcagt acgtgctgtc ggttctctcc gacatgggtg gggcgggtg 40080  
 tcacgaaacg gtttttaagg ggacgaatac gtatctgtct gcacggggag agccaattgc 40140  
 cggagtcatt gagaccacgg aaaacgtaat gcgaaaactg ttaaacaatgc taggtcaggt 40200  
 tgacgggggc atgtccggtc cggcgtctta cgccaattac gttgtcaggg gcgaaaatct 40260  
 cgtaaccgcc gtgacgtacg gtcgcgtcat gcgaacgttt gaccagttca tgaaacgcat 40320  
 agtggaccgt cccaacgcgc agcccagcgt cgacgatgat cgggacgcgg tggcgagcgg 40380  
 gcaggactcc ctcgccaaaa caccgatcgc ggcggctgtt atccagattg gagataaact 40440  
 ggtggtcttg gaaagtttac agcgaatgta caacgagacc cagtttccct tcccgttaa 40500  
 caggcgatg cactatactt attttttccc cattgggttg cacatgcccc gtcctcagta 40560  
 ttccacgtcg gccacaatta aggggggtcga gcaccagcg gaacaatccg tcgaaacgtg 40620  
 gattgtaaat aaaaaaacg tactgtgtgag tttcaattat caaaacgcgc tcaagtccat 40680  
 ctgtcatccg cgcattcaca acccgatgcc gtgtgggcaa gctttgggtc aggcgtttcc 40740  
 agatcccga cagttcaca ggtacggaca aagatctgag cccccccga acatgaacct 40800  
 atacgggctg gtgtacaact attaccaggg caaaaacgtg gcacacgttc cggatgtcgc 40860  
 cctaaggcg acgatgacca cagatgagtt gctgcacca acctcgacg agacgcttcg 40920  
 tttggagggt caccgatgt ttgatttttt cgttcatcag cagcctggtg cgcaagccgc 40980  
 gtatagggcg acccagagga ctatggtggg taacattcca caaccctgg cgcccaacga 41040  
 gtttcaaac agcagaggcc tgagtttga cagagcggcg gccgtggctc acgtgctgga 41100  
 ccagtcaacg atggaaatta tccaagatac ggcgtttgac acgtcgtacc cactactctg 41160  
 ttatgtcatc gaatgcctca ttcacggaca ggaagacaaa tttttgatta attctccttt 41220  
 aattgcatta accattgaaa cttactggaa caatgccgga aaactggcgt ttattaacag 41280

## Cloning of Radinovirus Genome and Methods for its Use.ST25

ctccctatg ctgcgattta tctgcgttca cctgggcaac ggtagtattt ctaaggacgt 41340  
 gtacgcccac taccgaaaag tttttggcga actcgtggtt ttgcagcagg cgctctcgaa 41400  
 aatcgcgggc cacgaggtgg tggggcgag gcccggtcc gagctgatta actgtcttca 41460  
 ggacccaat cttttgccgc cttttgctta caatgacgtt ttaccaacc tgctcaggca 41520  
 gtccctcggg caccctatgg tactcatagg cgacgagggg tacgaaacgg aaaatgacag 41580  
 ggatacgtac atcaacgtca gaggaaaaat ggaggaccta gtcggtgaca tggttaacat 41640  
 ttacgagacc agaaacaacg cggatcatga cggccgccac gtccttgacg tcggtccctt 41700  
 taatgaaaac gaacagcaca tggctgtgct ggaaaagctt ttttattacg tggttctgcc 41760  
 agcctgtacc aacggtcacg tctgcggcat gggcgctgat tttgacaacg tggccctggc 41820  
 cctgacgtac aacggcccag tgtttgctga cgtcgtgaac cccgacgatg agattttgga 41880  
 ccacctggag aacgggacgc tccgcgagat gtcgagggc tcggatatac accccaccgt 41940  
 tgacatgatt cgaactcttt gcacgtcgtt tctcacctgc ccgtttgtta cccaggcctc 42000  
 ccgtgtttgt actcagcggg accccgcgca actgttgacc actcacgacg acgggagata 42060  
 cgtgagccag actgtctctg ttaacgggtt cgcggcggtt gctatcgag ataggtctcg 42120  
 tgacgttgcc gagaccatgt tttaccgggt gccgttcacc aagctgtaca gcgatccct 42180  
 ggtggcgggc acgtccacc cgctggtcgc aaattacgtg acgcgcctgc cggcccagcg 42240  
 cgtgccggtc gcgtttaacg tccccccggc cctcatggcc gactacgagg agtggcaca 42300  
 gtctccaatg ctggcctacg ctaacacctg cccgatgacg cccacgtcgt tgagaccct 42360  
 ggcgagcatg cacatgaagc tgtccgcgcc ggggttcac tgccacgcaa agcacaagat 42420  
 tcaccggggc tttgcatga ccgcccgcg aaccgatgag gtgttggcgg agaacttgct 42480  
 atttagtgcc agggcctcga cgtccatggt tttagggcag ccatcggtta tgcgtcgga 42540  
 agtcagggcg gacgcagtca cgtttgaggt gaatcatgag ttggcatcgc tggacatggc 42600  
 gtcggttat tcttccacca tcacgcccgc ccacgttgcg gcgattacct cggacatggg 42660  
 cgttcactgt caggacatgt ttctcatggt tcccggggac tcgtaccagg acaggaccct 42720  
 caacgactac gttaaacaac aagccggatg ccaacgatc ggtggtcctg gccagattcg 42780  
 tgagcccgtc gcttacgttg cgggggtgcc gcactcggac aacataccgg gtctcagcca 42840  
 cggacagctg gccacgtgtg agattgtttt gacgccggtt actgcagacg ttacctattt 42900  
 tcaaaccccc aacagtcccc ggggacgggc atcctcgtg atctcgtgtg acgcgtacaa 42960  
 caacgaaagc gcggaacggt tgctctttga cactccatc ccgattctg cctacgaata 43020  
 ccgcactacg gttaacccat gggcgtcgca gcagggtcc ctcggagacg tgctgtacaa 43080  
 ctcaacctcg cgccaggtcg cagtgcagg gatgtacagt ccgtgtcgcc agtttttcca 43140  
 caaggacgct attttgcgta acaatcgggg cctgaacaca ctagtcacgg aatacgcggc 43200  
 ccgcctcacg ggaacgccg cgaccagcgc gacggacctg cagtacgtgg tggtaacgg 43260  
 aacggatgtg tttctagaac aaccgtgcca gtttctacaa gaagcgtttc ccacgctcgc 43320  
 cgccagtcac aggtctctgc tggacgaata tatgtcgaat aagctcacgc acgcccctgt 43380

Cloning of Radinovirus Genome and Methods for its Use.ST25  
gcacatggga cattatatga ttgaggaagt ggcccctatg aaaagactat taaagatcgg. 43440  
aaacaaggtc gcctattagt ttagctcaga cggctctggag ctaacgagag atggccctcg 43500  
ataagagcat cgttgctctcg gtgacgtcta gattattcgc cgacgagata gcaaactctc 43560  
agtcaaagat aggatgcatt ttgcctctca gagacgccc a cgtctgcag aatatacagg 43620  
cgctgggtct ggggaacctg tgctctaggg attccgcggt ggattttatt caggcatatc 43680  
actatttggg caaatgcact ctgcgcgtgt tggaagaggt cggcccac agtttacggc 43740  
taacgcgcat tgatcccatg gacaattatc aaataaaaaa cgcgtaccaa cgggccttcc 43800  
attgggataa ctactcagaa ttggtagtta taccaccggt ctttgggcgc aaagatgcga 43860  
ccgtctcact ggagtctaac ggggttgatg tggttttccc tgccgtgggt ccagaaccac 43920  
tggctcaaac agtgcttcag aagctgctgc tgtataacat atactacaga gtggcgagga 43980  
cgacgccac cgacgtcaac ctagccgagg tgacgctgta cagaccaat atcacttaca 44040  
tgggtcgcaa ctacgccctg gacgtggacc ccgttgggtc gagctcagct atgcggatgc 44100  
tggacgacct gtccatttac ctgtgcgttt tgtccgcggt aattccgcgc ggggtgcgta 44160  
ggctactgac ctcatgtgtg cgccacaaca aacacgaatt agtcgagatt ttcgaggggg 44220  
tgggtccacc tgaggtacag gccctggatc tcaacaacgt aagcgtggcc gacgacataa 44280  
cgcgcatggg tgccctcata acctatctac gaagtctcag ttctatatatt aatctgggcc 44340  
gcagatttca cgtttacgcg ttctcatcgg acacgaatac cgcttcctgt tgggtgtgcat 44400  
ataactagaa acgggcctcc ctgtgctttg acatgtcgat ccccaaaatt atgacggtgt 44460  
ccagagacaa cgagggtacg gtgtgtgaag tcgcggtgga caacggacga cacagagcga 44520  
tgatttatta ccctaagacc accaacttag caaacgagcg cgcggacggt gttaagggaag 44580  
cttttgatac cgaaacccca gtggacattg taaagcaaat tgtaacgag ggcctagcta 44640  
tatccaaaaa aaattgcgtc cgtttggcgt tgtatttata tttttatttg cagtacgtgt 44700  
gctttgctct gctcctcact tggcagttaa acccgtagat ggaccacccg ggtctgggtgt 44760  
ttgcggttaa ccccatgggt ccaaaacatg tcacgaaact accgcacccg gctattgttg 44820  
cggtaggttg tggggcagac gccatctgta agaactgtag cgtccccgat atcaaacgg 44880  
agcttggaat ggtttaccac aacgggtcta gcgattctg tcagcgcgca cactatgggc 44940  
tggccctgtt aaaggcggcc tggctgttca tgggaaatgt gtgtccgga ccagtagtgc 45000  
ggcaaggcgc tgcattactt ggtccatgga accggacgga gtggtcggat tttaaatcgg 45060  
caatggcggc aaccacgttt tgcggatcca gaggcgttct gtggtcaccg attcatgaaa 45120  
aaaacctctg tcgccccacc tggaatgatg taattaacac atcagttttt acaaatgaat 45180  
cactctgtcc aaatatacct gtggtgcccc aaagtgtaat agtgcttaat ggtgatgcat 45240  
gagaacaata aacgtattcc cagcacttc atgtacgttg tttttatttg tctggtaagg 45300  
tattaacagt aatgggaggt tccgctggtg cctataaagc aaaacgggtca tagagtaaca 45360  
atattgtgaa tgggggaaaat agtctgtaaa tagtttatcc gaacagtatg actgcacaca 45420  
cgaatgggggt ttaaccacg acgggctttt caacaagtca gccggaatcg gttcaagttt 45480

Cloning of Radinovirus Genome and Methods for its Use.ST25

```

ctccatttta tcgcgtaatt acaaaacctc ccgttatggg cttgtttttt tgcgtggcta 45540
tgtgcgttat cgcgttggtg tggtagctga tgcggagggt gtgttgtaag gggcgcggtg 45600
ttgccgattc gtgtcgcgac ccgcgtcaac ccgcgtatga gatgttgaat gttaggttgc 45660
gtccccacgg aaccaatcca tagagaactt tcacgtacat agccaaagcg cacgacgtgc 45720
tctctagctc gtttattcta gcgatttaaa aacaaattta tcgttggttg ccatgtagtg 45780
ggccatgacg gcggcgacaa gcacgtcgtc cgacatggtt ttttgtttcg cgcagtacgt 45840
gtgacctccg tcttttagtg gaatgcaacg tattgccttg atttgatcta ttagatacgc 45900
tacgggatca aacgatagct taatagtgtg agacaccaca gtttggttag cgctaaacgt 45960
tcccaggttc aatgcgtaaa taaaagattc aaacgccttg gctttctctg gcccacacat 46020
gtaaatgggc gaacgtataa gagtgttctt gtccacgtgg tgtaaaaaac taagagggac 46080
cgagcaaatc tcgtttaaca cggttgctat ggccactccg gcactctgac tgctgttgcc 46140
ttccacggcg acgttaacgt gcgtgatctg cgggtgaagg gtaacgatcg ctcgaattaa 46200
cgcgcgggca catgacgcta tctggtacgc ggcggtgccg gttagatctc ttagaaaaaa 46260
atgttccacg cctaataaaa tgcatttaat caccttgta tttaccgcaa tcaccgcacc 46320
gatgccggtg ccggacgcgt ctgtgttgtt ggtgtacgcc gggctctatgt aaacgtggag 46380
acacggcttc atcgcgcctt gtatatcttg tgacgtgctc tttacgcggc acagatccaa 46440
ttgtgacagc gaagagtcgc taacgatttt atgcatgctt tgagcggacg tggcagcgtc 46500
ccccattagc tccgtggaga atgcgccttc caaaaaaaga ttagtcgtgc tccgtaccgt 46560
ctcatcaatc gtaatatagg caggaatatg caggcgtag caccggcacg ccacgacagt 46620
gtcttgcaag ttaaaatcat ctttatgac cggacatacg tagttcacca cgttaagcat 46680
cttttcgtgg gcgtccttca aattaagtaa aaaactagtt gatttgtcag atgagttact 46740
tgaggatata aaaatcagtt ttgcgtcctt ttgaagcata aaaccagaa tcgcggggag 46800
ggcatctttt ttaatgaagt tcgcctcgtc gatatatagg aggtggaacg tctgtccccg 46860
gatgtcttaa aggcaaagaa aaacacaaaa cgagttacgc gggtatggag aacgatacgc 46920
ctaaggacaa aatctcgga gctgactttc aacagtgtca ggcgttcttt caccgtccca 46980
ttagagatct aatttcactt ggagctgacg ctttaaacca ctttagccta tctgaatcag 47040
acggacataa attggaacgg attgttcttc tgcttgacct ggtggggaca gaatgtctct 47100
cttataccac gatcgtgca aagaatgtca aatgacgcgc gtcaacagcc caatatgtcg 47160
atttcataac gtctctaact tataccagtg tttggattgt aagcgtatc acgtatgcga 47220
cgggggacgc aactgcgtga tcgtgtacac tcgcgaaaat ctagtgtgtg atttaacggg 47280
aaactgcgtt ttggataatg tgcaggacgt atgttcgtac ggtcctccag aacgccgcgt 47340
acccgacgcc ttcacgacgc cgctcgtgtc acacggcacg agggaatgtc ttaaaagcga 47400
tatactgagg tactttgaga cggtcggtgt gaaatctgag gcatattcta ccgttgtcaa 47460
gaatggacaa ttgaatggca tcataggtag attaatagac gctacgttta acgagtgcct 47520
tccggtaatg agcgacggcg aaggtggcag agacctcgcg gcgagcattt acatccacat 47580

```

## Cloning of Radinovirus Genome and Methods for its Use. ST25

aattatctcc atatactcca ctaaaacggt atatgataat ctctatttta aatgtacgag 47640  
aaataaaaaa tacgaccaca ttgtaaaaac tatcagagcg caatggatgc gcatggtctc 47700  
aaccggcgat ccgtcgcggg tcagtgcgac gggttgtttc acgtgatact tccgcgaggg 47760  
tttatcctcg cgaacaatat tacgtgcggt gaacggcagc gggtttttgc acacacttgg 47820  
ttcgtgcat ctggacgcac gtctaagact ttatacgtgt ggggacgggt atttcaaac 47880  
accgaccggy gccgcgggga cgggtccgtcc gggccgtggt ccggactggc gattagtctg 47940  
cctctgttta ccacaaatgg aaaatttcat ccgtttgatg tagttatact caaggccgat 48000  
acgcctgact ctggaagctc gtggaccgtg aagttcttgt atatgtcatt aattgcggct 48060  
tacagaaacg caatgcgagg tttaaaagat aaagtttcgc aatgtaccga tgccgccgtt 48120  
gacggtgagg ttcatcctct aaccgtctta aaagaagcgt tggatcacc ggacactgct 48180  
acgcgaccgg tgtccgcgtg caaccctcta cagatgttga ccggactctt acagtctagg 48240  
gtacgggacg actacgtgac acaccaccgt gcgctcgaac gccaggtaa tgtgagggga 48300  
caagtaatcg ccccgacgcy caccgagatg ccaaacggat cgccaagtcg tgtaaggctt 48360  
ggattccgcc ctcccaaaca agccaactat ccaaagacgt gggcgaggc gcgtcacgtt 48420  
ttctcgtctc gcgcatatta cgtgtgcgta tatgataacg aagaactaga taccaagtgg 48480  
cagcggcaag atccgcggcc gttgcgcta gattggtccg atccggtcgc gtacctgtta 48540  
gagggcgatt tgtttttagg agccaagcag aatgcgtttg tcgattctat agaaaagacg 48600  
tgcaggtgtc agaactatac cattaagcaa tttttccgg ttttgataaa tagggacaac 48660  
gaaacagtcg acttaattaa ggagcatttt atagaggcgt gcttcgtgat tagaaaccag 48720  
gtgtcagaga ggagcgcttg ggtaaaggcg gcgctgtttc gcaacgatag taacacgtat 48780  
tggaaggatg ttttgggatt atgggagcat gggcctcata agctgggtac ggctataaaa 48840  
ctaccaacat cggaaccttg caatgccgac gtaaactgga gctggctcct gtgtgacgag 48900  
gatataactc ggtcaattag cgggcagtct actgtttgct tagttgtctc gcctaccctg 48960  
accgcctggc tgggtctccc ggggggcttt gttattaaag gccgctacga cctatcaagc 49020  
gaggatttaa tgtttgtggc ttcgagatat ggccaccag cgctcgcaca ttcttaaate 49080  
gtttttaaac aaggaatgca tatggttgcy acaccgggt acgtccgctt ttgttcgggt 49140  
atacaccgcy accactgcgc attctgccgt ttttgaccg ccggtacta gcgaaaatgc 49200  
gatgtcactt aactttttaa atgttatgat cgtaatcatg aaaccaaag aatttgccc 49260  
gtgcgttacc gtgtacatga atggagatat tctagatttt tgtgccacgg aatctgtcgc 49320  
cataagggac gtgcctggta gggcggacct gtgtttaatt cgttttggta ccctttctaa 49380  
tgccgcgagg agcgttccga taccggggcc gttgaacca catccgcgag aaaccgtgcc 49440  
cgggctaaca aaacaggaaa ttatatacac ttcgcaaaca gtgccaagag gacagatacc 49500  
agatgccata aaggggaaag agttccacca aataaatccg tttttgtggt ttgacggagg 49560  
ggcgttttgg caactgttcc tctctgtgga ttttatgctg ctctgtccc cactcgacac 49620  
agttccgtcc ctggccagaa tcgttgggct tcttacacag tgcgataaga gcacgtgtaa 49680

## Cloning of Radinovirus Genome and Methods for its Use.ST25

aatttgtacg ggggccacg tacacgttaa cccgtatcgc ggatacacgc cacctgactc . 49740  
gcaagggacc tcaccctcgt gccctgcct tatctcgtgc ggggccaggc gcgcggcgga 49800  
tgtcctgggt accggacacg ttaatctttt gggcctgctc tttagaccca aagcctcccc 49860  
caaagtgacc aagctgcgtt taaaaagaaa cccacgcccg gtaccgatag aggacgcat 49920  
gtcgggcgtc acggccgaag ggaccgaggt gcaaccact tcgctaccgt gggccctcat 49980  
tcgcctgccg gatttagcca gtcgcgtgat gctatacggc tgccagaact taaaagcat 50040  
ctgcttacgt tcttattgaa gcacgtcga cacatcagcg aactcggccg ccgtccgggg 50100  
ctcgcgtaca cgatggttcc gttttccttc tttatgttca ggttcttcgc cggaaccac 50160  
ctggatagcg tggcgatgac ctcggagaaa acggcattgg cgacgtgttt ttggtgggccc 50220  
acgtaaccca cgtgaacggt ttcaaccgac gagagaagaa cgctgataat ggcgaccacg 50280  
atccatgttt tcccgtgacg acgcgggata acaaaaacgc tggctttctg cttaaacgtc 50340  
tgtaacacgt cgtccgtggt ttcaaataaa ccaaagtgtt gcttaaacgt ggcaaataac 50400  
tggtgtgtct tttcgggtgc tttgatagac gcgataaaat aaaacgtgtg catgattaat 50460  
tgttgttgaa agggctcaag gcaacaaacc ccgggcacgt aactccatt taaaaatgac 50520  
gacaggttg ctaaaaactg ccgcagttct gcataaacgg ggcactctag gaaagcttcg 50580  
tggtccgtt gggccgattg gtattccatg tactgttctt tggcgtttgc catttgacc 50640  
cgacaacatg tttgtttaag gtagtttgtg agttcctcgg ttaaccgggg caacgtagcg 50700  
tggttagaaa ttcggggctt tcccaacgta ggggccggca tgggttcttg aactctcggg 50760  
tacgtttgaa gataatcgtc taaaacagaa ctatatgcat taaccgcgtg aataactccc 50820  
aagcatgggt gggccattcg ttcggtcttg tcgttgcccg atataataac gggcggttgc 50880  
cgaaaccagt tttcgcaacc accgtccgtg accacgcgca agttattttg aagacgttcg 50940  
cgatagctgg ttaacaacat gttcccttca agttttttga ataacgggca ccccgaacg 51000  
gaacgccgt tcgttaaagg cgttcagtta gcttttagacc tgtgtgacaa cactccggga 51060  
cagtttaaac tagttgaaac acctcttaat agttttcttc tggatatcaa cgttctgccg 51120  
gaatcgccc cggttagaga ctgtccgcag ccggaagggt ttgactttga acacattcac 51180  
ctcccaaac taacacgcat gcagcgtgtc ctggggcgat actgcgacca tgtaacaac 51240  
gacgacacgt gcgttaacgt aaaggcaagt tcctcgaatt cacagggtgc cttgttttat 51300  
ctgccgtatg gacaggacga atggaattgg gcgtcacgt taaggaaaga caagttgggt 51360  
aaaatggctg tagagggctt gtcaaatccc acgacctgga aaggtttaga gcccggtgat 51420  
cctttaccgc tcatatggct tctgttttac ggttcccggt cgttctgtcg ggaaccagag 51480  
tgcctatatg aacgcaattt tggtagaag ggaccatac tcttaccgcc acatatgtat 51540  
gcccccaaa aggacgtaat gacttttgc catcatgtaa ttaagtacgt taaattttta 51600  
tacgtgaacg ccggtggggg tcttgaaact gaaccgtccc cgccgttcga ggcctcgcgg 51660  
ttgcgcgag ccacgctcg tctcggggac gtggaagcgg atgacgcata cctgtccgca 51720  
aagtgcattg tgtgtcacct gtacaagcaa aacgatacga ttctgattca tgaaacacac 51780

Cloning of Radinovirus Genome and Methods for its Use.ST25

gtgggaggag tcatcgcat aggcggagac ggtgcgagat atataacgtc tagtggtcgg 51840

gctcaacggt gcacgagtcg gggagatttt gttttaatcc ccctgtacaa cattgaaggg 51900

ctcgtaaagca tgataaggga acatggcctc ggcagcagct aaaaaaatgt taattaagtc 51960

ggagctcgag tcggaaatca acaaaaaact gtccatctcc gtatttgaca ggtttggggc 52020

cgacagtgcc gtgtttaacg cgcagtataa gggaaccagg gaatcgctgc ggtcgtacaa 52080

cagcctaaaa aagaaggacg atctggcgac cgttgctcga acgctagaaa cgtcgctgcg 52140

tgaaaaacaa agcgaattgg gattactaaa ggggtttaac aggaaaaaaa ttgaagagtt 52200

tgacgctgtg gcggacgcgg ttcgcgacct caaggacgag ctgtacggag aactggagat 52260

tctaggtagc cttgacaatg aatctgttcc cgtggaagaa gagtcccca aggacgacat 52320

tattaggtgg aaattggagc gtctgcccag agtgtgcccc aaaagccctt gatcccatc 52380

ccaaggttca gactgacgtc gacagaacag catcgctcca tataaccgtc attaaaaacac 52440

gtaagacgat cgcccaactg aagataccta acaactgggg ccagtgtagt caccaggcga 52500

cggactggac cgccgtgctc ggacgcggct cgtatggtgt ggtgaggtcc atgtctctcg 52560

gccgctgcgt taagcatttt ggcagccggc gtgagttttt ttacgagtgc atttttaacg 52620

atatagtacg gcgctgccgg gagaaacatc ccctgaaccg cgggggtgac cgtatactat 52680

gtttcctaga gccgtgcgta ccatgtcgcg ccctgatatt ccgcagttta acagggaatc 52740

tgctaaacgc ggatcttaaa cacgtgaacc ctgaacggct ggccgttgaa ttctctgagc 52800

tgagggaagg cgttagtttt cttaaataata tatgtggcat cgttcactgt gacatcagtc 52860

cagaaaatat actgataaag ggggaactga caactgcgta cgggagactt atgatcggag 52920

atctaggggc gcctcttta cacacgggaa ccccttgagc cggagtgatg gtgacctcca 52980

aactcgggtt cgtgcagcac acgtaccatt ttaaggcacc ggccagattt atctgtaagc 53040

acatttaccg gccgtcgtgt ctctctacc ggtgtctgct gtcgtgcgcc gggggccgcg 53100

aggcgcatat gctaaatcag ccgttccaaa tcaactccaca actcgtctc acaattgaca 53160

tatcgccctt gggttatagt ttgctagcat gcctagagaa atatcttcag ccagctgacc 53220

catttcccca gcaggggagc ttggcggagc ctctctcga atccgccac ccattgttct 53280

atttgcgttg catggtgcca agagtagtca tcgccgagat ttttctgtt gcctgggacg 53340

ttccactcga tttaggcatt gactcatctg gccacgcgcc agctattccc ctgagagaag 53400

cgtacaggcg gttttttgcc aaccagtgtg gtttatatag ggcgcaatac aaagaggatg 53460

cgttagaaaa cgcacccctc cggctgtgta actcaaaact taaactagtt ctccagaagc 53520

tgttggtcag ggactacttt agtcattgcg gaaactgcgg agatcatgga tttttctca 53580

gatgagccga tggttcagga gatggcgctt ctcgacatcg atgagcagca gcggctcctc 53640

tcgaaaatga gcctggccaa ctttttaaaa catgagcgag taaggcggtt ttttagcgat 53700

aacaaaaagg aaataagcat gccggctata cggttcgtgt ataattttta tctattcgcc 53760

aagggtggag attttatcgg caacaccgac gtgtacgatt ttacgtcac ttgcgtgttc 53820

agggggaggc gcctgacgcg cctgtcggaa gtgtacgacg cgtgcctaaa catgcacccg 53880

Cloning of Radinovirus Genome and Methods for its Use.ST25

cacgatcgac accacgtgtg tgcattgata gaacaggtca cgcgcgccca aaacatcaat 53940

cctctgtggg acgctctgag ggacggcata atttcgtcgt caaaatttca ctgggccata 54000

aaacaacaga attcgtccaa aaaaatTTTT aaccctggc ctatagtcaa caatcacttt 54060

gtagcggggc cgctcgcgtt tggactgcgt tgcgaggaag tggttaaaaa gatactggcg 54120

acgttgctgc atccaggcga ggcgcactgt gaaaactacg gattcatgca gagtcctctc 54180

aacgggggtt ttggcgtctc cttggatttt ggaattaacg tcaggctctga cccaaaagac 54240

ggtttgaggt ttcaccacga ctgcaaaatc tatgaaataa aatgccggtt taagtacact 54300

ttttccaaga tggagtgtga cccgatttac gctgcgtatg ctaaacttta tcagaagccc 54360

agcatgcaga cgcttaaggg gttttgttac tccatatcta aaccggcgat cgagtttgtc 54420

ggagaggaca ggctccccag tgaatcggac tatcttgttg catatgacaa agaatgggag 54480

gtgtgtccgc ggaaaaagag acgcttaact gcagtacacc atctagttaa aaagtgcag 54540

attcacaact ctacggcgcc ttctgatgtg tatatatgtt cagatccgca ggaaaccgga 54600

ggccaaatta atattaaagc tcatctgagc gccaacctat ttataaacgt caggcatccg 54660

tattattatc aagtgttgc cagctctctc gttgtacagg agtacatcag tctctccaag 54720

ggaactaaaa atttggaac ccagaaaaac tttatagcga ctggcttttt tagaaaacgg 54780

cagtttcaag acccgagctg ctgcacgac ggtgaatttg ccccgttgga tccacacgta 54840

gagataccga cctttttaat cgtgacaccg gtgtattttc ccagcgtggc caaacaccaa 54900

ctggtgaagc aggcgaccga attctgggag gctagtgtct gtgaggcatt tcccagcta 54960

ccatgggatt tatcctctct gtgtgcaaac gccccaccaa caccgtagat gtgaaggggg 55020

agcccataga tgtatccaaa gaattcgatc ctattatagg agaagaaagc attgtcttgt 55080

taacggcaga tgggactgcc cccgcggcgc tgtacaaacc caaaaccaag ccatccaaac 55140

ataaaaacaa taaattgtca gattttgttt aagcattcgt atctttattg gagtgggggtg 55200

gatggtgtgg ggttgggaag ggaatgggat tgaggggagg atgaaatgct agaatcatat 55260

gtattttgga tatgcatcct cgtaatcgct cacgtcttct tctgtttcat ataacgcgtt 55320

cagttccggg gagtacttaa cttttgtcgt cttctcttta gggccttgag gaaggggtgc 55380

gtattcgggc gactttgcgc accatttcca atcgtttctg ataattctta agatgatggc 55440

taggatgcaa gtgatcggaa tcatagagat gttcacggct atgactttgt gcaggctggc 55500

agatatgaat accttgctgt atcgaacgac ggaagaagc agaatcaggt aactgacaaa 55560

aacgccaacg tagaatccga tctgtgtgct taggtacttt actagaaata gttctgtgtt 55620

gatataccaa gctattgtaa ggacaaaaaa caagtttatt gaaccaaaga caatatcgga 55680

aacgagcata tagaaactgt ttccaatagc catcatcggt ccgagggaga atactaacat 55740

ctccatggct attaaggaca gataaagatt ggcgccaatc ggttttccgt aacgcaacag 55800

ggtgtctagc aagctattct caggaatctg ctgctctaag acgcgtagag accaggtggc 55860

cgaattgcac gatatcatag cctggacgtg cgtaaacgat aggcaaaaat gtatacagta 55920

tacaaacgag gctaaaagta tatgtttgta cgacagaacg tgaataaata actggatggt 55980

Cloning of Radinovirus Genome and Methods for its Use.ST25

```

ccacagcctc aaaatagaca taaaaactac actgtgggag cctatgagca cgatccatgt 56040
ctggaggctg gtcattgttg tcgctgacac gcgcttgccc ttgaatatgg ccaggatggc 56100
ccacgcatag taacacagca gatatccgtc caccaaaaac gccacagaga tgtagacaaa 56160
catttcttgt gcttccaaaa acaaagtcgg cgtcagatgt ttagcagaac ttctgaccgt 56220
taggtttaac gcgctgtagt tgaccaacgt gttaaagtag cacggaaatc caagtcccgg 56280
gaatgtggcg gtcagtggca ctaccgctga cattataaac ataagtccaa gaataaccag 56340
tagttttacc catgacgata agataaacga gtcgctccgt gaaattttca tagttcaaag 56400
aatctgctcg cgggtgcggt cggcaaaacta gcagtaaaat cagcaagtgg cttacatggt 56460
acggatttaa ataggctccg cttttaaata tcacattctg tgcaaaggag ttgagccacg 56520
gcacatgaa cggccgggag gtggcactca cgggacatgt ttgacacata tcgctgcata 56580
gcacgcacga gcgcgagaaa ttaataatct ggcaggttca tttacttgta tgtcaacaat 56640
gcggaattca gggagatgcc gcatacttat ttgtcaccga aacattaagc aatactgact 56700
ggggaaatat accggcgata aaccgtcacg caccgtccat aaatgagcac ggccgtaatt 56760
atatgcagtg ggaactccgt actcgtttac ggaatcccat cattcaattg ttaagtcgcc 56820
agcccggtgc ggttaacgta agggtcagcg agccgaatat ggtaatagtg ggctgcgaac 56880
gagcgttgga tcaactcgtg tcgggtgcg cgactggagc ctatcttcat tgcgatacca 56940
ctatggactt tagtttggt tctgttgtgt cccaacccg cgaattttgg ttctcagaga 57000
tgttttctca ctgtttagtt tccaacattg aagtttacct taaaacaacg ggccgggttat 57060
actatagggc atcgagtgcc acgcaatgcc gaaaaagggc gaaagatggc gcattgggta 57120
ttcttgatat ctttaattgc gaatctcgtg aaatacaagt tgccgggcag aagtacacct 57180
tgagtatcgc caccgcaaca ttacacgttc tctgggtgga cgaggcgtgt atgtggaacg 57240
gggccttggc cgaatttttt agggcgctgc acaataagtt gttcggcgac cgggaaggcg 57300
tagcgccaac gttaacgtac gtgtgtccg gggccactcc ggagggaacc cccttcccc 57360
cctacttttc cgcgtttcca cacctcccgc tcgtgttttg aagaccgga aggctcgacg 57420
taaccgggt ccaagaactc ccaaaagcac aaattgcggt aactggccc cgttttaaag 57480
attcaatctt aggggatcag cttctcatal ctggcatttc acctaataag ccaggtaccg 57540
taccgttcg ttggccgctt tgggtggagg atgttaactt gagtctctgc gagacgacag 57600
aaagcgttgc ccgcatagtc gaccacatt ctatagtaat cataaaattt tcatcactgt 57660
tgtgccagca cctaaaatgc caccgtgcgt ttgttaaaaa tgagttagaa tacatagcaa 57720
ccatctgttc cagcgacctt cgcctcttca tccaagagga atacaaccgg ttacttgcca 57780
ccatttttac gtggccgcg gcgagcgggt atacctgggc ggccattgat aaaacaacag 57840
tattcatcaa ggctccccag ctacgcgcag ctgtaagtgg tttctgcca tcaactaata 57900
gttgccgtag gaaacaatgt tacgaagggt aaaaataaca gttcatttcc ttacacagga 57960
acagcaaaag gtcgtgacct gtcttgaggc gcatttggga cttcccgtag aggaaacttc 58020
ccaccgcct gactggctca agtgtgaggt ctgctccg cgctgtttt taaaaatacc 58080

```

Cloning of Radinovirus Genome and Methods for its Use.ST25  
agccgggggtt ttgtatgccg gactcgcaag agaccaccac agggaagcaa aacgggactc 58140  
gtggctggac tgtctagtag aaggcgcgac gttgttgctt aacaactcag tgttaccgat 58200  
tggggcgctg gcggtatctt taccaccctt ttttgccaac aggcggtgtg ttaatttttg 58260  
gctgctgcca cgcgctggg taaaatcggc gcccatatgc cctcccctac cgattgactg 58320  
tgttacgcct ccacagtttg tcgtgacaaa gcgtggacca atctgctggt acaaggaatg 58380  
gccgttaccg gttgacgttg attttatgta ctacctacag gaggcactat gtgttttttag 58440  
tgttgtgtcc aacggggagg gtacggagag tcacgcggac aatatacgac aattagagaa 58500  
gtttgaaaag gtactatgtt tattttaaaa cagagtctgt ctggggatgc tgtgtaggct 58560  
ggttatttga aaatatttta ataccgatgc gttatgaagg tgtctggtaa aaattgtgcc 58620  
gcaataaaat atgttaaaag tctccgcgtg gccctcttct tctccaacgt tctctgttag 58680  
acgaaaggat tccaaataaa tgggtttcag taagcctttc atgtcgtctg cgttttcgtc 58740  
caacagctta tggagtttga accgcactag gggcggaacg cgcaaaatgc cttgggggtg 58800  
gtttaactcg tggtagtccg ccaaggtcga cgctatcact tcgatcccat acaatacaaa 58860  
cgcggaatca ttacacgtat acctctcgtg taggtacctg gcccggtcaa gcgcggacag 58920  
gataaatgat agggggggct tatcgtagtt ttccagcata gaaagaatgc agcagagttc 58980  
tgttacgctc gcgctcgccg gcttaaacag ctgcacgcgg tcagaaaaaa cgtgcggata 59040  
tatgtccagt gcgtcgatca tgtctcgtg ttcgaccacg cagcaaaga caaaccagct 59100  
aaacgttgc gactgaagcc tgggtgcgcac gtgcacgcct aaatcaggaa cgttttagtcg 59160  
tcctcgaaca cacagcttag gcgtattgga agccatgcaa atgctatttt ttttatgtac 59220  
ttccaacatc agtcgcggaa aaactggata attatagggc cctctggacg agcattctgt 59280  
ttcaggcatt accgcctcag atcggtgctg ctccccatt agacgcttca gtatttggtc 59340  
catcggttcc aggcgtggcta atttgttcgc aatatttgtg gcctatgtca tttatataca 59400  
cagacagcct gctgtccaca tacagctggt ctgcaatatc gtgtaaaactt aaggaaatga 59460  
gagagtgatt tatgaggtcc atgtgagtca gtttgccgat tatgtacgta aacgggccta 59520  
agagaatgga aaccgtgtcc tgcgagtagg cgatgctcgt tcgctgcccc tgattgtcga 59580  
ccacgggtgt gaggttgtag gtttgaaaca tttccccttc ccacaggcta gttagctctt 59640  
tgagcatctc cataaacgga gggacgtatt gtgaaaaaaa gctgtttact acggagctgc 59700  
ctttagggat gtgacattcg gataggttaa tgggtgggtc gcgcagaccg gataaagcct 59760  
gcaacgtatt ctgagtgaat atattaatat cgtgtctggg cctgcctccc tctggtaaac 59820  
tctgaagcaa ctgcgtttca atgcattgaa tcttctttac gtagtcgtct cgttctttct 59880  
caagggttaga aattgtatcg aactgctcgt tgatctgggt cgtcaggcat ttgaacacgg 59940  
tatttgaaac ctgtttccgg agaccctggg tcgtactttc cgtaccggtc ccaaagagct 60000  
tgtttttgtc cacaatgttt tgagagacgt ctgtgacgaa atcctcaaca acgtctgtta 60060  
tgccgctcac tgttttgttc tccgcgagct ttatcagcaa gtttaggagc tccctcttgg 60120  
ggtcgggttt ttgagacgat tgctctaagc gagccaatat gtctttatac atgtcgttgc 60180

Cloning of Radinovirus Genome and Methods for its Use.ST25  
acgtgctacc gaccagcgct tttagaggcg cggatatttag taactgacat aactttgcgt 60240  
gctccgcggt cctgtgacat gtcataatcg cggtaaataa ccggtacaga gggctatcaa 60300  
aggcgacgcg tccattgtaa attataggcc gtgaaacaac ttcaactggt atatcttttt 60360  
gtctgtaggt gccgagataa gcagccttat ctccgttaaa ctccacagac acctcggcgt 60420  
agtcgtgaat ataaaatagac gtcacatcgg tcattatcga ggtaatctcc tgtgccagtt 60480  
tgtcgacaat ccgcgatatc gtaacgtctc cggaagcgta cgttttcctc atctgttgac 60540  
agtgtgcttg taccctggcg atcgtgtcgc cgtcgggggt gcgcctgaca ataggcacca 60600  
acccaaggcg gaccaccag tcgacgtatc gttcgtacga taaaacagtc ctggtgtgta 60660  
gtacctgatt aatagtgttc agtaacagtt gatcgactgt tagacgaacg gtacgtgcc 60720  
acgattcaaa cgtagaccgt ttgaattccg gcgtcagggt ctcgacaccg cgccaacggg 60780  
tcttcagggt ggtctcgaag ttggtccagt cctttaagac gttgtcgtat gtgcagctcc 60840  
ccaatgccgt cttgtacagg tgtatgaaca gctgtcttcc aaagatccct ggatttcgaa 60900  
gactggagtg tagcgtttga ccgcgaacgt acgcgtactt gccctgtagg atctcgaaaa 60960  
gcgagatgga gagttccgtc ggatggacca aacacgtcga accaaatccg gggttcatct 61020  
tgaacatgac gtccgatgcc aaagtcagggt gtgtcgtgga tcacgtcagt cgcctgtcaa 61080  
atataactac cagcccaccg gaaatgggtt ggtacgacct ggccttcgat ccggctgaag 61140  
actccgggcc gttcttgccg tttaccgttt atctaattac gggaaactgct ggtgctggga 61200  
aaagtaccag catatcgccc ctgtacaaa atttaaaactg cctgatcacg ggcgcgacca 61260  
ccatagccgc acagaaccta tcgcgtcgcc taaagacgtt ctgtcccacg atcttcagcg 61320  
cttttggtt taagagccga cacatcaata tagccgtcag aaaagctcat cagaccggag 61380  
ccgtatccat agagcaaatt cagcaacagg agctatcgaa gtattggccg gttatagtgg 61440  
acattatgaa agaggttatg gcgaaaaaac ccaatggcat gtacgggact atatccaacg 61500  
cgaattttga aacctctcgc agaattgaccg gaccgtgttt atggacttcc aatattattg 61560  
taatcgacga ggccggaacc ctgtcctctt acatactcac caccgtcgtg ttcttttact 61620  
ggttcctaaa cagctggcta aataccctc tttaccgcca gggggcgggt ccgtgcatag 61680  
tatgcgtcgg ttcgccaacg cagacaaacg cgttccagtc aacttacaac cacgggacgc 61740  
aaaagacgga gatatcgtcg tgcgagaaca tcctaacatt catgataggg aagaaggctc 61800  
tatctgagta cgtacacttg gagagaaact gggcgctgtt tataaacaac aagcgtgca 61860  
ccgatctgca gttcggacac cttctaaaaa ttttagagta taatcttccc attcctgacg 61920  
aagtcattgag ttacgtagac agatttgcg ttcctaaaag taagattatg gatcctttag 61980  
aatacattgg ctggaccgca ctctttttgt cacatagcga ggtaaaggcg tatctaaca 62040  
acctacacac atgtctaacy ctagggggcg ataccaggga cacgaagctc tttacctgtc 62100  
ccgtggtgtg cgagggtgtt gtgaagccgt ttgaggaata caagcgggcc gtcaacctca 62160  
ccaacctcac cgtgaccgag tgggtgacaa aaaacctctt taagttaagt aattattcgc 62220  
agtttggtga ccaggacatg tccatagtcg ccacggaatc cactgaacgt tcgacccagg 62280

Cloning of Radinovirus Genome and Methods for its Use.ST25

ttacctttat caccaagttt gttaaaaaca gccacgtgtc tttaaatgga aaaacaaaaa 62340

aatgcatatg tgggttttcag ggtacgtact ttgagttcaa aagaatccta gacagcgaac 62400

tcttcgtgga gacgcattcg caagaccgtc cggaatacgt atacggtttc ttaaacacgc 62460

tactgtacaa cgccatgtac tcgtttcacg cgtacggcgt gactagggtca cacgagaaat 62520

atctgcaaga cctaaaattt gcaccctcc cgcccgctct ggcaaccggg cgtgtagacc 62580

ttcaaacggt tcgtgaagag ttaaacctgg aagacgacat cttctaccac gtgtgcagtc 62640

ccccgccacc cgcgggtatc acctccctcc aggttttggc cgacacgtac tgcgccctaa 62700

aggacgtgtt cgcctccaga ataaagggtg cgtgtcgctg gtttggcggg gagtttgaga 62760

aggaacggtt ttccgcgttt acggttaaca tggctgtaag ggacggagtt gactttgtct 62820

ccccttcaga acgtctcaac gggctgttgg cgtttgcatc gaccgttgaa tcgtataaaa 62880

ttaaggggta cacgttttta ccggtagcgt tcggtcgctg tcagggtttg ccactcagtg 62940

atgacctcag gaagaagatg ccctccctgg tcgtgcagga ctctagcggg tttatcgctg 63000

gcctagagaa taacataacc aaattgaccg aaaccatgga ggacgggagc gttttccaag 63060

tgtgctgtgc gggggactat ggggtcagct caaatttagc catgaccatc gtaaaggcac 63120

agggaatgtc gttggagcga gtagccgtag tatttgggtc ccacaagaac gtccagacaa 63180

gccacgtgta tgtagcaata tcaagggtg ttaactcaaa ttatttggc atggacagca 63240

accccttaa aacctctc agagaaccag tcgataacac ctccgccaag catatagtcc 63300

gcgccctca caacccaac acaacctca tctactaat aaataaaaac aagcaaatgg 63360

aaaacattgt gtttttattc agtccaacca cggccacgga tagttgtcat ttccacacac 63420

cgggggggtg gccgccatag tttgacgacc agaaacgccc gggccctctg ggtagaagt 63480

agccccgcc cccgtggtcg aggtcatagc tctcttaggg ccctgggttg taccaacata 63540

aatcacgtcg tcatcacgtg tgcagtcctt gcgtgacgcg cgcctcttgc aggcggcacg 63600

aacaccgccg cttgtaacgt gatctgcacg gtcgtcgctg tctgaagatg aacacaggtc 63660

aatcacatca gtggcgcccc tgccctcacc ggctctgat tcgtcccatg tctcaacaga 63720

gcctcggtcg tccacttcgt cgtcatctga aataataatg gtctcttgc ctgcagttga 63780

tccagcaaca acaggttctt cttcatcgga agaccatccg ccctctgccg gtgatctaga 63840

tatatcacct gaccaggcgg gcgaggcccg tggcgaaaag ccgtcagctt ctccgccact 63900

ttcatcagtg tctcgtagt catctataaa aaaatcgtct tcgctgtctg attcagatga 63960

ctgggggtcg cgggtgttgc cagtaaccac cgcaacgggc cgcggaccac caaacgcggt 64020

cagtggcgcg ggcgcgctcg gtggtgtggt ggcacctgtc gaagtaatga cggtaggtag 64080

ccggccgctc tggttaaagg actcacgctc ccgtgcgtgc ggatctattc taggtgggga 64140

ggagaccggc ggttcgtctt cttcatccac atcactgtag tcgctgttct ccgaatgaga 64200

gtcgggttcg tctggcggtt ttggagtagt gggaggggaa tcttggtaaa aaacatcctc 64260

aggtgcagtc atgtcaatca ctggggggcc tccgtacccg ggcggtaccg gcaaccccg 64320

acgggacccg gcgaacaaaa aacgtcttgt tctcttttct ctaggtgcc cgggaatcgg 64380

Cloning of Radinovirus Genome and Methods for its Use.ST25

cagcatcctg ggagtgccg gcgggtcct tgacgggtcg gataagaaca tagccatggc 64440

cgaaacgttc acctgtaaaa cgcactgcct atccccgac agttaatatt ccagtcaacg 64500

gcacccctcc gattctgaac tagatagtca ttcgcaagtt taaaatgggt gcagcctaga 64560

aactgcggcc agggagaacc ggttgccgcg tgggcggtag ccaggggaga cggtatggcg 64620

gccttgagga cgagatgtct ctgtccgttt atcagcgtcg ccttgtctat agcctttctt 64680

ccccacagca taaaaacgca cctctgaagc ttggcagaaa ggcagcttat tatgtagctg 64740

gtgaaccaat ccagccaag gttggcgtgt gaccccgctt tccctctttc caccgtcaga 64800

atggtgttta aaagcagaac tccccgtttt gcccaacagt ctaagcaccg gtgagaagga 64860

gcggtgaacc caggtacagt attggctatc tctttaaaaa tatttttgag gcttgagggt 64920

atactgtagt ccggagcaac gctaaaggct agtccggtgg cttgaccgcg atggtaagga 64980

tcctggccaa ggatcacgac tttaatatcc tccggttcgc aacaatacga ccaccacata 65040

attctatcta tcggtggata aatcacggtt acgttgctca tatccataac gcgcttcagc 65100

agagccgca gcttctgttt taaaaatgga gaaagattta aaaattcaag ccatgagtcg 65160

ctaagtagca acgtttgtgt ggagggttct tctaacactt ctggtgacat tttactccaa 65220

actattgttt taagccaacc ctccataaat ccccgctctt ggtaattact ttacgtatac 65280

gtgaaacttt tgtacttctg tctgagaaat ccaacagagg tggccgctga taagcagttc 65340

cgctttcact accgtttatg tgaaagtctt caaactcggc taaaaactca tcaagactat 65400

attgcatata attcaacaat tgaagctctt ctctggggac actgtaattt aacttgtagc 65460

aatccttat aaaaaacgcc ctaagggtga atccatttac acatatttct gtggtagagc 65520

gatcagcttt atatcgcaat gttgctgtac acagccctgg acataaagct aaatttgta 65580

aatgaaaaga agcaatctca aacggctccg gaaatataaa gtcactaagt ggtattattt 65640

tacaacatgg atttactaca agcccgttac aacatgtaat taaaaaaaat ccacatgtaa 65700

taaataaact taaggatata atacttctca tgttttatac ataatatgaa cgctaagtct 65760

gtacttatat aatatgtata gaattatgcc aatacagtc tggtaagtat attttaaggc 65820

ataatgcaaa catcaataa tataacacaa aatgcacgt tccggatata cgcccagctg 65880

ttaacccgaa aatacagaaa tgactacaca aacacacctg aaaccaattt tattctcaac 65940

atatgcaaca atatttcagg gtaacacat gtaataaaaa tacgcagcat gcacattttt 66000

agctaaagtc ctcaaagaca atttcctctt caattgatga ctcatcaacc tcggtttccg 66060

tgttaatgtc ggaaatata gagtccagga taccctcgtc atcgccacaa attaattcca 66120

gggcttgtaa aatatcatcc agtgaatcag ctgctaagt caaggatgtt gtttctaatt 66180

ttagccatc caaatggtga gtgggtgaca ctttgggaca agaccccgta aaattggcac 66240

gctccacaca aacggaagga tgcatttgat cgttcacgag gggcagcata tttattttta 66300

taacatcagg aaccggaccc gtcaatgacg cacatatgtc cattaagatt ggagtcgtga 66360

cactgggtga attgacgggtg aaaaaaatg tattcgtgtc acatgcgtaa ctatttttta 66420

accacacgag ggcggaataa aacgggtccc cggcgctaag gccgtgaatg cggcagggcac 66480

Cloning of Radinivirus Genome and Methods for its Use. ST25

```

ggctcattgc catttccaga ttgtttaa atctgtcgaac ataagagtct aaaatcaagt 66540
ataaccacga caagtcca caggaggcaa cgcggctggt ttccaccg acatccccgc 66600
tcacaaaccc gaactctcta ggaacgcaca tcaaagcggt cagacaaaat tccgaaaccg 66660
aaaccctagt tctgagcacc atctgggttat aaactgcggt taagagacga gcggccacac 66720
actgctgctt gtgaggattc agcttaggtg gcctgcaggc ttgctgacag gcccgtagct 66780
gcctggcggc gctcgcgcac ctttgacagc cgcacgccag ttccagagcg aggcagaagc 66840
gctctttgca gtcgcgcat atctcggcca taggagattc gtcgcgtga tcttttaggt 66900
gcatatatat ctgttggtga acaaacctca ctccctgtaa aaggggaata aggtccgttc 66960
tttctatcgt tttctctgaa tctatagtta catctttaag tataaccaa gacgctaaaa 67020
accaggatg gtcgacacct ttaaaaaatc gcaaaagcga ccggatggct ctatccgct 67080
ttccatgtcg ttcaaaggta gtcacgatg atctccagtt agactctgtc tccctgttaa 67140
cacccttaac tggaatggaa acagccatga caccgtgaac ttctgtatgt ctctaaaaac 67200
taaccccgaa acagagctaa ataccaatga ctgtcacccc taccacaagc cagcccccg 67260
tactattaga ccagggtgag taaccacgct atctttaa aaccatacg tggagtgtgt 67320
aaggtaaaca gctcgtgtat atttcagacg cctgtcataa aatggatacc gacgacaatc 67380
aggtaattaa acttttttta ttcaagattc aggagggcgt gtttacagt gtgtagggtg 67440
gagcatatct cgccaatggg aatggctgat gaatccacac ttagtgctcg gatcaggtgc 67500
tctgtgtact ttactagtgc cgatgaacct aaatttggcg tgtttaggtc gtaccaacca 67560
aaaaactgcc tggcctcgcc ttttagaagc tctatgcaag ctttaatcgt gtccaatagc 67620
ttgtctttaa aatgcaact ctggtacatc tttatgacag tgggtccaaa aaaacaaaga 67680
tttaaaaaca cgttaaaactg cgtgtcctgg tagtcctcgt atataacctc ctcaacaaga 67740
aaaaatttt taaccaaact cgccagggtac tgaaacgatg gtacggacag gtcgtgaaaa 67800
gtgtctatca tctcttcac ctcccctttg aaggttttgg ttacaccgac catgtgagat 67860
aggcaccagc tcagggggga ggtcggatcg tgagggggta acaattcgtg ggcgtggggg 67920
tactccagtt ttaggatctc cggcaggacg cgtacgagtt ctctgcaaa tcctacgcag 67980
cccgcacca ccaggggcag tactgagtta ataagtcacc gaattctatc gttcgttaatt 68040
ttgtggagct ctttagaca gtaaaccatg ttgctccgac actgcggtac gatgaaccgc 68100
tctcctgtc tgtgtgcat gagcacctgg agtatcttag acaggtatag ggcccgttcc 68160
actctaaggg ttgccgcttg gtagagcgga ttgcgggcat tgacggtcag tgtgttcatt 68220
tcaccgacta tcatgccgag tggcggatag tggaacttgt acatagtatt taaaagatgg 68280
tctttcccgt aatggcgact catggtcgtg ttttaacgtt cacagggtgt taaaaaactc 68340
agaaggctct gcgtggacaa cttttgcgga ctctccgaac cgctcaggga taagctgtac 68400
cacgcggtgc ttcttataaa cgaagcatat gtcaaaaaac atgaccacag tgacctaaat 68460
aagctcacag aagaagtctg tcgatgtatt gtaatggaat gtgcctccct gggtcccatc 68520
tccgggctca tcgcggatct gaatctcttt aacctgttct gcctctaccg gggttcccgg 68580

```

Cloning of Radinovirus Genome and Methods for its Use.ST25  
gttaaaaccc gcggggccgc cacctgtaac gtcccgtagc cagaatgcgc ccagggcac 68640  
gtgagaattc tcaccgagag ggccctttgt tgtaccgaaa agatgttcat agcgtctgcc 68700  
tgcagcgggg tcgttatacc gcccagttg gccagagttc tgcacgacgt ctacgcggaa 68760  
atgaaggcca agtgtttggg ggcgtggcgt cgtctcatat gttgcaggcg gcctatcatg 68820  
gctattgccg actcggctct cgtcacttat aataccctgg atgccgaggg aaaactggaa 68880  
cttagactca aagcactgtg caaacttggt tttaaccca tctttcttca aagaatctta 68940  
gccctatgc agctactggc caacgggaag atggttctg acaattatct taccatcacc 69000  
ggtacggccg agaagaggcg ccctgtcgtg actggaagta ctagcgggat gacgtgtccg 69060  
ggaagcagcc ttgtccccga ttccttaatc ctgccagtat gcgaaccggg gcttctccc 69120  
gcaccctgg ttgacctcag taatgtctta gaaaatccag aaatcatcct cagcgcccca 69180  
cccctgagtc aatttgtcat cacaacacg caccacagtc tgcctcagtc agtcagcatt 69240  
attacgcca cccagggcgt tgttcccgcc caatgtttta tggacacgtg gaaagcgggtg 69300  
tcacagagca ttcaccacca ggcacagacg cctattttgg ccgccgact aaccggttcg 69360  
acatctgcgg cccctggccc gcatactgca tgttccccag ttgccggcac gtctcggcag 69420  
gtggaagggt ccgcggggtg cgattgcggg aaaccagcat gcgttcgca gcccgcgta 69480  
ccgcccaatg tccccgcca gaggatggaa acggtagcac agttgggaaa cgctcccgta 69540  
aaaaacgtcc acatcgagg ccgcgtatac gctccactgg ttaatatacc aataatagac 69600  
ttaacgtccc cgtcagggtc cggccagagt ccggccgata tcgccaacac tccagagtcc 69660  
cgcatggcgg ccggtctctc gcccttcgcc gaaaccgcc caacggtccc cgctaagaga 69720  
aagcagccac gcgaggacgt ggcagacaaa agactgaagg gcgacgttcg gggcgccgca 69780  
acagtaaacc accctttccc gggaccgtcc gggatgcgcg ttcgcgagca gggcttattc 69840  
gatttaatcg aaagctccac ggatgtaacc gcgaacgcat ctggacccaa aaacgacgac 69900  
gacatgctag cggctatcct acaggacctg tatggactac agtccccccc ggccatcgat 69960  
tccccctcca gcaactcggg caatgaggag atatttccag aggttagtcc gccatctagc 70020  
ggccacggat cgccttgaaa gatgaccca agacgcaaga tcacaccacc gagacagtcc 70080  
cacgcaaccc ggcggatgtc taaccgtaaa aatatcaccg gttggaaagt cccttggtgc 70140  
gacaaaaatg agcttcaaac ttaccattt tctgtgctat ttcgggacac taaaaaattg 70200  
tcgccagtgg cgacaatttt taagtctgtg taaatgtcac tctttctcaa gtttctgtcc 70260  
tagaattttc acatccagtt tcatatcata taaagacacc tgttttgtt tcgtgaatct 70320  
ggcgtgtttt tatcttgaga gggccctaa aaacatgcct cgtgtgaaaa cacaacccaa 70380  
gagaccccaa gtgcttgaat ttatgccatt agatctccac ggtggaacac acacggagat 70440  
ggattctcaa aacctgtgtc ctgacggcca ggatctgtc gggctctata tctatacggg 70500  
gaataacggc ccgttttccc aaataatgca caatggacag agcaataaccg ggacaggatga 70560  
aagcttcggc agctacgctg ccggcgacgg ttttctgggc ggttctgtgt cagggatgta 70620  
tggaacaac accggagagg gcgcgtgttc taaaagaccg tccgcgtgcc gtaaacgctc 70680

Cloning of Radinovirus Genome and Methods for its Use.ST25

ggctgcacta attcacgcgg cgtccgaggg gtctgtggcc gagcaaggca cctcacaggg 70740

ggcacatgcc gtatctgacc ggataggcag agacgggtggc gctgacaata gactactcaa 70800

ggtgagtgcg cggctgtcgg acaaaacaaa gagcgccctt cgcagccatc cttgcttgcg 70860

ttgctattct ttgatgttta acacgtaatg tctgtttata ttaaccctgc catagcccga 70920

accgaacact gtgcgatgcg attataaaac gcaacactcg gacacgtcag atggacgcgc 70980

aaaacgcgcg cggcagtgca agacctcagg aaaaaataaa gcccaacagc tgcaacaggt 71040

acaataagca aatttagtaa tttgtatttt ttaagtttcc gaggttttcc cgctggcctg 71100

cggcaccgtg tccgtgcttt agttggaata cctctcctaa caagcacgta ttccaacagg 71160

agctggaag taaaacaacg caactgaccg tcctcaccgc tcaacacgaa gcccttcaaa 71220

agcacgcac ctttttacag aagatgatga tattgatgtg caaaaacggg aacagtaaaa 71280

aaagcacgtc atgatttaaa gccacctcgg gttactagtt taaaactgcc taattgattc 71340

tattcacctc tcaataaaat aaaattttta tacgtttgcg gtttgtccat ttctgtctt 71400

aaaactatta aacaattcat ttggaataa ggatttatgg gattaaggga ttaaattttt 71460

ttgatcatg ggatttggga acatacgtct gggatggagg ttatgcttca tggctctgggt 71520

ggcgtggatt gcacggggac ggtcgggtg cccaacctgg cacctgacag atgggaaata 71580

cgaggcggta tacaggcact acctcgaaga gtgccgcaa catgaaggct cggggagcct 71640

ggacggttcc ggacagacaa aggggtcttg aaccaaagca accaccgaag ctaatatatc 71700

gataagacct aacgttgtca catcaggtca aaataaagag ccgcctggga cagcaccgag 71760

ggccgaatca tcacacgacc tgccacgcat caagcaggtt aacgtctctc gattatcaac 71820

cccgaattg gcgcaaccac tcccgtagt aaaatcgact ccgcgcgagt cacagtcagg 71880

tgggacaccc tggaacgcgc gccccacgc gttcattatg cacacaaacg acatgctcaa 71940

cccatctgtg gtcctgtctt tcagagccat ccgtgcgagg tccacacgcg ataccgagca 72000

gtccgttcgc gatcggaaca cggtcacgac cagctatcgt acccctggcc gcccttccct 72060

ctttcaagcc agacctcgt ctcacgggtg gcgtctaccc ccttcgcccc gaacgatggc 72120

aagatacgcc gagtcgcgaa caatatgcga ccaaaattga ccgcaaagaa taccacgccg 72180

tccgttcgac gcagtcccc tatggacgct gcacgggacc tcaagcgtcc gtgtcagacc 72240

cattcctccc ttgcgcgacg ccgtggcacc tggttcacc cctgtgggct atggccggaa 72300

tattggcct cacgatcgcc ttgtacacga tatatcaaat atatgcacat agaaactaca 72360

cgacgttca ctgcgaataa aggtttattt atttgcaca ctagtccgcg tcgttatttc 72420

tggctctgga ctgggcgcgc ctctcctga gcgccccgtc cgcgctggca gcgattccgc 72480

ctctggtggt ctctccatt gacacgtcca cgcggatact aattccggcg agggcgtctt 72540

ccatctgccc gcgcgtcacg gccttggccg tggccgccct caccttagct tcaatcttac 72600

gggttgccac gttacataag gccgaaacgg cagctgcgat ttggcctcc ttttcggtgt 72660

tagagatgac ggggtcggag ccggacctgg tgggatcccc agaatttatc agctttttga 72720

gctgcttggt ttcaacggac aatttttgca cctgagcggc taactcctcc attgtcagct 72780

Cloning of Radinovirus Genome and Methods for its Use.ST25

```

cttttttggg ggcgcgcgtc ttgggacgcg tggaagacat ggcagctact acgcattaca 72840
gagtacagcg ggacgtttaa atactttcag gcgcccccctg aggtcactcg tgcgccacgg 72900
tttcaacaaa tttaaaaaag cacatatatg ttaggtacag aaatgttgca accgcgacca 72960
gaacagagtt gatcaccgcc catatactcg aaaaactaga cagcacgggc tggtagctgt 73020
ccgccgagca atcatagtca taaaaagagg gcgttacgga gggagccgcg gaggggtttg 73080
tagtcacagg aggcgtgccc gttcctgtag tcgaggaggt ggtgacggtg gcgcacaccg 73140
gcagacacag atataagcac gccaacaggg ctaacgcgag cacaattgac cctgtcattt 73200
tcaagccggc gttcggcagg caaccctcca ctttggcacg cgcgctctcc ttatatacta 73260
ccagttaaac attatggcag aagtgaccgc ccatacggtt ccgtacgcct ttgactcctg 73320
taagtttgaa ataataccaa aaaacaactc atctcgtata gcgttacgca acaaatttcc 73380
cgtcgtggtc aaaccgggag aacctctagt cgtgcccctg ggactaaaaa ttatccgcgc 73440
gccccagtgc gcattctttc tcagcggagc gccgacggat gaggtgtatt accacaccgg 73500
acttatagat caagggtatc gtggagaaat aaaactcatc gttctcaata agactaaaca 73560
ggtcgtcaca ctttaccggg gagaagtcaa cgtctcactc atcgcgttta tgtacgcctc 73620
gccccggccc ctaaaatgcc cgatactgaa cctaccacat tactctctgg acgctggatt 73680
tgatgttacg tcgccacatg ccatgaccat accccaacc gacagaacct cgtttacgtt 73740
gagtttgtat tataagagtc cacagctcag cccccccac gtcccactaa tcgtggggcg 73800
ctctggactg gcgacaaagg ggcttaccgt cgacgcgacc aaatggacct agtcgttggt 73860
acatctgagg ttttataact ttaccaaaga gccaatagat ataccagcaa acagccgcat 73920
atgtcaggta gtgtttatcc acgaagacca cgtcccaagc ggggtgaaca ttcttagatc 73980
ccgcgtacaa ctcggcagca ccctccagat atcgtgggcc aaaatcaggt ttaccgacgt 74040
ggccacgctc cccaaaacct acccgctcaa ctcccgccac actcaaagcc aaaccgaacc 74100
ggagaccgcc cgcggcgcaa aggggttggg gtcgtcaggg ttataatttt aaaacatggc 74160
attattttaa agttgtttat ttttaataaa acaatccaaa tttacgttaa ccatcagctt 74220
gcgcatcctg tattattttg tctggcacga tattatccgc caccgccaac tggggcgctc 74280
gttgtcgaat caccggatgg gaggggttgg aggacgcttc ggtgtctacc agcacattat 74340
taatttccgc agcccacgtg acagaatcat cggacgcgat cgtcgtagcc agtttttcca 74400
tttccaggag tgacacggtc tcgtcggccc gtttattcaa aagcgcgtga aaggcgtct 74460
cgtccaccgt aatatcccct atagccaggg acaacatggc gttccagata acgttctgta 74520
tagactttag cttagatatt tgaatectaa cgtctcctg gcaccccgcg ggtaccctag 74580
ccgcgtcaaa acgacgaaga tactcggtta ttttattgga ttgaacggcc aacagatacg 74640
tctgccgaag ggcggcgggtg cacatctctg cctgtttcac atctcccata tccactccc 74700
ggggcagacc catggctatt tcggtccgcc agtgagtagg acactcgta agaggatctg 74760
gcaggggacg atattgacat cccacgcgtc caaacggact aaaccgcaa cacgtccaaa 74820
acgaaccagg cgcggccatt gccaaacaaa atggtagatg aaattagggc aattttctct 74880

```

Cloning of Radinovirus Genome and Methods for its Use. ST25

actagtggag atatggccga agtaattacg gatatactga ctgaaacgca agcaacggcg 74940

tccttcttct gcgtgctcca cgatcggggc gacgcgcta taaatactcc acatgccgta 75000

attaaactct gctgcccgc caagcgccca ggcggcgggc caaggtgttt accgttgatg 75060

gtgctgaacc taccggcgtg gcaggttaat ctattcctaa caggtgacgc accattgacc 75120

tcggataaca ttaaagaccg cattgacctg gctcagaccg aggaaatact cgaacccata 75180

ttaagcgtac tggcatgcaa acggtccgcg cagcagacca aacatgactc gtttaaactc 75240

aaggtggcct ggttcagggc aaagtctgctc tcggccctaa gaaaagtgtg caaaatgacc 75300

ccatccccct attggatgat aacgctgctg ggctcgctcg aggcacgtt tgtactggcc 75360

ggcacgtttt attttttcca gtctcatata tgcacggcgg agacgctggt gcactaacg 75420

aggttattca gctccagtca gggccagagc ttggtcaccg taaacaccta tgacgaatta 75480

gggcgcgtat tcgggcggtc agatttctctt ggaattgttc caaatTTTTg ggcgtatcta 75540

aaatacaaaa tgcaacagga cgacgtggag tccaggggcca tcgatcaaac aatcaactcc 75600

atacgtgggg ggttgatgct gtcacctcag gacctcgtac acttcatcta cctgtcattt 75660

tacgagtgca tgaacgcaca gacgttctctg tcgtactctc gtaccacgctc cagtttaccg 75720

acccccgcaa cggttaaccc tccgcagctg tgcggcgct tagaagcgga ttttaaggag 75780

cacgtgatgg catattacaa taaagcaagc tacctgagta cttacataac cattttaacc 75840

gtacccgctc ctctcccga cggatacgaa aactttcagg aactagcatg tcaatactgg 75900

tgtggacaat cgagagacgt ggcggaatc atgactagaa ttaatgacca gtatccacag 75960

ctgaatctaa caaaagattt atccggctc cttgacctag cggccctaga tcagtattcc 76020

ggaggcccca aggaaaacct ttttacggtg gcttcgagaa ttcccacata caggtgcgag 76080

ttttgaata aacagtattt tgttctaatag cacgcagact gtatagacgc gtactggaaa 76140

caaaacatta tcgtgccga agacgcccga ttgcaaggcc tgacggatca agatctcacc 76200

tccaggatat tttactgcga cctcggccta tctctaccta catttaaaca acaaattcta 76260

gtttcacgcc acgagtattt caaccacga ctcccagttt atagatgggt gttggatttt 76320

gatctaaagg taaccgaagg tagacggact ctaaagcata tctacaacat atgcgtaacg 76380

ctgcggcagg tcatattaga aacgttgacg ttaataggct cactaaaacc gaaccacccc 76440

gtgtattttt ttaagtcggc ctgtccagcc gtaacctggc cggatgatat ctcagacacc 76500

gcgttctgtc actgtgacgc aaaaataggg atgagaattg taaccccggt tccgagcgga 76560

tactgtttgg tgggtccgc tccactcgtg tccctgaccg acattttaaa ccgctggtt 76620

aaactggaca cgcggctagc ctcagagtat cctgggatct tagaagataa aggaccattt 76680

gactctggca tttacgcaa gggcgatgc gtgcgcgtac ctcactgcta taagttggc 76740

ccggggggcg agctgtcacg gtcctaaaaa attattatct gtcaccccgga agagtcagat 76800

aatcggcgt atttgaaaaa cgcgtttaag gtttctaate tgctacatca cggccctgga 76860

gactctgtca ccaaaaacgg ccacctggtg tacgcgatca ctgacgaaaa cgagggttt 76920

ctagaaagca aaaccaagaa taatcttccc aaaacaatca cggacctggc cgaaaaaatt 76980

Cloning of Radinovirus Genome and Methods for its Use.ST25

gagcgaacca cagaaaaacc actaattgat tgggcagcga ccgcagtgtg gccaaaacta 77040

cacgatacca tacagcgttt ctttcgggat gaccgcatcg gccaatgtgc atctgtgagc 77100

ttcatgcact ccggagacaa cattatacaa gttaaaccac aaaaaggaaa caacttttcc 77160

tgtattaatc ataagcaccg aaaccacact cagacagtcc gtgtattttt aacctacat 77220

tccacaaaag aaagcgaggt cacggtgacc tttatgagtc agtgctttgc tgcaaatgt 77280

aatcataata gcccaactgc acatttttca tttatggtac ccataaccgg cacgtaagag 77340

acacgaataa aatcatccgt gatgggccag ctctccggct actttgttaa ttttaacacc 77400

gcgtaacccc aaaaacaaca tctggacgag ttttgctcgc gaacgtgaac atggcacagg 77460

caatggtgag cctggaatac atgaaggata ttttgacgag taagaagacc ccttggtggct 77520

cttacgactc ccatttaaaa ccgcaactta tcaaacggct ctttttatac gatttacatg 77580

cggtagtgtt ttcacgcact aatttgtttt atagggggca tatcatcgtc ggacttcgac 77640

gactcgtcct cggacgaaat ggacgacctg tccccaacgc cggagccaga accgtccaca 77700

acgccgaaca gctttccgga ggggcccaaa tcacaagtgg tggcggtacc taaaatccgt 77760

aaaagatctc gatctgagac gccggtaaaa attgagcaca gatctccact taaccgctcg 77820

cgatctcgat ccagaacgag gtccgggtcc ggtcaacgat caaacagtc aggcagatac 77880

gtcaagagat tcaaaccaac ggttgatgca ccccgatcgc gagaaccgtg gcacaggggc 77940

ggtaagggaa aggcccggtt tatccgcaga gacgcaatgg ctggccgcgg tcgacgcaca 78000

tacggccacg actatcgcgg aaaagccgct ttaacgcgga gcattaaaga gtctattaaa 78060

aagatgcacc ttccatccac catgctctct cgtgcgcacg ataaaaaggt attcgaggga 78120

ctgttgccac gacacctggg acagtgcttt caggtgtgcc tgccggcgcc gccaccgctg 78180

caacccgagg tgttcacgga tcgacagctt accgctatag tcaagtctgg cgggcgcaga 78240

gacgcgctgg tggccaaaaa agttagcctg gctaaactaa caagcctata caaacccctg 78300

ctcacgtttg tgacggggag aaacaaccag gccactggt tggcgacgcg caaaaacacg 78360

ctagcgtctg cgggactcga ggctctcgcg gcctttatcg aggaaggtct ggcgtgggcc 78420

caggtgtgag tatctcaaaa cagatcgttg aacgacagca acctagatat cattctagac 78480

agtagtcaga gcgtgtgcac ctggttcac tcacaaatca ggcatttgca catacagtgc 78540

ttcttgaga atcaggtgga ggttagcctg gtgaagcagc taacttacct cgtgtgtata 78600

aataaccgcc tggcggaggc ggcgaacctg gcgggagagg tgaaactgaa ttttaaacctc 78660

ggaatgctga ttgggttcgc cctaaccttg ccggcgctcc ttgcagagca taagttgtct 78720

ggcgagagcc tgtacctgtt taggtctttc ctggagaaat atagaccggg agatgtcatg 78780

ggactcttaa attcaatagt ggtggagcac tacaccaa atgctgtagcgc ggagtgtgtc 78840

attacaaccc acgccatggt aggatctggc gaaaacaaca agggactttt tttctttcca 78900

gtgtaataa taacccatgt gtgtaagtag ttacggtata ttattcacgg gcgtttaaat 78960

gcaataaccc acataacaaa ataaaaatgt gtaaaaccaa acacgcgtca agctttttct 79020

gcaagggttc tgtgctcgga acaaataggc agagttcgcc acctagcggc acgttctcta 79080

Cloning of Radinovirus Genome and Methods for its Use.ST25

tagccttggt atacagcgga tggtatttac ggaagtgcc catgaaaccg tggccgggtg 79140

cgtaacagta aaccgggtcc aatcgcgag ttacacaa acataaaata ggcgaccgtt 79200

tatagcggtt tatttgaaca tacaacacac atttcaggag ttccggtctt tataaaaaatc 79260

ttcattcatt caaagtgccg atatatttca cgctggtgga caacaataca tatcggcgcc 79320

tgtgattgat cctcctcctc gtataggagc caggcagaca cccaaatctg tgcaaaccga 79380

tcgggtggcc cgggatcaga gggctgtggt gactgggcta actttaacat gtattcatcg 79440

gtatcaaaaa cgcgatgtcc caccacagat ggcacgcgtc ttggttcaga ggtgtttgag 79500

gtattgccac ggaaccataa attaagaaat ccatagccat tcatcataat cccatactga 79560

caactgcaca aaacaatgcc gtccctccagg gcgtgtaacg cggtcacaag tctgctcaac 79620

ataaaatcgt catccatata aggcgcggg ggcaaccaca actgaagcgg cccgggagcc 79680

atgcagacgt ggtgttcatt tttatccgtt ggtctcgtgg ataaacgaac gcccatccca 79740

gaatgggtaa aagtctgtgc ttgaaggacc ccataataat aaacctgaat atgcataaat 79800

ccccacgggt cgtcaacaga tggcgccaaa cacgcagaaa gaccgctcga tgcagatagc 79860

ggcagggcgt gttccccggg caacgcaacc gcgccccctt gactattgtc ctgcctaccg 79920

tcttcaccgg aggcggttgc ggttgacagac gcctcgttgg ccggggcgggt catggtgaag 79980

gtaccggcgg gacgggtacg aagtagcccg agcagctgct ttaccgtgta ttcagataacc 80040

ctgcccgcct cgtcggcgcc cttgcgctta aacatccgaa acctcaagcc ccgcagttct 80100

gccgtaccc cagagggccc agggcacaac ctgcataaca tctcttcac ggagcgcaac 80160

ctgaagacca cgtttgcaaa tgaaaaactc cgtctcaaaa cgtccttttc ttctatgaaa 80220

taggcactct ttcttatcgc acccaatagg cgcgccttgg cctggcccag cctagacctc 80280

ccggacggaa gggggatggt tctctggttg cagtagtctt cgtacatctt cccatccga 80340

aggtaatcaa atccacaga ccacggggtc gtagtcgcca gcacgacctt ggttttttcg 80400

tcgtctgccc aaaacagtcc cgaatacgtt gcaagatttg cgtgagtaac gatccattct 80460

cgaagtcca tggcgagcgg accaccgctc tgaggtgggc gccaggtagc catggctgta 80520

tatgccaggt tgatactcac cgctttcagt tcgtgttaaa ataaccaaac tccgcccag 80580

cggctaccgc cgtgggcgca gatgtgtgca gccgtcaca aagaatocca cctgcggcaa 80640

ctaattccct cagcggccag tcagctggct accggttcat ttcactcac agcacgccac 80700

cccatcatct tcaccgctcg ttcccgcgtc cggatcgtcc attgaatctg gtccggagtc 80760

gccagctct actgccgggt catgcgattg gctcgtcccc tctcctggat cttccatctg 80820

gaatgaacag tcggtgagc cctctgatgt tacagtcgtc ccggggtaaa aacaaccctc 80880

tgtaccgcat acagacgagg tttcgacac gtaacgcagt ctcatggcga tgggcgcac 80940

gacgggattc ggcgactgga ccgacagaca caggcgatc tgtgcataat ctctaggtgg 81000

ttcgtctcca gggttcgggg accttgcaag agctetaaga taatccacca tatcaaaaac 81060

ctgaacgggt tgcctggatg gcaggtcctt atactcctcc tcattgttag taagcacctt 81120

catttcccg ttctccaggt ttttcacgca aatgccagta tccgtaagg taatcaaac 81180

## Cloning of Radinovirus Genome and Methods for its Use.ST25

acccttctcg cactttttgt gcataaccct tagatcttct ctggcaaact gacagtcaac 81240  
gacccccggt gacggtaaaa acaaagtcct ctcatcttgg aaacaacacg cgtggccagc 81300  
gaggacggga catggtcgac tgcagaccgg tattccagca tgaacacgtt cgaggccaac 81360  
ggtctctcca aaatatagaa acgttaattg gatggccctt ggcagccgat gctcgcgcac 81420  
acgcttgttt ttgtccatcc gactccgagc caataccgtt gcggtaaaaa cccgtcttct 81480  
ttcacgtcca gacccacccc cctggtcgta ttggaactca ctgattaaac caaggcactg 81540  
agtttcggtg gaagacatca gattacacat tgcacaactt accaccggtt ccggcaacag 81600  
gcgaaacagt ctatatcgag caccgggtcg cccataggcc ttattaataa atttaagctc 81660  
tcgtatactt ttgtggtgtc tcatgtcgta caagaatctc attttcctga atctgccata 81720  
gtgggacggt ttttcgccct gacatatgcc tcgcatgttg cagtagtcat caaaaaactt 81780  
ctcgtatttc catacggacc gatctgcagt tactttgttc cacgggaccc ggacaacggt 81840  
cttgtcctca ttctcccaaa ccaatccgcg gtactcgccc gattcgaccg cggaacgag 81900  
ccaggccctg atatcgactc cacggcccgc cattccgctt attgggagct tgacggatca 81960  
gctctcaaga caaatgaaac ccttgcgttc acggcaccag ttcataaatg tatctaaatg 82020  
acggagtcac gtgccctaaa catatggcta agactactca aactgtgctt aggggaagag 82080  
tgacaaacac ctggcactca ataaaatfff gaggtcgggc attgaccgct gccttctctt 82140  
ggttagtatt aaccccatcg ccacatatt caaggaacaa aacactccag atacaaaaca 82200  
ctttattaca gatagaaggc gtcaccggc ctcacaaaac cggtcgcgcg cacaggtaac 82260  
attaacatt agcggcggac aacgccggc acagacactc gtgccacagc tgaataatta 82320  
gcggtacagt gctttgcact ccgccctcgg gtgtaggtag gccccaaaa tataggtaaa 82380  
cacaagcttg tggaagcgcc gtcctcgccg gagatgttct ggccatggct gtcatatagt 82440  
caaccaagtt aaatgcacga cacgcgttgg cgcacgacag gaccgcaacc gccccgtag 82500  
attcgacgtt cccttgaacg aacgccaggg aatgccccaa ccatctaag taaatgccgg 82560  
aggggtcggc ccaaaacgcc aaccgcgcga aaagatcttt atccaggaag cgcaacgcct 82620  
cggcctgaaa ctctgctaag tggcctggaa tctccggaac cagtgcctgc tcggcgatcg 82680  
gtgcggcgca tatgtgccct tgaggcgac gttcggacaa tgggagcaca cggatgccgt 82740  
tggacgattc agtcaccact tcaccaactc tgtccccata atagtaaac attatacgta 82800  
gcatccaaca ctgttcaccc ccggctccca ccgcaccagt gtaccgaaca ccggcgccaa 82860  
ccggacaaa cttattcacg gcctcctcgc gcaacccccg taacatagca gtagtgccgg 82920  
aggcctgac gcaacgagca cacgacctca cggtaattgg taaaaggcga atgattcggc 82980  
atctgtccgg atatggagtc gaaagggtgt ccttagttga cacgtccgac acggtttgac 83040  
tatgccgtat ggcgtggat agccagtttt tgcattcctt agcggttaat tccctgccag 83100  
ccgogtgcaa gatccccctg gatcgacagt agtcaataaa aatgtttttt tccgcctcct 83160  
cgactcctct gtcctctctg tcgtgattcc acggtatgcg gattaaagtt ctttcctcgt 83220  
caaccacccg cattccggga tgacgacctg tctcgacga ttccaccagc catcctcgaa 83280

Cloning of Radinovirus Genome and Methods for its Use.ST25  
ggctggatgg ttgtgtcact cggaccggcc gctccatata ctcgccgcgt gcacggcaat 83340  
gccaaacctt gtccaagtta cctcctgaca agcacctgcg accctcacag acctacgcgt 83400  
ggcaaacggg aacttggtgt ctagtctgct gggacagtac cttagcgta tttttatctg 83460  
tcgtgcactc ctgcggcgga agtttggtgt ttatgagcac caccgggaag gattcatgtg 83520  
tccctgcacc agctcgtcct gacagaccac cacagaaata ggaacttggt ggctctcttg 83580  
ggcaccaggc tgctgtgaga gatacagtgt tgccccgttg cacggcgcat ggctctcttg 83640  
tcccgagag cgggcaagct ttctcatgaa acccatgaag ttaaaaattt tctgtttaga 83700  
gaggaacatg acctctcgtt ggataatatc accattacag tcgttaccgc ccgcgtacag 83760  
cgtttccctg ttcctattat cgacgtacac tccggtttcg ttgccgtgta cgtagatgcc 83820  
ctcgttatac ggcaccagca tcgtttttat ttgcgttata tgttctgcgg tcagtttttc 83880  
acgatctgga gatggaaacc agacagtga cccggtgcc tagaaacaca gatgaccggg 83940  
atggggaacc gggcgcggt gcaaacgaac acctctccga tcttgggacg tgtgatccag 84000  
tgccagaacg ccaaaataaa acacctgaat tctcaaccgc caaacggca caatttgatg 84060  
aggcagcggc gcttctggga ccccgagacg atgtgctcgg gcgtacgtg atctcgtcgg 84120  
agggaccaac gtgggcaagg gggcgggcag cggcattccc ggctctaacc cgatgccaca 84180  
cacctgctcc aaataattta taatcccttc agagttctca tcaaggatac acgcatagca 84240  
tccagaatcc atcaaaggtt ttaccggaa ggcggtccag ccgccaccgt gcgtccgcac 84300  
gaccccatgc tccacttctt gaaatccagc attctccctc aaaccctca aaaatcgtct 84360  
cttactctc agcagggttc catctagccc aacctgcaga cctctctcca cgcagtaggc 84420  
gacaacggct ggagttccag ctgccccctt cttccaagac agcttaaagc ttttttccc 84480  
tcctcgcacc aagttaggtc tgaataggtt ttctcgttga gatggttaaag ggtccacgat 84540  
cgtagatggc tgtagttaga atctcgattc gccatgacag cgtacaccta tacaataagg 84600  
cgcgatacga gtgtactttt cccctgatga tatttgcagg gctctatctc ctcaaacgt 84660  
gcacctggct aagcaagcag ctctatttct gccacttctt catttataaa accatattgt 84720  
ttctgggtctc acgttttgca gtcacctgc aacgacacgg tgaatgatcc cgagtctcgc 84780  
tcctccagtg ccttgacaaa cactggccca gagttaaaaa gtgaagcaaa aggcatagct 84840  
ttcgatttca gtcaccggca gtgagtggtg gacattagaa agtggttggc ccacacattc 84900  
agctgtgcac tcaagcccga ccaatatggc acgtgacat tcccctatca caacactagt 84960  
acagaaaaaa cgaaccaca cgcgaggtga cattttccag gttagagaaa tttattaagc 85020  
cggcgaatcc atctaacaaa acagcaaatg tttattcaaa gtgcctatag atttctgttt 85080  
gataaacaat aatagatagt ggagccctcg aagagtttcg ctctcgcgcc agggaacaac 85140  
ccgaaacca gagtttaaca aaggccgcgg ggggaccgt gtcgcgcggg gagggggacc 85200  
tgcccatatc aagcaaataa cgatcagtgt caaatgccca cacgtgcac cgggtgtagg 85260  
cacgatgtgg caaactgtac ggttccacgg tatttccctg aaaccacacg ttaggacccc 85320  
cggtaatcgt gaacataatt cccctgctgg tgctgcagaa aattattcca tccacgagcc 85380

Cloning of Radinovirus Genome and Methods for its Use.ST25  
atttcaaagc gtcctcgagt ctctgcacca cagacgactc agtcgtctgt ggtatcggag 85440  
gaaaccacgc ctgaaggggt ccatccaaaa cacacacgtg gtgtcccgcc ttatttggtg 85500  
gttttgaaga tagcctgatt ccctgcccg tggctgtcaa cagctcagcc tgcaattgcc 85560  
catagtaata aatctttata tgcatgtgac cccatggatc gccggcagat ggcgcagcac 85620  
acgccataag tctggcgcgc agaaggcccg aagaatacgc tgcacgtcgc tcctgcgcgt 85680  
cgtgtccatc ttgatgacct tcccataacc gtctctcttg atcacttacg gacgggtccc 85740  
aaagggcgtg aagcattccg cgcccagca tggcaaaccg catattgcgc aactcaaggc 85800  
ggagcgcgca cagcgcgga cacaccggac aagacatctc ttcggatgaa cgcaacctaa 85860  
agaccagcgc cgtgaacgga aattgatcgg tagggaattc cttatcttcc tcaaagtact 85920  
tgctctttct tacggtccc agcaggcgcc ccctggcttg acacagcctg ctccctccag 85980  
acggcagtgg gatgtgtctt aactcacagt aggcatac gtgttgaccg tcgcgttgat 86040  
aatcataatt gggaaacgac ggtggtgtag ctgccaacac cagcctcgtc ttttgctcgt 86100  
ctgccccaaa caggcccggtg tacagaccac tatcggtttt gaacgtcagc cattccttga 86160  
gggccaatgcc ataacgagat gggcccttc tcgattcccc agcggccatg attcagtcgg 86220  
caacgtttaa aacctatgta aagtttcagt tcaatttaaa atgacacaac tccgccccatg 86280  
ctgtgacaaa cataaagaaa gtggcacacg tgtgcgcttt ggccgtcctg tcagatgaac 86340  
cccgcggta acatttactt cctcccatc ggtgcgaggg tagatacaga tgtgcttccc 86400  
gttggtcccg aagcaccgac acccgctcca gacgggtccct cgtccccgct gtcacttccc 86460  
gcggcaccgt tgctgacatc atctgacaca tcatcattgc acacgtagcg aagtttcagg 86520  
gcaatgggag catcccatgt attttcggac tgagtagacg ggcacatgaa aatccacgca 86580  
cagtcacgcg gcgggacatc tcctggagtt ggcgatctcg ccagctccct caaataatgc 86640  
aagagatcga acgcctggag cggctgcgaa ggccgcagct catagtaatt ttcagaatag 86700  
ttggtcaatg ccgtcatggt gcgttcttcc aggtttttca cacagattcc agactccgtc 86760  
ataacacaga tcaaacctct ctgcgatgtt ttctgcaggg cctgcaaate tgccttgcca 86820  
aactcgcagg gaatacaactg ggacgacggc aagaacacg tcaatggatt atcggcacaa 86880  
cacaggtgtc cgggacgttt gggatcagga agccacata tacgcacacc cgagccggct 86940  
cgcaaaattt gaactccgac gttctctcca aagtaaaaaa aggatacctc aacagcccct 87000  
agcacagggt gcgcagaaga gtcctggagt cgtttggatt tccgtttata aacggagact 87060  
ctcagtggcg ccttagccct cggccgcccgt gtcctctcga aaacatcctc tcgaacgcaa 87120  
ctgccccatg aacagctatg caacgatgtg gtcgcgatga ggttacacag atcgagccc 87180  
accgtaacct caggaagcaa ttgaaagagt ctgtatcttt ccccagagac gcccccgcc 87240  
ttgctcggcg gtgtcagctc cctcaaatac ctgtgagatc tcaactgcata taacatccta 87300  
atcttcttaa atctctgggc atgtgaaccg gtttgacaca cgccacgcgc tgagcaaaaa 87360  
tcgtcaata tcttgttata atcttcatcg acgcgactgt cgggtgcaccg gttccacggg 87420  
acacgtataa tggctctgtc ctgcgtatcc cattccactc cggggtatcg cttagactcc 87480

## Cloning of Radinivirus Genome and Methods for its Use. ST25

acggcctcga tgaaccaagc ttttaaatcc atatcgcggt ccgcatctc gcgtattcaa 87540  
 tacctctgac cgagcggctc agttaaataa ccgagccccc agaaccacag gcctccgtaa 87600  
 caaaaaggat ctagatctga aagaagccta actatatacg cccacgggaa aactctgtaa 87660  
 caaatgaaaa aaatgttctc agaaaacgaa gagagaaaaa ctgacgacac gcaatctagt 87720  
 caaaccagaa cctaaaggcc gtcaactgacc catatctttc cccttcccga gcgagtgcgg 87780  
 tttctcacat gccgtgagca aacgaaaacg ctacacataa taagacacgt gtgagaggaa 87840  
 aactttattg cagggacagc gcaaaagcaa gctgtgcacg gtaacagtat gtgtcactgg 87900  
 gccgcatccc cgacgcccc ccacagacac tcgtgccaaa tttgaatgga caggggggatt 87960  
 gtgggacacg gctcgccttc cggagtggga acgcctccta ggtggagaga cgcataggcg 88020  
 gctggaaatc gcgttccgtg tggcggggtg gctgacaccg cactcagata ttgggcgagc 88080  
 gaaaacacgc gcagaactcg cgcgttggtt attatatcca ccggtccag cgaacctccg 88140  
 ttaccagca ggaaggctgg aacgtgaccc atataccgaa tgtaaatccc agaccctct 88200  
 gcgtaaatca tcaaccgcg tatgatctcc tccccagcc acttagcat gctcgtctgg 88260  
 tgaggaaaca tatcctgtgg ggtatgcggc aacagggcct gttccggccg aatgcccgca 88320  
 caaacgtgtc cttgcagtgg tcgctttggc gccggcaaca ggcgaacgcc gttgggcgac 88380  
 ccgacctcca tgttcccaac caaccgcca tagtaataaa caaccagccg tagcatcaa 88440  
 cactgctccc cgtcgcctcc cacggcgctc tcgtactcca tcccggcacc gagataccgg 88500  
 aatctggcgg ttacctcggt gcgtacgtcc aggagcatgc cgccggtggc atccgcttcg 88560  
 ttacagagcg ggcaagatcg tacaagatc ggcaacagcg gaataacgcg gcacctgtta 88620  
 ggcgccggcg ccgacaggtt ctctcagtg gatacatctt cgacggtctg actgtggcgt 88680  
 atagcgctgg ccaaccagtt cttacattcc ctgacgtca atcgtctgtt accggtctgc 88740  
 cgtatgcctt taaattgaca atagtccaga tacatgtttc tctcatctc agagacgcca 88800  
 cccgcgccct taaatgatt ccaaggtaaa cgaaccagag tcttttctc atccagccaa 88860  
 tgcatccag gatgcttacc attatcgcaa caatcgagca accatgccct caggccagac 88920  
 ggccggttta cgcggatcga ccctgccgt ccttcgcca tctctgaggg tccgctcgca 88980  
 taaactggct taaaaatcta tcccccccg tgcacctgta ctttacagtc acaccttcgg 89040  
 gcacacgccc tagggctggc agggacggca cccagcagct atttcatct ctagcgccgc 89100  
 ctactagcgg aaatctgcgg tctacaaaat ccaccgagcc gccgaatgt caccatgagt 89160  
 caattcatcc tgacagatca ccaaagtac agggacctgg ggtcttttac tggagccagg 89220  
 gcgaccccca aggtaaagag tgactgcgtt gctgggaaca gtgtcgccgg gaacgggtga 89280  
 ccgggcgagt ctgcgcagta gaccataac atagaagatt tgagatttga cagaggatcg 89340  
 cacagccggt tgtgcgtggt tccctctgc gtcgttcctt gcgcagcgaa ccgtgtgcct 89400  
 ggttctgtta tccacataca tcccagctc attgccatgc aaaaagacgc cctcctcaca 89460  
 cccgtttata atctcacaca cgtttctct ctgctccggc gttagcggcc catccaactg 89520  
 aggttttga agccacatct tatacgctgt cccatagaaa cactcgtgac ccggtttggg 89580

Cloning of Radinovirus Genome and Methods for its Use.ST25

gtcttggcgc ttatgcaatc gtacctctct acggtcctgg gacgtgtgtt ccgctaccag 89640

cgacccaaaa taaaaaactc gtatacgtag ccgccaaaat ggagtgatct ggtctggatg 89700

cggtggtgca accgtcgcca acctggcggc cctggcatat acggaccgcg ccgcaccgtc 89760

agcctccgcc ggagcgggag gaggcagggg cgtccctggc tcaagcccat ggacgcaggc 89820

cgctcttaag taatttagga cggctcctga atgactatct aagatgcagg cataacacag 89880

cggtaccacg gggggtctca agtaaaaaaa tctttctccg ccaaaacgcg ttgttgttgc 89940

ccgggcatcg tcctgttcaa acccagcgtt ttcccgaagc acccttagca gtcttttccg 90000

gcactccgac acgttgtgtc ggcgtccaca ttccagatcc ctatccaggc agtacgcaac 90060

cacagggttc atgccactca tacctcgggt ccatgatatc ctaaagctcc tcttttcctc 90120

gtcgcaccaa cacaagtgtt cgggaaacgt gttcgttcc aaattggaaa taatccatct 90180

tcgcaggtga ttgtgagtga tttctatctc ggtcattgtg aacttgggtc acgaaaacta 90240

actcaaaagc cctcaccact cccctaaact gtagctgaat tttatgtcca ccttataggg 90300

tgcacgtgta cgtatatgcc ccgtgaaaac ctcgcacttc ctcataaatt atccccaag 90360

cgtttcgggt cgctcaccta aactaactcg agcattacac gggtcatagt gtcccgggtt 90420

tcgccactcc cccaccgca cagagaaacg aaacgttcaa tttaaagggc accaagctca 90480

actttattta aggagaaaaa aaccaccgcc atcagaaggt ttccgcaggc acacaccccc 90540

aagactattc ttggcgagtt cgcggcacgc tgtagttttt ttctgattat ttgtaattcg 90600

catccaatcg ccccaaacat agtcaataaa aaaaccgtaa acacacacac tctggtgaac 90660

aaattatgag ttcctggccc caagacgtgc gtgagcgtca gcagcacagc ggctgctaaa 90720

acataaacca gggctaaaac gtttgaccga aacacgagtc cgaggcaaca aaaaagccca 90780

acgtggaaga caaaaaata gtgtacaagt ccgaggagca gaggcgtcgt caggccaaca 90840

gacagcgtag ccgcggccgc ccctccaatc aaaacagtca cgagataaaa gtcccatcca 90900

cacacctcaa gcgcttgctt tatagagtat gtgatgtacc gcctagaggt gagcgaaaaa 90960

attgcatggc gtcgctgcag gcccgctca taaagcggat gtgaccgcag cgctctgagt 91020

gaacaaacgc cacctactat aaaggccacc aggggcagca aaaacaccg ggctaaaaaa 91080

aggttcttaa gaactaaaaa ataatacacc gagaacgctg ctaaaaatcc aagttcgtag 91140

tatctgtggg caatcgtggg gcacaaatat accacgtcat tcgccgcaac aacacagagc 91200

agcaggcaca ggcacgaccc cacaaaaatg gaaacgtgaa cccatggaag gtcaacgccg 91260

aggttgatg ccatagaacc ggcggttaata agaaacgccg agatggtgca cggtagatcc 91320

acctgcgcg agagccaggc cggtagccca aatatacaga atagcaaaag cagcccatgt 91380

aagccaaccg cgccccagga gaatataatg ttctcaacgc taatcagggg ctctacaaaa 91440

tacagcgagt gataaataaa acacagaata aacggggaag ccgagaccgt cccgctcata 91500

aaagatagcc aggcgagggg cgctccgac gtgtacgtgc ccatggcgcg gcgtttaaaa 91560

caacgggttg aacgtcgcgc gaggcgtctt ggtttttcct ttcccgcgac tgggtgagct 91620

gctgtgtttt cgcttgccgt gtttttttcc cggtcgagag ccgctcgtcc gcagtgattt 91680

Cloning of Radinivirus Genome and Methods for its Use. ST25

ggcgcccccg tctgtcggct cggcaccgtc ctcggcaatt gggacgcact gctcttttaa 91740

gtccagggtca ggcgttctcg gaggggacgg gagctcagga accccctcgg gatcggcacc 91800

ttccgagaga ttgcccgga cggcattatt cgggtccgtc ggatctacct ttaatagcat 91860

gacgccaac ctgacgtcag caaggctatc tgtcagcggc aggccctcaa cttccagaat 91920

ctcattggcg tgccagcgga aaccaggcaa aaaaaatccc ggaatcttac atgcgttcaa 91980

tgcgggccacc agagactcta aactcacatg agtcgtcagg tcgctagaaa ccacaccac 92040

gtccagcttt cttctctag cgcaagtcca cttggcgtcc ggggtgtcgg gtttaaaatc 92100

aataatttta ctaaccccg cgaccgtaaa cgtggcaact gccagcgttt cgcttaacga 92160

gacggtgacc acctgcttgg ccctggtttt ctgctgcctt agccacttta acaacaaagt 92220

cagcgtctta accgtaagga acaggcgatt ccccgctccg gcctgtctta gcctgtcgtg 92280

gaacgagggt aggttgggtt cgtccacgac gctcttgtgc acggtgtcgt tgtgattgtc 92340

cccgtaggcg atggtcgtcc taacaaactg cggctttcct tccgcgtccg actcgtcccc 92400

gtggtggtag aacgccacgt tcatttccgc aatgttaact ccaacatct caccgggtgtg 92460

tgtgaacgtg ttcccaaggg aggtgtttcg aaagctaaag ctaacctcgt ccgtcatgtc 92520

agaatatacc atcagcggcg ccagtgcatt tttaagcctg agaccgagaa cgcccgcgtc 92580

ccccacgtg gagagcacgc taaggacggg ggccctgccc tggccgctga tctgtataac 92640

gcctttctta acgatgccct taatgtggtc gtaaaccctg ctaatgctgc caagcgcac 92700

gacgtccacc ctggcgccgt aatgaaacga gacaggcatg gctaaggcga aattaacacc 92760

ctaaaagacg agaagagaat ggcaaacacg acagacacag cgttcaatgt tcaacctttt 92820

aatagagcct ctggcccga aaatgagtaa catgggacac atggggacta cagatcatta 92880

tgaacggatg tgacatattc agaattatca cgctcaaaaa agttcacact cttggcactc 92940

gtatacgaca agggacacgc gtttggggg cgggcaccga acaggggagg tatgtttatt 93000

gactttagaa tcctgtcggc cgtggcctgc aaaaactgct cgatgtctcc gacgttcacc 93060

atggtcacgt ctcggctctt ggaacgaata aacagagtct ctatctccac ggcttcgcga 93120

aagaggccgt ggatgtatgc gacggagggg gattcgtctc gggagatcat ggtgtgtac 93180

agcaagctgg cgccctggt gtgtagcagc tcgtccctgg agatgtagtc gttagccagg 93240

cacacccgc gcatgattcc gcgaaggcga aaaagtccta tagagtaaaa tgaacttata 93300

aagtatatcc cttcgataac caggaaacgc agcaccttct cggcccgct ggtggccttg 93360

cgcactcggg aatgcagcca gtcaatcttc ttcgccaggg tagcgtctc gactattttt 93420

ttggcataaa tcattaagtc cccccgatta ccgcaaaaa ataagttcag tatgttggca 93480

tacactttgc cgtggatgtt ttccatggct acctgttcgg cgtaatagt ggtcacgtcg 93540

tgattgctga actctttaac taggtcttcg atgttaaagt ttaccagact ctctgccata 93600

cccaaaatg tgaagagaaa ctggtaaaac tccctatcgg tgggactcaa tagtcgcacc 93660

tcacggaggt cctcgtgcag ggaaatttga ctggggaacc atctgttctg ccagtctcc 93720

tgggtgagtg ctaaaaagcc aggggtggtc ctcgcgtaca gaaaccgatc tggggactcc 93780

Cloning of Radinovirus Genome and Methods for its Use. ST25

```

atggcgcgcg ttactattga caggccaaac ataccttggc ccgctcaccg tcggcctttt 93840
gtacgcagtt agactccgcc ccctctgaag agatgttgtc acccacgacc tgatctaagc 93900
actgcagggc attaagtttt gtctgtttct gaattcgaca ataatacagc atgggttttta 93960
accctagcct gtatccggtc aggagcaagt ctcgaatata actcgcccgc gtggcctgct 94020
cctcctttta aaagaaatta agcgactgac tctggtctac aaatggagcc cgcgcaccgg 94080
cccgtccaa ctgcttaatt gggcagtaat caaaggccgt caaaaaaatc ttgtatctgt 94140
ccttcagggg ttctggaaat gaagccacgt cacctccgta acggcgacc gttcgcagg 94200
caccaggcct cactctctta aaaaaagtca cgtttggtt caagatctct tctttgctgg 94260
tgaccttcca tgcgatattg gcaaagaacg gataaaatgc ttcggtgtac cccgtaagct 94320
gagaggttcc ggccgttgcc atcagcgcca aaaactggct gttgaaaatt ccatgctggg 94380
caatgctgcg cccagctgc tcccatctct ccaaggagg gtgggacggc ttaacgccgt 94440
cccagctttg ccagtgaac acaccctgag ccaatcgact ccgctcccat ccacgaaacg 94500
gagtccctc gccgagtaaa acaatctcat gactggttg caccgccgta aaatacattg 94560
cctgaaaaat ctccacgtcc agcttggcgc tctcggcgtc aaggtagcca aagcccagtt 94620
cggcaaacac gtcggccagt ccttgacgc caatgccat tgatcgttcc tctggccgc 94680
gcctaacgct ctcggtaggc gccgtcccgc ccaaaatgca cgcattgaca atgataactg 94740
cggcctccac ggcatcatcg agcagttcaa aacaaatgt tacatcccc tcccaggct 94800
ccacaccaga ctctcccctg tgggtctga ggcactttg taggctaag tttgccaagt 94860
tacacacgga agcctgaccc tcgggttgct gcacgatttc cgcacagaga ttagaacagt 94920
ttatggcgct gccttgctc tcacaccagt ggtgtttgt gagcgctcc tttagcagga 94980
cgtagggact gccgtctta atgacagtgt taataagggc atacatcatc gattttaacg 95040
gcaacgagct agagtgttg ccagcgcca ctagtctgtt gtattcaatc tcaaattcgg 95100
caccgtagag ttttaggaga tttggcgcca cctctggcgc aaacagggtc cactggccat 95160
ctgggtttgt ttcgtacagt cggaaaaaaa gctccggcac acacacgcc tgaaacagg 95220
tgtgacaccg ctctgattc tccggcatct tcgcttcaa aaaatcaca atctgatgat 95280
gccatagttc catgtaggcg ctggcaccaa caggacggat attgttatcg ttgaaatacc 95340
caacgtgggc gtttattaat tttaaacagc tggatgatt cttgtgttcc gcaaaagacg 95400
agacatctat cccacgcct gacttgctag cgagaagggg ggacatttcc tcatgaagt 95460
ctttgagggt tttgtcttc gtcgccatgg acggctttta aataaaacag ctagaagct 95520
gacctccgcg aagcccggt gaccttaata caggcggtgc gcagcacaca atctgtgacg 95580
agatgtaatg gaacgcgtaa ccaaccagg acatctcatc cagctccgtt tcgctctcca 95640
ccagggtgtc gaggtgtcc cgcaaacacg gaaatttat acactgacag gccacaaaa 95700
cagccaccct cataaacatc tggccacgc tttcaaaaat gggatgaaga ccctgggttc 95760
tcagcacgta cgtatcgtaa aacctaacg cagacaggta gccgcagtta acgaaatttg 95820
tgtatgcctt gctctgtta aagtctgtta aaagaccgtc aagggccgct tcgtgttttg 95880

```

Cloning of Radinovirus Genome and Methods for its Use. ST25

acataaacgc gcgaacctcg tcgcttagcc tttccccgaa taccgcgaga tagtctcgca 95940

ccgtaaccag gcacctgtcc tccattattc tgtgccaaag gagaccggtt agtgagttgg 96000

cctctatgtc ccatccaagt gttgccttta aagaattcac gagtgattcg gcgcatcggt 96060

caggggtcaag gcttgagcta cccccccag ttcccgcgtc ggtaactagg gttaaagggt 96120

tggcagattht tgccgcagag aaagaagttt cgggtgtcat tgtaaagaa atagcttcca 96180

agaccccgga ttggaacaa actccgtaaa ttttaacacc ggtaaagcag cgcctttaaa 96240

gtgaaggctt tgaaaagatg gttgtaaac ggaaggcacg cttccaagtc tgcaaacac 96300

gccgaacgca agcctattta tatacaggtc attctgcagc tgaatgtatt tgggtgcgaat 96360

cacgccgctg taaaaatccc tcaattgggc agctatttca caatatcctt taccagactt 96420

aaaaaaccca agtcctagcg ccggtctatt atttacccta atgtagggtta agcaaacata 96480

aatagacgag tgggcgggca aaggctcgtc gcgcaggctg gacgggcacg agtcacttaa 96540

atccacaaac atgtcactag gaagcgtaag gccaatatgt gtaacaacgg gctctctggc 96600

gactacgttg ccctttaacg cagacgtcac cttggtgaca aacgtactgt ggaccgtttg 96660

aaccaacggc ccgaccggcg caagaaactg atgaagcgag ccggtttcca acaattcttc 96720

aaaattgggt atggcgtaaa gtagaccgct ctcgtggccg taccaaacac acgctattct 96780

gttggtcttg ggggcagagt ccgcgtccat cctagacagt cgcgccagcg acgtaggcgt 96840

gaataacatg tcaatggagg acccagtgtc agtctgttta aaggaaaaca ggtaggtgcc 96900

ccgaggttcc tgtgaactca tggcttgaga ataaatcaaa aaatctccat acgtttgaca 96960

tgtaggcgag acagataaaa atccatcttt gatggcctcc accccagtgg tggctcgacac 97020

cacatattta gagagcagat cacgaacacc cttagaaaag tcgcgaccgc gagataacga 97080

aaccgggtga ggagcgggcg gcagtagacg catcaaaacta tcattcagct tgttcacgtt 97140

tgcgtccctg gtcttcatgg cgtcgtcaat tcctgccgca cgggctgata acgggtgacga 97200

gaacaccggc gggctttaca aattaactga caacctccta acgtgcaccg gatcgctaca 97260

acagcttaaa ctctgatgg agttccaact aaaaccacta ccaaccgcac accttttaag 97320

catgccacc gtgaccgggt ttttaaatat tgcattcaaa atagacaacc ccctggtttc 97380

atttattcaa aaacaccctg tgtttttttt aatgagagtc gccaggcttc cggagccagt 97440

cattacagac caccaaagcg cagaaacgtc aacaggcata ctatccgagg ttgtgaatgt 97500

tcttaataca gctattcgaa aaccacacga gtccccagcg gctaaagaca acgattatct 97560

cgacaaccgt gccatattgg ccatgattac agaatacatc catcacgtaa cttcacgtac 97620

gccctcgggg atcccaccga caccaccaat gggatatcagc catctaccgt gcgtagagca 97680

aattttacac gaaaccaccc ggcaataactg gaacctaacct ctcccgaggt cgctatttat 97740

cgacatcggc gaagtcgcgt ctccgcttca gacgtggcta atcctatcgt attgtaaaaa 97800

actgcaactg gcaccaccgc ccctattccc acctgtcgac gaactggccc gtcgtctggt 97860

taccggccac cacgaattgt ttgtccccct atcgacgtca ctggaaacgt acatcaccat 97920

gccagtatca aaacagcgag cgtttgagat atacagcgtc tttgccaat caaaaaacat 97980

## Cloning of Radinovirus Genome and Methods for its Use. ST25

agttgacggc acaccaattt tagcgttcac cgacacagaa cttacaacgt tcacccccga 98040  
 actgttattc ctgtacgact tcgtaatcga gtccctgtgc aaaaaccagg catacgggtg 98100  
 ttcgcgcaac gcaattgagc attttattaa gaaaggatc gattttatgg cggagtggg 98160  
 ggcgttcatt gaaaaaacgt gtggctatcg atcaaccgta agcctgtcca acgtgagagc 98220  
 cgtaaaggcc aggctcgcga gctgtggcct atccaaagag gcgtgtgaag atttccgcgc 98280  
 aatgatactg atgacaccgc acgagacgac gccaaagtgg gaaaatttta cggacttttt 98340  
 agaaatggta aaccaattaa cactatacgg gttctatttt tacgagtgtc ttaaccagta 98400  
 cagccccact agcatatcgc tggccaaaat tcaaatatc ttaaaccgag tcgatgccga 98460  
 acagagcgat cgcgcctgt ggcgcactcc attaatcggg tctttcccg tcccctggaa 98520  
 attgaacaac gtgctggcgt tttttaagcc tagcaccgcc gtggcaacgc taaaaaaat 98580  
 ctacaaggca ataccgtcgt acctaatgag gtctttgttc gaaatagcgg ccaacaaatc 98640  
 gtggggtaac atcgcgctcg cagagagcgc ccgctaacc gacatacaga ccgccgaacc 98700  
 agaccagggt cccgtgtccg cccaggttat cgcaaaatat tgcagccgtc tccaaataag 98760  
 cgcgacagat tatgacgcag ccatcgtctc cagcccggga ttcgccgcg agttcattaa 98820  
 aaaaaactg tatccgatcc ttagcgagggt gctccgaaac acgtccaaaa aaaatcgatc 98880  
 gctattccaa attagatggc tcatagtctt cgcggcagag gacgccagag acctagcccc 98940  
 tatcagacgc tcgctggccc tggcgtattt tcaataatg gacattttgg aagaaaagca 99000  
 ttctccggag tcgttttaca acctgctgga ctatcttcag gaaacattta ggtgcatacg 99060  
 acaggtgata ccggaagcca cgtgccaca agaatttcta caatacttgt ttacttttca 99120  
 aaacattcca atagcagcga gcttcattca aacatccatg acctttgtag acgacctgaa 99180  
 aaacggcatc cccggtatcc tggacctgt ctccttaggt gccgcgtttt ataacatgaa 99240  
 actactgtac gattcaacgc tagacaccgt cgagattcca acggaagaag ggcaaccat 99300  
 cgtcgtgagc atgttcgtat tcaaatccac gattcgcgtc ctcgagaagc tcttacagga 99360  
 agccgttatc gcgttaactc aaacgtccga accgatgtac gcagcgcaca tccgtctgat 99420  
 gcaacacctc acgtacatgc aaaagatcgc cggacacgaa ataataacca cacaacttcc 99480  
 atccgtgttt cacgaaatac acgagggata tttgcagtgt ttaagcgtt ttaaacgtct 99540  
 catgttacac gttacgggaa gctgtgtgta ctactgacg cgatactttg gattcctata 99600  
 tcaaccccc ctaatacccg ataccatcgt acaaaaaatt ttaacttta acgacaaaac 99660  
 ggacacaacc gacgacatct taaagagcct gtcacagccc gtgagacaag gacctctatc 99720  
 ggctgaaaac gaaagtagca gtcgactctc aaaaaacaac gttgagctgc ttcaaaaact 99780  
 gtacgacgac tttcggaccg cctccacaaa caataacccc acctctatta aacttgaata 99840  
 ttcgggtaat tataacgaaa cacaagtgtc cgtagattgg agcacatata acctggtgac 99900  
 atacaccgca cccgacgata cgttaaaatt caccgccgtt aacacggagg cactagatcg 99960  
 catgtttgca gaataaacga tgggaattgcc gccaatTTTT tcgaaattta aaatagaggg 100020  
 cgtggcaacg acgcaccagg ccgactgcag gttcggacaa tacgccggct cgcagtgcct 100080

Cloning of Radinovirus Genome and Methods for its Use.ST25  
aagcaactgc gttatctacc tcgcacaaag ttatttcaat agagagtccc ccgtgacgga 100140  
cactaacgac ctgcagcagc ttttacggca aggggcgacg ttggacttta tactgagacg 100200  
gtccgggacg ctcggtata accaatatgc ccaactgcac cacataccca gctttatcaa 100260  
gaccaacgag tggaccgcg ccatctttca atctcaggag tactttggac taattggact 100320  
tgacgcggcc atccgcgaac ctttcatcga atccctaaaa tcgatcctaa cgcgaaatta 100380  
cgccggcacc gttcaatact ttctgtttat atgcggcgac aaagccgggg ccgtaattat 100440  
caaaaacaaa acgttttacc tgttcgatcc ccattgcgta cccacgtac caaatagtcc 100500  
ggcacacgta atcagttcgt cagacccac cgccatacta gactacgtgt caccgccaga 100560  
cagagaatac actggcagtt ttctatacat tatgccagc gaatatgtca atccagagca 100620  
ctacatcacc aaccactata gaactataac gttcgccaaa gtacacggcc cgcacataga 100680  
tatatccacc ggcatagagc cgtgcacat cgaagacatc ccaagccgc cgcgatcgcc 100740  
ggatgtgacg tcaaatcat ccaacctgc acgctgccc agaaccacca ccgacacgtc 100800  
gagcgccaaa cccccaccg cgacgtatc cggtttacg ggcgcggaac caccgacaag 100860  
ctaccagac ccggcaacca acgacgga caaaaactc ttaactccg ctccagcgca 100920  
aaccgcgctc gaccacccg aattccaaac aacacctgga gccacgtac ttctttcaga 100980  
actgtcggca tccaggggtc ggaaacgcaa gctttccagc cttcagcgat attcggattc 101040  
cgacgaagcg tcgtctgacg acgaagggc ccacgtagg cgcgtacacg acgatcgat 101100  
atccgcgag gtgatctgga tggacgacga tatatctcct ctatattcac cgtcggcgac 101160  
tccatcgttt gacgagctgt tcgacagccc ccaatgagc ccggagtta catacgaaga 101220  
cgcgacagag gacacggatg gcgcgtttct agaacagatc gtcgagacg cggaacgcc 101280  
gttctctgcg ttcgacgacc ttataacgga ccacgacttt tcttcccttg ataaaaaat 101340  
agaacagtta atcaagtacg aagcgccctc gcagcacctg ccaaacatct cggacaaaca 101400  
aaacggcgga gccgtccgag aagcgggcg cctccaggcg atggacaaaa ttatgattaa 101460  
tatcatactt gaacacggtc taattacaga cgcgcaggcc cggggaccgt ccgcgtgca 101520  
aaacgttctt caatttttca tcctgtggg agaaaaactc aacataccaa taagcgacgc 101580  
caagcaggtc ctagaactcg atctgcaact gataccgtta catacggcta tcagcgaagg 101640  
aaaattcaaa cagggggcgt tcaaaaaaca cctaacaact aaaatcaacc ggtgtctggc 101700  
gtcaatgagg gccacgcacg cagatgcgca aaaaaactg gcgtcggctt tcaacgtcga 101760  
aggctcacag atttcgtcca gcgaagcgaa aatatcagtc cggcgctga aggaacagat 101820  
cgccaaccac ctgagtccag gctttttagc ggtctactcc gcggacgag taaaacatct 101880  
acgggataaa attcaggacc taaaaacagg catcgagcag cgcaacaaag aaatccaaca 101940  
ggaagaactg ttttttgatg ccatgtcac agccctggac acgttccaac cccctccga 102000  
aacggcattt ccaatggaga tctttccgca ccgtaaaacc gaagtatatgc tcgaccacct 102060  
ggcgccata accaccaggt taaccgagga cgccaccgaa gccctcaaca attacctgga 102120  
gaccccgccc gaccaaggaa cgcacattac caacattcca aacttttcat ccatcgtggc 102180

## Cloning of Radinovirus Genome and Methods for its Use.ST25

aaatatcata tccacgttaa aaatcctaac gtacgcagaa aacgacatgc aattaaacgt 102240  
 aacgcccattg gcaacgtaca ggcgtcagct gttgtacctc ggaggcgagt tagcaaccat 102300  
 ctttaattta gagtggccat acgaaaccgt gccaccggtt caagaactgc ccctcgtggc 102360  
 gcgggcgaaa gcaaaaatgg aatcggtaac aaaaatggaa aagaaccaac aggtctctga 102420  
 ccaataactg ggagacgccg aaacgttact tgacacaata accgcaacat ccggagatga 102480  
 gaaccgggtc cgcgccatgt ccataccgat actggagacc tacattacaa acgcaggcgc 102540  
 cctgataggc agttctcgaa accagcgggt cgaaaaactc aaggccgcca tccacgacct 102600  
 ggcatcatcg gagtctgtta taataatgct gctaaacaac acgcggctcg ataacatatc 102660  
 agacaatctg gccaagatcg acggcatcct gaccaacaac acacgttttc tttcaaacgc 102720  
 cactgttagc aaaacgctcc aaacgtggg aggcagccta atacgcgaat gcgtagaagc 102780  
 gctaaataaa aggagcccct cttccctcaa caacgcgcgt ctctctcgcg ttcaaaccat 102840  
 actggggcac gcgtccgttc cagatcacga gacgtgacg cgaatcggtt ccggcgtcgc 102900  
 cagcgcacaa aaggaatccg ctggcgatga tccagatagg tggacgcgag taaccgggtca 102960  
 cctaaacgag ctgaagctcg taactacca atcgcgtgtc gacaaagcca ccaggcgcaa 103020  
 actgttaatg ataataaccc gtgacctcaa ggaggcggag gtgtctcagg aaacggtcct 103080  
 ggaaacacgg tggcaagaaa acgtgctaaa gtttcaaccg tcgacgtcca aagaaatcga 103140  
 agacttttta cagtcggcac cgtcagcaaa ggcccga aaa ttcgcagaaa aacacctacg 103200  
 gacgtgatc acccaattca acggccacga gcgaccgccg tccgaggcca ccgccgttcc 103260  
 catggactac acgccgacgc ccataccac gccacaggcc gtttctacgg ctaccgcgga 103320  
 aaagggaaag gccgcatgga ataaaattca acaggccttt caggatttca actttcacct 103380  
 catcgacgct tcggattggc aagagatggc atcagaatac tccagacacg gctcgtccct 103440  
 tcttggtacg gttggaccaa agctggtgcg cttcatggag agcatctcaa acaccctgga 103500  
 cgacatctc acgcagaagc tggcatctct gcttccaaac gggcccgcgt tcagaccccc 103560  
 agcgtttgac tggatcgcg cctatcaaac acgcgtaaac gcgtttctaa aaaccatagg 103620  
 cctgccatg gtgcgcaacc tggcggaaca gatccatcac caatgccaaa ctgtcagtca 103680  
 cgcggtgcaa tccgcagacc ttcaacaggc cacggtggga acaagttag aacgaccgcg 103740  
 ggccgaatac tgtcgaatac tctctgacat gcaagtcgcg ttcaacgacc acggaatcgc 103800  
 cgtaagatcg gaggccgcgg cgtacacgga cgcaatcaac tcgccggcca acgtcgtgac 103860  
 tccccgaaa cccaacctag aagcccccaa gaagctaata acggcaactg acgccctaac 103920  
 cgtcaggagc tttccagatt tcctaaaaac gtcaatcctt caacaggagc agcgactcat 103980  
 tgcgctccag agagcggaat ttacgcaact agaggccagc atctcggcgg ccgaacggct 104040  
 ccgccaatcc acccgtgacg agatcgacg caagatggca accgctatca cgcaactctt 104100  
 accccgcgcc ccgctcgcaa tatcatcgag accgttgaa ttatcaaaac ctatagactt 104160  
 tttgagttca acggtatacg acaaaatcct ggacaaggag ccttacgaga cagccatagc 104220  
 gggattcgcg tggctgga aa tcgcgacaaa atccgtaatg gtctacagtc aacaaaacga 104280

## Cloning of Radinovirus Genome and Methods for its Use.ST25

aacgcaacag ttaaactgtac tgctgagcga ggtagaaaaa cagagcaccg tcgcgagcgc 104340  
tctacacgat ttggaactgt cggcgaaaaa cacggacgac gtaaaggtgc tgaagcaggc 104400  
gctagacgaa ctcgcccc tcagggtaaa gggcgaaaaa accaccgtag acgctggaa 104460  
acaaaaactg gaaagcatag aatccctgct tcgcgccacg aggacggcag gcgaaatatt 104520  
atcggagctt gaacgcacg gcacacaggc ggttggcacc atcaccgtcc gcgatttagg 104580  
aacgctctcc gatcaatgcc gggaagccgc aaatttcctc agacaggcca gtctacccga 104640  
aggcttctcg gacataggca caaaactcag cgagcttcag gcgtacatta agtacaaaaa 104700  
acagtttctg gagcattttg aaacaaccca gcctaacgtc tttcaacgct tcccgtatc 104760  
cåaaaacata accgaaaacg ttccggcgcg cccggcgatg gactcgttg ccagactgac 104820  
caatcacctt cagtgcgcg gcagcgcgcc ccactttaca acgtggatag aaacgctacc 104880  
gaccgtcgat ccgaaaaaac caactcacgt cccggcgcac ggaggagccc ctctgcaccg 104940  
ccagatcacg tactcaaacg tcctagaggc gttgttttca ttatgttcca ccacgctaac 105000  
cccgttccg acggcccccg gtctggaaat cgcaaccagg gcacggcgcg gggcagaggc 105060  
cgcaacgtgg atggacagac agtgggccga catcgctcag acgtccaag acgttctcga 105120  
cacgtacgaa cacaccaccg cccacgcaaa cggggacgcg gcatttaaca cattcttggc 105180  
gatgtgcgtt ttacgcaaa tcatcagggg cgctagcaga gccgtgacgc tccgaagtt 105240  
accgagcacc gccgtcgatt ttccagaaga gatcgttcta acaccaggg aatgcacaac 105300  
actggtcacc gccatgtggc ccaccctggc ggccgcaatc ttacgattaa aatcctactc 105360  
ggaagcccta ggactaatga gtcgtttcct cccgctaattg ttccaggcgcg tgccgcacct 105420  
aacgctagag gcccagggtca aaaacggccc acataacacc ccgcctcagt tgagatgctt 105480  
tgccaaaaca gaggcaattc cgtattttccc ggcgcaatgg cagtcagcga acctagagca 105540  
gagcctgtgg ggacagacgg actttttgca aatctcgcat aacaatcaac gcaaggccag 105600  
ggtggcgggc gtcacctggg cgctcacgac gatagacggc gtggttttgg accaactgtg 105660  
gtccacattt aaacccatga cagccgcgtc agacgacacg tacgtcgacc tagtcgagac 105720  
cctacacctg accacctttg gcccgcgcg tccaacgccc aggcgagaaa cgaccaccga 105780  
gcaccgcgg tacgagtacg gacagcccac gggctactgc atctcgggtc aatcgacgac 105840  
gccggtccag gcttcaaaca caccggtatc cgcttcgag gcggtgctcg gagcaatggt 105900  
gtttcacgta ccgatcagaa tatttttggc ggccacgccc aagcgccttg gccaggcgcg 105960  
cggcgcatg gggctcctca caccatcct ggaatgcgtc cccgacgtcg agcccttcaa 106020  
aagcctgtat aacgcacccc gcaaaccctg gccattgaa acgctaccg catccctcca 106080  
cccgaegac gagcgacagg tctttctgag acaggcacag tggctatcct accgattcac 106140  
accacagaa gccgcccgt cgctgactcc gccgcttctg gtggtcatag accctgaaaa 106200  
cctcgtaacg gcaacgtact ccagtggcgg gcctgcaaat ttcgagagca ggccgtttta 106260  
cgtgatgccc ggaccatacc cccagactg gccaaaaacg ctgtcggtaa catcaaacac 106320  
gtccgtgacg cacctcagcc acgacgagat atgtaacctc ttactacgc tatcccgaga 106380

Cloning of Radinovirus Genome and Methods for its Use.ST25  
acacgggacc gtgcaaggca gggatatctt cgcagcggct ccgacaaacg tcacaccgga 106440  
acaaaccgcc aatcctccgg catgggaaac ggataaccga ttaataacgc aaacagaaac 106500  
cgccaaaaaa cctcatataa ttcttgcgtc tcctaaagcg cggacagatc caccggtgga 106560  
aaccacgacc caccattcac aagggaagc gtcgcaacac gcaaacagca acgtaaacca 106620  
gcccgggtcaa attacttcac acgcgtcacg taacacaccg tcaaccgcac ctcaggcctc 106680  
atcttcaccg gaaaaattca acacgcaaac ggtgcctcga ctaatatctc aaacgtcgga 106740  
aacggcccat ataaaccagc cagcctccgg ccaggtcacc gaaccaagg gaatctttgg 106800  
gacgtataaa ccccgagtgc tcaccgaacc cgccaaacc gcaaacgcg gcgtagcctc 106860  
tcgccaacca gaggaacca ccacggtccc caagttaccg attaatccac ccaccgctag 106920  
ggtctttata gggaccgct ccaaactctc gccagccgtc gaagagagcc acggcgccac 106980  
acccgacgca catcagtcga agatagatcg ggaaaaatac gccgagagtc ggctcgcgcg 107040  
caccacacac ctcgaagagg ggccacggga gcctcacgtc aacactcaa ccagcgacac 107100  
cataaacgtc ccctctagcc aaggtcaaaa aacagtacac gggcgcgaaa atcccggcct 107160  
tcaaacagca actcccagc ccccccaacc aaccgcatca aaccgcgca ttcaatacac 107220  
gtccccaga acggacggcc ggttgcttca cgacgaatcg gaggtggaat cgacccaac 107280  
cgaggaggta aaacgatcgc caaaacaca agatgtgtct cacgggcccg aaccggacga 107340  
ctccagggtg accgccccgc tcggtccaac catagagatt catcgactgg aacacccca 107400  
aatttcaaaa aatataacat cactcaccgt cccactccc agagtcaccc caatccctcc 107460  
cactaacatc tggatacccc tatcccacgt caacatcaa cacgaagaaa tcacacgagc 107520  
caagaatgtg ttaatgcgat ttattcaaaa cgtacgaaga aaacttcaag cgtcgtctga 107580  
cgctctatcc gaggetattg ccagaataaa gtttttatat ctgtaacgcg cccatctcac 107640  
ttgctttttt tattttgaga cgagcgtctt gtgtccagag tagttgcgtc gctaggtgat 107700  
aacgaagtgg accctatgcc agaagacgcc acgctcccg gtccgccgc accgggcgcg 107760  
gggcccacg agcctatcaa tgaatggggc ccgctggaga tcgtagtaaa gctatttgac 107820  
ccgagggtg aggccaccg ggcaacgctc gggcgggccg agccggaccc ggacaaaacg 107880  
cccagatac tagaactagc gtcctttttg ccgcaaggc cccggagggtg gtctttgcgc 107940  
agaattccat tcttcttttg catatacatg tcgtaatgat gtttgccgt taaaaacacc 108000  
agataattac gtttcgcgat ggcatactgg gcgggagaca tgtcaccctg gggaggttg 108060  
ttcatctcgy caaccagcgy gtgatttggg taatcgtgct caaggcgtcc ctgaacgatt 108120  
ggctccttaa ccgcaaggga cgacatctct ttttaactct attacacttt ccacaggaca 108180  
gggacgatat agacgaggtc aaataaaaca gtcggccac acgcaaatgc tttaataggc 108240  
cggtcgcgca gtccggcgac gccaaacagg gcacgacgac gctaaccagg gagttcgcgt 108300  
ctcgtatggc atgtgccgcy ttgttggcga gcacgcaccg taaataggga tctccaacac 108360  
acgtgatctc gaatagagat ataaccgca tgtcgatcc gccacaataa gagcaatata 108420  
cgcgcccggt ggtagcacag atcgaaagct gcttctctt ttggtcgcga ctgaaaaaca 108480

Cloning of Radinovirus Genome and Methods for its Use.ST25  
cgttggtggg tgggaaattt acggtttcaa atttaccctg tccgaaattc aaacagtaac 108540  
cgactcgag gcacaccacc accctcgag ctggcacggt cttctccagt acgctcctgg 108600  
ccaccacctg ggaccaaaca ggtagagaga tacacggaaa cagtacgtta tacgccaata 108660  
cttttgacc caggtcgagg gatattctcg tctcggtcga ctcccctatg ggcaacacaa 108720  
cacgggacat gctcagcagg gccctaaacg tcaggctcct cagaagggcg ttaaaccgggt 108780  
tgccgcacgg gacggtcggc gccagttctc gcagcgaggc cagaagtcct gcgtccgaag 108840  
ggcccgggac actctcattc aggttagctc ccagacgtct ggaaatggac ggaacgttca 108900  
actgcatcga gacacaaccg ccccgttcc atttcttccg caaacgggc agatccaacg 108960  
cgtgctgtgg caaacaggta accaggggaa accgctggcg acagttaagg gttttgcaca 109020  
cgagacaaca cgccctctga aacgacacaa caagatacct ggaccacgag ctcctgggaa 109080  
cggccgttaa acttaaacct tcgtcgctgg gacagccac gccggtgcag atacacctca 109140  
gcaccacgc gtacgcctct aacaacgacc ggccgatatc gtgcagccgc gatctcacgt 109200  
cgccgttttt aggtgggtta tccggcctcc agccggtagc aatctcgttc agggcggtct 109260  
gaaaggatgg ggcagaaatt aacgtgcaag ccatttttg gggtcgtccg tcccaggcac 109320  
cgagcccgta cgtcacaaaa cacacgtagc attcggggca tagtccgatt gagcgtatag 109380  
aggccgcgag atctaagccc agccgagaac catccagcca acgatgggca ggataagaac 109440  
cgcgcccatg acaggcagct tcgtcttcag ccagggttagg caagcgccc gaggccatcc 109500  
cccaattgta ccgattgaat tggtaattg gtcacgcgcg cacgctctcc gcgccaata 109560  
tccttcaact ccgacccga agggcgggcc acggagcccg ttgcctcaa cgcaccgagg 109620  
ccgtcgaggt gaccgcgcag ggcaaaaacc gttctaagaa gggtttttaa ccgttttagcg 109680  
ctctttggag tcacgaccaa aaactgtaaa acctgtcggg gtcctgtaaa gtaggtgcgg 109740  
catatgacca tggagctgta aacgttttag tctccggaga aaaccagacg tgccttaaat 109800  
ttcataaaat cgtcctggcc cagggacacg gacgagttcc tctcaagata cacgtccgaa 109860  
tttataggca ggttttttcc aaactgggca tcggcgctac gtggcttaca caaaaaacat 109920  
ttcagcgtgg tggccaaacc gttgttgata attacaaaac acggggcaaa cgggtaggcc 109980  
agtctctcta gtttgtggag ccaaaactta tacacaaact cgagatgata gacgcagccg 110040  
tgctgcaggc gcacggtgca cacggggacc gccccgcctt tagcgtatac gggagccccg 110100  
tcctgacacc tctccaagtc cagggagatt ccagagggtc ccaggtaga gacaactaaa 110160  
tcgcacagct cgtcaactaa acgttttccg gaactcatcg ttataaagat ccttttaggtg 110220  
ctgtgcgtgg ctcccgtaaa aaccgcgtcc gtgctaacga tttgtgaat gacctgtttt 110280  
acggcgttta ccttggcgtc caggaccatg cagtgtcac agtgagctga ccgctctga 110340  
gcacgatgac agaggaaagt ttttaatac tgacagtagt taatggcggt gagcctggaa 110400  
tatatggtgg gaaacataat tttcatgtca tcgggcagca gggactcgaa cgccaataaa 110460  
tcgtcaccga acatcacgtg agacagaggt aaaagatgct caccgccggt accgcgtaac 110520  
acgcgaccag ccacccttc aaatatttta gccttaaaaa gcgggcccc taaagtcgtc 110580

Cloning of Radinovirus Genome and Methods for its Use.ST25  
caactcagct taaaaactcc tacccattat gttcgtcccg tggcaactgg agaccctcat 110640  
gagacactgg ccctctctgc ggggactcgt agaacaatcc ttcctccccg gtaccccgga 110700  
cggagctttt aacagcccgg tattaatcca cactcaggac tctctacaac ccgcctcatc 110760  
gtgcaggggtg tgtagcctcc tgttcaactct ggtccggaca ttcccacccc ccgactcttt 110820  
cttcgaagac tacggctggt tgtgcctcac ctgcctatac gcccccgat catggacggc 110880  
taccctcatg gtggctgccc accttttggg actaacgcac gtgtacttcc cgcaatgcgt 110940  
gaaagatggg ccagtataca ccgcccagg catcctcgga atcgacgtcc agctgcactt 111000  
cttcgcaacc cgctgcttcc gacccatcga cagagaacaa atactccaca catctcattt 111060  
aaatttttta caaacagggt ttattagggg catgttagaa ggcacgattc cgggatcggt 111120  
ctgtttttaa acgtcctggc cgcgcacaga aaaggacgac caacaacctt ccgttgctgt 111180  
ttgttccgtt ggccgcggaa gtcacaccaa ccgggataac cgctacccc aggacctgga 111240  
agaggcggtt aactccacga acgcccagga aaagcccagc ctctcggcg tcttttcggc 111300  
aacgtgggca gaatcccagc ttcttggtc cgacacacaa caggcagata cccatttaca 111360  
accctccgcc ttcccaaccc cagaagatgc tgaccaatca caggggccct gcctgatgca 111420  
cccaacgctc aacctaaaa caaaaaacca caccgcatcc atatgcgttc tatgcgagtg 111480  
tctggccgca caccgggacg ccggtccggt tctgaaagat ctgcgtcgcg acattctgga 111540  
aaacatggaa aacaacgtta agctcgtcaa tcgcatatcg tacatcctaa acgatccgga 111600  
ctcactgtca cagtgcgcg acgaacatct gcgcggccta attaaacggt gctcggcaca 111660  
agaaatccac aagcattttt ttgcgaccc ggtgtgctc ctgaacacgt actcgactg 111720  
tcccgcggtt ttattttaat gccacctcc cgaaaagtat aagaagctca aagctcgtct 111780  
ggcaaccgga gagttcctag actgcaacag aatatttgac tgcgagacct tacagacctt 111840  
ggccgtcctc tttaaggggt ctcaactggc caaatcggc aaaaccacgt cgctcgagat 111900  
aatccgtgaa ctcggtttc aactgcgtc acacaacatt caaatcacc acccgtttca 111960  
aacctccaac ctatacattt aatcttcaga agcgcaccag acaatgcaa aacagcccag 112020  
aagtcgattg gcgtctcgag cgccgtacgc acctagcgtc aggcgaccgg acgggcccc 112080  
gtccacgca ccggcatcca ggcacggcag ctgcaaaagc gaaatcatgc agtggaataa 112140  
gttagtttca gacacgcagt tttttctgc cctaacgcgc cgccacgagc tgggggtgga 112200  
ctttttaaga gaaatgggga ccccgatatg cacctcaaag tccgttatgt tgccgttaaa 112260  
cctaaaaacc atcgccccg gtcggtgct ctctctctca tcattcggac actcgtcaaa 112320  
catgggggtt aactgttcgt cgtgcacgcc aactgacagg tcagcgggtg ctctggacgc 112380  
aaacgcgctc ggcgaagatt ccgccaggaa aaacagcgag ctgtgttcag tggcgtaaac 112440  
cttttaccac cagccgaaa aggtcgtgca gcacaagggc ttttacctgt ctctgctcag 112500  
ccactccatg gaagtcgtta ggaaaagctt cagcaaccc gggttgctct acgcccacct 112560  
agtcctaaaa acctttggcc acgatccttt acctatttt acagtcgatg ccgatgagag 112620  
actcgactc tgggcggtgt tccacactag agacctacac ctgggggaaa ccagtctgcg 112680

Cloning of Radinovirus Genome and Methods for its Use.ST25  
actcattatg gacaaccttc caaattatga cataacggtg gactgcatca agcaaacgta 112740  
cataatgaag ttacaccct cgcgaccgga caacgcaacc gtgacggttc ctgtcaacag 112800  
catttgcgag gccgtggcca ccctagactg caccgacgag ttctgagaag aaattcaaag 112860  
gggcacggcc atcataaact cccaggggct attgtaacct ttccctagac ggaaacagat 112920  
gtaattcacc tattcaaag ttaagttttt gttttgaaca tatcaccaat aaaaacaact 112980  
tatgtttaca caaattgaag agcggtttcaa ttttaccata aacatagcaa aaaccacggt 113040  
aactaaaact caatagcgat attcggtatg gatccctaga gagcaatcga cgtgcgccgg 113100  
tattaattga cgggaacgca cggttaactgc tctccacgaa tcgcaaactc cgcgttttta 113160  
ggaccattcg acgccgttaa taattggcag taaactgcga aagggcgtag atcgtagtag 113220  
tgattttacg atgtgcacac ctttccgagg ttcaccgcca acaacaaaag cgggtcacca 113280  
ggcacctaaa tcgcccgggc cttttatgcc aaagtacaaa agggaccggc gttctacgtt 113340  
cacgaacaac actgttgatc gcaaatacaa tagtggtgtt ggtgaccgca aactgccaaa 113400  
tcctaaaatg catggacata gtcctcaaaa tctagaacga acttccaaaa acatgcggca 113460  
atpacaacac ccttgagttt aatgcacatc gtaacgagac ggaatccaaa gaacacgccc 113520  
gatcttaaga ccacgggcac gtgtctttgg gttccggggg cgttacgatg gaagtccatc 113580  
accaagtatc ccatcaacct gttacaaaag cgtaaagata atcggtttac aataaacaat 113640  
aaaaaatagt ggacgaagtt acattccgac atacaagcgg acccaaaaaa acacccaac 113700  
gcaaaaacac tggagactgt gtctttgggt cccttcacg tcgcaatgag atttctggtg 113760  
accgtgtgct gcttaacgag ttacagttgt gttttatggc tacgtaaaaca caccaatcta 113820  
gaatgctaac acgtgcaccg cgcttagggc cgtttgtgca actaactgct gtcaggttac 113880  
tactcttatt ttaacaagt agcatacaca ctgcaattaa ttgcactaaa cccagtttag 113940  
tctttttagt cgagtcggcc catagtcttc atggagaacc atcattcatc tccgtcaacg 114000  
gcgtcgggtg taccgttgtt attgcgggca aaacaggctc gggggaaaaa agagcaacat 114060  
atcgtcagtt taaaacaact caagttctaa aatctcacc actcgtaaac aaaaaacatc 114120  
gcagttaagg tgtatgtacc gaacataaca acacaagttt tttaaaacac agctgcggta 114180  
agtaaccccc attgccacgc gtgtcgcgtg ctaagtgtt ttaaaattac attgtgcgtt 114240  
ttacacaccg agcagtaatc tcaggagggc ggtaaacgag cgatatacat attccctaaa 114300  
cacgggaacg cgcgctgacc gccctccca aatcacaaca cgggactaca aagcctagt 114360  
ttaatatat caaattaaaa aaccacagaa acctttagtc gtgcgcaaac actagcaaag 114420  
gtacctagag ctttcccta tacttcaaaa aacagcgggt gggtatttga ccacagtta 114480  
agtaaacacc cgtaagaatt attcccggtt atcaaaatgg aaaaattaag gctttgcgtt 114540  
aaaatctgct aacgcaaagg gcacttaatt ttccagttt ggactcgga ctttaccgct 114600  
aacgttaaaa ttaataatg caaaaggcac ataattttt ttgtgtaacc taaaactct 114660  
acagctaaag ttaataacgg cgactttggg cagcgaatca gtgtctgtcg caaacctgt 114720  
taaatttaaa cacaacagg agcgcgacta aacacggact aactgctcat cgggccctgt 114780

Cloning of Radinovirus Genome and Methods for its Use.ST25  
tgaagaagtt ggtgttgcaa tgcattaggg aatctaaaaa cgaaatcctg ctcggtaaca 114840  
cggaattgt ctttagttcc ctacagcatc acaacaattg taaaccataa acgtacgcg 114900  
gtggggttg tgtggtgtga aatgcttgg gcaactgtta catgggcgga ttgtaaatgt 114960  
ggtgcttgg gcaacggtgg tggggtgcaa gtcccccggt ggggtgcaag tcccccggtg 115020  
gggtgcaggt cccccggtgg ggtgcaggtc ccccggtggg gtgcaagtcc cccggtgggg 115080  
tgcaagtccc ccggtgggg gcaagtcccc cgggtggggtg caagtcccc ggtggggtgc 115140  
aagtccccg gtggggtgca agtcccccg tggggtgcaa gtcccccggt ggggtgcaag 115200  
tcccccggtg ggggtgcagt cccccggtgg ggtgcaagt ccccggtggg gtgcaagtcc 115260  
ccccggtggg tgcaagtccc ccggtgggg gcaagtcccc cgggtggggt caagtcccc 115320  
ggtggggtgc aagtccccg gtggggtgca agtcccccg tggggtgcag gtcccccggt 115380  
gggagcggt cggtccggg gtggtccgg gtggggcggt ctcggtccg ggtggtcc 115440  
gggtggggc ggctcggtc cggggtgggt cggggtggg gcggtcggt tccgggtgg 115500  
ctccgggtg gggcggtcg gctccgggt gggtccgggt gggggcggt cggtccggg 115560  
gtggtccgg gtggggcggt ctcggtccg ggtggtccg ggggtgggg ggctcggtc 115620  
cggggtgggt cggggtggg gcggtcggt tccgggtgg ctcgggtgg gggcggtcg 115680  
gctccgggt gggtccggg gggggcggt cggtccggg gtggtccg gtggggcggt 115740  
ctcggtccg ggtggtccg ggtggggc gggtcggtc cgggtgggt ccgggtggg 115800  
gcggtcggt tccgggtgg ctcgggtgg gggcggtcg gctccgggt gggtccgggt 115860  
ggggcggt cggtccggg gtggtccg gtggggcggt ctcggtccg ggtggtcc 115920  
gggtggggc gggtcggtc cggggtgggt cggggtggg gcggtcggt tccgggtgg 115980  
ctccgggtg gggcggtcg gctccgggt gggtccgggt gggggcggt cggtccggg 116040  
gtggtccg gtggggcggt ctcggtccg ggtggtccg ggtggggc gggtcggtc 116100  
cggggtgggt cggggtggg gcggtcggt tccgggtgg ctcgggtgg gggcggtcg 116160  
gctccgggt gggtccgggt gggggcggt cggtccggg gtggtccg gtggggcggt 116220  
ctcggtccg ggtggtccg ggtggggc gggtcggtc cgggtgggt ccgggtggg 116280  
gcggtcggt tccgggtgg ctcgggtgg gggcggtcg gctccgggt gggtccgggt 116340  
ggggcggt cggtccggg gtggtccg gtggggcggt ctcggtccg ggtggtcc 116400  
gggtggggc ggcctaaaat ccttaccggt aaatttagca gtaaatcaa cgcagtaaat 116460  
ccgcaagcta gccgcacaga ggtgcgactg cctgccaagg ctcctggcg ctttttata 116520  
gcgctaaatg ccctcccaa atggttacta tggtttagtt atgcaaccat aataccaata 116580  
aatgaatcac caagaatacg gccaacgcg cagcgtccaa ccgccctcca accgtgcagc 116640  
gccgtatatt cgaattgcct tccgcacgaa tacggggcg agcatgggtc cgggagggtg 116700  
gcattgcgca atattcccg cattccaacg ggcacgcaag ggtccagggt accggggatt 116760  
ccccaaacat catccagcg atagaggtt tgggtgagct gcctatctg ggattcccca 116820  
aaccgagac ccactgagat gctattcagt gggactgcag gctgggtcct ccaggacag 116880

Cloning of Radinovirus Genome and Methods for its Use.ST25  
gtgcctgcgt gtgtggtaag ggagttcccc taattaaaat attatattaa taaataaacc 116940  
aggctaagct gtaattaatg aggacacaggc tgccgaccta ggtacctggg gaacccccta 117000  
acgggatgta attaattcaa acctatataa attccaccct gttaggggga tccccacgtg 117060  
tacctgaatt aatgcgggat acaggctgta ggtttggtaa tgggtaccag gctggagtga 117120  
ctcataccat gggattaaat accagggata caagctgtag gttcggtaac ggggtaccagg 117180  
ctggagtgaac tcataccatg ggattaaata ccagggatac aggctgtagg ttcggtaatg 117240  
gggtaccaggc tggagtgaac cataccatgg gattaaatac cagggataca ggctgtaggt 117300  
tcggtaatg gtaccaggct ggagtgaac ataccatggg attaaatacc agggatacag 117360  
gctgtaggtt cggtaattta aacctatata aattttaccc tgttggggga atccccgttt 117420  
gtacctgaat taatatagga atacaggctg tagaatcggg aatggaaacc aggtgtagg 117480  
actaggctg agtgactcat accatggaat tcaattaaca aggaaaatat aatagaatat 117540  
atatatata agggaacttg taaacaaaac ccaactcgcg gattggctgc ctgtttgggc 117600  
caaccagcag cgagaattcc ctgattgaca ggccgactgg ccaatggttt gcgagcattt 117660  
ttgattgaca gaacggcccg ccaatcgaa cggagaactc ggcagcgaag caaaagacag 117720  
acggccgcgg cgaccaatgg ccgcccggg ttagttgat tgacggctt gccggccaat 117780  
gggaaacgtc cctgccggcg gccctaata cccctggctt aagggttac ggccgtaaac 117840  
atcgtggcg cgtgcccacc gccgccgaac ccccgcgccc ggttcggcgt gacctcgccg 117900  
cgaccccgcc gccctcatgc gcacatggg tgcgatggc accggcgga acattattcg 117960  
ctgaccggcg gacgaccccg gcgccaaga gcggccgat ggtacgcgc gcgacatcg 118020  
aaacattttt caataacccc agtctgaccc cgcgcccaa atctggggcc catggtggcg 118080  
cgcgccccc accgtcccca tttccacgg tttgctcat ggccacgac gtgcccgtgg 118140  
tgatatgtt cagtaccct cggatgaccc gggcgacgtt ttgcgcacca tggccccgaa 118200  
ttccccatg agtacatgtt tcggtgaccc gccggcgacc ccggcgga aaagccgccc 118260  
catgggcacc ggacggcacc atgtgcacat ctttcagtga ccccgggcg accccggcg 118320  
cggcaccgg ggcgtgggg gtgatgtt ctgatgacc ccgccttac tttgcagcg 118380  
tgtcagcga acatattct cccggtccc gagccgggg ccccgggacc cgagttgggt 118440  
tattaaagt acgttaggga ttaattttta tccactacc ccctaatgt gcggctcggc 118500  
ctgcggcgac gctgacgcg gcgggttcga cccattgacc gcatcctcg tggccgggca 118560  
gaggccggcc ggccaaaggt gcgatcgcg ggtctgaccc acccggtgga gaaacccctc 118620  
cgttcggtt tcttctgcct gcggtccctg gccccctg ccaccgggga tgtcttgtga 118680  
gcactttccc cggtgagaat agacaggaga gtgccgcaa gacatcgac gggttgccgg 118740  
tcggtgaacg ggaggcgcg cgcttgctg cgtgaggtgt cggcggtgg ccgtatgacc 118800  
cccgaacgc gaggggccc tggcgggaa atttcccag aaccggcgc gccgcttggc 118860  
ggcgcggtt cctccccaa cgaccctaa tttggtttt aagttgttat ttaaagctcc 118920  
gctgtgtttg tggcagcgc ttaagcgtt ccacctgtt cggagatccc ccgtgcgcac 118980

Cloning of Radinovirus Genome and Methods for its Use.ST25  
cgccgccctc ctcgcctcgg tgcacgctgc cgagcgtgcc acctgtttgg ttgtgtcatc 119040  
ccatgtgctc atcccccat cttatttccc cgaccaggca acataaacgt cacgtcgttt 119100  
gtaagaaata attgcttttt ttattttcgt taaccccgca accgcgatac agtctctcgc 119160  
ctttcaccgg ttgttttggt accagcccct cttggcggcc ggcaccggcg ttaaccgggt 119220  
gcgttggcgg ccacgacctt ggccacgtcg cgcctggaga cggcctgcag caggtcactt 119280  
aaaacatgt agtttgaggg gctgaccagg gccgcctttt ccatttgca gagccaccga 119340  
aaaaagggtg gtgactggtt gcgcctgcga ccaagctggt cgcccgttag aaaaactaaa 119400  
ttttcacgt ccctttctga gagctggcgg tcaatggaga gcatcagggtg tttgtatgga 119460  
ctaaagtaac tggggctgga ccggagcctc tcgataataa atcccacgtc tagtaaaaaa 119520  
aagggtggaga ccaggtccaa tcgccaacg agaaacacgg cctccagcaa caccgggagg 119580  
ggaataccgg gttctccagt tgaggggac agcccgtttg caaacccctc gggcgatcgc 119640  
tcggacggcg gccggtcaaa aagccacagc acggcctctc tgctcgtctgc ctctagggtg 119700  
cgaccgaagt ccactaacg cttatgcggg aacatgggtc cggtgccggcg ctcccgaca 119760  
ccctcttcta cctacactag agcgtttgat aaatcacgac gaaccgggg cgttacttaa 119820  
aatgtggtct tcgtcaaatt ccgcaagggt ggtggcaacc gactcggcg cgcccgag 119880  
ggttgccggc gaaacgccga cggcctccgc caatctggcc ggaggcggcg cagcggcacc 119940  
gaggctaacc agcgcgcagg cggccggcac cagggacggg ggcagaccgc cggtgccgg 120000  
gttcacgatg gctttgtgaa cagactccac cacctggctg tgaagggcaa agagctgctc 120060  
ttttgtaaag ccgcttttaa acagggtggg ccgatggcg tccgttggtg agacggcctc 120120  
tagtttccac cttaaagcct taaggattga ttttctctgt tttagtaaat ccgccacgga 120180  
aaaatcctcc gccgcgcaaa agcataaaaa ggcggccttg aaaggattca ggtctcta 120240  
cttgccggct aaaaatagac aggcggcccc cagcctctga aaccgccgac gggggatgct 120300  
gcgacactct agatagcgat ccagaatact aacggccagt gggaaaacgc tagcatccgc 120360  
ctggtgggcc ctggcaacag accgcatcca cgtccccaag ataactcgca tgcccaccgt 120420  
cacctccgtt tgtatcgtcc catagcaggc cgtggatgtt acaaaggacg cttcgtgggc 120480  
caggaggtta gagagggccc ggtcctggtg caggacgggg tcaatggtcc cggtgggcac 120540  
tgggccaaca gaagccattg tcaaggcaag gtaagaaaag cgatataagt cctacctgcg 120600  
gctcacggag gcttaatacg aacgtccggc ttaacacaca atcttcttg cgctctatgt 120660  
ccgtccaca ctgggtcccat gtcttctgca gttcagccct gcctgttccc ggaagcggc 120720  
ggactagatg caacgcggaa gcggctgtt atttaagggt agtcacaggc ggggcaattt 120780  
gccaaccagt gacgcgtttc ctgcagtctg ggttttcacc tggcaagcgc cactggttct 120840  
tggcagccgg ccggtgggga tttttttagt gctgaattgg cagtctctg tccatgcgca 120900  
ctatgctgac ctggaagtgg gggcggtg ggtgatgtc tcccaccgg cgacgggcct 120960  
ttttgacggc cttggcggtt ccgggcttt gacagaacac cgtaatgcaa aaagccggga 121020  
tgacgggact gccaggtgcg tccggcaaaa cgcggacgct ggatgctcta atgccgggaa 121080

Cloning of Radinovirus Genome and Methods for its Use.ST25  
actgtaggca ccttgccagg cgatacagtg aataggggtc tgagttacaa aagatgactc 121140  
cgtgacacca cgggcccggc cgaggggggt cgatcctggg tcccaatacc tgacgataaa 121200  
atcttctctg tgggcggtat tttctgggta cctcttcctc tgatgaggga tacggtatgg 121260  
gaatggggta tcgcggcggg cgcggggggc gcggggggcg cgccggttgc tgctgccgct 121320  
cctccccctc ttgctcctgt tgtctttcag gagcttcgtc ctcgtgggag ttgtgactcg 121380  
tgcatctgag acgtaaacia ggaactcctc cggcacgcgt ggggtggacc caacccccta 121440  
cgggtgtacga gtgggatgta tggccaggaa acgggggtcc tggccgagac ggcccgggtg 121500  
gggtgtctgt gtggctcacc gcctgttgcg tgtagggga tggggcctgt tgaggcgttg 121560  
gcgattgggg tggccccgtt gagtcgggcg gggattgcgg agggggcgag gacgtcggcg 121620  
ttggcgattg tggcggtcca ggtgagtcgg gagggggcaa ggacgtcggg ggctcaggcg 121680  
gttcagggtga gtcgtggtgc gatggttgca aaaacgacga aggctgctga ttgggcgatg 121740  
gattatgcga cgacggcggg gcagggtgag gggggccggg gtgtgacggg ggtgatggtg 121800  
ggggcgaatg cgatgcgggg gatgccgggg acgacctga cgtgttttga ggtgacaggc 121860  
ctgaagctaa caccggcgca gaccgcttg gcgacggcgt tggagatccc aacacgatga 121920  
cggactcaga ccctgaccct gatggcgacc cttgggatga cccgtgcctg gattcgggtg 121980  
ccgtttcggg gtccgatccg tgcccttgtt ctgcaaccgc ccgcacttgc ggccctgatg 122040  
ttgttgagc gggggggcgc ggtgcggcgg ctggcgcggc cgtgccacgc cccctgccgc 122100  
gcctcccggc ctgttctcta gtgcgcgcgc gtcttcgcga atgtcccctg caggaaactc 122160  
gcaaccctg tcccataact atgcgggaac gatgttgccg gctgccccac atgttcgcgg 122220  
tttactgctg gtaaaaaacg gcagattaag tagattgcc tttccacgac ccgcagccac 122280  
ctgagcgcgc gcacgcagaa cctatgttta gtgcgattgc gattatgtcc gctaggtggc 122340  
gggtatattt gatcctgccg cgcacgcatt gaccgttagg tggcgagag cgccgttaac 122400  
cgcagcgagc accgcacggc ggttttagtt tcgttactat aacgtttagt taaaatccgt 122460  
ggccgatatt ggggtggcagt gtgtaagtca cgcgcgcgcg gggcccctta ccttgtcgcc 122520  
ggcgaaccgc ggaagtctg ttccgcgcgc cagcgcgcgc ccgctgccga aaccaacgcc 122580  
gcttgaattt cgcggggcgc tgggcttggg gtcagtgatt cacacagatg cgatgtgatt 122640  
gggcgtggtg gtcaacgtca cttgttaacc cgtaaatctg gaaattcttg tccgcgcgcg 122700  
cgggtgagccg cggccctaag ccttatagtg ctgtgcagcg atcctgaaac tcgaaagctg 122760  
gccatataaa cccagtatg gcgttgctg tcggtggcaa cctttttgaa aaagatttat 122820  
tgccgcgggg tgtaagcac caacaccgac cgtgcgtttt caattatgtc gggaggaatt 122880  
acattaacgc tgctgctggc gacgcttgcc acggttcggt gcgctcttca aacgcactat 122940  
gcggcggtcc ccgtgcactc taccgcgtcc ctgggggtgc tgtaacgac accccacgac 123000  
gttcttatcg ttacctggca aaaacaggaa tcgcctagtc ccgttaacgt ggccacatat 123060  
agttccgaag cgggcacggt ggttcagccc ccgttcgccg gtagggttga cattcccga 123120  
cacaagttga ccagaacgac cctgaagttt tttaatgcca ccctggagga cgaggggtgc 123180

Cloning of Radinovirus Genome and Methods for its Use.ST25  
tacctgtgta tctttaacgc gtttgagtg ggaaagctgt cgggaaccgc ctgcttgacg 123240  
gtttacgtcc ccctgtccat gtccgtcacg ttttaccccc cgattaaccc gacgcagctc 123300  
gtctgtcggg ccgagggccag tcccgcaccg tcggtcaact ggaccggcgt gccgcccag 123360  
ctgtgcagcg aacctgaagt gtttccccgg cccaacggaa caaccctggt tgtgggtcgc 123420  
tgcaacgtaa cgtcgggtga cccgaagac cttgagaacg ccacgtgcct ggtcactcat 123480  
ataggcgggt tggcccgccg gcggccctg gaccccggtt ttccggatcc cctggaagg 123540  
acgagccact acgtgggtgg tgtgtgtgca gcggccggc ttttaggcat tttttaacg 123600  
gggtgttttt tgtataggtc tatgtgagcg cgcgtgtccc ccgtgtctag tgtttgttc 123660  
cccagtgagt gtctccatga caaatacaaa tttgaggctg gcttttagg gtggtttctt 123720  
gtgcgacgct tctgtgtgaa ctgcatacac cggggtgtcg ccaggaaacc gcgtctccc 123780  
tttatgtccg ctgcctccc cagagcgaat gtgagaatgg ttccgtgggc gttttggcg 123840  
tgagagagtc gggcgatggt gccgtagcgg cgtctgcaaa ggctcaccg cttctgttt 123900  
ttttcttttt gtcagacaac aacatggacg ccttgaacaa taacctaac ctgctgatgg 123960  
atttctgtc taactattcg aatagctaca gtagttatga cgacaatatg tcttacacct 124020  
tagacacgga atccacgctg tgtcggctga cgggtgtttt cccacctacc gtttatgca 124080  
ttatatgctt ttttattttt tgcattacgc tgtttgggaa cgcgttggtg ctatatatt 124140  
tttttaaatt taaagcgctc gccaaactctg tggatgtact gatggctggg ttgtgtgtg 124200  
actccctgtt tctgtgcgcg tcgtttttgt tcagctggct gctgtacgtc gcgccacaga 124260  
tgctcacgtc cgcgacgtgc aagggtgaaa tctttttctt ttacctgtac acgtactttg 124320  
gcgtgtacat tgtgtgtgt atcagcctta tcaggtgcct gttagtgtg ttttcccgcc 124380  
gcccggtggg caagcacggg gcctccggct ttctctgcgt gtgtgtgtct ttaatcgtgg 124440  
cgctggcgct gtctgccaac gcgagcctct ataggacggc cctgcgtcac ccagagacca 124500  
gcgagtggat atgctacgaa gatgccggg aagataccgt caactggaag ctgagaatca 124560  
gaaccaccag cgcgatctgc gggtttttgg ttccgtttgg gctgatggg ctcttttacg 124620  
gacttacgtg gtgtatggtt aaaagcacga agctggccag aaaggagcc gttaggggtg 124680  
taattgtgac ggtgtgtgtg ctgtttttta tttttgcct gccctatcac ctgtgcaact 124740  
tttttgacac cctgttgagg accggttttc tggccgaaac gtgtactctc agggacgtga 124800  
tcagcgtggc catgcacata tgctccctgc tacagagcat gtatagcgcg ttcgtgccag 124860  
tcgtgtattc tggctctggg tctctgttta ggagaagggt tagggatacc tgggtccgtg 124920  
ttaggtgttt ttccacttca ggtagtttat gagacactca cgcgacactt ggttggtattg 124980  
tttgtgtaca tttattttca ttttgtgtac atttattttc attaaagcga tctgacctgc 125040  
agaccttacc tgacgtttac tgtctgtttc ttatgcacca gaggaacagg gactggaagg 125100  
ccagcgccca cggggaaact gtcatgtccg caagctcggg cggcacgtac gccactgcc 125160  
aggggtggaa cgtcacggcg gggtcgacca gggaggccag gtggcgccc tccgtgtacg 125220  
tgatggcgcc cacggccgag ttggcagacg ggttcggtg gtagtgctgc gcgaacatcc 125280

Cloning of Radinovirus Genome and Methods for its Use.ST25  
tcgggtcggc gttgcccggtg tggtagttca gggcgatgcg ctgctgctgg ttgagatggt 125340  
actccatggc gtcgcgcggg tatctcacgc ccaggtaccg gccgttgccc caccctggga 125400  
ggacgaggcc ccgaagaacc ctaaacaatga tgctgatggt ggtctggggg atgtggaggt 125460  
ttagccagag gcactcgtgg ttccctgatg cgttctcctc caggtggatg tcccactggt 125520  
cggggggttt ggggtccgggc gtgtcgtgag ggggtctctct aagaagaccg agcgccccc 125580  
ggagctggaa cccaaactcc ccgcagcata gtgaaaaatgt atccgctcgg cggaagaagg 125640  
ccataaggcc cccatagcac ccagggtcgt tgagaagacc catgatcgcg catcggggccc 125700  
ccacgtagct gtcttcgatg cccacgggtc caccgatggt cagaccggag aatccccgga 125760  
ggatgttccc tcctctaagg tcgtcgggtg agacggccgc gacgtcgaac ccgacgttg 125820  
tgaaggcggc catcagcgcc ctgggaagcg gggcaccggg ggtgaccaag gcggccactg 125880  
ctggcgccct cgacggcggt gcaaacagag tcagtctcgt gtttctgcaa acctcggcga 125940  
ggtggcccag gttgtgttg ttgcacccgt agtcctttct gtagagtcc tgcgcgggcg 126000  
tgaagctggg ccccatgag taccactgtt cgtccgagaa cgaggtccag tttgccgcca 126060  
ccgaagtgag ggtctgtgaa tagacttcat cgttgttgtg tgagatgacg attctttctg 126120  
acagaccctc ctgaccacg gtgccgcaca cgggtggccc gcagtcaaag ttttggcacg 126180  
cctggcgcac ctgcgcgacg tgctggggct ggatttcgaa gatgacgccc ggggtttcgg 126240  
acaccagcca ctgcaggggc gtttctctg acgggatgcg aatctgtagg cctcggttac 126300  
cggccagggc catctcgata gcggtaacca ccatgcctcc gtcgctgacg tcgtggccgg 126360  
acaccaccag accccgggag agcagggcct ctgttagcat gaagagggtg gccaggtgtg 126420  
tcgcctgaac gtccggtagg gtgggactcg gcaagagaca cagggtctca aaggctcgatc 126480  
cctgggtcag gtgcggcacg gggaaggaca ccagcacgat gaggttaccg gtggccttca 126540  
ggtcaggtgt gacgcgttg ctggacgact tcacctcggc ggtggccgtg atgacgactg 126600  
cgtaaaccg cacgggggct accgtctgat gctgttgggt ggcgctgatc agttcttccg 126660  
acaggcacgg ggtgctgccg gccgacgtga tggcgaagtt gatgctcagg tccctgcata 126720  
gttccttgca ggcaaacagt gtgtgctgca ggagccaggc ctggtcgtec tccgggttcc 126780  
aaccgaccga cgcctgcagc gtgatgtcgc ttagacgccg cacgtgcgct agcatgatgt 126840  
tggtgaccgc ctgcgagatg gcgtatctcg cgcctactgc cgcgttgatg cccatcttgt 126900  
atgcctgttc tcataagcc acgcactgtc cgaccacccg gttcctgccc ctgccctggg 126960  
tgaccaggt ttctgggcta accaggcggt ccgtcgcgtc ctgcctggtg atcggtggg 127020  
ggcgatatat gggcaccgc gccattctgt ccgtaaacac cgacgtgtgg ttgacaatgt 127080  
ggtaatctga cagcgccgg cccaggggtc ccacttcgca ctgctgagcc acgagtccgt 127140  
tgagcatct gtccacgtgt cgcgtgacaa actctttgct gccaacgtc ggacatcgca 127200  
gaagctgatc gaccacggag gccaggcgga ataggcccca gtcggtcggc gagggtgcct 127260  
gttcgccacc atcctcaggt tcttctgggc gcaccagcca gttggaggaa acgggctgct 127320  
cgtcgaaccc aaaagttgcg atgacttcgg ccgatgttg ctgtctgatc ggccacgctc 127380

Cloning of Radinovirus Genome and Methods for its Use.ST25  
ccgggttcca cagctccagg tcgttcacga actgaattcc aagctcttcg cagggttccc 127440  
caacgacggc gaaagggcat ccgcagatgc gtgcggccct cctgatggca tccaacgggc 127500  
ccggttccgg ctccgtgtcg cgcgaggga cggcaaagac cacgcaggca gacacgttga 127560  
gaaacttggt aactaggatg tcgttcacgg tttcccgta gatgtctggc gtggcggtca 127620  
gttggtcag aatggttggt ggaagctgag agacaaagag gcgcaggccg ccccgcgaga 127680  
ccagggtcc cagggtggcg atgacagagg cgggttcag ggccgatta atgctggtaa 127740  
ataggggccc ttccaaaatc tcgtaagcca gcgacaacgt ttgggtgatg cgggtaatac 127800  
ctgcggcgct cccaggtaa agcgagcgct ggttgccatc gccgtcaacg ggttcaaaag 127860  
accaagaca gatgataggc tgactgaata aagacctcct gaggaatgtg tatgcttgag 127920  
gcacgcacga taacagcgat gtggtggtaa taacgttcgc ctgcgtggtg gtggcgctgt 127980  
ggacggtttt aagaaagcca ccgaggacag gcgtgccgt gcgcgccagc tgctggcagt 128040  
ggagtgtcgc tgttgtgtta atagctctgt ggcgtgcgcg agaaaatgcg cccactgacg 128100  
gcgtagtggc gtaaaatcca cacagggccg atctgatttc gccccgggc agcagcgtgg 128160  
catggaacag aatgttttgc agcgacactg cacctgtctg aatggcgctg tgcaggtgtg 128220  
taaagtgtc agctatgtgg gttacgtttt cgcacgggag gcgctggaaa acgcagctgt 128280  
agctcctgcg ggccatgacg gcgtatctgg acaccgtata gctgttgccg ttggaggcct 128340  
gcacggccag cggtaatatg ttccgttgta acgggagcat caccgcggcg catattgggt 128400  
ctctctcggg caacggtctc caggcggtgg attgcaatgt caccgggagc tggcgctgca 128460  
cgcgcacatc atattctact agtgtgccaa gtgtcagggc ggccaagggtg cccgggggta 128520  
cccgatcggc gacaaaccgt ctgcctggc agctcagatg tctgccacc tctaaccgca 128580  
acgttctatc gagggcgctg tctctaaggc actgcactat ttcgctagat cttgtggtag 128640  
gttgcgcat caggctctgg ccatagggca gggatatagt atgatggccc tggaggtgcg 128700  
ccgaccgagt ttccagagg gcataattaa ccagaggcgc cagaagatgc cagataacgc 128760  
ccagcgctgg gtcgtcatcg tcgttgtcaa agttatcaga gggcggtgtt acaagccaaa 128820  
gtaaaaattc actaaagcac tgttctggca caagcgcaa aacactttct gcgtccgaat 128880  
tgtcatgaat aaaagcctcc tcttctggac taagggtgc agcgcccag cgagggttcg 128940  
tgcgttggc catatttgct aagtctagcc ggcgcaaaag caagcgggtg ggactttaat 129000  
agggcgata ggggttgta ggtatgcgt ggggagccgt ccatgttaca tggacttcaa 129060  
tattaattta tgttagtttt gggcaccttg ggtatgttaca cttataactt ccccatgtc 129120  
acagtaatca cttgacagat ccccttctaa ctcataacaa ctgttctggg gtgttgagg 129180  
tacaggtaag ggtgggagg gaatgttagg tggcgaacca aagcataacg tcgcggggcg 129240  
ggagtgggag cctgtaacc cagagatgtc acttacgctt gttaggcgat cgacaactac 129300  
ctccgaaagt gtgtcctgtt ggatgttttg tggattagg aaaacagaaa gttgtggaga 129360  
aagtaacctt atagatgacc tctgctggc gcgtggctg gtgacagctg gttgttgatg 129420  
aatgaacact tcctcgggcg ttctggggg ggtgggtgtg gtctcactaa ggacggccaa 129480

## Cloning of Radinovirus Genome and Methods for its Use.ST25

ctcaacacta acttcctccc gttcagaccg tgagcggttt cgtctgtagc gtcttgtgga 129540  
gggggttgcc tgaacccttg ttggtgtaaa caatccaggt aaccggtaaa tgcacgcggt 129600  
cagggcgatt tgtaacaaac ctaaaaacgc ataataagct tacaacgcga tttttggtaa 129660  
cagtttgtat aatttagccc caaagtttat acaaagcgaa actacttacc gattagttaa 129720  
atgcaaaccg caagaaggat aacactcact gattctgttc caattgggtc gaatttaaga 129780  
atggagagta aatttgcccc gctgagaatg cctggaaata agaggcgctg attttcatg 129840  
tggtacaggg tagaaaaacct tgtaggtttc agttgagtca ccctgccacg taaacccgcc 129900  
tagagtgtg cagcgcggtg ttggtgcagg aagtacatcc taattttaac tctaaaagg 129960  
gttccttgta aaattattta agttatggtg tacttacata atatccaatg agtagttaca 130020  
ctccaaaaag atactcgata aaatgcgtga tatgtgaagt ttgcaacaaa tgcagcggtg 130080  
agtaggcccc agaaaatgat aaaccctata tgaggaaatt ttattagtac gtttgtgtaa 130140  
ctgcaaaaata aaatttttaa taaatacttt atattcatgt taccaagttt aatttgtggt 130200  
ggttgttctt gaattatatg tactcctagt tctgaggcaa ctgtatgtag tgcaagcacg 130260  
ctgccttgca acataacca taggcatgtt ccatgattcg atattcgcca tgccatttta 130320  
agtccacgc agattgcagc aatagctata aaaaaacaaa agtatgttaa tagtctataa 130380  
agtataaac attaaacaa aattaaaaa ttaaatacct gtatttgccg taactataga 130440  
gtatgataat agtaagggtg aagactgtgt tgttgtagtt tctgttaatg cataaagtcc 130500  
cacaagtgtt aaaataaaaa aataaatgtt agttatttaa tttttaaag tttatactat 130560  
tcaagtaatt caaagttgtg tcatacctgc gtaaattgca aaccaagatc caattattct 130620  
tagtatgttt gttttccac atagccacac ataaccataa aacacaatgg gcattaaaat 130680  
tactggcaac agcgagata ctttgtagtt tggagtccac ataagaaatg ccgtaagaat 130740  
aacagtgctt atccatgttg gtcccacaag aagacatgat gttgttttac tagaaacaat 130800  
tttcggtggt tttataacaa atattaatat gcctgaaaaa tataaacaaa cgattaattt 130860  
aaggccaata tcatagtaaa acaacttta aacaggtaaa aagttacgtc ttacctatgt 130920  
aaaattgaga tacgcatgca atagcactac acgtctgtac caaataactt gcgttggtcca 130980  
aggccaatgc cgatagtaaa acacaacatg ctgcaacaaa gtacacaaaa tataagttta 131040  
atttgctaatt taaaattaat atttcaaatg tattataaaa tcatacctgt aatccatggg 131100  
aaaaaaattg aaggcaacgg agttaattga cctgctctgc ttcgattaca atacaaacta 131160  
atagttttcc ataaaagaga acaacacgta acaaatgaac aaataattgt gactgcttga 131220  
ttagaagtgt ccctggcatg ttgtaccaag gctattatcc aaaacgttaa tgtaagaagg 131280  
tttgaagta accaactact ccaaataaaa aaggtatagc tacacgccat tttaaaataa 131340  
tcaaaactgt attatcaagt taagggggag tttgagcttt aaaaggttg ttacatcggt 131400  
tccaggcaaa cctcactg agtcacacaa aggtttctgt gtgccctgt acgggaatct 131460  
gccttattgc tgattttgtt ggcaaccaac caaagaaatc atggaaaagc agagtgggaa 131520  
tatttgtttt tgttcgttg cctggatgct tggaaacatt cctgttattt tgatgttagg 131580

Cloning of Radinovirus Genome and Methods for its Use.ST25  
ccaaactgtg gaaaacatta agagtgtgta ttgaaaatat tttttggtta caaaaccatg 131640  
ttttagggtcc caaaaggaac ataaaaatgt ttaatagaaa catgcctagt acagaacatt 131700  
ttgttttgta cgtaaacata aaatatgtat ggtaagggtt aggggtaagg gcaaggggta 131760  
agggttaggg gtaagggcaa ggggtaaggg caaggggtaa gggcaagggg taagggcaag 131820  
gggtaagggt aaggggtaag ggcaaggggt aagggcaagg ggtaagggtt aggggtaagg 131880  
gctaggggtt agggctaggg gtaagggtt ggggtaaggg ctagggtgag ctagggtgag 131940  
ctagggttat agttatagt taaaataata ggcctacgat aaaatgtcaa catatatatt 132000  
ttaattttgt tttcattaac agccatggtt tattagagta aagggttaacg cttcaataca 132060  
atatacaagt aaaagtaaac cacacgaatt tataacatat ttacaaaagc gaaccaagct 132120  
ggcacatgta acttcacgct accctaaacg tacaatactg ggactagaac ccagaggtag 132180  
ttagaatata cggtagttac agaactttgc agttccctta ggccagcagg gctctgcggg 132240  
taattaaaca aagtttaaag ataactgaaa ctttaggaag tgcgtatggg tgcaatgtgt 132300  
tccaaatagg gcaaggggta cataaactgt tgcctagcgg ccgggcccgg aggcgcccgg 132360  
ccggcgccgc ccggggccgc cgccgcccat cttgcgccc gggcgagggt ccccgccgcg 132420  
cccccgggc ccgcgccgcg ggccgccgcg gcctccccg gctcccgcc ctcgccccg 132480  
ccggccccg ccccgccgcg ccgccccgcg ccgccccgcg ccgcgccgcg ggccgctttc 132540  
ggttcgccg gccgggggtc ccgcgggggg ccggggccgc ccccggtgct cgtccgcgcg 132600  
ggcccgccgc actcccgga gcgccccgt ccggccgagc ccggcgccgc cgcgccccga 132660  
cgcccccg gcggggggcc ccacaagccg cggcgccgcg ctcccgatgc cggcgccgcg 132720  
ccgccccga tggcggtcct ccgccccct cccctcccc acgcgcccc gaaagggtgt 132780  
ctccgcgcg ccgggagggg ggccggggcc cggggcgct cggcgggg ccggcgggg 132840  
cgcgaccgag ggccccgga gaacggggga tcgggaaaac gcgaggggag cgggggacag 132900  
gggacggcgt gtgcgtgctt gtgagacacc gggtagggtt gcctgcctgc tcgctggcct 132960  
gcttgctgag gggacagtag gcctgcttgc tcgctggcct gcttgctgag gggacagtag 133020  
gcctgcttgc tgaggggaca gtaggcctgc ttgctcgtg gcctgcttgc tgaggggaca 133080  
gtagggctgc tggcttgcta gtagggctgc tcgctggcct gcttgcttgc tcgctggcct 133140  
gcttgcttgc tcgctggcct gcttgcttgc tcgctggcct gcttgcttgc tcgctggcct 133200  
gcttgcttgc tcgctggcct gcttgcttgc tcgctggcct gcttgcttgc tcgctggcct 133260  
gcttgctgag gggacagtag ggctgcttgc ttgctaagg gacggtacgc ctgcctgatg 133320  
gcttgatagt agggctgctg ggctgctagt agggctgctg ggctgctagt agggctgctg 133380  
ggctgctagt agggctgctg ggctgctagt agggctcctg ggctgctagt agggctgctg 133440  
ggctgctagt agggctcctg ggctgctagt agggctgctg ggctgctagt agggctgctg 133500  
ggctgctagt agggctgctg ggctgctagt agggctgcct gctggcttgc ttgcttgctt 133560  
gctagtggg ccgcttgctt gctactagg ctgctgtgca gctgggagaa cagagtaggg 133620  
ctgccggcca gctgcgtgcg agggcgccg agggccagac gaggacacg gacccgggccc 133680

Cloning of Radinovirus Genome and Methods for its Use.ST25  
tctccccgc ccggaccgcc gggcaccgcg ccagatct 133719

<210> 2  
<211> 426  
<212> DNA  
<213> Cosmid 3 Fragment 7 T7 Sequence

<400> 2  
gaattcatat tgcataatgac ctctatggac acagtttgta cacacaactg aaccatttgt 60  
tccggtgtga gatattgcat catcaccacac gtacagaaca cggcgtggta cgccacacgt 120  
acctgtcgca agtagttttg cgtgattcct ttttcttctt tgccgcctcg actttgaatg 180  
cgctgtgctg cctccgaact gttgagcgtt agcaaaacga ccacatcacc gtcgtgtgcc 240  
gagaaaagag ataggatttg aaacaaatga tccggcggtta gcctgttgta ctttacgtga 300  
accagcggaa aaacaacggt ggcggacagt aggtgtctgt caaaaacaat ccaattcgct 360  
ggctttgtgc taccgtttcc cactagccac gggtgcaggt tgcgaccgat gccggcggcc 420  
gttgca 426

<210> 3  
<211> 141  
<212> PRT  
<213> Deduced Amino Acid of Cosmid 3 Fragment 7 T7 Sequence

<400> 3  
Ala Thr Ala Ala Gly Ile Gly Arg Asn Leu Gln Pro Trp Leu Val Gly  
1 5 10 15  
Asn Gly Ser Thr Lys Pro Ala Asn Trp Ile Val Phe Asp Arg His Leu  
20 25 30  
Leu Ser Ala Thr Val Val Phe Pro Leu Val His Val Lys Tyr Asn Arg  
35 40 45  
Leu Thr Pro Asp His Leu Phe Gln Ile Leu Ser Leu Phe Ser Ala His  
50 55 60  
Asp Gly Asp Val Val Val Leu Leu Thr Leu Asn Ser Ser Glu Ala His  
65 70 75 80  
Arg Arg Ile Gln Ser Arg Gly Arg Lys Glu Glu Lys Gly Ile Thr Gln  
85 90 95  
Asn Tyr Leu Arg Gln Val Ala Trp Ala Tyr His Ala Val Phe Cys Thr  
100 105 110  
Trp Val Met Met Gln Tyr Leu Thr Pro Glu Gln Met Val Gln Leu Cys  
115 120 125  
Val Gln Thr Val Ser Ile Glu Asp Ile Cys Asn Met Asn  
130 135 140

<210> 4  
<211> 524  
<212> DNA  
<213> Cosmid 3 Fragment 7 SP6 Sequence

<400> 4  
gaattcaatg actggcatgg tgccgcagga aaacgtctta agctgtccag agcccatgaa 60  
atattggacg tgtgtttatt caaattgcct taaagagcag cgcagcatag ttaagcaagg 120

## Cloning of Radinovirus Genome and Methods for its Use.ST25

caccacggg aaatcgatca cttctgctcg cgtatacgcg tgtcagagca agtttgcgct 180  
 accttttcgt gcaacggccg ccggcatcgg tcgcaacctg caaccgtggc tagtgggaaa 240  
 cggtagcaca aagccagcga attggatgtg ttttgacaga cacctactgt ccgccaccgt 300  
 tgtttttccg ctggttcacg taaagtacaa caggctaacg ccggatcatt tgtttcaaatt 360  
 cctatctctt ttctcggcac acgacggtga tgtggtcgtt ttgctaacgc tcaacagttc 420  
 ggaggcgcac aggcgcattc aaagtcgagg ccgcaaggaa gaaaaaggaa tcacgcaaaa 480  
 ctacttgcga caggtagcgt gggcgtagca cgccgtgttc ttgt 524

<210> 5  
 <211> 174  
 <212> PRT  
 <213> Deduced Amino Acid of Cosmid 3 Fragment 7 SP6 Sequence

<400> 5  
 Asn Ser Met Thr Gly Met Val Pro Gln Glu Asn Val Leu Ser Cys Pro  
 1 5 10 15  
 Glu Pro Met Lys Phe Trp Thr Cys Val Tyr Ser Asn Cys Leu Lys Glu  
 20 25 30  
 Gln Arg Ser Ile Val Lys Gln Gly Thr His Gly Lys Ser Ile Thr Ser  
 35 40 45  
 Ala Arg Val Tyr Ala Cys Gln Ser Lys Phe Ala Leu Pro Phe Arg Ala  
 50 55 60  
 Thr Ala Ala Gly Ile Gly Arg Asn Leu Gln Pro Trp Leu Val Gly Asn  
 65 70 75 80  
 Gly Ser Thr Lys Pro Ala Asn Trp Ile Val Phe Asp Arg His Leu Leu  
 85 90 95  
 Ser Ala Thr Val Val Phe Pro Leu Val His Val Lys Tyr Asn Arg Leu  
 100 105 110  
 Thr Pro Asp His Leu Phe Gln Ile Leu Ser Leu Phe Ser Ala His Asp  
 115 120 125  
 Gly Asp Val Val Val Leu Leu Thr Leu Asn Ser Ser Glu Ala His Arg  
 130 135 140  
 Arg Ile Gln Ser Arg Gly Arg Lys Glu Glu Lys Gly Ile Thr Gln Asn  
 145 150 155 160  
 Tyr Leu Arg Gln Val Ala Trp Ala Tyr His Ala Val Phe Leu  
 165 170

<210> 6  
 <211> 630  
 <212> DNA  
 <213> Cosmid 3 Fragment 5 T7 Sequence

<400> 6  
 agcgagtcmg tgagcgagga agcggaagag cgccaatac gcaaaccgcc tctccccgcg 60  
 cgttggccga ttcattaatg caggttaacc tggsktrtcg aaattaatac gactcactat 120  
 agggagaccg gcctcgagca gctgaagctt gcatgcctgc aggtcgactc tagaggatcc 180  
 ccgggtaccg agctcgaatt ccagacaggt aagatttttag ctcctaattg ttgccttgcc 240  
 gcctagctcc taatgtttgc cttgccgcct agtcctaatt gtttgccttg ccgcctagct 300

## Cloning of Radinovirus Genome and Methods for its Use.ST25

```

cctaattgtt gccttgccgc ctagctccta atgkttgcct tgccgcctag ctcctaattgt 360
ttgccttgcc gcctagctcc taatgtttgc cttgccgcct agctcctaatt gtttgcccttg 420
ccgcctagct cctaattgtt gccttgccgc ctagctccta atgtttgccc acgtttatgt 480
ttaagcacac taaaatttaa aaacgtttgt gttggttttt atgaccggct tggtaaaaaa 540
cctgctggtg attttttacc caacaaaaat aataaataaa aaagttaaaa cttattttctg 600
ttgtctgtgg taattgcgtt ccccgagggt 630

```

<210> 7  
 <211> 406  
 <212> DNA  
 <213> Cosmid 3 Fragment 5 SP6

```

<400> 7
gaattcgag cccctcttga aacactgatg gccaaaggcga tcgacgccgg atttatccga 60
gatcgacag acctgctcaa aacagataaa ggcggtggcca gagtcgcgag aagtacgtat 120
ttaaaggcca gccagtctcc ctctctcag caccggcgga accgcgacac ccaaaccatg 180
agcgccctcc cggatgacaa catcaccatt cccaagagca cttttctaac catggtgcag 240
agcagtctcg atcacatgcg caaccagggc caacgcgcgt acgtttccgc gccaccctcg 300
atgccggcaa cggcggcgta tccctcgtgg ataccgccac cagaactgac cgtcccgtcg 360
tacgcgccgc ccgtagcgcc accgttcctt tttcagtcgg cgtttt 406

```

<210> 8  
 <211> 135  
 <212> PRT  
 <213> Deduced Amino Acid of Cosmid 3 Fragment 5 SP6

```

<400> 8
Glu Phe Ala Ala Pro Leu Glu Thr Leu Met Ala Lys Ala Ile Asp Ala
1          5          10          15
Gly Phe Ile Arg Asp Arg Thr Asp Leu Leu Lys Thr Asp Lys Gly Val
20        25        30
Ala Arg Val Ala Arg Ser Thr Tyr Leu Lys Ala Ser Gln Ser Pro Ser
35        40        45
Ser Gln His Gly Gly Asn Arg Asp Thr Gln Thr Met Ser Ala Leu Pro
50        55        60
Asp Asp Asn Ile Thr Ile Pro Lys Ser Thr Phe Leu Thr Met Val Gln
65        70        75        80
Ser Ser Leu Asp His Met Arg Asn Gln Gly Gln Arg Ala Tyr Val Ser
85        90        95
Ala Pro Pro Ser Met Pro Ala Thr Ala Ala Tyr Pro Ser Trp Ile Pro
100       105       110
Pro Pro Glu Leu Thr Val Pro Ser Tyr Ala Pro Pro Val Ala Pro Pro
115       120       125
Phe Pro Phe Gln Ser Ala Phe
130       135

```

<210> 9

## Cloning of Radinovirus Genome and Methods for its Use.ST25

<211> 630  
 <212> DNA  
 <213> Cosmid 3 Fragment 3 T7

<220>  
 <221> misc feature  
 <222> ()..()  
 <223> n = any nucleotide

<400> 9  
 grgcgcagcg agtcagttag cgaggnaagc ggaagagcgc ccaatacgca aaccgcctct 60  
 ccccgcgcggt tggccgattc attaatgcag gttaacctgg sttatcgaaa ttaatacgac 120  
 tcactatagg gagaccggcc tcgagcagct gaagcttgca tgctgcagg tcgactctag 180  
 aggatccccg ggtaccgagc tcgaattcca gattgactca tcggtttcta accctaacaa 240  
 agttgcatga acagagtatg ataccaatgg tggtagaaat gttagcagcg gttaaagaac 300  
 acgtgacctt aatggaggtc tgtttgggcc tctttaaga gctacgaaag cttcagattt 360  
 taattgttga cgcgggagaa catttagatg atacgtgtgg cctttgggga aatatttatg 420  
 ggcaggtaat gtcaaatgag gctattaaac cacgagccgt gaactggcca gcccttgaaa 480  
 gctacattca aacgctaacc agcttggaag gcaatgcagc caattaacca cggtttgtgt 540  
 ttgttggtta ttacattctc tgtaattaat ggatatgaat ataatgaaga aaatgtacct 600  
 ggacttgaaa tagttctttt taccctgcc 630

<210> 10  
 <211> 124  
 <212> PRT  
 <213> Deduced Amino Acid of Cosmid 3 Fragment 3 T7 Sequence

<400> 10  
 Ser Leu His Ala Cys Arg Ser Thr Leu Glu Asp Pro Arg Val Pro Ser  
 1 5 10 15  
 Ser Asn Ser Arg Leu Thr His Arg Phe Leu Thr Leu Thr Lys Leu His  
 20 25 30  
 Glu Gln Ser Met Ile Pro Met Val Val Glu Met Leu Ala Ala Val Lys  
 35 40 45  
 Glu His Val Thr Leu Met Glu Val Cys Leu Gly Leu Phe Lys Glu Leu  
 50 55 60  
 Arg Lys Leu Gln Ile Leu Ile Val Asp Ala Gly Glu His Leu Asp Asp  
 65 70 75 80  
 Thr Cys Gly Leu Trp Gly Asn Ile Tyr Gly Gln Val Met Ser Asn Glu  
 85 90 95  
 Ala Ile Lys Pro Arg Ala Val Asn Trp Pro Ala Leu Glu Ser Tyr Ile  
 100 105 110  
 Gln Thr Leu Thr Ser Leu Glu Ser Asn Ala Ala Asn  
 115 120

<210> 11  
 <211> 524  
 <212> DNA  
 <213> Cosmid 3 Fragment 3 SP6

## Cloning of Radinovirus Genome and Methods for its Use.ST25

<400> 11  
 gaattcaata cgctccaaaa gatagagatc acaattttat ttttgacgcc aatcaaaacc 60  
 cagatcgaca taaacaagtg caccacgacc accagaccga accgcttcca gacatgttcg 120  
 atccagtaaa gcacctaagt ttacacaact tcaaaatctc agttttcaat accaatatgg 180  
 taattaatac caaaatcacg tgccggtctc tcaccggtac cttcgagtca atcatcgaca 240  
 tccccaggct cacaataaac tttgtaatga aaaaattctc cgtgaaagaa ccgtcattca 300  
 ctgtgagcgt gttctactcc gacaacctgt gcaacggggc tgcgattaac gttacataa 360  
 gcggggacat gctgcacttt atgttcgcta tgggaaacct gaggtgcttt ttgccggtga 420  
 agcacatttt cccggtttcg attgcgaact ggaactctac gttagacctc cacgggctcg 480  
 aaaaccaata catagttaga cgggggcggc gagacgtttt ctgg 524

<210> 12  
 <211> 174  
 <212> PRT  
 <213> Deduced Amino Acid of Cosmid 3 Fragment 3 SP6

<400> 12  
 Ile Gln Tyr Ala Pro Lys Asp Arg Asp His Asn Phe Ile Phe Asp Ala  
 1 5 10 15  
 Asn Gln Asn Pro Asp Arg His Lys Gln Val His His Asp His Gln Thr  
 20 25 30  
 Glu Pro Leu Pro Asp Met Phe Asp Pro Val Lys His Leu Ser Leu His  
 35 40 45  
 Asn Phe Lys Ile Ser Val Phe Asn Thr Asn Met Val Ile Asn Thr Lys  
 50 55 60  
 Ile Thr Cys Arg Ser Leu Thr Gly Thr Phe Glu Ser Ile Ile Asp Ile  
 65 70 75 80  
 Pro Arg Leu Thr Asn Asn Phe Val Met Lys Lys Phe Ser Val Lys Glu  
 85 90 95  
 Pro Ser Phe Thr Val Ser Val Phe Tyr Ser Asp Asn Leu Cys Asn Gly  
 100 105 110  
 Ala Ala Ile Asn Val Asn Ile Ser Gly Asp Met Leu His Phe Met Phe  
 115 120 125  
 Ala Met Gly Asn Leu Arg Cys Phe Leu Pro Val Lys His Ile Phe Pro  
 130 135 140  
 Val Ser Ile Ala Asn Trp Asn Ser Thr Leu Asp Leu His Gly Leu Glu  
 145 150 155 160  
 Asn Gln Tyr Ile Val Arg Arg Gly Arg Arg Asp Val Phe Trp  
 165 170

<210> 13  
 <211> 398  
 <212> DNA  
 <213> Cosmid 3 Fragment 1 T7

<400> 13  
 gatcccatag agtcctgtt ctgcggcggc ctttttaact ctatagacga taccattaac 60  
 gcactgagcc gggattgttc ggtaacgttc tttcaacagg caaactatac caacgtcatg 120

## Cloning of Radinovirus Genome and Methods for its Use.ST25

cgaaaacaaa acgagctgtt taccagactc aacagcatat tgtgtcaggg gagcgcgga 180  
 tcgcaaaaac cgccacccc ctggagcca cggaccgcca ccgtcgcggc gaccgcgga 240  
 agcgagctca ttaaagacgc acaatatcgc aaagaacagt acatgaaaaa ggtggccagg 300  
 gacggcttta aaaaactaac agagtgtctg cagacgcaa gcgcggtgtt ggcaaacgcg 360  
 ctctgcatgc gcgtatggg ggcgtcgca tacggcga 398

<210> 14  
 <211> 132  
 <212> PRT  
 <213> Deduced Amino Acid of Cosmid 3 Fragment 1 T7

<400> 14

Asp Pro Ile Glu Ser Leu Phe Cys Gly Gly Leu Phe Asn Ser Ile Asp  
 1 5 10 15  
 Asp Thr Ile Asn Ala Leu Ser Arg Asp Cys Ser Val Thr Phe Phe Gln  
 20 25 30  
 Gln Ala Asn Tyr Thr Asn Val Met Arg Lys Gln Asn Glu Leu Phe Thr  
 35 40 45  
 Arg Leu Asn Ser Ile Leu Cys Gln Gly Ser Ala Gly Ser Gln Lys Pro  
 50 55 60  
 Ala Thr Pro Ser Glu Pro Arg Thr Ala Thr Val Ala Ala Thr Ala Ala  
 65 70 75 80  
 Ser Asp Val Ile Lys Asp Ala Gln Tyr Arg Lys Glu Gln Tyr Met Lys  
 85 90 95  
 Lys Val Ala Arg Asp Gly Phe Lys Lys Leu Thr Glu Cys Leu Gln Thr  
 100 105 110  
 Gln Ser Ala Val Leu Ala Asn Ala Leu Cys Met Arg Val Trp Gly Gly  
 115 120 125  
 Val Ala Tyr Gly  
 130

<210> 15  
 <211> 524  
 <212> DNA  
 <213> Cosmid 3 Fragment 1 SP6

<400> 15  
 gaattcacac ccgaacaaat ctaaaagcaa aattacacaa attaacaaaa atacaactat 60  
 aacacagtta aaaaattcaa tacataatta caatggtaaa attcacggt acataattac 120  
 aattttaaat tcaatttaaa aattcacgtg tacacaatta caaaattcac acaattttaa 180  
 aatcctttta accataaaat tagaacggca ctgtatatat gcagcggtatt gcaaactggc 240  
 agctttgtgt taaagaccac ggcattaaat tttaaattcg ccaggtcgcc aaaagtactg 300  
 gttacgtag ttcattctaaa agcttaacgt gcttgtgctt aaatttacgc cgtgccattg 360  
 ctccatttta aattaaaatt taaaatgtag tgcgagcgag ctagaacag aaaccgcgac 420  
 gcggggcagg ttgcgtagg tgcgcgtttt tggctccagt gacaatccaa aagctgcggt 480  
 ttacgagcca ttgtttttgt caaccactaa accgaaagca tgcg 524

## Cloning of Radinovirus Genome and Methods for its Use.ST25

<210> 16  
 <211> 438  
 <212> DNA  
 <213> Cosmid 3 EcoR1 Fragment 1 Kpn 1 Fragment 1 T7

<400> 16  
 ggtaccccca cgactataaa aagagacacc ctggtggccg ccgccgcgcc ctgccccgtg 60  
 gtgcgagtaa gctccgccga cgacgcgcgc cgggatctcg tcgcgtcacc agacaccggg 120  
 gcgctctcca ttgacgcgtt cacaatcccg gtcggtctcc ccgggggtgt ctcggcgagg 180  
 tgtcacgtgt ctatgcgcga caacgggggc cacgaacgca tgagccatta acggcgacaa 240  
 tgggaacacc ggtgcgtttc tttcgcggcg agtggcaaac ctcgagtctg gtggacaacg 300  
 gcacgccacg gtacagctcc ctggtgtggg ccgccactat ccacgacggc tacctgacac 360  
 tgggtgaacag gtcggagctg tgcgtcacgg agcgggtctc gtgtctgccg gcgtgcccc 420  
 gcatcgggag actggtcg 438

<210> 17  
 <211> 76  
 <212> PRT  
 <213> Deduced Amino Acid Cosmid 3 EcoR1 Fragment 1 Kpn 1 Fragment 1 T7; C - Ter  
 minus of Protein

<400> 17  
 Gly Thr Pro Thr Thr Ile Lys Arg Asp Thr Leu Val Ala Ala Ala Ala  
 1 5 10 15  
 Pro Cys Pro Val Val Arg Val Ser Ser Ala Asp Asp Ala Pro Arg Asp  
 20 25 30  
 Leu Val Ala Ser Pro Asp Thr Gly Ala Leu Ser Ile Asp Ala Phe Thr  
 35 40 45  
 Ile Pro Val Gly Leu Pro Gly Val Val Ser Ala Glu Cys His Val Ser  
 50 55 60  
 Met Arg Asp Asn Gly Val His Glu Arg Met Ser His  
 65 70 75

<210> 18  
 <211> 497  
 <212> DNA  
 <213> Cosmid 3 EcoR1 Fragment 1 Kpn 1 Fragment 2 SP6

<220>  
 <221> misc\_feature  
 <222> ()..()  
 <223> n = any nucleotide

<400> 18  
 ggtaccgagc cgcttccaga cggacattat tccgagcgga accgtgctca agctcctggg 60  
 gcgaaccgag aacggcacca gcgtgtgcgt gaacgtgttc cgtcaacagg tatatttcta 120  
 cgcgaaagtc ccagccggcg tcaacgtcac ccacgtcctc cagcaggccc tcaagaacac 180  
 cgccggcagg gccgcgtgcy gttctctgac cagacgagta accaaaaaaa ttctcaaaac 240  
 gtacgacgtc gcggagcatc ccgtcactga aatcacgcta tcgtccggtt ccatgctctc 300  
 gaccctcagc gaccgcctcg tcgcgtgcgg gtgcgaggtg ttcgagtcaa acgtggacgc 360

Cloning of Radinivirus Genome and Methods for its Use.ST25  
 cggttcgccg ttcgtcctgg atcacgggtt taccacgttc ggggtgtact cgtgcgcgcg 420  
 tgccacgccc cgcctagcgg ncagagatgc cagaacggcc ctggagtgtg actgcagctg 480  
 ggaggacctc agcggtc 497

<210> 19  
 <211> 165  
 <212> PRT  
 <213> Deduced Amino Acid of Cosmid 3 EcoRI Fragment 1 Kpn 1 Fragment 2 SP6  
 <220>  
 <221> misc\_feature  
 <222> ()..()  
 <223> X = any amino acids

<400> 19  
 Val Pro Ser Arg Phe Gln Thr Asp Ile Ile Pro Ser Gly Thr Val Leu  
 1 5 10 15  
 Lys Leu Leu Gly Arg Thr Glu Asn Gly Thr Ser Val Cys Val Asn Val  
 20 25 30  
 Phe Arg Gln Gln Val Tyr Phe Tyr Ala Lys Val Pro Ala Gly Val Asn  
 35 40 45  
 Val Thr His Val Leu Gln Gln Ala Leu Lys Asn Thr Ala Gly Arg Ala  
 50 55 60  
 Ala Cys Gly Phe Ser Thr Arg Arg Val Thr Lys Lys Ile Leu Lys Thr  
 65 70 75 80  
 Tyr Asp Val Ala Glu His Pro Val Thr Glu Ile Thr Leu Ser Ser Gly  
 85 90 95  
 Ser Met Leu Ser Thr Leu Ser Asp Arg Leu Val Ala Cys Gly Cys Glu  
 100 105 110  
 Val Phe Glu Ser Asn Val Asp Ala Val Arg Arg Phe Val Leu Asp His  
 115 120 125  
 Gly Phe Thr Thr Phe Gly Trp Tyr Ser Cys Ala Arg Ala Thr Pro Arg  
 130 135 140  
 Leu Ala Xaa Arg Asp Ala Arg Thr Ala Leu Glu Phe Asp Cys Ser Trp  
 145 150 155 160  
 Glu Asp Leu Ser Val  
 165

<210> 20  
 <211> 314  
 <212> DNA  
 <213> Cosmid 3 EcoRI Fragment 1 Kpn 1 Fragment 2 T7

<400> 20  
 ggtaccgttg ggggtgaata ggcgcagggtg tgttgtgcaa ccggaagca aaagtgttg 60  
 ggtgacgatg aataggggct ccggtgccac gcccgcaact agaaacgcca gatcgccccg 120  
 agcggcgctc cctgttgaa agattaactg aacccggact tccgcggagc ttccaggttg 180  
 gatggttttt tcggcgctcg cgtaaccccc caatacgcgg ccgccggtgt gggtagggcag 240  
 gacgggtccg gactggccca agactatctc ggcgttgggg tccccggag cgtaaagat 300  
 tttcatttgc gccg 314

## Cloning of Radinovirus Genome and Methods for its Use.ST25

<210> 21  
 <211> 104  
 <212> PRT  
 <213> Deduced Amino Acid of Cosmid 3 EcoR1 Fragment 1 Kpn 1 Fragment 2 T7

<400> 21

Ala Gln Met Lys Ile Ile Tyr Ala Pro Gly Asp Pro Asn Ala Glu Ile  
 1 5 10 15  
 Val Leu Gly Gln Ser Gly Pro Val Leu Pro Thr His Thr Gly Gly Arg  
 20 25 30  
 Val Leu Gly Val Tyr Ala Asp Ala Glu Lys Thr Ile Gln Pro Gly Ser  
 35 40 45  
 Ser Ala Glu Val Arg Val Gln Leu Ile Phe Pro Thr Gly Ser Ala Ala  
 50 55 60  
 Arg Gly Asp Leu Ala Phe Leu Val Ala Gly Val Ala Pro Glu Pro Leu  
 65 70 75 80  
 Phe Ile Val Thr Pro Thr Leu Leu Leu Ser Gly Cys Thr Thr His Leu  
 85 90 95  
 Arg Leu Phe Asn Pro Asn Gly Thr  
 100

<210> 22  
 <211> 681  
 <212> DNA  
 <213> Cosmid 3 EcoR1 Fragment 1 Kpn Fragment 3 SP6

<400> 22

ggtaccgcaa ggtggccacc tcggtaacgg tctatcgagg gtggaccgag accgccgtga 60  
 ccggttaagca agagggtcatt cgaccggtgc cgcagtagca gattaaccac atggacacga 120  
 cctaccagtg tttcagctcc atgcgcgtga acgttaacgg catcgaaaac acctacacgg 180  
 acagggactt cactaaccag accgtgttcc tgcaaccggt cgaggggctc acggataaca 240  
 ttcagcgata cttcagtcag ccggtgctgt acacgacacc gggatggttt cctggaatct 300  
 acaggggccg aaccacggtc aactgcgaga tcgtggacat gatcgcgctg tcggcggaac 360  
 cgtactctta ctttgtcacc gccctgggag acacggtaga ggtatcgccg ttctgcttaa 420  
 acgactcgac gtgctccgtc gctgataaag ccgaaaacgg cctcggcgtg cgcgtgctta 480  
 caaattacac cattgttgac ttcgctaccc gcacgcccac caccgaaacg cgagttttcg 540  
 cagactcggg agaatacacc gtatcgtgga aggcggaaga ccctaagtcg gcagtctgtg 600  
 cgctgacgct ctggaaaacc tttcccaggg ccatacagac gacgcacgaa agccagctac 660  
 cactttgtgg ccaacgacgt g 681

<210> 23  
 <211> 226  
 <212> PRT  
 <213> Deduced Amino Acid of Cosmid 3 EcoR1 Fragment 1 Kpn Fragment 3 SP6

<400> 23

Tyr Arg Lys Val Ala Thr Ser Val Thr Val Tyr Arg Gly Trp Thr Glu  
 1 5 10 15

## Cloning of Radinovirus Genome and Methods for its Use.ST25

Thr Ala Val Thr Gly Lys Gln Glu Val Ile Arg Pro Val Pro Gln Tyr  
 20 25 30  
 Glu Ile Asn His Met Asp Thr Thr Tyr Gln Cys Phe Ser Ser Met Arg  
 35 40 45  
 Val Asn Val Asn Gly Ile Glu Asn Thr Tyr Thr Asp Arg Asp Phe Thr  
 50 55 60  
 Asn Gln Thr Val Phe Leu Gln Pro Val Glu Gly Leu Thr Asp Asn Ile  
 65 70 75 80  
 Gln Arg Tyr Phe Ser Gln Pro Val Leu Tyr Thr Thr Pro Gly Trp Phe  
 85 90 95  
 Pro Gly Ile Tyr Arg Val Arg Thr Thr Val Asn Cys Glu Ile Val Asp  
 100 105 110  
 Met Ile Ala Arg Ser Ala Glu Pro Tyr Ser Tyr Phe Val Thr Ala Leu  
 115 120 125  
 Gly Asp Thr Val Glu Val Ser Pro Phe Cys Leu Asn Asp Ser Thr Cys  
 130 135 140  
 Ser Val Ala Asp Lys Ala Glu Asn Gly Leu Gly Val Arg Val Leu Thr  
 145 150 155 160  
 Asn Tyr Thr Ile Val Asp Phe Ala Thr Arg Thr Pro Thr Thr Glu Thr  
 165 170 175  
 Arg Val Phe Ala Asp Ser Gly Glu Tyr Thr Val Ser Trp Lys Ala Glu  
 180 185 190  
 Asp Pro Lys Ser Ala Val Cys Ala Leu Thr Leu Trp Lys Thr Phe Pro  
 195 200 205  
 Arg Ala Ile Gln Thr Thr His Glu Ser Gln Leu Pro Leu Cys Gly Gln  
 210 215 220  
 Arg Arg  
 225  
 <210> 24  
 <211> 389  
 <212> DNA  
 <213> Cosmid 3 EcoR1 Fragment 1 Kpn 1 Fragment 3 T7  
 <400> 24  
 ggtacctcgg cgacacctgtc cgccgcgtac gtcgtttcaa cgacgtcgta cgcgtgaaac 60  
 gtaatggatt ggtcttgggg gtccgggacg actggccgtt ggccgcgcgc cgtccacatg 120  
 gaccgttcgt gggcgagcag cacgtctccg cgcgcccggt tttcaaagta cgtcggcggg 180  
 aacgggatcg tgaccgggat catccgcct gccccggcg ttcggaggca ggcggaatg 240  
 agcctgcaga cgtctggtgg cggctgaacg gcgccggcg gggcgggcg atcgggtcat 300  
 ttgtgtgagg gggggcgtgg tcctcgagga ccaggtacg ggttaaaaaa atccatgctc 360  
 gatacagaac gctgacgcc gggggcgcc 389  
 <210> 25  
 <211> 129  
 <212> PRT  
 <213> Deduced Amino Acide of Cosmid 3 EcoR1 Fragment 1 Kpn 1 Fragment 3 T7 Sequ  
 ence

## Cloning of Radinovirus Genome and Methods for its Use.ST25

&lt;400&gt; 25

Gly Ala Pro Gly Arg Gln Arg Ser Val Ser Ser Met Asp Phe Phe Asn  
 1 5 10 15  
 Pro Tyr Leu Gly Pro Arg Gly Pro Arg Pro Pro Ser His Lys Cys Thr  
 20 25 30  
 Asp Ala Pro Ala Pro Ala Gly Ala Val Gln Pro Pro Pro Asp Val Cys  
 35 40 45  
 Arg Leu Ile Pro Ala Cys Leu Arg Thr Pro Gly Ala Gly Gly Met Ile  
 50 55 60  
 Pro Val Thr Ile Pro Phe Pro Pro Thr Tyr Phe Glu Asn Gly Ala Arg  
 65 70 75 80  
 Gly Asp Val Leu Leu Ala His Glu Arg Ser Met Trp Thr Ala Arg Gly  
 85 90 95  
 Gln Arg Pro Val Val Pro Asp Pro Gln Asp Gln Ser Ile Thr Phe His  
 100 105 110  
 Ala Tyr Asp Val Val Glu Thr Thr Tyr Ala Ala Asp Arg Cys Ala Glu  
 115 120 125

Val

<210> 26  
 <211> 330  
 <212> DNA  
 <213> Cosmid 3 EcoR1 Fragment 1 Kpn 1 Fragment 4 T7

<220>  
 <221> misc\_feature  
 <222> ()..()  
 <223> n = any nucleotide

<400> 26  
 ggtaccgcct aaccttaaag atgtggggga cgatatTTTT tttaaacacc attagaatgc 60  
 cttcttggtg cgttttgnc tgggtgccag gacacgtctt ttccagggtta aacctgaaga 120  
 gttcgccggt ggccgaggcg ctgcacacgc gaaacttgaa cgcctcggcc ctgggtgggt 180  
 tttcgggagg tgtgggcgtc gacgggcccgc gctgggactt tgcaagtgtg gtcacgccct 240  
 ttggggtggt gacgttttcg ccaaccggcg cgccaatcgc gattatcacg acccagcccc 300  
 gcagcagacg acgcgtccgg ttaggtatca 330

<210> 27  
 <211> 109  
 <212> PRT  
 <213> Deduced Amino Acide of Cosmid 3 EcoR1 Fragment 1 Kpn 1 Fragment 4 T7 Sequ  
 ence

<220>  
 <221> misc\_feature  
 <222> ()..()  
 <223> X = any amino acid

&lt;400&gt; 27

Ile Pro Asn Arg Thr Arg Arg Leu Leu Arg Ala Trp Val Val Ile Ile  
 1 5 10 15

## Cloning of Radinovirus Genome and Methods for its Use.ST25

Ala Ile Gly Ala Pro Val Gly Glu Asn Val Thr Thr Pro Lys Gly Val  
20 25 30

Thr Thr Thr Ala Lys Ser Thr Pro Gly Pro Ser Thr Pro Thr Pro Pro  
35 40 45

Glu Asn Pro Pro Arg Ala Glu Ala Phe Lys Phe Arg Val Cys Ser Ala  
50 55 60

Ser Ala Thr Gly Glu Leu Phe Arg Phe Asn Leu Glu Lys Thr Cys Pro  
65 70 75 80

Gly Thr Glu Xaa Lys Thr His Gln Glu Gly Ile Leu Met Val Phe Lys  
85 90 95

Lys Asn Ile Val Pro His Ile Phe Lys Val Arg Arg Tyr  
100 105

<210> 28

<211> 140

<212> PRT

<213> Orf 29b

<400> 28

Asn Val Ala Val Glu Gly Asn Ser Ser Gln Asp Ala Gly Val Ala Ile  
1 5 10 15

Ala Thr Val Leu Asn Glu Ile Cys Ser Val Pro Leu Ser Phe Leu His  
20 25 30

His Ala Asp Lys Asn Thr Leu Ile Arg Ser Pro Ile Tyr Met Leu Gly  
35 40 45

Pro Glu Lys Ala Lys Ala Phe Glu Ser Phe Ile Tyr Ala Leu Asn Ser  
50 55 60

Gly Thr Phe Ser Ala Ser Gln Thr Val Val Ser His Thr Ile Lys Leu  
65 70 75 80

Ser Phe Asp Pro Val Ala Tyr Leu Ile Asp Gln Ile Lys Ala Ile Arg  
85 90 95

Cys Ile Pro Leu Lys Asp Gly Gly His Thr Tyr Cys Ala Lys Gln Lys  
100 105 110

Thr Met Ser Asp Asp Val Leu Val Ala Thr Val Met Ala His Tyr Met  
115 120 125

Ala Thr Asn Asp Lys Phe Val Phe Lys Ser Leu Glu  
130 135 140

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/16274

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : Please See Extra Sheet.

US CL : 435/5, 6, 7.1, 91.2, 173.3, 235.1, 362; 536/23.72; 530/300

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/5, 6, 7.1, 91.2, 173.3, 235.1, 362; 536/23.72; 530/300

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

BIOSIS, COMPUGEN, MEDLINE, WEST 2.0

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	SEARLES, R. P., Sequence and Genomic Analysis of a Rhesus Macaque Rhadinovirus with Similarity to Kaposi's Sarcoma-Associated Herpesvirus/Human Herpesvirus 8, Journal of Virology, April 1999, Vol. 73, No. 4, pages 3040-3053.	1-51

☐ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"B" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"A" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

16 SEPTEMBER 2001

Date of mailing of the international search report

18 OCT 2001

 Name and mailing address of the ISA/US  
 Commissioner of Patents and Trademarks  
 Box PCT  
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

LAURIE SCHEINER

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US01/16274

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (7):

C12Q 1/70; G01N 33/53; C12P 19/34; C12N 5/08, 7/00; C07H 21/04; A61K 38/00



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C12N 15/38, 7/00, 5/10, 15/00, A01K 67/027, C07K 14/03</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 00/28040</b> <b>(43) International Publication Date:</b> 18 May 2000 (18.05.00)
<b>(21) International Application Number:</b> PCT/US99/26260 <b>(22) International Filing Date:</b> 5 November 1999 (05.11.99)  <b>(30) Priority Data:</b> 60/107,507 6 November 1998 (06.11.98) US 60/109,409 20 November 1998 (20.11.98) US  <b>(71) Applicant (for all designated States except US):</b> OREGON HEALTH SCIENCES UNIVERSITY [US/US]; Office of Technology Management, 3181 S.W. Sam Jackson Park Road, L335, Portland, OR 97201-3098 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> WONG, Scott, W. [US/US]; 7926 S.W. 167th Place, Beaverton, OR 97007 (US). AXTHELM, Michael, K. [US/US]; 1345 S.E. 35th Avenue, Hillsboro, OR 97123 (US). SEARLES, Robert, P. [US/US]; 18300 N.W. Heritage Parkway #106, Beaverton, OR 97006 (US).  <b>(74) Agent:</b> NOONAN, William, D.; Klarquist, Sparkman, Campbell, Leigh & Winston, LLP, Suite 1600 - One World Trade Center, 121 S.W. Salmon Street, Portland, OR 97204 (US).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>  <b>(88) Date of publication of the international search report:</b> 31 August 2000 (31.08.00)
<b>(54) Title:</b> CLONING OF RHADINOVIRUS GENOME AND METHODS FOR ITS USE		
<b>(57) Abstract</b>		
<p>A novel rhesus macaque rhadinovirus, herein designated RRV, is disclosed. The genomic, cDNA and proteins sequences are provided. RRV has some similarity to human Kaposi's sarcoma-associated herpesvirus and causes Kaposi's sarcoma-like symptoms in immuno-compromised non-human primates. RRV possesses genes for both Interleukin-6 and macrophage inflammatory protein 1. The genome of RRV is useful for research, clinical and diagnostic applications aimed towards the rhadinoviruses and herpesviruses in general and KSHV in particular. In addition, methods for using RRV to produce a non-human primate model for the testing of Kaposi's sarcoma-associated herpesvirus therapeutics and vaccines are presented.</p> <div style="text-align: right;"> <p>Phylogenetic Comparison of the Gammaherpesviruses</p> <pre> graph LR     EBV --- Node1     Node1 --- Node2     Node2 --- AHV     Node2 --- Node3     Node3 --- Node4     Node4 --- MHV     Node4 --- Node5     Node5 --- Node6     Node6 --- HVS     Node6 --- Node7     Node7 --- KSHV     Node7 --- RRV           </pre> <p>             EBV - Epstein-Barr virus              AHV - Alcelaphine herpesvirus              MHV - Murine herpesvirus 68              HVS - Herpesvirus saimiri              KSHV - Kaposi's sarcoma-associated herpesvirus              RRV - Rhesus rhadinovirus 17577           </p> </div>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/26260

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/38 C12N7/00 C12N5/10 C12N15/00 A01K67/027  
C07K14/03

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A01K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DESROSIERS, R.C. ET AL.: "A herpesvirus of rhesus monkeys related to the human Kaposi's sarcoma-associated herpesvirus." J. VIROL., vol. 71, no. 12, December 1997 (1997-12), pages 9764-9869, XP000891219 the whole document	2
X,P	SEARLES RP, BERGQUAM EP, AXTHELM MK, WONG SW: "Sequence and genomic analysis of a Rhesus macaque rhadinovirus with similarity to Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8." J VIROL, vol. 73, no. 4, April 1999 (1999-04), pages 3040-3053, XP000891221 the whole document	1

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

### \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

Date of the actual completion of the international search

21 March 2000

Date of mailing of the international search report

26.06.2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

CHAMBONNET, F

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/26260

**C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	DAMANIA B, LI M, CHOI JK, ALEXANDER L, JUNG JU, DESROSIERS RC: "Identification of the R1 oncogene and its protein product from the rhadinovirus of rhesus monkeys." J VIROL., vol. 73, no. 6, June 1999 (1999-06), pages 5123-5131, XP000891220 the whole document	1
P,X	--- KALEEBA, J.A. ET AL.: "A Rhesus Macaque Rhadinovirus related to Kaposi's Sarcoma- Associated Herpesvirus/Human Herpesvirus 8 encodes a functional homologue of interleukin-6" J VIROL., vol. 73, no. 7, July 1999 (1999-07), pages 6177-6181, XP000891222 the whole document -----	1

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 99/26260

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-3, 13, 14 (complete)

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 99/26260

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-3, 13, 14

An isolated virus (RRV) as deposited with ATCC as deposit accession number VR-2601, or having nucleic sequence shown in SEQ ID NO 1 or having at least 80% sequence identity to the nucleic acid sequence shown in SEQ ID NO 1; non human mammal infected with said virus;

2. Claims: partially 4-12, 15, 16, 17

A purified protein having an activity of an RRV protein and comprising an amino acid sequence SEQ ID NO 3; an nucleic acid molecule encoding said protein or comprising the sequence SEQ ID NO 2; a recombinant molecule comprising a promoter sequence linked to said nucleic acid molecule; a cell transformed with said recombinant nucleic acid molecule; an oligonucleotide comprising at least 20 contiguous nucleotides of the sequence shown in SEQ ID NO 2; an isolated nucleic acid molecule that hybridizes under stringent conditions with a nucleic probe comprising said oligonucleotide sequence and encodes a protein having an RRV protein biological activity;

3. Claims: partially 4-12, 15, 16, 17

Inventions 3 to 88 : Idem as subject 2 but limited to each of the designated proteins, where the amino acid sequences are respectively limitedo SEQ ID NO 5 to 165 and the corresponding nucleotide sequences to SEQ ID NO 4 to 164: For the sake of conciseness, the first subject matter is explicitly defined, the other subject matters are defined by analogy thereto.

4. Claims: partially claims 4, 15, 16, 17, 18

Invention 89 : An isolated nucleic acid molecule encoding at least one RRV protein, as far not covered by one of the previous inventions; an oligonucleotide comprising at least 20 contiguous nucleotides of said sequence or an isolated nucleic acid molecule that hybridizes under stringent conditions with a nucleic probe comprising said oligonucleotide sequence and encodes a protein having an RRV protein biological activity, .

5. Claims: 19-34

Invention 90 :A method for testing the efficacy of a drug in the treatment of a condition associated with infection by RRV, the method comprising administering the drug to a

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 99/26260

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

non-human primate infected with an RRV and observing the effects; method for producing a non-human primate model for testing potential treatments for a condition associated with RRV infection; a method for testing the efficacy of a candidate vaccine against RRV infection or conditions associated with it;

## PCT

REC'D 18 APR 2001

WIFO

PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 178-53683	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US99/26260	International filing date (day/month/year) 05/11/1999	Priority date (day/month/year) 06/11/1998
International Patent Classification (IPC) or national classification and IPC C12N15/38		
Applicant OREGON HEALTH SCIENCES UNIVERSITY et al.		


1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 7 sheets, including this cover sheet.
- ☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 4 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

**CORRECTED  
VERSION**

Date of submission of the demand  03/06/2000	Date of completion of this report  20.02.2001
Name and mailing address of the international preliminary examining authority:   European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer  Surdej, P  Telephone No. +49 89 2399 7334



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US99/26260

**I. Basis of the report**

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments (Rules 70.16 and 70.17).):*

**Description, pages:**

1-64 as originally filed

**Claims, No.:**

1-34 as received on 03/06/2000 with letter of 02/06/2000

**Drawings, sheets:**

1-13 as originally filed

**Sequence listing part of the description, pages:**

1-59, as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☒ furnished subsequently to this Authority in computer readable form.
- ☒ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☒ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US99/26260

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application.
- ☒ claims Nos. 4-12,15-34.

because:

- ☐ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (*specify*):
- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
- ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
- ☒ no international search report has been established for the said claims Nos. 4-12,15-34.

2. A meaningful international preliminary examination report cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

- ☐ the written form has not been furnished or does not comply with the standard.
- ☐ the computer readable form has not been furnished or does not comply with the standard.

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US99/26260

## 1. Statement

Novelty (N)	Yes:	Claims	1
	No:	Claims	2-3,13-14
Inventive step (IS)	Yes:	Claims	
	No:	Claims	1-3,13-14
Industrial applicability (IA)	Yes:	Claims	1-3,13-14
	No:	Claims	

## 2. Citations and explanations **see separate sheet**

## VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:  
**see separate sheet**

Reference is made to the following documents:

D1: DESROSIERS, R.C. ET AL.: 'A herpesvirus of rhesus monkeys related to the human Kaposi's sarcoma-associated herpesvirus.' J. VIROL., vol. 71, no. 12, December 1997 (1997-12), pages 9764-9869

Sequence comparisons referred to in this report are already known to the applicant.

## **Introduction**

The application discloses isolated rhesus macaque rhadinovirus and its complete genomic sequence.

## **Re Item V**

Reasoned statement under Article 35(2) PCT with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

## **Novelty (Art. 33(1) and (2) PCT)**

1. **Claims 2 and 3** are not novel. D1 discloses a strain of rhesus monkey rhadinovirus which is related to the Kaposi's sarcoma-associated herpesvirus, human herpesvirus 8. The virus described in D1 is very closely related to the virus described in the present application. The genome of the virus disclosed in D1 has the same organisation as the virus described in the present application over the known portion of the genome of the virus of D1; the open reading frames (ORFs) are in the same order with the same assigned function and e.g. a homolog of interleukin-6 is present at the same position (Fig.2 and page 9766, right column, 2nd paragraph). More importantly, the amino acid sequence of the DNA polymerase disclosed in D1 has a 100% identity in a 1014 amino acids overlap to sequence SEQ ID No. 15 of the present application (which is the entire length of the open reading frame; see also sequence comparisons). Such conservation of the amino acid sequence and genome organisation strongly suggests that the virus disclosed in D1 is a close variant of the virus disclosed in the application and falls into the scope of claims 2 and 3. Unless the applicant can convincingly show that the subject-matter of claims 2 and 3 is clearly different from the prior art,

novelty is denied for said claims.

2. **Claims 13 and 14** are not new. D1 discloses rhesus monkeys infected with rhesus rhadinoviruses (page 9764, right column, last paragraph to page 9766, left column, first paragraph) which fall into the scope of claim 2 (see point 1). It should be also noted that the non-human mammals referred to in claim 13 may eliminate the virus; thus, any non-human mammal falls into the scope of the claim.

**Inventive step (Art. 33 (1) and (3) PCT)**

3. The subject-matter of **claim 1** is novel but it is not inventive. D1 discloses a rhesus rhadinovirus which has the same genome organisation over the known portion of its genome as the virus disclosed in the present application (Fig. 2). The DNA polymerase open reading frame disclosed in D1 is 100% identical in a 1014 amino acids overlap to the the corresponding ORF of the present application (SEQ ID No. 15; see sequence comparisons). In the light of the prior art, the technical problem of the application is to provide an alternative way to isolate rhesus rhadinovirus genome and the solution is the provision of the rhesus rhadinovirus having the nucleic acid sequence SEQ ID No.1. D1 addresses the same technical problem as the present application. The same solution as the present application is disclosed in D1 with the isolation of e.g. one rhesus rhadinovirus isolate (H26-95; page 9766, left column, 1st paragraph). The mere disclosure of a variant of the rhesus rhadinovirus of D1 does not confer an inventive step to the subject matter of claim 1. Thus, no inventive step is acknowledged for claim 1.

**Re Item VIII**

Certain observations on the international application

4. In **claim 2**, the sentence "a purified virus having a nucleic acid sequence shown in SEQ ID No. 1" is not clear since it cannot be seen which part of sequence SEQ ID No. 1 is present in the said purified virus. Hence, the scope of claim 2 is unclear (Art. 6 PCT).
5. In **claims 2 and 3**, the length of nucleic acid sequence having 80% and 95%

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/US99/26260

identity to sequence SEQ ID No.1, respectively, is not given. Thus, claims 2 and 3 are not clear (Art. 6 PCT).

6. The expressions such as "incorporated by reference" for example on page 17, line 11 seem to imply that other subject matters are incorporated by reference, however, the application should be self-explanatory (Art. 5 and 6, Rule 9.1 iv) and Preliminary Examination Guidelines Ch. II-4.17 PCT).
7. Vague statements such as "spirit of the invention" for example on page 64, line 36 imply that the subject matter of the invention may be different from what is defined by the claims, thereby resulting in lack of clarity (Art. 6 PCT) when use to interpret them (see also the PCT Preliminary Examination Guidelines Ch. III-4.3a).

## CLAIMS AS AMENDED UNDER ARTICLE 34

- 5
1. An isolated virus (RRV) as deposited with ATCC as deposit accession number VR-2601.
2. A purified virus, having a nucleic acid sequence
- (a) shown in SEQ ID NO 1 or
- 10 (b) a conservative variant thereof.
3. The purified virus of claim 2, wherein the nucleic acid sequence has at least 95% sequence identity to the nucleic acid sequence shown in SEQ ID NO 1.
- 15
4. A purified protein encoded by an open reading frame of the virus of claim 2.
5. A purified protein of claim 4, wherein the protein comprises an amino acid sequence selected from the group consisting of:
- 20 (a) an amino acid sequence shown in odd numbered sequences of SEQ ID NOS. 3-165; and
- (b) amino acid sequences that differ from those specified in (a) by one or more conservative amino acid substitutions wherein the function of the protein is preserved.
- 25
6. A purified protein with an amino acid sequence that is at least 95% sequence identity to the sequences specified in claim 5(a) or 5(b).
7. The purified protein of claim 5, wherein the amino acid sequence is selected from odd numbered sequences within the group consisting of SEQ ID NOS 3-19 and 23-165.
- 30
8. An isolated nucleic acid molecule encoding a protein according to claim 5.
- 35
9. An isolated nucleic acid molecule according to claim 8, wherein the molecule comprises a sequence selected from the group consisting of even numbered sequences of SEQ ID NOS 2-164.

71 05 . 00 00

66

10. The isolated nucleic acid molecule according to claim 9, wherein the molecule comprises a sequence selected from the group consisting of even numbered sequences of SEQ ID NOS 2-18 and 22-164.

5

11. A recombinant nucleic acid molecule comprising a promoter sequence operably linked to a nucleic acid molecule according to claim 8.

10

12. A cell transformed with a recombinant nucleic acid molecule according to claim 8.

13. A non-human mammal purposefully infected with the virus of claim 2.

14. The mammal of claim 13, wherein the mammal is a primate.

15

15. An oligonucleotide comprising a sequence selected from the group consisting of:

A

(a) at least 20 contiguous nucleotides of the nucleic acid sequence of the virus of claim 2;

20

(b) at least 30 contiguous nucleotides of the nucleic acid sequence of the virus of claim 2; and

(c) at least 50 contiguous nucleotides of the nucleic acid sequence of the virus of claim 2.

25

16. An isolated nucleic acid molecule that:

(a) hybridizes under stringent conditions with a nucleic acid probe comprising the sequence of claim 15; and

(b) encodes a protein of claim 6.

30

17. An isolated nucleic acid molecule encoding a protein of claim 6.

18. An isolated nucleic acid molecule encoding all proteins encoded by the virus of claim 2, and having a biological activity of an RRV virus.

35

19. A method for testing the efficacy of a drug in the treatment of a condition associated with the virus of claim 2, the method comprising:

(a) administering the drug to a non-human primate infected with the virus of claim 2; and

(b) observing the primate to determine if the drug prevents or reduces the presentation of one or more symptoms associated with viral infection.

20. The method of claim 19, wherein the primate is immunocompromised.

21. The method of claim 20, wherein the drug is for the treatment of Kaposi's sarcoma and lymphoproliferative disorders.

22. The method of claim 20, wherein the primate is immuno-compromised as a result of infection by Simian Immunodeficiency Virus (SIV).

23. The method of claim 19, wherein the condition associated with infection with the virus of claim 2 is one or more of B-cell hyperplasia, lymphadenopathy, splenomegaly, hypergammaglobulinemia or autoimmune hemolytic anemia.

24. The method of claim 19, wherein the non-human primate is a Rhesus macaque monkey.

25. A method for producing a non-human primate model for testing potential treatments for a condition associated an infection with the virus of claim 2, comprising

(a) administering a treatment to the primate to render the primate immunocompromised; and

(b) infecting the primate with the virus of claim 2.

26. The method of claim 25, wherein the condition is Kaposi's sarcoma and lymphoproliferative disorders.

27. The method of claim 25 wherein the treatment used to render the primate immuno-compromised is infection with SIV.

28. The method of claim 25 wherein the non-human primate is a Rhesus macaque monkey.

29. A method for testing the efficacy of a candidate vaccine against the virus of claim 2, or conditions associated infection with virus of claim 2, the method comprising:

7705.06.00

67a

(a) administering the vaccine to a subject capable of infection with the virus of claim 2;  
(b) inoculating the subject with the virus; and  
(c) observing the subject to determine if the vaccine prevents or reduces an incidence of viral infection or presentation of one or more conditions associated with the viral infection.

30. The method of claim 29, wherein the subject is a primate.

31. The method of claim 30, wherein the primate is a non-human primate.

32. The method of claim 29, wherein the primate is immunocompromised.

33. The method of claim 29, wherein the conditions associated with infection include B-cell hyperplasia, lymphadenopathy, splenomegaly, hypergammaglobulinemia or autoimmune hemolytic anemia.

34. The method of claim 31, wherein the non-human primate is a Rhesus macaque monkey.

add  
A1 >

Ins. 2  
B2 >